0001571049-15-008783.txt : 20151104 0001571049-15-008783.hdr.sgml : 20151104 20151104102933 ACCESSION NUMBER: 0001571049-15-008783 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151104 DATE AS OF CHANGE: 20151104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARQULE INC CENTRAL INDEX KEY: 0001019695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043221586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21429 FILM NUMBER: 151195828 BUSINESS ADDRESS: STREET 1: ONE WALL STREET CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 781-994-0300 MAIL ADDRESS: STREET 1: ONE WALL STREET CITY: BURLINGTON STATE: MA ZIP: 01803 10-Q 1 t83410_10q.htm FORM 10-Q

  

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

FORM 10-Q

 

Quarterly report pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

For the Quarter Ended September 30, 2015

 

Commission File No. 000-21429

 

ArQule, Inc.
(Exact Name of Registrant as Specified in its Charter) 

   
Delaware 04-3221586
(State of Incorporation) (I.R.S. Employer Identification Number)

  

One Wall Street, Burlington, Massachusetts 01803
(Address of Principal Executive Offices)
 
(781) 994-0300
(Registrant’s Telephone Number, including Area Code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405) of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒   No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): 

     
Large accelerated filer ☐   Accelerated filer ☒
     
Non-accelerated filer ☐   Smaller reporting company ☐
(Do not check if a smaller reporting company)    

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐   No ☒

 

Number of shares outstanding of the registrant’s Common Stock as of October 22, 2015: 

   
Common Stock, par value $.01 62,891,548 shares outstanding

  

 

  

 
 

 

ARQULE, INC.

 

QUARTER ENDED SEPTEMBER 30, 2015

 

TABLE OF CONTENTS

 

       
PART I - FINANCIAL INFORMATION    
       
Item 1. — Unaudited Condensed Financial Statements    
       
  Condensed Balance Sheets (Unaudited) September 30, 2015 and December 31, 2014   3
       
  Condensed Statements of Operations and Comprehensive Loss (Unaudited) three and nine months ended September 30, 2015 and 2014   4
       
  Condensed Statements of Cash Flows (Unaudited) nine months ended September 30, 2015 and 2014   5
       
  Notes to Unaudited Condensed Financial Statements   6
       
Item 2. — Management’s Discussion and Analysis of Financial Condition and Results of Operations   13
       
Item 3. — Quantitative and Qualitative Disclosures about Market Risk   23
       
Item 4. — Controls and Procedures   24
       
PART II - OTHER INFORMATION    
       
Item 1. — Legal Proceedings   24
       
Item 1A. — Risk Factors   24
       
Item 2. — Unregistered Sales of Equity Securities and Use Of Proceeds   24
       
Item 3. — Defaults Upon Senior Securities   24
       
Item 4. — Mine Safety Disclosures   24
       
Item 5. — Other Information   24
       
Item 6. — Exhibits   24
       
SIGNATURES   25

 

2
 

 

ARQULE, INC.

 

CONDENSED BALANCE SHEETS (Unaudited) 

         
   September 30,
2015		   December 31,
2014		 
   (IN THOUSANDS,
EXCEPT SHARE AND
PER SHARE DATA)		 
ASSETS          
Current assets:          
Cash and cash equivalents  $13,130   $12,525 
Marketable securities-short term   30,629    46,683 
Prepaid expenses and other current assets   193    1,893 
Total current assets   43,952    61,101 
Marketable securities-long term   —    2,058 
Property and equipment, net   298    133 
Other assets   251    102 
Total assets  $44,501   $63,394 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable and accrued expenses  $5,691   $6,947 
Current portion of deferred revenue   7,373    11,098 
Deferred gain on sale leaseback   —    232 
Total current liabilities   13,064    18,277 
           
Deferred revenue, net of current portion   —    4,572 
Total liabilities   13,064    22,849 
Commitments and contingencies          
           
Stockholders’ equity:          
Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued or outstanding   —    — 
Common stock, $0.01 par value; 100,000,000 shares authorized; 62,891,548 and 62,821,781 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively   629    628 
Additional paid-in capital   510,072    508,270 
Accumulated other comprehensive income (loss)   1    (10)
Accumulated deficit   (479,265)   (468,343)
Total stockholders’ equity   31,437    40,545 
Total liabilities and stockholders’ equity  $44,501   $63,394 
           

The accompanying notes are an integral part of these interim unaudited financial statements.

 

3
 

 

ARQULE, INC.

 

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) 

                 
   THREE MONTHS ENDED
September 30,		   NINE MONTHS ENDED
September 30,		 
   2015   2014   2015   2014 
   (IN THOUSANDS, EXCEPT PER SHARE DATA) 
                 
Research and development revenue  $2,653   $2,662   $8,442   $8,239 
                     
Costs and expenses:                    
Research and development   3,180    5,014    11,920    17,981 
General and administrative   1,839    2,997    7,802    9,318 
Restructuring and other costs   —    1,099    —    1,099 
Total costs and expenses   5,019    9,110    19,722    28,398 
                     
Loss from operations   (2,366)   (6,448)   (11,280)   (20,159)
                     
Interest income   17    62    81    233 
Interest expense   —    (11)   —    (28)
Other income (expense)   (5)   (2)   277    75 
                     
Net loss   (2,354)   (6,399)   (10,922)   (19,879)
                     
Unrealized gain (loss) on marketable securities   8    (21)   11    (42)
Comprehensive loss  $(2,346)  $(6,420)  $(10,911)  $(19,921)
                     
Basic and diluted net loss per share:                    
Net loss per share  $(0.04)  $(0.10)  $(0.17)  $(0.32)
                     
Weighted average basic and diluted common shares outstanding   62,827    62,652    62,753    62,621 

 

The accompanying notes are an integral part of these interim unaudited financial statements.

 

4
 

 

ARQULE, INC.

 

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) 

         
   NINE MONTHS ENDED
SEPTEMBER 30,		 
   2015   2014 
   (IN THOUSANDS) 
Cash flows from operating activities:          
Net loss  $(10,922)  $(19,879)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   129    532 
Amortization of premium on marketable securities   406    893 
Amortization of deferred gain on sale leaseback   (232)   (416)
Non-cash stock compensation   1,741    2,643 
Gain on auction rate securities   —    (75)
Impairment of property and equipment   —    280 
Gain on sale of property and equipment   (277)   — 
Changes in operating assets and liabilities:          
Prepaid expenses and other assets   1,551    558 
Accounts payable and accrued expenses   (1,256)   (1,275)
Deferred revenue   (8,297)   (8,228)
Net cash used in operating activities   (17,157)   (24,967)
Cash flows from investing activities:          
Purchases of marketable securities   (24,203)   (27,504)
Proceeds from sale or maturity of marketable securities   41,920    52,934 
Additions to property and equipment   (315)   — 
Proceeds from sale of property and equipment   298    — 
Net cash provided by investing activities   17,700    25,430 
Cash flows from financing activities:          
Proceeds from employee stock plan purchases   62    57 
Net cash provided by financing activities   62    57 
Net increase in cash and cash equivalents   605    520 
Cash and cash equivalents, beginning of period   12,525    15,579 
Cash and cash equivalents, end of period  $13,130   $16,099 

 

The accompanying notes are an integral part of these interim unaudited financial statements.

 

5
 

 

ARQULE, INC.

 

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

 

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

 

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

 

We are a clinical-stage biotechnology company organized as a Delaware corporation in 1993 engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to produce novel drugs with differentiated mechanisms of action that will extend and improve the lives of our patients. These drugs target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our prioritized clinical stage pipeline consists of four product candidates, all of which are in targeted, biomarker-defined populations. Our drug discovery efforts focus on a number of pre-clinical programs based on our insights into kinase biology and are derived from our extensive library of proprietary compounds.

 

Our lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (“c-MET”) and its biological pathway. C-MET is a promising target for cancer therapy based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. We and our partners, Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) and Kyowa Hakko Kirin Co., Ltd. (“Kyowa Hakko Kirin”), are implementing a worldwide clinical development program with tivantinib. Our strategy is to focus on the most promising indications within our clinical programs based upon continually generated and updated clinical and pre-clinical data. Our lead indication is liver cancer (“hepatocellular carcinoma” or “HCC”), and we are currently conducting two Phase 3 trials with our partners. We have also completed earlier-stage single agent and combination therapy trials and pre-clinical experiments with tivantinib and other anti-cancer agents that may provide data to support later-stage trials in additional indications.

 

We have licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where we have licensed commercial rights to Kyowa Hakko Kirin. Our agreements with these partners provide for possible future milestone payments, royalties on product sales, and development funding, in addition to significant payments that we have already received. During 2011, we received $25 million from Daiichi Sankyo resulting from the dosing of the first patient in the MARQUEE trial and $10 million from Kyowa Hakko Kirin resulting from dosing of the first patient in the ATTENTION trial. On January 31, 2013, we announced that the first patient had been enrolled in the pivotal Phase 3 METIV trial of tivantinib, entitling us to a $15 million milestone. That milestone was netted against our cumulative share of Phase 3 collaboration costs in 2013, and consequently we did not receive any cash proceeds from this milestone.

 

We regained worldwide rights for the development and commercialization of ARQ 092, designed to inhibit the AKT serine/threonine kinase, and all other compounds included under our AKT collaboration with Daiichi Sankyo pursuant to their formal notice to terminate our license and co-commercialization agreement received on March 26, 2013. Following the termination, we became responsible for funding the remainder of the Phase 1 trial with ARQ 092 beyond the contractual termination period, as well as any future clinical development and commercialization of this compound. The license agreement had provided exclusive rights to Daiichi Sankyo for the development, manufacturing and marketing of ARQ 092 on a worldwide basis. Under this agreement, we received a $10 million upfront fee from Daiichi Sankyo in November 2011. Following the termination of this agreement, ARQ 092 became our proprietary asset, and Daiichi Sankyo has no further financial or other obligations or rights related to this program. ARQ 092 is part of our proprietary pipeline of product candidates directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers and rare diseases. Our priorities within this pipeline include ARQ 092, ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (“FGFR”) family, and ARQ 761, a Beta lapachone analog being investigated in investigator-sponsored testing as a promoter of NQ01-mediated cancer cell necrosis.

 

Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have consisted primarily of payments received from our collaborators for services performed or upfront payments for future services. For the nine month periods ended September 30, 2015 and 2014, our net use of cash was primarily driven by payments for operating expenses which resulted in net cash outflows of $17.2 million and $25.0 million, respectively.

 

Our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, our ability to enter into additional corporate collaborations and the terms of such collaborations, results of research and development, unanticipated required capital expenditures, competitive and technological advances, acquisitions and other factors. We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product. It is likely we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, and due to global capital and credit market conditions or for other reasons, we may be unable to raise capital when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates.

 

6
 

  

We have prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with our audited financial statements and footnotes related thereto for the year ended December 31, 2014 included in our annual report on Form 10-K filed with the SEC on March 4, 2015.

 

The unaudited condensed financial statements include, in our opinion, all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of our financial position as of September 30, 2015, and the results of our operations and cash flows for the nine months ended September 30, 2015 and September 30, 2014. The results of operations for such interim periods are not necessarily indicative of the results to be achieved for the full year.

 

2. COLLABORATIONS AND ALLIANCES

 

Beryllium Discovery Corp. Agreement

 

In May 2015, we entered into a collaborative research and development agreement with Beryllium Discovery Corp. (“Beryllium”). Pursuant to the agreement, we will jointly focus on the identification and preclinical development of inhibitors of PD-1 and PDL-1. We and Beryllium will each be responsible for our respective internal and outsourcing costs during pre-clinical development. Following lead optimization of any potential drug candidates, we and Beryllium will jointly decide whether to advance compounds into GLP/toxicology and clinical testing, initially on a shared cost basis, provided that we will have the right to advance compounds on our own should Beryllium vote against such advancement. The agreement also provides that we will be responsible for clinical development and commercialization of product candidates that are not out-licensed. Beryllium will have the right to participate financially throughout the program but will also have the option to opt out at certain times and receive a royalty. The agreement will terminate after the last payment obligation is satisfied, or prior to that upon 60-days’ notice by either party.

 

Daiichi Sankyo Tivantinib Agreement

 

On December 18, 2008, we entered into a license, co-development and co-commercialization agreement with Daiichi Sankyo to conduct research, clinical trials and the commercialization of tivantinib in human cancer indications in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan, where Kyowa Hakko Kirin has exclusive rights for development and commercialization.

 

The agreement provides for a $60 million cash upfront licensing payment from Daiichi Sankyo to us, which we received in December 2008, and an additional $560 million in potential development and sales milestone payments offset by our share of Phase 3 costs. Upon commercialization, we will receive tiered, double-digit royalties from Daiichi Sankyo on net sales of tivantinib commensurate with the magnitude of the transaction. We retain the option to participate in the commercialization of tivantinib in the U.S. We and Daiichi Sankyo will share equally the costs of Phase 2 and Phase 3 clinical studies, with our share of Phase 3 costs payable solely from milestone and royalty payments by Daiichi Sankyo.

 

In each quarter the tivantinib collaboration costs we incur are compared with those of Daiichi Sankyo. If our costs for the quarter exceed Daiichi Sankyo’s, we recognize revenue on the amounts due to us under the contingency adjusted performance model. Revenue is calculated on a pro-rata basis using the time elapsed from inception of the agreement over the estimated duration of the development period under the agreement. If our costs for the quarter are less than those of Daiichi Sankyo, we report the amount due to Daiichi Sankyo as contra-revenue in that quarter. To the extent that our share of Phase 3 collaboration costs exceeds the amount of milestones and royalties received, that excess is netted against future milestones and royalties if and when earned and is not reported as contra-revenue.

 

Our cumulative share of the Daiichi Sankyo Phase 3 costs through September 30, 2015 totaled $99 million. We received a milestone of $25 million in February 2011 upon enrolling the first patient in the MARQUEE trial, the cash proceeds of which were subsequently applied to our share of Phase 3 collaboration costs. On January 31, 2013, we announced that the first patient had been enrolled in the pivotal Phase 3 METIV trial of tivantinib, entitling us to a $15 million milestone. That $15 million milestone was also netted against our cumulative share of Phase 3 collaboration costs in 2013, and consequently we did not receive any cash proceeds from this milestone. Our cumulative share of Phase 3 collaboration costs has exceeded the amount of milestones received through September 30, 2015 by $59 million which will be netted against future milestones and royalties, if any, when earned and has not been reported as contra-revenue.

 

For the quarter ended September 30, 2015 our non-Phase 3 tivantinib collaboration costs incurred were less than those of Daiichi Sankyo and $130 was recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue. For the nine months ended September 30, 2015, our non-Phase 3 tivantinib collaboration costs incurred exceeded those of Daiichi Sankyo and $119 was recognized as tivantinib Daiichi Sankyo net research and development revenue.

 

7
 

 

For the quarter ended September 30, 2014 our non-Phase 3 tivantinib collaboration costs incurred were less than those of Daiichi Sankyo and $102 was recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue. For the nine months ended September 30, 2014, no research and development revenue was recognized related to our non-Phase 3 tivantinib collaboration as our costs incurred were offset by an equal amount of contra-revenue.

 

The duration and termination of the agreement are tied to future events. Unless earlier terminated due to breach, insolvency or upon 90 days notice if prior to Phase 3 clinical trials or 180 days notice if on or after the beginning of Phase 3 clinical trials by Daiichi Sankyo, the agreement shall continue until the later of (i) such time as Daiichi Sankyo is no longer developing at least one licensed product or (ii) if Daiichi Sankyo has commercialized a licensed product or products, such time as all royalty terms for all licensed products have ended. The royalty term, on a country-by-country basis for a product, ends as of the later of (i) the expiration of the last valid claim under a patent covering the manufacture, use, or sale of a licensed product or (ii) a certain number of years from the date of the commercial sale of the licensed product in such country.

 

Revenue for this agreement is recognized using the contingency-adjusted performance model. Through September 30, 2012, revenue was recognized based upon an estimated development period through December 2013. As a result of the October 2012 decision to discontinue the MARQUEE trial, the development period as of October 1, 2012 was extended to June 2015. Commencing with the fourth quarter of 2012 and through the third quarter of 2013 revenue was recognized over that development period. In the fourth quarter of 2013, following a recommendation by the Data Monitoring Committee that the METIV-HCC trial continue with patients receiving a lower dose of tivantinib than the dose originally employed in the trial, we reviewed the estimated development period and extended it to June 2016. For the three months and nine months ended September 30, 2015, $1.2 million and $4.2 million, respectively, were recognized as net revenue. For the three months and nine months ended September 30, 2014, $1.2 million and $4.0 million, respectively, were recognized as net revenue. At September 30, 2015, $4.1 million remains in deferred revenue.

 

Kyowa Hakko Kirin Licensing Agreement

 

On April 27, 2007, we entered into an exclusive license agreement with Kyowa Hakko Kirin to develop and commercialize tivantinib in Japan and parts of Asia. A $3 million portion of an upfront licensing fee was received by the Company under this agreement in the first quarter of 2007, and an additional $27 million in upfront licensing fees was received on May 7, 2007. The agreement includes $123 million in upfront and potential development milestone payments from Kyowa Hakko Kirin to ArQule, including the $30 million cash upfront licensing payments. In February 2008, we received a $3 million milestone payment from Kyowa Hakko Kirin. Upon commercialization, ArQule will receive tiered royalties in the mid-teen to low-twenty percent range from Kyowa Hakko Kirin on net sales of tivantinib. Kyowa Hakko Kirin will be responsible for all clinical development costs and commercialization of the compound in certain Asian countries, consisting of Japan, China (including Hong Kong), South Korea and Taiwan. In July 2010, we announced the initiation of a Phase 2 trial with tivantinib by Kyowa Hakko Kirin in gastric cancer, for which we received a $5 million milestone payment in September 2010.

 

In August 2011, Kyowa Hakko Kirin announced the initiation of the Phase 3 ATTENTION trial. Dosing of the first patient in this trial triggered a $10 million milestone payment, which we received in August 2011. The milestone payment was recorded as deferred revenue and is being recognized as revenue using the contingency-adjusted performance model with an estimated development period through April 2016.

 

In addition to the upfront and possible development milestone payments totaling $123 million, the Company will be eligible for future milestone payments based on the achievement of certain levels of net sales. The Company will recognize the payments, if any, as revenue in accordance with the contingency-adjusted performance model. As of September 30, 2015, the Company had not recognized any revenue from these sales milestone payments, and there can be no assurance that it will do so in the future.

 

The duration and termination of the agreement are tied to future events. Unless earlier terminated due to breach, insolvency or upon 90 days notice by Kyowa Hakko Kirin, the agreement terminates on the date that the last royalty term expires in all countries in the territory. The royalty term ends as of the later of (i) the expiration of the last pending patent application or expiration of the patent in the country covering the manufacture, use, or sale of a licensed product or (ii) a certain number of years from the date of the commercial launch in such country of such license product.

 

Revenue for this agreement is recognized using the contingency-adjusted performance model with an estimated development period through April 2016. For both the three and nine months ended September 30, 2015 and 2014, $1.4 million and $4.3 million, respectively were recognized as revenue. At September 30, 2015, $3.3 million remains in deferred revenue.

 

8
 

 

3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

 

We generally classify our marketable securities as available-for-sale at the time of purchase and re-evaluate such designation as of each balance sheet date. Since we generally intend to convert them into cash as necessary to meet our liquidity requirements our marketable securities are classified as cash equivalents if the original maturity, from the date of purchase, is ninety days or less and as short-term investments if the original maturity, from the date of purchase, is in excess of ninety days but less than one year. Our marketable securities are classified as long-term investments if the maturity date is in excess of one year of the balance sheet date.

 

We report available-for-sale investments at fair value as of each balance sheet date and include any unrealized gains and, to the extent deemed temporary, unrealized losses in stockholders’ equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense) in the statement of operations and comprehensive loss.

 

We conduct quarterly reviews to determine the fair value of our investment portfolio and to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. In the event that the cost basis of a security exceeds its fair value, we evaluate, among other factors, the duration of the period that, and extent to which, the fair value is less than cost basis, the financial health of and business outlook for the issuer, including industry and sector performance, and operational and financing cash flow factors, overall market conditions and trends, our intent to sell the investment and if it is more likely than not that we would be required to sell the investment before its anticipated recovery. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in accumulated other comprehensive income (loss).

 

For available-for-sale debt securities with unrealized losses, we perform an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in the statement of operations and comprehensive loss as an impairment loss.

 

Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

 

The following is a summary of the fair value of available-for-sale marketable securities we held at September 30, 2015 and December 31, 2014:

                           
September 30, 2015     Amortized
Cost		     Gross
Unrealized
Gains		     Gross
Unrealized
Losses		     Fair
Value		  
Security type                          
Corporate debt securities-short term   $ 30,628   $ 6   $ (5 ) $ 30,629  
Corporate debt securities-long term     —     —     —     —  
Total available-for-sale marketable securities   $ 30,628   $ 6   $ (5 ) $ 30,629  

 

                           
December 31, 2014     Amortized
Cost		     Gross
Unrealized
Gains		     Gross
Unrealized
Losses		     Fair
Value		  
Security type                          
Corporate debt securities-short term   $ 46,690   $ 16   $ (23 ) $ 46,683  
Corporate debt securities-long term     2,061     —     (3 )   2,058  
Total available-for-sale marketable securities   $ 48,751   $ 16   $ (26 ) $ 48,741  

 

The fair value of our available-for-sale marketable securities in a continuous unrealized loss position for more than 12 months was $1,126 at September 30, 2015. The unrealized loss on these marketable securities was under $1 at September 30, 2015. None of our available-for-sale marketable securities were in a continuous unrealized loss position for more than 12 months at December 31, 2014.

 

9
 

 

The following tables present information about our assets that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. We value our level 2 investments using quoted prices for identical assets in the markets where they are traded, although such trades may not occur daily. These quoted prices are based on observable inputs, primarily interest rates. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. There were no transfers in or out of Level 1 or Level 2 measurements for the periods presented:

                 
   September 30,
2015		   Quoted
Prices in
Active
Markets
(Level 1)		   Significant
Other
Observable
Inputs
(Level 2)		   Significant
Unobservable
Inputs
(Level 3)		 
Cash equivalents  $11,935   $11,935   $—   $— 
Corporate debt securities-short term   30,629    —    30,629    — 
Corporate debt securities-long term   —    —    —    — 
Total  $42,564   $11,935   $30,629   $— 
                     

 

   December 31,
2014		   Quoted
Prices in
Active
Markets
(Level 1)		   Significant
Other
Observable
Inputs
(Level 2)		   Significant
Unobservable
Inputs
(Level 3)		 
Cash equivalents  $10,740   $10,740   $—   $— 
Corporate debt securities-short term   46,683    —    46,683    — 
Corporate debt securities-long term   2,058    —    2,058    — 
Total  $59,481   $10,740   $48,741   $— 

 

4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses include the following at September 30, 2015 and December 31, 2014:

       
   2015  2014
Accounts payable  $346   $259 
Accrued payroll   1,537    2,130 
Accrued outsourced pre-clinical and clinical fees   3,173    3,753 
Accrued professional fees   355    157 
Other accrued expenses   280    648 
   $5,691   $6,947 

 

5. NET LOSS PER SHARE

 

Net loss per share is computed using the weighted average number of common shares outstanding. Basic and diluted net loss per share amounts are equivalent for the periods presented as the inclusion of potential common shares in the number of shares used for the diluted computation would be anti-dilutive to loss per share. Potential common shares, the shares that would be issued upon the exercise of outstanding stock options, were 8,342,725 and 7,999,284 for the three and nine months ended September 30, 2015 and 2014, respectively.

 

6. STOCK-BASED COMPENSATION AND STOCK PLANS

 

Our stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employees’ requisite service period (generally the vesting period of the equity grant). We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, expected option term, expected volatility of our stock over the option’s expected term, risk-free interest rate over the option’s expected term, and the expected annual dividend yield. We believe that the valuation technique and approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of our stock options granted in the nine months ended September 30, 2015 and 2014.

 

 10 

 

 

The following table presents stock-based compensation expense included in our Condensed Statements of Operations and Comprehensive Loss:

                 
   Three Months Ended
September 30,		   Nine Months Ended
September 30,		 
   2015   2014   2015   2014 
Research and development  $142   $186   $538   $854 
General and administrative   359    494    1,203    1,706 
Restructuring   —    83    —    83 
Total stock-based compensation expense  $501   $763   $1,741   $2,643 

 

In the three and nine months ended September 30, 2015 and 2014, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation expense.

 

Option activity under our stock plans for the nine months ended September 30, 2015 was as follows:

         
Stock Options  Number of
Shares		   Weighted Average
Exercise Price		 
Outstanding as of December 31, 2014   7,724,614   $4.89 
Granted   1,513,850    1.25 
Cancelled   (895,739)   4.79 
Outstanding as of September 30, 2015   8,342,725   $4.24 
           
Exercisable as of September 30, 2015   5,793,400   $5.12 

 

The aggregate intrinsic value of options outstanding at September 30, 2015 was $908, and $51 related to exercisable options. The weighted average grant date fair value of options granted in the nine months ended September 30, 2015 and 2014 was $0.77 and $1.65 per share, respectively. No options were exercised in the nine months ended September 30, 2015 or 2014.

 

Shares vested, expected to vest and exercisable at September 30, 2015 are as follows:

                 
   Shares   Weighted-Average
Exercise Price		   Weighted-Average
Remaining
Contractual
Term (in years)		   Aggregate
Intrinsic
Value		 
Vested and unvested expected to vest at September 30, 2015   8,156,021   $4.24    5.44   $843 
Exercisable at September 30, 2015   5,793,400   $5.12    4.04   $51 

 

The total compensation cost not yet recognized as of September 30, 2015 related to non-vested option awards was $3.1 million, which will be recognized over a weighted-average period of 2.5 years. During the nine months ended September 30, 2015, 689,759 shares expired and 205,980 shares were forfeited. The weighted average remaining contractual life for options exercisable at September 30, 2015 was 4.0 years.

 

In 2013, we granted 242,697 shares of restricted stock to employees, vesting annually over a four year period. The weighted average fair value of the restricted stock at the time of grant in 2013 was $2.51 per share, and is being expensed ratably over the vesting period. Through September 30, 2015, 82,564 shares have been forfeited, and 101,498 shares have vested. We recognized share-based compensation expense related to restricted stock of $59 and $77 for the nine months ended September 30, 2015 and 2014, respectively.

 

 11 

 

 

Restricted stock activity under the Plan for the nine months ended September 30, 2015 was as follows:

         
Restricted Stock  Number of Shares   Weighted Average
Grant Date
Fair Value		 
Unvested as of December 31, 2014   105,665   $2.51 
Vested   (36,101)   2.51 
Cancelled   (10,929)   2.51 
Unvested as of September 30, 2015   58,635   $2.51 

 

The fair value of restricted stock vested in the nine months ended September 30, 2015 and 2014 was $68 and $55 respectively.

 

In July 2010, the Company amended its chief executive officer’s (the “CEO’s”) employment agreement to grant the CEO 100,000 stock options, of which 25% vested upon grant and 25% vested annually over the next three years, and a maximum of 390,000 performance-based stock units that vest upon the achievement of certain performance and market based targets. In March 2013, the Company amended its CEO’s employment agreement to modify the performance and market based targets.

 

In February 2012, the Company amended its chief medical officer’s (the “CMO’s”) employment agreement to grant the CMO 50,000 performance-based stock units that vest upon the achievement of certain performance based targets.

 

In March 2013, the Company amended its chief operating officer’s (the “COO’s”) employment agreement to grant the COO 125,000 performance-based stock units that vest upon the achievement of certain performance based targets. In March 2013, the Company amended its CMO’s employment agreement to grant the CMO 120,000 performance-based stock units that vest upon the achievement of certain performance based targets.

 

Through September 30, 2015, no expense has been recorded for any performance-based stock units granted to the CEO, COO, or CMO.

 

7. RECENT ACCOUNTING PRONOUNCEMENTS

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

 

In August 2014, the FASB issued Accounting Standard Update (“ASU”) 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods beginning after December 15, 2016, and for annual and interim periods thereafter. We are currently evaluating the potential impact that this ASU may have on our disclosures.

 

In June 2014, the FASB issued ASU No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period.” This ASU requires a reporting entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition, and apply existing guidance under the Stock Compensation Topic of the ASC as it relates to awards with performance conditions that affect vesting to account for such awards. The provisions of this ASU are effective for interim and annual periods beginning after December 15, 2015. We are currently evaluating the potential impact that this ASU may have on our financial position and results of operations.

 

During the quarter ended June 30, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.

 

 12 

 

 

8. INCOME TAXES

 

As of December 31, 2014, we had federal NOL, state NOL, and research and development credit carryforwards of approximately $331,909, $152,434 and $27,761, respectively, which expire at various dates through 2034, which can be used to offset future income tax liabilities. Federal capital loss carry forwards of approximately $571 can be used to offset future federal capital gain income and expire in 2015. Approximately $15,014 of our federal NOL and $863 of our state NOL were generated from excess tax deductions from share-based awards, the tax benefit of which will be credited to additional paid-in-capital when the deductions reduce current taxes payable. We have determined that it is more likely than not that we will not recognize the benefits of our federal and state deferred tax assets and, as a result, we have a full valuation allowance against our net deferred tax assets.

 

At September 30, 2015 and December 31, 2014, we had no unrecognized tax benefits. We do not expect that the total amount of unrecognized tax benefits will significantly increase in the next twelve months. Our policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of September 30, 2015 and December 31, 2014, we had no accrued interest or penalties related to uncertain tax positions. Our U.S. federal tax returns for the tax years 2011 through 2014 and our state tax returns for the tax years 2010 through 2014 remain open to examination. Prior tax years remain open to the extent of net operating loss and tax credit carryforwards.

 

Utilization of NOL and research and development credit carryforwards may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income, and may, in turn, result in the expiration of a portion of those carryforwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three year period. We undertook a detailed study of our NOL and research and development credit carryforwards through January 31, 2015, to determine whether such amounts are likely to be limited by Sections 382 or 383. As a result of this analysis, we currently do not believe any Sections 382 or 383 limitations will significantly impact our ability to offset income with available NOL and research and development credit carryforwards. However, future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits.

 

9. RESTRUCTURING AND OTHER COSTS

 

On July 30, 2014, we approved plans to restructure our operations to better align our human and financial resources with our primary focus on clinical stage development programs and to extend our cash runway beyond the anticipated time for achievement of key milestones, such as the completion of the METIV-HCC trial. Commencing on August 4, 2014, we began to reduce our current workforce from 62 to approximately 40 employees by the end of 2014. Most of this reduction came from our Discovery Group, which had been engaged primarily in early-stage, pre-clinical research. The costs associated with this action were comprised of severance payments of $662 and benefits continuation costs of $74. In the year ended December 31, 2014, $319 of these costs was paid and the remaining amount of $417 was paid by March 31, 2015. In addition, in the three months ended September 30, 2014, we incurred non-cash charges of $83 related to the modification of employee stock options, and $280 for impairment of property and equipment impacted by the restructuring.

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion should be read in conjunction with our financial statements and related notes contained in this report.

 

We are a clinical-stage biotechnology company engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to produce novel drugs with differentiated mechanisms of action that will extend and improve the lives of our patients. These drugs target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our prioritized clinical stage pipeline consists of four product candidates, all of which are in targeted, biomarker-defined populations. Our drug discovery efforts focus on a number of pre-clinical programs based on our insights into kinase biology and are derived from our extensive library of proprietary compounds.

 

Our product candidates and programs are based on our understanding of biological processes that lead to the proliferation and metastasis of cancer cells, combined with our ability to generate product candidates possessing certain pre-selected, drug-like properties. We believe that these qualities, when present from the earliest stages of product development, increase the likelihood of producing safe, effective and marketable drugs. Our discovery and development efforts are also guided when possible by an understanding of the role of biomarkers, which are indicators of a particular biological condition or process and may predict the clinical benefit of our compounds in defined patient populations.

 

Our lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (“c-MET” or “MET”) and its biological pathway. C-MET is a promising target for cancer therapy, based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. We and our partners, Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) and Kyowa Hakko Kirin Co., Ltd. (“Kyowa Hakko Kirin”), are implementing a worldwide clinical development program with tivantinib. Our strategy is to focus on the most promising indications within our clinical programs based upon continually generated and updated clinical and pre-clinical data. Our lead indication is liver cancer (“hepatocellular carcinoma” or “HCC”), and we are currently conducting two Phase 3 trials with our partners. We have also completed earlier-stage single agent and combination therapy trials and pre-clinical experiments with tivantinib and other anti-cancer agents that may provide data to support trials in additional indications.

 

 13 

 

 

Our most advanced ongoing clinical trial, the METIV-HCC trial, is a pivotal Phase 3 randomized, double-blind, controlled study of tivantinib as single agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC conducted by Daiichi Sankyo and us. The primary endpoint is overall survival (“OS”) in the intent-to-treat (“ITT”) population, and the secondary endpoint is progression-free survival (“PFS”) in the same population. A dose reduction in the METIV-HCC trial from 240 mg twice daily (“BID”) tablets to 120 mg BID tablets was implemented in September 2013 following the observation of a higher incidence of neutropenia in the initial phase of the METIV-HCC trial than was observed in the Phase 2 trial in the same patient population, which employed a 240 mg BID capsule dose, and in other trials with tivantinib. Certain enhanced patient monitoring procedures were temporarily instituted to confirm the safety profile of the lower dose. Following a review of data analyses from a predefined number of patients who received this lower dose, the Data Monitoring Committee (“DMC”) of the METIV-HCC trial recommended in January 2014 continuation of the ongoing trial, with patients receiving the lower dose. Pharmacokinetic analyses among a predefined number of patients treated with the 120 mg BID tablet dose showed that the incidence of neutropenia was reduced with this lower dose and that the plasma exposure of the lower dose was comparable to the 240 mg BID capsule dose in the Phase 2 trial with similar medians and overlapping ranges.

 

Approximately 300 patients are being enrolled in the METIV-HCC trial at more than 100 clinical sites worldwide. Our current estimate of the time frame for completion of patient accrual is the end of 2015. We define patient accrual as the process of screening and identifying patients for subsequent randomization into the treatment arms of the trial. This trial is being conducted under a Special Protocol Assessment (“SPA”) agreement with the U.S. Food and Drug Administration (“FDA”). An SPA is an agreement establishing the design, endpoints and statistical analysis of a clinical trial intended to provide the necessary data, depending on the outcome of the trial, which could support the filing of a New Drug Application (“NDA”). Final marketing approval depends on the results of the trial. Because the METIV-HCC trial is enrolling patients with MET-diagnostic high HCC whom we believe are likely to benefit from treatment with tivantinib, the SPA also includes an immunohistochemistry (“IHC”)-based companion diagnostic (“CDx”) under development by a third party provider of such tests in collaboration with Daiichi Sankyo and ourselves. The CDx is being developed to enable the identification of the MET status of patients seeking to be enrolled in this trial. Our collaborator for the companion diagnostic test and our collaborator for a second test will each need to submit a Premarket Approval (“PMA”) application to FDA that establishes the predictive value of the respective CDx in connection with the registration and commercialization of tivantinib in the U.S., and additional regulatory applications will need to be made in other geographic areas.

 

In addition to METIV-HCC, a second Phase 3 clinical trial in HCC with tivantinib known as JET-HCC is ongoing in Japan. On February 4, 2014, Kyowa Hakko Kirin, our partner for the development of tivantinib in Asian territories, announced the initiation of this trial in Japanese patients with MET diagnostic-high, inoperable HCC treated with one prior therapy with sorafenib. The trial is a randomized, double-blind placebo-controlled study to compare PFS in patients treated with tivantinib with those treated with placebo. Kyowa Hakko Kirin plans to enroll approximately 160 patients in this study. Kyowa Hakko Kirin is also developing a CDx for the JET-HCC trial to enable the identification of the MET status of patients to be enrolled in this trial. There are no milestone payments associated with the initiation of this trial.

 

Two Phase 3 clinical trials have been conducted evaluating the combination of tivantinib and erlotinib in second-line patients with advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”). We and our partner, Daiichi Sankyo, conducted the first of these, named MARQUEE, in Western territories. MARQUEE was a randomized, double-blind, controlled pivotal Phase 3 trial conducted under an SPA. At the time of the interim analysis of MARQUEE, the independent DMC recommended that the study be discontinued early after concluding that it would not meet its primary endpoint of improved OS, although the interim analysis showed a statistically significant improvement in PFS in the ITT population. Final data from the trial demonstrated particular clinical benefits in a sub-group of patients with non-squamous NSCLC whose tumors expressed high levels of MET protein. No safety concerns were identified by the DMC at the interim analysis, and this did not change in the final data analysis. We are awaiting the results of the MARQUEE trial with respect to a sub-population of approximately 100 patients with EGFR mutant NSCLC. OS and PFS in these patients have been designated as secondary efficacy endpoints in the trial.

 

The second Phase 3 trial in NSCLC, named ATTENTION, was a randomized, double-blind, controlled pivotal trial conducted in non-squamous NSCLC patients with wild-type epidermal growth factor receptor (“EGFR”) in Asia by Kyowa Hakko Kirin, our partner for the development of tivantinib in Asian territories. Recruitment of new patients in ATTENTION was permanently suspended before the target patient recruitment goal was completed based on a recommendation by the trial’s Safety Review Committee following an observed imbalance in interstitial lung disease (“ILD”) cases as a drug-related adverse event. Patients already recruited were allowed to continue in the trial after being re-consented. The safety profile observed in ATTENTION was in line with what was previously observed in other NSCLC trials with tivantinib, with the exception of ILD, which is a known adverse event observed in Japanese patients treated with EGFR inhibitors such as erlotinib. In the ITT population, OS favored the treatment arm of tivantinib plus erlotinib compared to the erlotinib only control arm, but it was not statistically significant. PFS and overall response rate (“ORR”) results also showed a trend toward improvement favoring the treatment arm.

 

 14 

 

 

On January 11, 2013, we announced the top-line results of a randomized Phase 2 signal generation trial of tivantinib used in combination with irinotecan and cetuximab in patients with refractory or relapsed colorectal cancer (“CRC”). The trial did not meet its primary endpoint of PFS. The PFS and ORR results obtained in both the control arm and the treatment arm were longer than expected compared to previously published historical norms. Additional data and analyses from this trial were presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in June 2013, showing that the median PFS in the treatment arm was 8.3 months, compared with 7.3 months in the control arm. Median OS in the treatment arm was 19.8 months, compared with 16.9 months in the control arm. ORR in the treatment arm was 45 percent versus 33 percent in the control arm. Adverse events were reported at similar rates in the treatment and control arms of the trial, except for increased neutropenia observed in the treatment arm, with no discontinuations of treatment for this reason. Tivantinib was generally well tolerated in combination with the approved doses of irinotecan and cetuximab studied in this trial.

 

We have licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where we have licensed commercial rights to Kyowa Hakko Kirin. Our agreements with these partners provide for possible future milestone payments, royalties on product sales, and development funding, in addition to significant payments that we have already received. During 2011, we received $25 million from Daiichi Sankyo resulting from the dosing of the first patient in the MARQUEE trial and $10 million from Kyowa Hakko Kirin resulting from dosing of the first patient in the ATTENTION trial. On January 31, 2013, we announced that the first patient had been enrolled in the pivotal Phase 3 METIV trial, entitling us to a $15 million milestone from Daiichi Sankyo. That milestone was netted against our cumulative share of Phase 3 collaboration costs in 2013, and consequently we did not receive any cash proceeds from this milestone. The terms of our tivantinib licensing agreements with Daiichi Sankyo and Kyowa Hakko Kirin remain in effect following the recent developments in these trials.

 

We have collaborated with the National Cancer Institute (“NCI”) through its Cancer Therapy Evaluation Program (“CTEP”) to explore the clinical potential of tivantinib in a variety of tumor indications while we focus our internal efforts on the two Phase 3 programs in HCC. These CTEP-sponsored trials include Phase 2 single agent trials in prostate cancer (randomized), multiple myeloma, breast cancer and malignant mesothelioma, and Phase 2 combination therapy trials in kidney cancer (with or without erlotinib, randomized) and head and neck cancer (with or without cetuximab, randomized).

 

The NCI has reported to us that the randomized, double blind, placebo-controlled CTEP Phase 2 clinical trial of tivantinib as a single agent in prostate cancer met its primary endpoint of PFS. Data from this trial were presented at the 2015 Genitourinary Cancers Symposium (ASCO GU). We and our partner, Daiichi Sankyo, intend to discuss with the NIH the potential for additional trials in this indication. In addition, in the uncontrolled single agent, signal generation CTEP studies in breast cancer, multiple myeloma and mesothelioma, the primary endpoint of response rate was not met. The Phase 2 trials in kidney cancer and head and neck cancer also did not meet their end points. As a result, we do not plan to prioritize development in these indications at this time.

 

Our proprietary pipeline of product candidates is directed toward molecular targets and biological processes with demonstrated roles in the development of both human cancers and rare, non-oncology diseases. These product candidates include: ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (“FGFR”) family; and ARQ 761, a Beta lapachone analog being evaluated in investigator-sponsored testing as a promoter of NQ01-mediated programmed cancer cell necrosis. Specific tumor types and biomarkers have been identified to guide our clinical testing, based on analyses of Phase 1a anti-cancer activity in humans, preclinical findings and the scientific literature.

 

Under our agreement with the National Human Genome Research Institute of the NIH, a Phase 1 clinical trial investigating ARQ 092 as a potential treatment for Proteus syndrome, a rare overgrowth disorder caused by a mutation in the AKT 1 gene, is expected to dose the first patient in the fourth quarter of 2015. A Phase 1b clinical trial for ARQ 092 is on-going in lymphoma, endometrial and other cancers harboring the AKT 1 mutation. Thus far in this enriched cohort of the trial, we have observed four patients with confirmed responses, two of which had the same AKT 1 mutation which occurs in Proteus syndrome. Clinical development of ARQ 087 has advanced into Phase 2 for intrahepatic cholangiocarcinoma (“iCCA”) following the observation of two confirmed partial responses in this patient population in the Phase 1 portion of the program. Additional testing is on-going in solid tumors as part of a Phase 1b clinical trial. ARQ 761 is currently in a Phase 1b clinical trial for solid tumors.

 

We regained worldwide rights for the development and commercialization of ARQ 092 and all other compounds included under our AKT collaboration with Daiichi Sankyo pursuant to their formal notice to terminate our license and commercialization agreement received on March 26, 2013. Following the termination, we became responsible for funding the remainder of the Phase 1 trial with ARQ 092 beyond the contractual termination period, as well as any future clinical development and commercialization of this compound. The license agreement had provided exclusive rights to Daiichi Sankyo for the development, manufacturing and marketing of ARQ 092 on a worldwide basis. Under this agreement, we received a $10 million upfront fee from Daiichi Sankyo in November 2011. Following the termination of this agreement, ARQ 092 became our proprietary asset, and Daiichi Sankyo has no further financial or other obligations or rights related to this program.

 

 15 

 

 

On July 30, 2014, we approved plans to restructure our operations to better align our human and financial resources with our primary focus on clinical stage development programs and to extend our cash runway beyond the anticipated time frame for achievement of key milestones, such as the completion of the METIV-HCC trial. Commencing on August 4, 2014, we began to reduce our workforce from 62 to approximately 40 employees by the end of 2014. Most of this reduction came from our Discovery Group, which had been engaged primarily in early-stage, pre-clinical research. As a result of this near-term focus on our proprietary clinical pipeline, including ARQ 092 and ARQ 087, we will concentrate our discovery efforts on the development of a number of preclinical programs derived from our insights into kinase biology and library of proprietary compounds, as well as the enhancement and preservation of such library. We plan to achieve progress in these areas through greater reliance on academic and other collaborations and on outsourcing strategies.

 

We have incurred a cumulative deficit of approximately $479 million from inception through September 30, 2015. We recorded a net loss for 2012, 2013 and 2014 and expect a net loss for 2015.

 

Our revenue consists primarily of development funding from our alliances with Daiichi Sankyo and Kyowa Hakko Kirin. Revenue and expenses fluctuate from quarter to quarter based upon a number of factors, notably the timing and extent of our cancer-related research and development activities together with the length and outcome of our clinical trials.

 

In May 2015, we entered into a Collaborative Research and Development Agreement with Beryllium Discovery Corp. (“Beryllium”). Pursuant to the agreement, we will jointly focus on the identification and preclinical development of inhibitors of PD-1 and PDL-1. We and Beryllium will each be responsible for our respective internal and outsourcing costs during pre-clinical development. Following lead optimization of any potential drug candidates, we and Beryllium will jointly decide whether to advance compounds into GLP/toxicology and clinical testing, initially on a shared cost basis, provided that we will have the right to advance compounds on our own should Beryllium vote against such advancement. The agreement also provides that we will be responsible for clinical development and commercialization of product candidates that are not out-licensed. Beryllium will have the right to participate financially throughout the program but will also have the option to opt out at certain times and receive a royalty. The agreement will terminate after the last payment obligation is satisfied, or prior to that upon 60-days’ notice by either party.

 

On December 18, 2008, we entered into a license, co-development and co-commercialization agreement with Daiichi Sankyo to conduct research, clinical trials and commercialization of tivantinib in human cancer indications. The agreement provides for a $60 million cash upfront licensing payment from Daiichi Sankyo to us, which we received in December 2008, and an additional $560 million in potential development and sales milestone payments offset by our share of the Phase 3 costs. Upon commercialization, we will receive tiered, double-digit royalties from Daiichi Sankyo on net sales of tivantinib commensurate with the magnitude of the transaction. We retain the option to participate in the commercialization of tivantinib in the U.S. We and Daiichi Sankyo will share equally the costs of Phase 2 and Phase 3 clinical studies, with our share of Phase 3 costs payable solely from milestone and royalty payments by Daiichi Sankyo.

 

The dosing of the first patient in the Phase 3 MARQUEE clinical trial of tivantinib in NSCLC, announced in January 2011, triggered the payment of a $25 million development milestone from Daiichi Sankyo that was received in February 2011. Revenue for this agreement is recognized using the contingency-adjusted performance model. Through September 30, 2012, revenue was recognized based upon an estimated development period through December 2013. As a result of the October 2012 decision to discontinue the MARQUEE trial, the development period as of October 1, 2012 was extended to June 2015. Commencing with the fourth quarter of 2012 and through the third quarter of 2013 revenue was recognized over that development period. In the fourth quarter of 2013, following a recommendation by the Data Monitoring Committee that the METIV-HCC trial continue with patients receiving a lower dose of tivantinib than the dose originally employed in the trial, we reviewed the estimated development period and extended it to June 2016.

 

Under the terms of our tivantinib collaboration agreement with Daiichi Sankyo we share development costs equally with our share of Phase 3 costs funded solely from milestones and royalties. In each quarter the tivantinib collaboration costs we incur are compared with those of Daiichi Sankyo. If our costs for the quarter exceed Daiichi Sankyo’s, we recognize revenue on the amounts due to us under the contingency adjusted performance model. Revenue is calculated on a pro-rata basis using the time elapsed from inception of the agreement over the estimated duration of the development period under the agreement. If our costs for the quarter are less than those of Daiichi Sankyo, we report the amount due to Daiichi Sankyo as contra-revenue in that quarter. To the extent that our share of Phase 3 collaboration costs exceeds the amount of milestones and royalties received, that excess is netted against future milestones and royalties if and when earned and is not reported as contra-revenue.

 

Our cumulative share of the Daiichi Sankyo Phase 3 costs through September 30, 2015 totaled $99.0 million. We received a milestone of $25 million in February 2011 upon enrolling the first patient in the MARQUEE trial, the cash proceeds of which were subsequently applied to our share of Phase 3 collaboration costs. On January 31, 2013, we announced that the first patient had been enrolled in the pivotal Phase 3 METIV trial of tivantinib, entitling us to a $15 million milestone. That $15 million milestone was also netted against our cumulative share of Phase 3 collaboration costs in 2013, and consequently we did not receive any cash proceeds from this milestone. Our cumulative share of Phase 3 collaboration costs has exceeded the amount of milestones received through September 30, 2015 by $59.0 million which will be netted against future milestones and royalties, if any, when earned and has not been reported as contra-revenue.

 

 16 

 

 

For the quarter ended September 30, 2015 our non-Phase 3 tivantinib collaboration costs incurred were less than those of Daiichi Sankyo and $130 thousand was recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue. For the nine months ended September 30, 2015, our non-Phase 3 tivantinib collaboration costs incurred exceeded those of Daiichi Sankyo and $119 thousand was recognized as tivantinib Daiichi Sankyo net research and development revenue.

 

For the quarter ended September 30, 2014 our non-Phase 3 tivantinib collaboration costs incurred were less than those of Daiichi Sankyo and $102 thousand was recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue. For the nine months ended September 30, 2014, no research and development revenue was recognized related to our non-Phase 3 tivantinib collaboration as our costs incurred were offset by an equal amount of contra-revenue.

 

In November 2012, we completed our ARQ 092 research collaboration with Daiichi Sankyo entered into on November 7, 2008 for the discovery of therapeutic compounds that selectively inhibit certain kinases in the field of oncology. The agreement provided for a $15 million upfront payment, which we received in November 2008, research support payments for the first two years of the collaboration (which was extended for an additional two years in 2010), licensing fees for compounds discovered as a result of this research, milestone payments related to clinical development, regulatory review and sales, and royalty payments on net sales of compounds from the collaboration. Daiichi Sankyo’s obligation to provide further research funding to ArQule under this agreement terminated in November 2012.

 

On April 27, 2007, we entered into an exclusive license agreement with Kyowa Hakko Kirin to develop and commercialize tivantinib in Japan and parts of Asia. A $3 million portion of an upfront licensing fee was received by the Company under this agreement in the first quarter of 2007, and an additional $27 million in upfront licensing fees was received on May 7, 2007. The agreement includes $123 million in upfront and potential development milestone payments from Kyowa Hakko Kirin to ArQule, including the $30 million cash upfront licensing payments. In February 2008, we received a $3 million milestone payment from Kyowa Hakko Kirin, and in September 2010, we received a $5 million milestone payment. Upon commercialization, ArQule will receive tiered royalties in the mid-teen to low-twenty percent range from Kyowa Hakko Kirin on net sales of tivantinib. Kyowa Hakko Kirin will be responsible for all clinical development costs and commercialization of the compound in certain Asian countries, consisting of Japan, China (including Hong Kong), South Korea and Taiwan. In addition to the upfront and possible development milestone payments totaling $123 million, the Company will be eligible for future milestone payments based on the achievement of certain levels of net sales.

 

The Company will recognize the payments, if any, as revenue in accordance with its revenue recognition policies. As of September 30, 2015, the Company has not recognized any revenue from these potential sales milestone payments, and there can be no assurance that it will do so in the future. Revenue for this agreement is recognized using the contingency-adjusted performance model with an estimated development period through April 2016.

 

LIQUIDITY AND CAPITAL RESOURCES

                 
   September 30,   December 31,   Increase (decrease) 
   2015   2014   $   % 
   (in millions) 
Cash, cash equivalents and marketable securities-short term  $43.8   $59.2   $(15.4)   (26)%
Marketable securities-long term   —    2.1    (2.1)   (100)%
Working capital   31.0    42.8    (11.8)   (28)%
                     
   Nine Months Ended             
   September 30,
2015		   September 30,
2014		   Increase
(decrease)		         
   (in millions)         
Cash flow from:                       
Operating activities  $(17.2)  $(25.0)  $7.8         
Investing activities   17.7    25.4    (7.7)        
Financing activities   0.1    0.1    —         
                        

Cash flow from operating activities. Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have consisted primarily of payments received from our collaborators for services performed or upfront payments for future services. For the nine months ended September 30, 2015 and 2014, our net use of cash was primarily driven by our net loss and the difference between cash receipts from our collaborators and payments for operating expenses which resulted in net cash outflows of $17.2 million and $25.0 million, respectively.

 

17
 

 

Cash flow from investing activities. Our net cash provided by investing activities of $17.7 million for the nine months ended September 30, 2015, was comprised of net sales of marketable securities of $17.7 million, proceeds from sale of equipment of $0.3 million offset by additions to property and equipment of $0.3 million. Our net cash provided by investing activities of $25.4 million for the nine months ended September 30, 2014, was comprised of net sales of marketable securities. The composition and mix of cash, cash equivalents and marketable securities may change frequently as a result of the Company’s constant evaluation of conditions in financial markets, the maturity of specific investments, and our near term liquidity needs.

 

Cash flow from financing activities. Our net cash provided by financing activities for both the nine months ended September 30, 2015 and 2014 of $ 0.1 million were from employee stock plan purchases.

 

Our cash equivalents and marketable securities typically include U.S. Treasury bill funds, money market funds and commercial paper. Our cash equivalents and our portfolio of marketable securities are subject to market risk due to changes in interest rates. Fixed rate interest securities may have their market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates.

 

Our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, our ability to enter into additional corporate collaborations and the terms of such collaborations, results of research and development, unanticipated required capital expenditures, competitive and technological advances, acquisitions and other factors. We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product. It is likely we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, and due to global capital and credit market conditions or for other reasons, we may be unable to raise capital when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates.

 

On July 30, 2014, we approved plans to restructure our operations to better align our human and financial resources with our primary focus on clinical stage development programs and to extend our cash runway beyond the anticipated time for achievement of key milestones, such as the completion of the METIV-HCC trial. Commencing on August 4, 2014, we began to reduce our current workforce from 62 to approximately 40 employees by the end of the year. Most of this reduction came from our Discovery Group, which has been engaged primarily in early-stage, pre-clinical research. The costs associated with this action were comprised of severance payments of $662 thousand and benefits continuation costs of $74 thousand. In addition, in the year ended December 31, 2014, we incurred non-cash charges of $83 thousand related to the modification of employee stock options, and $280 thousand for impairment of property and equipment impacted by the restructuring. In the year ended December 31, 2014, $319 of these costs was paid and the remaining amount of $417 was paid by March 31, 2015. The restructuring actions for which charges were incurred in the year ended December 31, 2014 are expected to result in annual cost savings of approximately $2.5 to $3.0 million commencing in 2015.

 

We anticipate that our cash, cash equivalents and marketable securities on hand at September 30, 2015, financial support from our collaboration agreements, and savings from our workforce reduction described above, will be sufficient to finance our working capital and capital requirements into 2017.

 

Our contractual obligations were comprised of the following as of September 30, 2015 (in thousands):

                                 
    Payment due by period  
Contractual Obligations   Total   Less than
1 year		   1 - 3 years   3 - 5 years   More than
5 years		  
Operating lease obligations   $ 2,426   $ 524   $ 1,479   $ 423   $ —  
Purchase obligations     3,173     3,173     —     —     —  
Total   $ 5,599   $ 3,697   $ 1,479   $ 423   $ —  

 

Operating lease obligations are for our facilities under non-cancelable operating leases. In January 2015, we entered into a lease agreement for a new headquarters facility. The lease commenced on May 1, 2015 for a term of five years and three months with an average annual rental rate of $455 thousand. The obligations for this new facility are included in the table above.

 

Purchase obligations are comprised primarily of outsourced preclinical and clinical trial expenses and payments to license certain intellectual property to support the Company’s research efforts. Under our tivantinib collaboration with Daiichi Sankyo, our share of Phase 3 costs are payable solely from future milestones and royalties. As of September 30, 2015 our portion of these costs was $59.0 million and is excluded from the table above. These costs are netted against any future milestones and royalties due to us. Daiichi Sankyo has the right to offset future milestone and royalty payments by this amount.

 

18
 

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

A “critical accounting policy” is one which is both important to the portrayal of the Company’s financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For additional information, please see the discussion of our significant accounting policies in Note 2 to the Financial Statements included in our Annual Report for the fiscal year ended December 31, 2014 on Form 10-K filed with the SEC on March 4, 2015.

 

RESULTS OF OPERATIONS

 

The following are the results of operations for the three and nine months ended September 30, 2015 and 2014:

 

Revenue

                 
           Increase (decrease) 
   2015   2014   $   % 
   (in millions)         
For the three months ended September 30:                
Research and development revenue  $2.7   $2.7   $—    — 
                     
For the nine months ended September 30:                    
Research and development revenue  $8.4   $8.2   $0.2    2%

 

Research and development revenue in the three and nine months ended September 30, 2015 and 2014 is comprised of revenue from the Daiichi Sankyo tivantinib development agreement and the Kyowa Hakko Kirin exclusive license agreement. The revenue increase in the nine month period is due to higher revenue from our Daichii Sankyo tivantinib program.

 

Under the terms of our tivantinib collaboration agreement with Daiichi Sankyo we share development costs equally with our share of Phase 3 costs funded solely from milestones and royalties. In each quarter the tivantinib collaboration costs that we incur are compared with those of Daiichi Sankyo. If our costs for the quarter exceed Daiichi Sankyo, we recognize revenue on the amounts due to us under the contingency adjusted performance model. Revenue is calculated on a pro-rata basis using the time elapsed from inception of the agreement over the estimated duration of the development period under the agreement. If our costs for the quarter are less than those of Daiichi Sankyo, we report the amount due to Daiichi Sankyo as contra-revenue in that quarter. To the extent that our share of Phase 3 collaboration costs exceeds the amount of milestones and royalties received, that excess is netted against future milestones and royalties if and when earned and is not reported as contra-revenue.

 

Revenue for this agreement is recognized using the contingency-adjusted performance model. Through September 30, 2012, revenue was recognized based upon an estimated development period through December 2013. As a result of the October 2012 decision to discontinue the MARQUEE trial, the development period as of October 1, 2012 was extended to June 2015. Commencing with the fourth quarter of 2012 and through the third quarter of 2013 revenue was recognized over that development period. In the fourth quarter of 2013, following a recommendation by the Data Monitoring Committee that the METIV-HCC trial continue with patients receiving a lower dose of tivantinib than the dose originally employed in the trial, we reviewed the estimated development period and extended it to June 2016.

 

Our cumulative share of the Daiichi Sankyo Phase 3 costs through September 30, 2015 totaled $99 million. We received a milestone of $25 million in February 2011 upon enrolling the first patient in the MARQUEE trial, the cash proceeds of which were subsequently applied to our share of Phase 3 collaboration costs. On January 31, 2013, we announced that the first patient had been enrolled in the pivotal Phase 3 METIV trial of tivantinib, entitling us to a $15 million milestone. That $15 million milestone was also netted against our cumulative share of Phase 3 collaboration costs in 2013, and consequently we did not receive any cash proceeds from this milestone. Our cumulative share of Phase 3 collaboration costs has exceeded the amount of milestones received through September 30, 2015 by $59 million which will be netted against future milestones and royalties, if any, when earned and has not been reported as contra-revenue.

 

For the quarter ended September 30, 2015 our non-Phase 3 tivantinib collaboration costs incurred were less than those of Daiichi Sankyo and $130 thousand was recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue. For the nine months ended September 30, 2015, our non-Phase 3 tivantinib collaboration costs incurred exceeded those of Daiichi Sankyo and $119 thousand was recognized as tivantinib Daiichi Sankyo net research and development revenue.

 

19
 

 

For the quarter ended September 30, 2014 our non-Phase 3 tivantinib collaboration costs incurred were less than those of Daiichi Sankyo and $102 thousand was recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue. For the nine months ended September 30, 2014, no research and development revenue was recognized related to our non-Phase 3 tivantinib collaboration as our costs incurred were offset by an equal amount of contra-revenue.

 

Research and development

                 
           Increase (decrease) 
   2015   2014   $   % 
   (in millions)         
For the three months ended September 30:                
Research and development  $3.2   $5.0   $(1.8)   (37)%
                     
For the nine months ended September 30:                    
Research and development  $11.9   $18.0   $(6.1)   (34)%

 

Research and development expense in the quarter ended September 30, 2015 decreased by $1.8 million primarily due to lower labor related costs of $0.5 million from reduced headcount, outsourced clinical and product development costs of $0.6 million, facility costs of $0.6 million and lab expenses of $0.1 million.

 

Research and development expense in the nine months ended September 30, 2015 decreased by $6.1 million primarily due to lower labor related costs of $2.2 million from reduced headcount, outsourced clinical and product development costs of $1.7 million, facility costs of $1.4 million and lab expenses of $0.7 million. At September 30, 2015 we had 21 employees dedicated to our research and development program compared to 27 at September 30, 2014.

 

Overview

 

Our research and development expense consists primarily of salaries and related expenses for personnel, costs of contract manufacturing services, costs of facilities and equipment, fees paid to professional service providers in conjunction with our clinical trials, fees paid to research organizations in conjunction with pre-clinical animal studies, costs of materials used in research and development, consulting, license, and sponsored research fees paid to third parties and depreciation of associated laboratory equipment. We expect that our research and development expense will remain significant as we continue to develop our portfolio of oncology programs.

 

We have not accumulated and tracked our internal historical research and development costs or our personnel and personnel-related costs on a program-by-program basis. Our employee and infrastructure resources are allocated across several projects, and many of our costs are directed to broadly applicable research endeavors. As a result, we cannot state the costs incurred for each of our oncology programs on a program-by-program basis.

 

The expenses incurred by us to third parties for pre-clinical and clinical trials in the current quarter and since inception of our lead clinical stage program were as follows (in millions):

              
Oncology program  Current status  Nine Months Ended
September 30, 2015		   Program-to-date 
c-Met program—tivantinib  Phase 3  $0.7   $84.5 
              

 

Under the terms of our tivantinib collaboration agreement with Daiichi Sankyo we share development costs equally with our share of Phase 3 costs funded solely from milestones and royalties. Our cumulative share of Phase 3 collaboration costs has exceeded the amount of milestones received through September 30, 2015 by $59.0 million and is not reflected in the above table.

 

Our future research and development expenses in support of our current and future oncology programs will be subject to numerous uncertainties in timing and cost to completion. We test potential products in numerous pre-clinical studies for safety, toxicology, and efficacy. We may conduct multiple clinical trials for each product. As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain products in order to focus our resources on more promising products. Completion of clinical trials may take several years or more, and the length of time generally varies substantially according to the type, complexity, novelty, and intended use of a product. It is not unusual for the pre-clinical and clinical development of each of these types of products to take nine years or more, and for total development costs to exceed $500 million for each product.

 

20
 

 

We estimate that clinical trials of the type generally needed to secure new drug approval are typically completed over the following timelines:

     
Clinical Phase   Estimated Completion
Period
Phase 1   1 – 2 years
Phase 2   2 – 3 years
Phase 3   2 – 4 years

 

The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others, the following:

 

·the number of clinical sites included in the trials;

 

·the length of time required to enroll suitable patients;

 

·the number of patients that ultimately participate in the trials;

 

·the duration of patient follow-up to ensure the absence of long-term product-related adverse events; and

 

●the efficacy and safety profile of the product.

 

An element of our business strategy is to pursue the research and development of a broad pipeline of products. This is intended to allow us to diversify the risks associated with our research and development expenditures. As a result, we believe our future capital requirements and future financial success do not substantially depend on any one product. To the extent we are unable to build and maintain a broad pipeline of products, our dependence on the success of one or a few products increases.

 

Our strategy includes entering into alliance arrangements with third parties to participate in the development and commercialization of our products, such as our collaboration agreements with Daiichi Sankyo and Kyowa Hakko Kirin. In the event that third parties have control over the clinical trial process for a product, the estimated completion date would be under control of that third party rather than under our control. We cannot forecast with any degree of certainty whether our products will be subject to future collaborative arrangements or how such arrangements would affect our development plans or capital requirements.

 

As a result of the uncertainties discussed above, we make significant estimates in determining the duration and completion costs of our oncology programs or when and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our oncology programs in a timely manner or our failure to enter into appropriate collaborative agreements could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time-to-time in order to continue with our product development strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.

 

General and administrative

                 
           Increase (decrease) 
   2015   2014   $   % 
   (in millions)         
For the three months ended September 30:                    
General and administrative  $1.8   $3.0   $(1.2)   (39)%
                     
For the nine months ended September 30:                    
General and administrative  $7.8   $9.3   $(1.5)   (16)%

 

General and administrative expense decreased by $1.2 million in the three months ended September 30, 2015, principally due to lower facility costs of $0.9 million, labor related costs from reduced headcount of $0.2 million, and professional fees of $0.1 million.

 

General and administrative expense decreased by $1.5 million in the nine months ended September 30, 2015, principally due to lower facility costs of $0.7 million, labor related costs from reduced headcount of $0.6 million, and professional fees of $0.2 million. General and administrative headcount was 15 at September 30, 2015, compared to 19 at September 30, 2014.

 

21
 

 

Restructuring and other costs

 

On July 30, 2014, we approved plans to restructure our operations to better align our human and financial resources with our primary focus on clinical stage development programs and to extend our cash runway beyond the anticipated time for achievement of key milestones, such as the completion of the METIV-HCC trial. Commencing on August 4, 2014, we began to reduce our current workforce from 62 to approximately 40 employees by the end of 2014. Most of this reduction came from our Discovery Group, which had been engaged primarily in early-stage, pre-clinical research. The costs associated with this action were comprised of severance payments of $662 thousand and benefits continuation costs of $74 thousand. In the year ended December 31, 2014, $319 thousand of these costs was paid and the remaining amount of $417 thousand was paid by March 31, 2015. In addition, in the three months ended September 30, 2014, we incurred non-cash charges of $83 thousand related to the modification of employee stock options, and $280 thousand for impairment of property and equipment impacted by the restructuring.

 

The restructuring actions for which charges were incurred in the quarter ended September 30, 2014 are expected to result in annual cost savings of approximately $2.5 to $3.0 million commencing in 2015.

 

There were no restructuring expenses incurred in the three or nine month periods ended September 30, 2015.

 

Interest income, interest expense and other income (expense)

                 
           Increase (decrease) 
   2015   2014   $   % 
   (in thousands)         
For the three months ended September 30:                
Interest income  $17   $62   $(45)   (73)%
Interest expense   —    (11)   (11)   (100)%
Other income (expense)   (5)   (2)   3    150%
                     
For the nine months ended September 30:                    
Interest income  $81   $233   $(152)   (65)%
Interest expense   —    (28)   (28)   (100)%
Other income (expense)   277    75    202    269%

 

Interest income is derived from our portfolio of cash, cash equivalents and investments and decreased in the three and nine month periods ended September 30, 2015 primarily due to a decrease in our portfolio balance. We had no interest expense in the three and nine month periods ended September 30, 2015 because our notes payable were repaid in full in 2014. Other income (expense) in the three and nine month periods ended September 30, 2015 includes a loss of $5 thousand and a gain of $277 thousand, respectively, from the sale of property and equipment. Other income (expense) in the three and nine-month periods ended September 30, 2014 includes a loss of $2 thousand and a gain of $75 thousand, respectively from the change in fair value of our auction rate securities.

 

RECENT ACCOUNTING PRONOUNCEMENTS

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

 

In August 2014, the FASB issued Accounting Standard Update (“ASU”) 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods beginning after December 15, 2016, and for annual and interim periods thereafter. We are currently evaluating the potential impact that this ASU may have on our disclosures.

 

In June 2014, the FASB issued ASU No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period.” This ASU requires a reporting entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition, and apply existing guidance under the Stock Compensation Topic of the ASC as it relates to awards with performance conditions that affect vesting to account for such awards. The provisions of this ASU are effective for interim and annual periods beginning after December 15, 2015. We are currently evaluating the potential impact that this ASU may have on our financial position and results of operations.

 

22
 

 

During the quarter ended June 30, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.

 

FORWARD LOOKING STATEMENTS

 

In addition to historical information, this report contains forward-looking statements. You can identify these forward-looking statements by their use of words such as “anticipate,” “assume,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “target,” “will” and other words and terms of similar meaning. You also can identify them by the fact that they do not relate strictly to historical or current facts. All statements which address operating performance, events or developments that the Company expects or anticipates will occur in the future, such as projections about its future results of operations, its financial condition, research, development and commercialization of its products and anticipated trends in its business are forward-looking statements.

 

In this report we make forward-looking statements regarding our drug development pipeline and our clinical trials involving tivantinib. Additional forward-looking statements relate to our agreements with Kyowa Hakko Kirin and Daiichi Sankyo, including potential future milestones and royalty payments that could result from the future development of tivantinib.

 

Drug development involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. For example, pre-clinical efforts associated with our product pipeline may fail or prove disappointing because our technology platform did not produce candidates with the desired characteristics. Animal xenograft pre-clinical studies may be unpredictive of human response. Positive information about early stage clinical trial results will not ensure that later stage or larger scale clinical trials will be successful.

 

Furthermore, our drugs may not demonstrate promising therapeutic effects; in addition, they may not demonstrate appropriate safety profiles in ongoing or later stage or larger scale clinical trials as a result of known or as yet unidentified side effects. The results achieved in later stage trials may not be sufficient to meet applicable regulatory standards. Problems or delays may arise during clinical trials or in the course of developing, testing or manufacturing our drugs that could lead us or our partner to discontinue development.

 

Even if later stage clinical trials are successful, the risk exists that unexpected concerns may arise from analysis of data or from additional data or that obstacles may arise or issues be identified in connection with review of clinical data with regulatory authorities or that regulatory authorities may disagree with the Company’s view of the data or require additional data or information or additional studies. Also, the planned timing of initiation of clinical trials and the duration and conclusion of such trials for our drugs are subject to the ability of the company to enroll patients, enter into agreements with clinical trial sites and investigators, and other technical hurdles and issues that may not be resolved.

 

We also make forward-looking statements regarding the adequacy of our financial resources. Our capital resources may not be adequate because our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, the outcomes of our clinical trials, our ability to enter into additional corporate collaborations in the future and the terms of such collaborations, results of research and development, the need for currently unanticipated capital expenditures, competitive and technological advances, acquisitions, financial market conditions and other factors. Additionally, our corporate collaborators may terminate their agreements with us, thereby eliminating that source of funding, because we may fail to satisfy the prescribed terms of the collaborations or for other reasons.

 

We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product generating revenues. If we experience increased losses, we may have to seek additional financing from public and private sales of our securities, including equity securities. There can be no assurance that additional funding will be available when needed or on acceptable terms.

 

The factors, risks and uncertainties referred to above and others are more fully described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the SEC on March 4, 2015, as updated from time to time in our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The forward-looking statements contained herein represent the judgment of the Company as of the date of this report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

We own financial instruments that are sensitive to market risk as part of our investment portfolio. We have implemented policies regarding the amount and credit ratings of investments. Our investment portfolio is used to preserve our capital until it is used to fund operations, including our research and development activities. Our investments are evaluated quarterly to determine the fair value of the portfolio.

 

23
 

 

Our cash equivalents and marketable securities typically include commercial paper, money market funds, and U.S. Treasury bill funds that have investment grade ratings.

 

Our cash equivalents and our portfolio of marketable securities are subject to market risk due to changes in interest rates. Fixed rate interest securities may have their market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates. Based on the type of securities we hold, we do not believe a change in interest rates would have a material impact on our financial statements. If interest rates were to increase or decrease by 1%, this would not result in a material change in the fair value of our investment portfolio.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Our management, with the participation of our Chief Executive Officer (Principal Executive Officer) and President and Chief Operating Officer (Principal Financial Officer), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2015. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2015, our Chief Executive Officer (Principal Executive Officer) and President and Chief Operating Officer (Principal Financial Officer) concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

 

There have been no changes in the Company’s internal control over financial reporting during the most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

PART II - OTHER INFORMATION

 

ITEM 1. — LEGAL PROCEEDINGS. None.

 

ITEM 1A. — RISK FACTORS. For information regarding factors that could affect the Company’s results of operations, financial condition and liquidity, see the risk factors discussion provided under “Risk Factors” in Item 1A of ArQule’s Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on March 4, 2015, as updated from time to time in our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See also, “Forward-Looking Statements” included in this Quarterly Report on Form 10-Q.

 

ITEM 2. — UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. None.

 

ITEM 3. — DEFAULTS UPON SENIOR SECURITIES. None.

 

ITEM 4. — MINE SAFETY DISCLOSURES. Not applicable.

 

ITEM 5. — OTHERS INFORMATION. None.

 

ITEM 6. — EXHIBITS.

     
EXHIBIT NO.   DESCRIPTION
31.1   Rule 13a-14(a) Certificate of Chief Executive Officer, filed herewith.
31.2   Rule 13a-14(a) Certificate of Principal Financial Officer, filed herewith.
32   Rule 13a-14(b) Certificate of Chief Executive Officer and Principal Financial Officer, filed herewith.
101   Interactive Data File
     

 

24
 

 

ARQULE, INC.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

   
  ArQule, Inc.
   
Date: November 4, 2015 /s/ PETER S. LAWRENCE
  Peter S. Lawrence
  President and Chief Operating Officer
  (Principal Financial Officer)
   
  /s/ ROBERT J. WEISKOPF
  Robert J. Weiskopf
  Chief Financial Officer and Treasurer
  (Principal Accounting Officer)

 

25

 

 EX-31.1 2 t83410_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER

 

I, Paolo Pucci, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of ArQule, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 4, 2015

   
  /s/ PAOLO PUCCI
  Paolo Pucci
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 

 EX-31.2 3 t83410_ex31-2.htm EXHIBIT 31.2

 

Exhibit 31.2

 

CERTIFICATE OF THE PRINCIPAL FINANCIAL OFFICER

 

I, Peter S. Lawrence, certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of ArQule, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

 

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 4, 2015

   
  /s/ PETER S. LAWRENCE
  Peter S. Lawrence
  President and Chief Operating Officer
  (Principal Financial Officer)

 

 

 

 EX-32 4 t83410_ex32.htm EXHIBIT 32

 

Exhibit 32

 

ARQULE, INC.

 

CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER AND

 

PRINCIPAL FINANCIAL OFFICER

 

The undersigned, Paolo Pucci Chief Executive Officer (Principal Executive Officer) of ArQule, Inc. (the “Company”) and Peter S. Lawrence President and Chief Operating Officer (Principal Financial Officer), of the Company, both duly elected and currently serving, hereby certify that, to the best of his or her knowledge:

 

1.the quarterly report on Form 10-Q for the period ending September 30, 2015, filed on behalf of the Company pursuant to the Securities Exchange Act of 1934 (the “Exchange Act”) and containing the financial statements of the Company, fully complies with the requirements of section 13(a) of the Exchange Act; and

 

2.the information contained in such quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by such quarterly report.

 

This certification accompanies the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2015, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (the “2002 Act”) and shall not be deemed filed by the Company for purposes of Section 18 of the Exchange Act.

 

This certification is being made for the exclusive purpose of compliance by the Principal Executive Officer and Principal Financial Officer of the Company with the requirements of Section 906 of the 2002 Act, and may not be disclosed, distributed or used by any person for any reason other than as specifically required by law.

 

IN WITNESS WHEREOF, the undersigned have executed this Certificate as of the 4th day of November 2015.

     
/s/ PAOLO PUCCI  
Name: Paolo Pucci  
Title: Chief Executive Officer  
  (Principal Executive Officer)  
     
/s/ PETER S. LAWRENCE  
Name: Peter S. Lawrence  
Title: President and Chief Operating Officer  
  (Principal Financial Officer)  

 

 

 

 EX-101.INS 5 arql-20150930.xml XBRL INSTANCE DOCUMENT 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2007-01-01 2007-03-31 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2007-04-01 2007-04-27 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2007-05-01 2007-05-07 0001019695 arql:KyowaHakkoKirinMember arql:KyowaHakkoKirinLicensingAgreementMember 2008-02-01 2008-02-29 0001019695 arql:DaiichiSankyoTivantinibAgreementMember 2008-12-01 2008-12-31 0001019695 arql:ChiefExecutiveOfficerEmploymentAgreementMember us-gaap:ChiefExecutiveOfficerMember us-gaap:PerformanceSharesMember 2010-07-01 2010-07-31 0001019695 arql:ChiefExecutiveOfficerEmploymentAgreementMember us-gaap:ChiefExecutiveOfficerMember arql:VestedUponGrantMember us-gaap:EmployeeStockOptionMember 2010-07-01 2010-07-31 0001019695 arql:ChiefExecutiveOfficerEmploymentAgreementMember us-gaap:ChiefExecutiveOfficerMember arql:VestedAnnuallyMember us-gaap:EmployeeStockOptionMember 2010-07-01 2010-07-31 0001019695 us-gaap:ChiefExecutiveOfficerMember arql:ChiefExecutiveOfficerEmploymentAgreementMember us-gaap:EmployeeStockOptionMember 2010-07-01 2010-07-31 0001019695 arql:PhaseTwoTrialKyowaHakkoKirinMember arql:KyowaHakkoKirinLicensingAgreementMember 2010-09-01 2010-09-30 0001019695 arql:DaiichiSankyoTivantinibAgreementMember 2011-02-01 2011-02-28 0001019695 arql:PhaseThreeAttentionTrialAsiaMember arql:KyowaHakkoKirinLicensingAgreementMember 2011-08-01 2011-08-31 0001019695 arql:DaiichiSankyoCompanyLtdMember us-gaap:LicenseAgreementTermsMember 2011-11-01 2011-11-30 0001019695 arql:DaiichiSankyoCompanyLtdMember us-gaap:LicenseAgreementTermsMember 2011-01-01 2011-12-31 0001019695 arql:KyowaHakkoKirinCompanyLtdMember us-gaap:LicenseAgreementTermsMember 2011-01-01 2011-12-31 0001019695 arql:ChiefMedicalOfficerEmploymentAgreementMember arql:ChiefMedicalOfficerMember us-gaap:PerformanceSharesMember 2012-02-01 2012-02-29 0001019695 arql:DaiichiSankyoTivantinibAgreementMember 2013-01-01 2013-01-31 0001019695 arql:DaiichiSankyoCompanyLtdMember us-gaap:LicenseAgreementTermsMember 2013-01-01 2013-01-31 0001019695 arql:ChiefMedicalOfficerEmploymentAgreementMember arql:ChiefMedicalOfficerMember us-gaap:PerformanceSharesMember 2013-03-01 2013-03-31 0001019695 arql:ChiefOperatingOfficerEmploymentAgreementMember us-gaap:ChiefOperatingOfficerMember us-gaap:PerformanceSharesMember 2013-03-01 2013-03-31 0001019695 us-gaap:RestrictedStockMember 2013-01-01 2013-12-31 0001019695 us-gaap:EmployeeSeveranceMember 2014-08-04 0001019695 us-gaap:SpecialTerminationBenefitsMember 2014-08-04 0001019695 2014-07-01 2014-09-30 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2014-07-01 2014-09-30 0001019695 arql:DaiichiSankyoTivantinibAgreementMember 2014-07-01 2014-09-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-09-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2014-07-01 2014-09-30 0001019695 us-gaap:RestructuringChargesMember 2014-07-01 2014-09-30 0001019695 2014-01-01 2014-09-30 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2014-01-01 2014-09-30 0001019695 arql:DaiichiSankyoTivantinibAgreementMember 2014-01-01 2014-09-30 0001019695 us-gaap:RestrictedStockMember 2014-01-01 2014-09-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-09-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-09-30 0001019695 us-gaap:RestructuringChargesMember 2014-01-01 2014-09-30 0001019695 2014-01-01 2014-12-31 0001019695 us-gaap:DomesticCountryMember 2014-01-01 2014-12-31 0001019695 us-gaap:StateAndLocalJurisdictionMember 2014-01-01 2014-12-31 0001019695 2014-12-31 0001019695 us-gaap:DomesticCountryMember 2014-12-31 0001019695 us-gaap:StateAndLocalJurisdictionMember 2014-12-31 0001019695 us-gaap:CorporateDebtSecuritiesMember arql:CurrentMember 2014-12-31 0001019695 us-gaap:CorporateDebtSecuritiesMember arql:NonCurrentMember 2014-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2014-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0001019695 us-gaap:ResearchMember 2014-12-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001019695 arql:NonCurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001019695 arql:NonCurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001019695 arql:NonCurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001019695 arql:NonCurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2014-12-31 0001019695 us-gaap:DomesticCountryMember us-gaap:CapitalLossCarryforwardMember 2014-12-31 0001019695 2015-07-01 2015-09-30 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2015-07-01 2015-09-30 0001019695 arql:DaiichiSankyoTivantinibAgreementMember 2015-07-01 2015-09-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-09-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2015-07-01 2015-09-30 0001019695 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0001019695 us-gaap:RestructuringChargesMember 2015-07-01 2015-09-30 0001019695 2015-01-01 2015-09-30 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2015-01-01 2015-09-30 0001019695 arql:DaiichiSankyoTivantinibAgreementMember 2015-01-01 2015-09-30 0001019695 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2015-01-01 2015-09-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-09-30 0001019695 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0001019695 us-gaap:RestructuringChargesMember 2015-01-01 2015-09-30 0001019695 2015-09-30 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2015-09-30 0001019695 arql:DaiichiSankyoTivantinibAgreementMember 2015-09-30 0001019695 us-gaap:EmployeeStockOptionMember 2015-09-30 0001019695 us-gaap:CorporateDebtSecuritiesMember arql:CurrentMember 2015-09-30 0001019695 us-gaap:CorporateDebtSecuritiesMember arql:NonCurrentMember 2015-09-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2015-09-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001019695 arql:NonCurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001019695 arql:NonCurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001019695 arql:NonCurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001019695 arql:NonCurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-09-30 0001019695 us-gaap:RestrictedStockMember 2013-01-01 2015-09-30 0001019695 2015-10-22 0001019695 2013-12-31 0001019695 2014-09-30 0001019695 us-gaap:RestrictedStockMember 2014-12-31 0001019695 us-gaap:RestrictedStockMember 2015-09-30 0001019695 us-gaap:EmployeeStockOptionMember 2014-12-31 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure ARQULE INC 0001019695 arql --12-31 Accelerated Filer 62891548 10-Q 2015-09-30 false 2015 Q3 12525000 13130000 15579000 16099000 46683000 30629000 1893000 193000 61101000 43952000 2058000 133000 298000 102000 251000 63394000 44501000 6947000 5691000 11098000 7373000 232000 18277000 13064000 4572000 22849000 13064000 628000 629000 508270000 510072000 -10000 1000 -468343000 -479265000 40545000 31437000 63394000 44501000 0.01 0.01 1000000 1000000 0 0 0 0 0.01 0.01 100000000 100000000 62821781 62891548 62821781 62891548 2662000 1400000 1200000 8239000 4300000 4000000 2653000 1400000 1200000 8442000 4300000 4200000 5014000 17981000 3180000 11920000 2997000 9318000 1839000 7802000 9110000 28398000 5019000 19722000 -6448000 -20159000 -2366000 -11280000 62000 233000 17000 81000 11000 28000 -2000 75000 -5000 277000 -6399000 -19879000 -2354000 -10922000 -21000 -42000 8000 11000 -6420000 -19921000 -2346000 -10911000 0.1 0.32 0.04 0.17 62652 62621 62827 62753 532000 129000 -893000 -406000 416000 232000 2643000 1741000 75000 277000 -558000 -1551000 -1275000 -1256000 -8228000 -8297000 -24967000 -17157000 27504000 24203000 52934000 41920000 315000 298000 25430000 17700000 57000 62000 57000 62000 520000 605000 <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">We are a clinical-stage biotechnology company organized as a Delaware corporation in 1993 engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to produce novel drugs with differentiated mechanisms of action that will extend and improve the lives of our patients. These drugs target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our prioritized clinical stage pipeline consists of four product candidates, all of which are in targeted, biomarker-defined populations. Our drug discovery efforts focus on a number of pre-clinical programs based on our insights into kinase biology and are derived from our extensive library of proprietary compounds.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Our lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (&#8220;c-MET&#8221;) and its biological pathway. C-MET is a promising target for cancer therapy based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. We and our partners, Daiichi Sankyo Co., Ltd. (&#8220;Daiichi Sankyo&#8221;) and Kyowa Hakko Kirin Co., Ltd. (&#8220;Kyowa Hakko Kirin&#8221;), are implementing a worldwide clinical development program with tivantinib. Our strategy is to focus on the most promising indications within our clinical programs based upon continually generated and updated clinical and pre-clinical data. Our lead indication is liver cancer (&#8220;hepatocellular carcinoma&#8221; or &#8220;HCC&#8221;), and we are currently conducting two Phase 3 trials with our partners. We have also completed earlier-stage single agent and combination therapy trials and pre-clinical experiments with tivantinib and other anti-cancer agents that may provide data to support later-stage trials in additional indications.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">We have licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where we have licensed commercial rights to Kyowa Hakko Kirin. Our agreements with these partners provide for possible future milestone payments, royalties on product sales, and development funding, in addition to significant payments that we have already received. During 2011, we received $25 million from Daiichi Sankyo resulting from the dosing of the first patient in the MARQUEE trial and $10 million from Kyowa Hakko Kirin resulting from dosing of the first patient in the ATTENTION trial. On January 31, 2013, we announced that the first patient had been enrolled in the pivotal Phase 3 METIV trial of tivantinib, entitling us to a $15 million milestone. That milestone was netted against our cumulative share of Phase 3 collaboration costs in 2013, and consequently we did not receive any cash proceeds from this milestone.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">We regained worldwide rights for the development and commercialization of ARQ 092, designed to inhibit the AKT serine/threonine kinase, and all other compounds included under our AKT collaboration with Daiichi Sankyo pursuant to their formal notice to terminate our license and co-commercialization agreement received on March 26, 2013. Following the termination, we became responsible for funding the remainder of the Phase 1 trial with ARQ 092 beyond the contractual termination period, as well as any future clinical development and commercialization of this compound. The license agreement had provided exclusive rights to Daiichi Sankyo for the development, manufacturing and marketing of ARQ 092 on a worldwide basis. Under this agreement, we received a $10 million upfront fee from Daiichi Sankyo in November 2011. Following the termination of this agreement, ARQ 092 became our proprietary asset, and Daiichi Sankyo has no further financial or other obligations or rights related to this program. ARQ 092 is part of our proprietary pipeline of product candidates directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers and rare diseases. Our priorities within this pipeline include ARQ 092, ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (&#8220;FGFR&#8221;) family, and ARQ 761, a Beta lapachone analog being investigated in investigator-sponsored testing as a promoter of NQ01-mediated cancer cell necrosis.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have consisted primarily of payments received from our collaborators for services performed or upfront payments for future services. For the nine month periods ended September 30, 2015 and 2014, our net use of cash was primarily driven by payments for operating expenses which resulted in net cash outflows of $17.2 million and $25.0 million, respectively.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, our ability to enter into additional corporate collaborations and the terms of such collaborations, results of research and development, unanticipated required capital expenditures, competitive and technological advances, acquisitions and other factors. We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product. It is likely we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, and due to global capital and credit market conditions or for other reasons, we may be unable to raise capital when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">We have prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with our audited financial statements and footnotes related thereto for the year ended December 31, 2014 included in our annual report on Form 10-K filed with the SEC on March 4, 2015.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The unaudited condensed financial statements include, in our opinion, all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of our financial position as of September 30, 2015, and the results of our operations and cash flows for the nine months ended September 30, 2015 and September 30, 2014. The results of operations for such interim periods are not necessarily indicative of the results to be achieved for the full year.</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>2. COLLABORATIONS AND ALLIANCES</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><i>Beryllium Discovery Corp. Agreement</i></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In May 2015, we entered into a collaborative research and development agreement with Beryllium Discovery Corp. (&#8220;Beryllium&#8221;). Pursuant to the agreement, we will jointly focus on the identification and preclinical development of inhibitors of PD-1 and PDL-1. We and Beryllium will each be responsible for our respective internal and outsourcing costs during pre-clinical development. Following lead optimization of any potential drug candidates, we and Beryllium will jointly decide whether to advance compounds into GLP/toxicology and clinical testing, initially on a shared cost basis, provided that we will have the right to advance compounds on our own should Beryllium vote against such advancement. The agreement also provides that we will be responsible for clinical development and commercialization of product candidates that are not out-licensed. Beryllium will have the right to participate financially throughout the program but will also have the option to opt out at certain times and receive a royalty. The agreement will terminate after the last payment obligation is satisfied, or prior to that upon 60-days&#8217; notice by either party.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><i>Daiichi Sankyo Tivantinib Agreement</i></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">On December 18, 2008, we entered into a license, co-development and co-commercialization agreement with Daiichi Sankyo to conduct research, clinical trials and the commercialization of tivantinib in human cancer indications in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan, where Kyowa Hakko Kirin has exclusive rights for development and commercialization.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The agreement provides for a $60 million cash upfront licensing payment from Daiichi Sankyo to us, which we received in December 2008, and an additional $560 million in potential development and sales milestone payments offset by our share of Phase 3 costs. Upon commercialization, we will receive tiered, double-digit royalties from Daiichi Sankyo on net sales of tivantinib commensurate with the magnitude of the transaction. We retain the option to participate in the commercialization of tivantinib in the U.S. We and Daiichi Sankyo will share equally the costs of Phase 2 and Phase 3 clinical studies, with our share of Phase 3 costs payable solely from milestone and royalty payments by Daiichi Sankyo.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In each quarter the tivantinib collaboration costs we incur are compared with those of Daiichi Sankyo. If our costs for the quarter exceed Daiichi Sankyo&#8217;s, we recognize revenue on the amounts due to us under the contingency adjusted performance model. Revenue is calculated on a pro-rata basis using the time elapsed from inception of the agreement over the estimated duration of the development period under the agreement. If our costs for the quarter are less than those of Daiichi Sankyo, we report the amount due to Daiichi Sankyo as contra-revenue in that quarter. To the extent that our share of Phase 3 collaboration costs exceeds the amount of milestones and royalties received, that excess is netted against future milestones and royalties if and when earned and is not reported as contra-revenue.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Our cumulative share of the Daiichi Sankyo Phase 3 costs through September 30, 2015 totaled $99 million. We received a milestone of $25 million in February 2011 upon enrolling the first patient in the MARQUEE trial, the cash proceeds of which were subsequently applied to our share of Phase 3 collaboration costs. On January 31, 2013, we announced that the first patient had been enrolled in the pivotal Phase 3 METIV trial of tivantinib, entitling us to a $15 million milestone. That $15 million milestone was also netted against our cumulative share of Phase 3 collaboration costs in 2013, and consequently we did not receive any cash proceeds from this milestone. Our cumulative share of Phase 3 collaboration costs has exceeded the amount of milestones received through September 30, 2015 by $59 million which will be netted against future milestones and royalties, if any, when earned and has not been reported as contra-revenue.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">For the quarter ended September 30, 2015 our non-Phase 3 tivantinib collaboration costs incurred were less than those of Daiichi Sankyo and $130 was recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue. For the nine months ended September 30, 2015, our non-Phase 3 tivantinib collaboration costs incurred exceeded those of Daiichi Sankyo and $119 was recognized as tivantinib Daiichi Sankyo net research and development revenue.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">For the quarter ended September 30, 2014 our non-Phase 3 tivantinib collaboration costs incurred were less than those of Daiichi Sankyo and $102 was recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue. For the nine months ended September 30, 2014, no research and development revenue was recognized related to our non-Phase 3 tivantinib collaboration as our costs incurred were offset by an equal amount of contra-revenue.</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The duration and termination of the agreement are tied to future events. Unless earlier terminated due to breach, insolvency or upon 90 days notice if prior to Phase 3 clinical trials or 180 days notice if on or after the beginning of Phase 3 clinical trials by Daiichi Sankyo, the agreement shall continue until the later of (i) such time as Daiichi Sankyo is no longer developing at least one licensed product or (ii) if Daiichi Sankyo has commercialized a licensed product or products, such time as all royalty terms for all licensed products have ended. The royalty term, on a country-by-country basis for a product, ends as of the later of (i) the expiration of the last valid claim under a patent covering the manufacture, use, or sale of a licensed product or (ii) a certain number of years from the date of the commercial sale of the licensed product in such country.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Revenue for this agreement is recognized using the contingency-adjusted performance model. Through September 30, 2012, revenue was recognized based upon an estimated development period through December 2013. As a result of the October 2012 decision to discontinue the MARQUEE trial, the development period as of October 1, 2012 was extended to June 2015. Commencing with the fourth quarter of 2012 and through the third quarter of 2013 revenue was recognized over that development period. In the fourth quarter of 2013, following a recommendation by the Data Monitoring Committee that the METIV-HCC trial continue with patients receiving a lower dose of tivantinib than the dose originally employed in the trial, we reviewed the estimated development period and extended it to June 2016. For the three months and nine months ended September 30, 2015, $1.2 million and $4.2 million, respectively, were recognized as net revenue. For the three months and nine months ended September 30, 2014, $1.2 million and $4.0 million, respectively, were recognized as net revenue. At September 30, 2015, $4.1 million remains in deferred revenue.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><i>Kyowa Hakko Kirin Licensing Agreement</i></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">On April 27, 2007, we entered into an exclusive license agreement with Kyowa Hakko Kirin to develop and commercialize tivantinib in Japan and parts of Asia. A $3 million portion of an upfront licensing fee was received by the Company under this agreement in the first quarter of 2007, and an additional $27 million in upfront licensing fees was received on May 7, 2007. The agreement includes $123 million in upfront and potential development milestone payments from Kyowa Hakko Kirin to ArQule, including the $30 million cash upfront licensing payments. In February 2008, we received a $3 million milestone payment from Kyowa Hakko Kirin. Upon commercialization, ArQule will receive tiered royalties in the mid-teen to low-twenty percent range from Kyowa Hakko Kirin on net sales of tivantinib. Kyowa Hakko Kirin will be responsible for all clinical development costs and commercialization of the compound in certain Asian countries, consisting of Japan, China (including Hong Kong), South Korea and Taiwan. In July 2010, we announced the initiation of a Phase 2 trial with tivantinib by Kyowa Hakko Kirin in gastric cancer, for which we received a $5 million milestone payment in September 2010.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In August 2011, Kyowa Hakko Kirin announced the initiation of the Phase 3 ATTENTION trial. Dosing of the first patient in this trial triggered a $10 million milestone payment, which we received in August 2011. The milestone payment was recorded as deferred revenue and is being recognized as revenue using the contingency-adjusted performance model with an estimated development period through April 2016.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In addition to the upfront and possible development milestone payments totaling $123 million, the Company will be eligible for future milestone payments based on the achievement of certain levels of net sales. The Company will recognize the payments, if any, as revenue in accordance with the contingency-adjusted performance model. As of September 30, 2015, the Company had not recognized any revenue from these sales milestone payments, and there can be no assurance that it will do so in the future.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The duration and termination of the agreement are tied to future events. Unless earlier terminated due to breach, insolvency or upon 90 days notice by Kyowa Hakko Kirin, the agreement terminates on the date that the last royalty term expires in all countries in the territory. The royalty term ends as of the later of (i) the expiration of the last pending patent application or expiration of the patent in the country covering the manufacture, use, or sale of a licensed product or (ii) a certain number of years from the date of the commercial launch in such country of such license product.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Revenue for this agreement is recognized using the contingency-adjusted performance model with an estimated development period through April 2016. For both the three and nine months ended September 30, 2015 and 2014, $1.4 million and $4.3 million, respectively were recognized as revenue. At September 30, 2015, $3.3 million remains in deferred revenue.</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">We generally classify our marketable securities as available-for-sale at the time of purchase and re-evaluate such designation as of each balance sheet date. Since we generally intend to convert them into cash as necessary to meet our liquidity requirements our marketable securities are classified as cash equivalents if the original maturity, from the date of purchase, is ninety days or less and as short-term investments if the original maturity, from the date of purchase, is in excess of ninety days but less than one year. Our marketable securities are classified as long-term investments if the maturity date is in excess of one year of the balance sheet date.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">We report available-for-sale investments at fair value as of each balance sheet date and include any unrealized gains and, to the extent deemed temporary, unrealized losses in stockholders&#8217; equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense) in the statement of operations and comprehensive loss.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">We conduct quarterly reviews to determine the fair value of our investment portfolio and to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. In the event that the cost basis of a security exceeds its fair value, we evaluate, among other factors, the duration of the period that, and extent to which, the fair value is less than cost basis, the financial health of and business outlook for the issuer, including industry and sector performance, and operational and financing cash flow factors, overall market conditions and trends, our intent to sell the investment and if it is more likely than not that we would be required to sell the investment before its anticipated recovery. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in accumulated other comprehensive income (loss).</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">For available-for-sale debt securities with unrealized losses, we perform an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in the statement of operations and comprehensive loss as an impairment loss.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The following is a summary of the fair value of available-for-sale marketable securities we held at September 30, 2015 and December 31, 2014:</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"></p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"></p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"></p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 533px; vertical-align: bottom;">&#160;</td> <td style="width: 48px; vertical-align: bottom;">&#160;</td> <td style="width: 16px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 204px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 32px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 16px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 204px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 32px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 203px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 31px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 203px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: top;">&#160;</td> </tr> <tr> <td style="border-bottom: black 2px solid; vertical-align: bottom;"><b>September 30, 2015</b></td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Amortized</b><br /><b>Cost</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Gross</b><br /><b>Unrealized</b><br /><b>Gains</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Gross</b><br /><b>Unrealized</b><br /><b>Losses</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Fair</b><br /><b>Value</b></td> <td style="text-align: center; vertical-align: top;">&#160;</td> </tr> <tr> <td style="vertical-align: bottom;"><i>Security type</i></td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="text-indent: -8.65pt; padding-left: 17.3pt; vertical-align: bottom; padding-top: 2pt;">Corporate debt securities-short term</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">30,628</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">6</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">(5</td> <td style="vertical-align: bottom;">)</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">30,629</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="text-indent: -8.65pt; padding-left: 17.3pt; vertical-align: bottom; padding-top: 2pt;">Corporate debt securities-long term</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#8212;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#8212;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#8212;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#8212;</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="vertical-align: bottom;">Total available-for-sale marketable securities</td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">30,628</td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">6</td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">(5</td> <td style="text-align: left; vertical-align: middle;">)</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">30,629</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr> <td style="width: 533px; vertical-align: bottom;">&#160;</td> <td style="width: 48px; vertical-align: bottom;">&#160;</td> <td style="width: 16px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 204px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 32px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 16px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 204px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 32px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 203px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 31px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 203px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: top;">&#160;</td> </tr> <tr> <td style="border-bottom: black 2px solid; vertical-align: bottom;"><b>December 31, 2014</b></td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Amortized</b><br /><b>Cost</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Gross</b><br /><b>Unrealized</b><br /><b>Gains</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Gross</b><br /><b>Unrealized</b><br /><b>Losses</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Fair</b><br /><b>Value</b></td> <td style="text-align: center; vertical-align: top;">&#160;</td> </tr> <tr> <td style="vertical-align: bottom;"><i>Security type</i></td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="text-indent: -8.65pt; padding-left: 17.3pt; vertical-align: bottom; padding-top: 2pt;">Corporate debt securities-short term</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">46,690</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">16</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">(23</td> <td style="vertical-align: bottom;">)</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">46,683</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="text-indent: -8.65pt; padding-left: 17.3pt; vertical-align: bottom; padding-top: 2pt;">Corporate debt securities-long term</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">2,061</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#8212;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">(3</td> <td style="vertical-align: bottom;">)</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">2,058</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="vertical-align: bottom;">Total available-for-sale marketable securities</td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">48,751</td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">16</td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">(26</td> <td style="text-align: left; vertical-align: middle;">)</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">48,741</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"></p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The fair value of our available-for-sale marketable securities in a continuous unrealized loss position for more than 12 months was $1,126 at September 30, 2015. The unrealized loss on these marketable securities was under $1 at September 30, 2015. None of our available-for-sale marketable securities were in a continuous unrealized loss position for more than 12 months at December 31, 2014.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The following tables present information about our assets that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. We value our level 2 investments using quoted prices for identical assets in the markets where they are traded, although such trades may not occur daily. These quoted prices are based on observable inputs, primarily interest rates. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. There were no transfers in or out of Level 1 or Level 2 measurements for the periods presented:</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"></p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">September 30,<br />2015</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Quoted&#160;<br />Prices in<br />Active&#160;<br />Markets<br />(Level 1)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; width: 627px;">Cash equivalents</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">11,935</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">11,935</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">&#8212;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">&#8212;</td> <td style="text-align: left; width: 15px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;">Corporate debt securities-short term</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,629</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#8212;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,629</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#8212;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-long term</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 34.55pt;">Total</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">42,564</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">11,935</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">30,629</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">December 31,<br />2014</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Quoted&#160;<br />Prices in<br />Active&#160;<br />Markets<br />(Level 1)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; width: 627px;">Cash equivalents</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">10,740</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">10,740</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">&#8212;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">&#8212;</td> <td style="text-align: left; width: 15px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;">Corporate debt securities-short term</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">46,683</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#8212;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">46,683</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#8212;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-long term</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">2,058</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">2,058</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 34.55pt;">Total</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">59,481</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">10,740</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">48,741</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Accounts payable and accrued expenses include the following at September 30, 2015 and December 31, 2014:</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"></p> <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 1253px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="3">&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="3">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold;" colspan="3">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold;" colspan="3">2014</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 722px;">Accounts payable</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px; border-top: black 2px solid;">$</td> <td style="text-align: right; width: 188px; border-top: black 2px solid;">346</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px; border-top: black 2px solid;">$</td> <td style="text-align: right; width: 190px; border-top: black 2px solid;">259</td> <td style="text-align: left; width: 16px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accrued payroll</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,537</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,130</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accrued outsourced pre-clinical and clinical fees</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,173</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,753</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accrued professional fees</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">355</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">157</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Other accrued expenses</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">280</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">648</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">5,691</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">6,947</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> <div>&#160;</div> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>5. NET LOSS PER SHARE</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Net loss per share is computed using the weighted average number of common shares outstanding. Basic and diluted net loss per share amounts are equivalent for the periods presented as the inclusion of potential common shares in the number of shares used for the diluted computation would be anti-dilutive to loss per share. Potential common shares, the shares that would be issued upon the exercise of outstanding stock options, were 8,342,725 and 7,999,284 for the three and nine months ended September 30, 2015 and 2014, respectively.</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>6. STOCK-BASED COMPENSATION AND STOCK PLANS</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Our stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employees&#8217; requisite service period (generally the vesting period of the equity grant). We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, expected option term, expected volatility of our stock over the option&#8217;s expected term, risk-free interest rate over the option&#8217;s expected term, and the expected annual dividend yield. We believe that the valuation technique and approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of our stock options granted in the nine months ended September 30, 2015 and 2014.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The following table presents stock-based compensation expense included in our Condensed Statements of Operations and Comprehensive Loss:</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"></p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="6">Three Months Ended<br />September 30,</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="6">Nine Months Ended<br />September 30,</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">2015</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">2014</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">2015</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">2014</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; width: 627px;">Research and development</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">142</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">186</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">538</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">854</td> <td style="text-align: left; width: 15px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;">General and administrative</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">359</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">494</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,203</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,706</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 2px;">Restructuring</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">83</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">83</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px; padding-left: 17.3pt;">Total stock-based compensation expense</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">501</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">763</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">1,741</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">2,643</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In the three and nine months ended September 30, 2015 and 2014, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation expense.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Option activity under our stock plans for the nine months ended September 30, 2015 was as follows:</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"></p> <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 1253px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; font-weight: bold;">Stock Options</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Number of<br />Shares</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Weighted Average<br />Exercise Price</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 722px;">Outstanding as of December 31, 2014</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="text-align: right; width: 188px;">7,724,614</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 190px;">4.89</td> <td style="text-align: left; width: 16px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>Granted</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,513,850</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.25</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 2px;">Cancelled</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(895,739</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">4.79</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 4px;">Outstanding as of September 30, 2015</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">8,342,725</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">4.24</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#160;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#160;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 4px;">Exercisable as of September 30, 2015</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">5,793,400</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">5.12</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The aggregate intrinsic value of options outstanding at September 30, 2015 was $908, and $51 related to exercisable options. The weighted average grant date fair value of options granted in the nine months ended September 30, 2015 and 2014 was $0.77 and $1.65 per share, respectively. No options were exercised in the nine months ended September 30, 2015 or 2014.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Shares vested, expected to vest and exercisable at September 30, 2015 are as follows:</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"></p> <table style="widows: 1; text-transform: none; text-indent: 0px; width: 1567px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Shares</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Weighted-Average<br />Exercise Price</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Weighted-Average<br />Remaining<br />Contractual<br />Term (in years)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Aggregate<br />Intrinsic<br />Value</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; width: 627px;">Vested and unvested expected to vest at September 30, 2015</td> <td style="width: 32px;">&#160;</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="text-align: right; width: 157px;">8,156,021</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 32px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 189px;">4.24</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 31px;">&#160;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="text-align: right; width: 188px;">5.44</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 31px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">843</td> <td style="text-align: left; width: 15px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>Exercisable at September 30, 2015</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,793,400</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">5.12</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4.04</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">51</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The total compensation cost not yet recognized as of September 30, 2015 related to non-vested option awards was $3.1 million, which will be recognized over a weighted-average period of 2.5 years. During the nine months ended September 30, 2015, 689,759 shares expired and 205,980 shares were forfeited. The weighted average remaining contractual life for options exercisable at September 30, 2015 was 4.0 years.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In 2013, we granted 242,697 shares of restricted stock to employees, vesting annually over a four year period. The weighted average fair value of the restricted stock at the time of grant in 2013 was $2.51 per share, and is being expensed ratably over the vesting period. Through September 30, 2015, 82,564 shares have been forfeited, and 101,498 shares have vested. We recognized share-based compensation expense related to restricted stock of $59 and $77 for the nine months ended September 30, 2015 and 2014, respectively.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Restricted stock activity under the Plan for the nine months ended September 30, 2015 was as follows:</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"></p> <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 1331px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; font-weight: bold;">Restricted Stock</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Number of Shares</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Weighted Average<br />Grant Date<br />Fair Value</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 801px;">Unvested as of December 31, 2014</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="text-align: right; width: 188px;">105,665</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 189px;">2.51</td> <td style="text-align: left; width: 16px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-left: 17.3pt;">Vested</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(36,101</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2.51</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 2px; padding-left: 17.3pt;">Cancelled</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(10,929</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">2.51</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 4px;">Unvested as of September 30, 2015</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">58,635</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">2.51</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">The fair value of restricted stock vested in the nine months ended September 30, 2015 and 2014 was $68 and $55 respectively.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In July 2010, the Company amended its chief executive officer&#8217;s (the &#8220;CEO&#8217;s&#8221;) employment agreement to grant the CEO 100,000 stock options, of which 25% vested upon grant and 25% vested annually over the next three years, and a maximum of 390,000 performance-based stock units that vest upon the achievement of certain performance and market based targets. In March 2013, the Company amended its CEO&#8217;s employment agreement to modify the performance and market based targets.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In February 2012, the Company amended its chief medical officer&#8217;s (the &#8220;CMO&#8217;s&#8221;) employment agreement to grant the CMO 50,000 performance-based stock units that vest upon the achievement of certain performance based targets.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In March 2013, the Company amended its chief operating officer&#8217;s (the &#8220;COO&#8217;s&#8221;) employment agreement to grant the COO 125,000 performance-based stock units that vest upon the achievement of certain performance based targets. In March 2013, the Company amended its CMO&#8217;s employment agreement to grant the CMO 120,000 performance-based stock units that vest upon the achievement of certain performance based targets.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Through September 30, 2015, no expense has been recorded for any performance-based stock units granted to the CEO, COO, or CMO.</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>7. RECENT ACCOUNTING PRONOUNCEMENTS</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (&#8220;FASB&#8221;) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In August 2014, the FASB issued Accounting Standard Update (&#8220;ASU&#8221;) 2014-15, Presentation of Financial Statements&#8212;Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity&#8217;s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods beginning after December 15, 2016, and for annual and interim periods thereafter. We are currently evaluating the potential impact that this ASU may have on our disclosures.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">In June 2014, the FASB issued ASU No. 2014-12, &#8220;Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period.&#8221; This ASU requires a reporting entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition, and apply existing guidance under the Stock Compensation Topic of the ASC as it relates to awards with performance conditions that affect vesting to account for such awards. The provisions of this ASU are effective for interim and annual periods beginning after December 15, 2015. We are currently evaluating the potential impact that this ASU may have on our financial position and results of operations.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">During the quarter ended June 30, 2014, the FASB issued ASU No. 2014-09, &#8220;Revenue from Contracts with Customers&#8221; (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.</p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>8. INCOME TAXES</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">As of December 31, 2014, we had federal NOL, state NOL, and research and development credit carryforwards of approximately $331,909, $152,434 and $27,761, respectively, which expire at various dates through 2034, which can be used to offset future income tax liabilities. Federal capital loss carry forwards of approximately $571 can be used to offset future federal capital gain income and expire in 2015. Approximately $15,014 of our federal NOL and $863 of our state NOL were generated from excess tax deductions from share-based awards, the tax benefit of which will be credited to additional paid-in-capital when the deductions reduce current taxes payable. We have determined that it is more likely than not that we will not recognize the benefits of our federal and state deferred tax assets and, as a result, we have a full valuation allowance against our net deferred tax assets.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">At September 30, 2015 and December 31, 2014, we had no unrecognized tax benefits. We do not expect that the total amount of unrecognized tax benefits will significantly increase in the next twelve months. Our policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of September 30, 2015 and December 31, 2014, we had no accrued interest or penalties related to uncertain tax positions. Our U.S. federal tax returns for the tax years 2011 through 2014 and our state tax returns for the tax years 2010 through 2014 remain open to examination. Prior tax years remain open to the extent of net operating loss and tax credit carryforwards.</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">Utilization of NOL and research and development credit carryforwards may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income, and may, in turn, result in the expiration of a portion of those carryforwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three year period. We undertook a detailed study of our NOL and research and development credit carryforwards through January 31, 2015, to determine whether such amounts are likely to be limited by Sections 382 or 383. As a result of this analysis, we currently do not believe any Sections 382 or 383 limitations will significantly impact our ability to offset income with available NOL and research and development credit carryforwards. However, future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits.</p> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">&#160;</p> <table align="center" style="width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="width: 533px; vertical-align: bottom;"></td> <td style="width: 48px; vertical-align: bottom;">&#160;</td> <td style="width: 16px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 204px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 32px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 16px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 204px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 32px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 203px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 31px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 203px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: top;">&#160;</td> </tr> <tr> <td style="border-bottom: black 2px solid; vertical-align: bottom;"><b>September 30, 2015</b></td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Amortized</b><br /><b>Cost</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Gross</b><br /><b>Unrealized</b><br /><b>Gains</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Gross</b><br /><b>Unrealized</b><br /><b>Losses</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Fair</b><br /><b>Value</b></td> <td style="text-align: center; vertical-align: top;">&#160;</td> </tr> <tr> <td style="vertical-align: bottom;"><i>Security type</i></td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="text-indent: -8.65pt; padding-left: 17.3pt; vertical-align: bottom; padding-top: 2pt;">Corporate debt securities-short term</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">30,628</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">6</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">(5</td> <td style="vertical-align: bottom;">)</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">30,629</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="text-indent: -8.65pt; padding-left: 17.3pt; vertical-align: bottom; padding-top: 2pt;">Corporate debt securities-long term</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#8212;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#8212;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#8212;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#8212;</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="vertical-align: bottom;">Total available-for-sale marketable securities</td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">30,628</td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">6</td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">(5</td> <td style="text-align: left; vertical-align: middle;">)</td> <td style="border-bottom: black 4px double; vertical-align: bottom; border-top: black 2px solid;">$</td> <td style="border-bottom: black 4px double; text-align: right; vertical-align: bottom; border-top: black 2px solid;">30,629</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> </table> <p style="text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;">&#160;</p> <table align="center" style="width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td style="width: 533px; vertical-align: bottom;">&#160;</td> <td style="width: 48px; vertical-align: bottom;">&#160;</td> <td style="width: 16px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 204px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 32px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 16px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 204px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 32px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 203px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 31px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 203px; vertical-align: bottom;">&#160;</td> <td style="text-align: center; width: 15px; vertical-align: top;">&#160;</td> </tr> <tr> <td style="border-bottom: black 2px solid; vertical-align: bottom;"><b>December 31, 2014</b></td> <td style="vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Amortized</b><br /><b>Cost</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Gross</b><br /><b>Unrealized</b><br /><b>Gains</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Gross</b><br /><b>Unrealized</b><br /><b>Losses</b></td> <td style="text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; vertical-align: bottom;"><b>Fair</b><br /><b>Value</b></td> <td style="text-align: center; vertical-align: top;">&#160;</td> </tr> <tr> <td style="vertical-align: bottom;"><i>Security type</i></td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="text-indent: -8.65pt; padding-left: 17.3pt; vertical-align: bottom; padding-top: 2pt;">Corporate debt securities-short term</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">46,690</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">16</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">(23</td> <td style="vertical-align: bottom;">)</td> <td style="vertical-align: bottom;">$</td> <td style="text-align: right; vertical-align: bottom;">46,683</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="text-indent: -8.65pt; padding-left: 17.3pt; vertical-align: bottom; padding-top: 2pt;">Corporate debt securities-long term</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">2,061</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">&#8212;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">(3</td> <td style="vertical-align: bottom;">)</td> <td style="vertical-align: bottom;">&#160;</td> <td style="text-align: right; vertical-align: bottom;">2,058</td> <td style="text-align: right; vertical-align: top;">&#160;</td> </tr> <tr> <td style="widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Total available-for-sale marketable securities</td> <td style="widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</td> <td style="border-bottom: black 4px double; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; border-top: black 2px solid; word-spacing: 0px; -webkit-text-stroke-width: 0px;">$</td> <td style="border-bottom: black 4px double; text-align: right; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; border-top: black 2px solid; word-spacing: 0px; -webkit-text-stroke-width: 0px;">48,751</td> <td style="widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</td> <td style="border-bottom: black 4px double; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; border-top: black 2px solid; word-spacing: 0px; -webkit-text-stroke-width: 0px;">$</td> <td style="border-bottom: black 4px double; text-align: right; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; border-top: black 2px solid; word-spacing: 0px; -webkit-text-stroke-width: 0px;">16</td> <td style="widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; word-spacing: 0px; -webkit-text-stroke-width: 0px;">&#160;</td> <td style="border-bottom: black 4px double; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; border-top: black 2px solid; word-spacing: 0px; -webkit-text-stroke-width: 0px;">$</td> <td style="border-bottom: black 4px double; text-align: right; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; border-top: black 2px solid; word-spacing: 0px; -webkit-text-stroke-width: 0px;">(26</td> <td style="text-align: left; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: middle; word-spacing: 0px; -webkit-text-stroke-width: 0px;">)</td> <td style="border-bottom: black 4px double; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; border-top: black 2px solid; word-spacing: 0px; -webkit-text-stroke-width: 0px;">$</td> <td style="border-bottom: black 4px double; text-align: right; widows: 1; text-transform: none; text-indent: 0px; font: 13px 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; vertical-align: bottom; border-top: black 2px solid; word-spacing: 0px; -webkit-text-stroke-width: 0px;">48,741</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">September 30,<br />2015</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Quoted&#160;<br />Prices in<br />Active&#160;<br />Markets<br />(Level 1)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; width: 627px;">Cash equivalents</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">11,935</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">11,935</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">&#8212;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">&#8212;</td> <td style="text-align: left; width: 15px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;">Corporate debt securities-short term</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,629</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#8212;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">30,629</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#8212;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-long term</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 34.55pt;">Total</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">42,564</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">11,935</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">30,629</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#160;</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">December 31,<br />2014</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Quoted&#160;<br />Prices in<br />Active&#160;<br />Markets<br />(Level 1)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; width: 627px;">Cash equivalents</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">10,740</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">10,740</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">&#8212;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">&#8212;</td> <td style="text-align: left; width: 15px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;">Corporate debt securities-short term</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">46,683</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#8212;</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">46,683</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">&#8212;</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-long term</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">2,058</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">2,058</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 34.55pt;">Total</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">59,481</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">10,740</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">48,741</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="3">&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="3">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold;" colspan="3">2015</td> <td style="padding-bottom: 1pt; font-weight: bold;">&#160;</td> <td style="text-align: center; font-weight: bold;" colspan="3">2014</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; width: 722px;">Accounts payable</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px; border-top: black 2px solid;">$</td> <td style="text-align: right; width: 188px; border-top: black 2px solid;">346</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px; border-top: black 2px solid;">$</td> <td style="text-align: right; width: 190px; border-top: black 2px solid;">259</td> <td style="text-align: left; width: 16px;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accrued payroll</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,537</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2,130</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accrued outsourced pre-clinical and clinical fees</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,173</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">3,753</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Accrued professional fees</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">355</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">157</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Other accrued expenses</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">280</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> <td style="padding-bottom: 1pt;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">648</td> <td style="text-align: left; padding-bottom: 1pt;">&#160;</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">5,691</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> <td style="padding-bottom: 2.5pt;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">6,947</td> <td style="text-align: left; padding-bottom: 2.5pt;">&#160;</td> </tr> </table> <div>&#160;</div> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="6">Three Months Ended<br />September 30,</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="6">Nine Months Ended<br />September 30,</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">2015</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">2014</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">2015</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">2014</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; width: 627px;">Research and development</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">142</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 48px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 157px;">186</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">538</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 47px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">854</td> <td style="text-align: left; width: 15px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left;">General and administrative</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">359</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">494</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,203</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,706</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 2px;">Restructuring</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">83</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#8212;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">83</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px; text-indent: -8.65pt; padding-left: 17.3pt;">Total stock-based compensation expense</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">501</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">763</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">1,741</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">2,643</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 1253px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; font-weight: bold;">Stock Options</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Number of<br />Shares</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Weighted Average<br />Exercise Price</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 722px;">Outstanding as of December 31, 2014</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="text-align: right; width: 188px;">7,724,614</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 190px;">4.89</td> <td style="text-align: left; width: 16px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>Granted</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1,513,850</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">1.25</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 2px;">Cancelled</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(895,739</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">4.79</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 4px;">Outstanding as of September 30, 2015</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">8,342,725</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">4.24</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#160;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">&#160;</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 4px;">Exercisable as of September 30, 2015</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">5,793,400</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">5.12</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Shares</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Weighted-Average<br />Exercise Price</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Weighted-Average<br />Remaining<br />Contractual<br />Term (in years)</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Aggregate<br />Intrinsic<br />Value</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: left; width: 627px;">Vested and unvested expected to vest at September 30, 2015</td> <td style="width: 32px;">&#160;</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="text-align: right; width: 157px;">8,156,021</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 32px;">&#160;</td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 189px;">4.24</td> <td style="text-align: left; width: 16px;">&#160;</td> <td style="width: 31px;">&#160;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="text-align: right; width: 188px;">5.44</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 31px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 156px;">843</td> <td style="text-align: left; width: 15px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td>Exercisable at September 30, 2015</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">5,793,400</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">5.12</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">4.04</td> <td style="text-align: left;">&#160;</td> <td>&#160;</td> <td style="text-align: left;">$</td> <td style="text-align: right;">51</td> <td style="text-align: left;">&#160;</td> </tr> </table> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <table align="center" style="widows: 1; text-transform: none; text-indent: 0px; width: 1331px; border-collapse: collapse; font: 10pt 'times new roman', times, serif; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right;" colspan="2">&#160;</td> <td>&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; font-weight: bold;">Restricted Stock</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Number of Shares</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2">Weighted Average<br />Grant Date<br />Fair Value</td> <td style="padding-bottom: 2px; font-weight: bold;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 801px;">Unvested as of December 31, 2014</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="text-align: right; width: 188px;">105,665</td> <td style="text-align: left; width: 15px;">&#160;</td> <td style="width: 46px;">&#160;</td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 189px;">2.51</td> <td style="text-align: left; width: 16px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="text-indent: -8.65pt; padding-left: 17.3pt;">Vested</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">(36,101</td> <td style="text-align: left;">)</td> <td>&#160;</td> <td style="text-align: left;">&#160;</td> <td style="text-align: right;">2.51</td> <td style="text-align: left;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 2px; text-indent: -8.65pt; padding-left: 17.3pt;">Cancelled</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">(10,929</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: left;">&#160;</td> <td style="border-bottom: black 2px solid; text-align: right;">2.51</td> <td style="text-align: left; padding-bottom: 2px;">&#160;</td> </tr> <tr style="vertical-align: bottom;"> <td style="padding-bottom: 4px;">Unvested as of September 30, 2015</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">&#160;</td> <td style="border-bottom: black 4px double; text-align: right;">58,635</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> <td style="padding-bottom: 4px;">&#160;</td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">2.51</td> <td style="text-align: left; padding-bottom: 4px;">&#160;</td> </tr> </table> 3000000 5000000 25000000 10000000 25000000 10000000 15000000 15000000 3000000 27000000 60000000 10000000 123000000 560000000 99000000 59000000 0 119000 P90D P180D 3300000 4100000 30000000 mid-teen percent low-twenty percent P90D 48751000 46690000 2061000 30628000 30628000 46683000 2058000 46683000 46683000 2058000 2058000 30629000 30629000 30629000 10740000 10740000 11935000 11935000 59481000 10740000 48741000 42564000 11935000 30629000 1126000 1000 259000 346000 2130000 1537000 3753000 3173000 157000 355000 648000 280000 7999284 7999284 8342725 8342725 763000 186000 494000 83000 2643000 77000 854000 1706000 83000 501000 142000 359000 1741000 59000 538000 1203000 8342725 7724614 100000 1513850 895739 5793400 4.24 4.89 1.25 4.79 5.12 8156021 4.24 P5Y5M9D 843000 5793400 5.12 P4Y0M15D 51000 105665 58635 390000 50000 120000 125000 101498 82564 2.51 2.51 2.51 2.51 908000 51000 0.77 1.65 3100000 P2Y6M 689759 205980 P4Y 242697 P3Y P4Y 2.51 55000 68000 0.25 0.25 331909000 152434000 27761000 571000 15014000 863000 more than 50 percentage points P3Y 1099000 1099000 280000 <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;"><b>9. RESTRUCTURING AND OTHER COSTS</b></p> <p style="widows: 1; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">&#160;</p> <p style="widows: 1; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal;">On July 30, 2014, we approved plans to restructure our operations to better align our human and financial resources with our primary focus on clinical stage development programs and to extend our cash runway beyond the anticipated time for achievement of key milestones, such as the completion of the METIV-HCC trial. Commencing on August 4, 2014, we began to reduce our current workforce from 62 to approximately 40 employees by the end of 2014. Most of this reduction came from our Discovery Group, which had been engaged primarily in early-stage, pre-clinical research. The costs associated with this action were comprised of severance payments of $662 and benefits continuation costs of $74. In the year ended December 31, 2014, $319 of these costs was paid and the remaining amount of $417 was paid by March 31, 2015. In addition, in the three months ended September 30, 2014, we incurred non-cash charges of $83 related to the modification of employee stock options, and $280 for impairment of property and equipment impacted by the restructuring.</p> 662000 74000 319000 16000 6000 23000 3000 5000 130000 102000 0001019695us-gaap:CorporateDebtSecuritiesMember2015-09-30 6000 5000 30629000 0001019695us-gaap:CorporateDebtSecuritiesMember2014-12-31 16000 26000 48741000 36101 10929 00010196952015-03-012015-03-31 417000 0001019695us-gaap:OtherRestructuringMember 2014-07-012014-09-30 83000 0001019695arql:ImpairmentOfPropertyAndEquipmentMember 2014-07-012014-09-30 280000 EX-101.SCH 6 arql-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED BALANCE SHEETS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - COLLABORATIONS AND ALLIANCES link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - NET LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - RESTRUCTURING AND OTHER COSTS link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - COLLABORATIONS AND ALLIANCES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - COLLABORATIONS AND ALLIANCES (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - NET LOSS PER SHARE (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Restricted stock activity (Details 3) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 2) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - INCOME TAXES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - RESTRUCTURING AND OTHER COSTS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 arql-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 arql-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 arql-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 arql-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`,939$>0&ZUDM`$``(L6```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V8RV[",!!%?P5E6Q%CIZ4/`9O2;8O4_H";3(A%'%NV"?#WM0-4;916 MT!)I-GEPQW-O,LY9,'G;:;"#K2PK.XT*Y_0#(38M0'(;*PV55W)E)'?^UBR) MYNF*+X&PT6A,4E4YJ-S0A1[1;/)2@S$B@\'C7@B]IQ'7NA0I=T)5I*ZR5M>A MRG.10J;2M?1+8N>MXM2[%````*P(```L```!?.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?' M5$Q^#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7. MU49V[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997 M'L=V+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_ MV/P"4$L#!!0````(`,939$=+^1`9A`$``(,5```:````>&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'/%V$MN@S`0QO&K1!R@9L9Y*\FJFVS;7L`B$T`)#]FN MVMR^E$5%'QYU$>G;@`!I_-_PD^5=&_+MDUQ=K+LV5'4?9N_-M0W;X?T^JV+L MM\:$HI+&A8>NEW;X>NY\X^+PZ$O3N^+B2C&^O\)50B,9CQ1@_#`L/G6R__6;X[G^M"'KOBM9$V_E%AOA;(3#J( MTT$,";+I(`L)FJ>#YI"@13IH`0E:IH.6D*!5.F@%"5JG@]:0H$TZ:`,)HER1 M,<C-&; M%;T9HSC-&;ZOH;3%Z6T5OB]';*GI;T%F)=EB"T=LJ>EN,WG:B=ZBAQF%%FIF6+P(#E-CRK(,1,L&*1XDGY]%XA=G!"W M^%"?Q.J]7;VWB\5$Z?YX462Y+$PB-7K:I$J/(7C56QN3CRU+1VNY$?H"(`IV M5UFQ$08>BWLK6ZV22$ZSZ'$CE;'L?O_2DD]&JEC&Y_D^:<^9E%5PGJ=))$R2 M*6>>1$6FLY5!]"F2Z<1Z#:@8D)G)Z+%(S+/3KS'-4(5AD4@E@5K.2J1:UJ@_ MP0I#LDTNU+-5/WF)>M#+G&=38623=;A19U^+0L90]"#[/EAA9L^@,RVY9"W4 MO8R;V+>;.R]N9:%+I0/[H@^_O06[>)U;BCA1]PN1%-J9;,UX*R.3%2]MVII3 MNQ1G4=ET?T9+\B@3^E/J-3=(T][!.*V(Q2SM#94HG' M^`3.\"\ MJ>-Y^#IHHK'GN:4RUDJ8X_`;Y?C:`^64+$.7N[3FW6`W;"^""0F6I8`%_E$Q MJS*$A$O01^_:Q5".O(`!AX;@,0YI*XSQ@'P[!X&0B03S!7A62:E*,-[*"2D! M.]'+J5S_*UJ$@0]K4OG>VB?,@=T^!\US<)S3/@?-5_^@,X_P M5?&A^Y\!.GMS03=OVE?WJG7X/>C\!E!+`P04````"`#&4V1'FW'ZQSX!``!I M`P``$0```&1O8U!R;W!S+V-O&ULS9/!3L,P#(9?!?7>)=D`H:CK`1`G M)B$Q!.(6$F\+:Y,H\=3U[W_\^\X*:3CTGIX\M:!1PWA8E]7 M)G#IYMD&T7%"@MQ`+<(D5IB87%E?"XRA7Q,GY%:L@4PIO28UH%`"!3D`<]<3 ML[)0DDL/`JWO\$KV>+?S58(I2:""&@P&PB:,9.6+V1K;F((,^K*(CBL1<&&5 M7FE0M^U0]CL5.R/X.ASEH/KVZ>^?'E*&9%WE/NB^JFF:23-+=7%@1MX6C\_I M;')M`@HC(:J"YM@ZF&>GSJ^SN_OE0U9.*;O*&.3P;1=U%C!R-TFC4K+39\)I"!(KQUJ:T;A$N:;.,'"[N,3)(X'=<)T MV;;0-M:K4*;[-42'EQ-7MK:^/:9^1&>OJOP"4$L#!!0````(`,939$>97)PC M$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V M;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[ MSD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\,`*I4Q>M5II M`,,X?+&A`T%11 M6F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_. M;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:CTQ4(,@T[.IU8SG9\]L3M MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ- M4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'PZZ)QJO0=.MI)B?]KFND MZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;% M!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0UL\IM5`:")K(@?5'@B'% MW*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+`GQ^R-; M88C'(CN]WV6'WV M3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0'`*D"3&6H8;XM,:L M$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6 MQKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+ MRO`JQ`GH9%LE"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q? MY[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.7 M0[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&P MH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&ULK"0L1K=@N-?Q+!3@9&`M MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG" M:9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3 MON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QY MQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC" M1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MBOKJO3_DEG#NT>_&!()O\ MUMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA M9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%7C&9MC:CY$X*/-S^[PVP MPL2.X>V+OP%02P,$%`````@`QE-D1QB$3U),`@``=@H```T```!X;"]S='EL M97,N>&ULS59;:]LP%/XK0AFCA1';*4UI:QM&(3#8RJ!YZ%N1;=D6Z.+)5U!$NEJAO/J],2,U1/ M186Y7LF%9$CIJ2R\NI(89;79Q*@W\_VYQQ#A,`YYPQ9,U2`5#5<1O!@@X/;? MB0Q'\.GLZY]&J-LOP(V3;Y.)_W1^NXN?V85S"!S'CRR"P?P2>B\GG?K[>?7: M#O7\==3_8=XAOC+$7I><.,P%'W,T@PZ(P_H9K!#5_H%Q3P45$BA]"5J!13AB MV'G<(4H220R8(T;HVL$S`]A[Z_P8X4+:V"[";IRI/T:211)!O_N]/%PRLMO! M'(]0NGT\#<1AA93"DB_T!'3V.96"3ZFVR.>Y-VN-X09L/`?1N5%5T_9V2@C/LQ#IH M(;K9(?I@#WTZSU7L&%"0-H8KP7@(RKX5[(YMNM86Q M[VC.K!U;CEU5*-&/P*THFBS#.6JH^DU60MG%"([V3R,_F`]>RX$B@J/]"V>D M8==6P?C2C/\!4$L#!!0````(`,939$?F0M!#F0,``#8,```/````>&PO=V]R M:V)O;VLN>&ULE991;YLP$(#_BL53][`EF"1MHZ42)>Z*1B$"I]L>W>`LU@Q$ MV*S=?OULTFZ7Q6+K4["!S^>[#^?>J_ECTWY[:)IOZ*F2M9JW"V^G]7X^&JG- MCE=,O6OVO#;WMDU;,6V&[==1L]V*#5\VFZ[BM1[A\7@V:KED6C2UVHF]\IYI MZG]H:M]R5JH=Y[J2!UC%1.U=O5?SK9#\GK?*@!';[U-6\87W)#TDF=*D%)J7 M"V]BALTC/YIHN_UU)Z0=3,=3;V1A+UM=M6C3E/P`HSNA/CW?\%#)MZR3FII@ M7]9=>#Z>8#P[,.QC]X(_*@BT$XAMM/C.*7M8>&,/L4XW-T)JWBZ9YA_:IMN+ M^JMA>6@K6J4+N]W^R4K4HA(_;=QFI';-XVW3BI]-K9DL-FTC9?^6O=&_9%90 MOV=,C%ILCA[4["&WE5AXL[$!?A=*/`@I](^%UU]+;G@M*0KG,"8LC2`H6IW6D1%PB`9@`T)R;%)%KG,8W)`783QCD,YP*`+DY!811E:YN45?BE MQ_4!15&^-CDCGP'H$H`N'0DB%"5984`D-V4/^@V7VIQ`%_?4= M`@\6VI]!%#38=R@\6"S_'**@QK[#X\'/RK^`*"BR[S!YZ,-"9TN(@BK[#I<' M47@,#T0H-G:(/5A![$,4%!L[Q!Y&88@Z.J<=8@^CX$&-H>O8X?J@5W@"4=!V M[+#]]`@Q=>.:"8DH?](0!6W'#ML'%<70=@QMQZ^U'4/;,;0=.VP?1D';,;0= M.VP?1EU"%+0=.VP?1`70]@#:'KSV&`^@[0&T/7#8/HR"M@?0]N`?Q_B141V3 MZ@TD';4EKSW8T1E$0=F#R7-7]Z>1,[VLJ'EIVUS5+V/ZQ(WM?&PO=V]R:W-H965T&UL?57+CILP M%/T5Q`<,V#P"$4%*4E7MHM)H%NW:(4Y`8S"UG3#]^]J&$,8VL\$/SKGGVKZ/ M8J#LG=<8"^^C)1W?^;40_38(>%7C%O$7VN-._KE0UB(AE^P:\)YA=-:DE@0P M#-.@14WGEX7>>V5E06^"-!U^91Z_M2UB_PZ8T&'G`_^Q\=9<:Z$V@K((9MZY M:7''&]IY#%]V_AYLCR!6$(WXW>"!+^:>T?5!\KT4?X]AT>AS&/W$TT=P$.!'@3`#9EX1H(D1/@KZZ M8/1,G^L;$J@L&!T\-CY&C]2;@VTD;ZY2F^JBY)FX_*<097$OPR*X*S,3XK!$ M0(T`,R*0MF&P(CH-"(9;S@$>9HG;IG4*9-:,IDA8R-RM\#&*;"QZ,`,%0=D M)58RIT1F\XU@.3@@*]&2.R5RFQ\;\9A;SY'"+`=)G+F%5)EP959H2YFAY<*L M!!=8R5]@6S#CRX59.XLSB?<`VA9R4\7&P'!%Q9W)(+(M`%,ELEX'AF`E4X`[ MY8&=T=",LT^8=,28@18LBFR+V54W'^Y5]-:)L9K.NW.#VT-=I)_PLNC1%?]" M[-ITW#M1(4N]+M872@66KH0OLC[4L@7/"X(O0DTW&PO=V]R:W-H965T&UL?9?+;MLP$$5_1?`^$8Z.UO;16UTUW6IQ[/O371QWNZ.MB^[6 MG6SC_SFXMBYZ_]@^Q=VIM<5^#*JK6`J1Q'51-HOUMU'W M4M=%^W=C*W=>+6#Q_N*A?#KVPXMXO8RO8?G7L>'G[L5PLQ>+"5W?5#$X6_O-JMK:JA)9_YSZ71_SF'P/G] M>^O?QG*]_<>BLUM7_2[W_=&[%8MH;P_%2]4_N/-W>ZG!#`WN7-6-O]'NI>M= M_1ZRB.KB;;J6S7@]3_]DXA+&!\A+@+P&@/XT0%T"%`J()V=C75^+OE@O6W>. MVNECG(KAF\.=\CVW&UX.'>5KZOQ_@V*]?%U+O8Q?AW8NDLU<(B?)1\6649BK M)/;YKR8D:T+.XM44G_#QBHU7LW@]Q:>HB$G2C))TE(`")5`AC$J:4"V:]:*I MEPQYT;,L9I0HD<@<>:$JG229XKT8UHNA7E"6C2%9(%?(":/)\H"1A#62$".X MZS<)+5?E!H\TJDH`!/!>4M9+2KT`RI*2+%*8C$^2L4DRF@25LLEHDAR-E"W5 M@`IT?,[ZR*D/]'4W.?5A<(=0#0C)^QB@R7%&4"<$-(*.`6T$-L/($J5R'?`3 MX!X0YJC`/`<>6B!I10FN2!*K)LE)0525Y#H-N.$1")2!"C,0%,F3JA3/=D;E MIU@>&/[`4Q`H!A4>W$`))U5H5/&``THXA0D'#+X\;S5VPU%.IJ&OP',.*.@T M7F.`(9U)0W7S#`,*,0VX[CG%TG#=5"9EIO.`'QYW0'FG,>\X#1E[GVH^.N&! M!SF9USI`!LF32E)2:8-JX32XEL\U'YWPC))`6\"$N6CFGX]N)5A18$++P!:- MTDYCODB&=B!$BA=Q3B?\7!,!1SSQ)"6>QCLMR;`,FZ&2&P@YX6$G*>PTII"D ML+O1:2X3@_UP0K_O"XX=GHR2DM'@+9>DR%.@\;*Q961:&!W:X?-DE)2,>)>Q MD0D9IMSZS\BX]3^>'8%.Q9/]6;1/9=-%CZ[WIZGQ/'1PKK>^27'K2SSZ4^[U MH;*'?KA-_7T[G?NFA]Z=WH^QU[/T^A]02P,$%`````@`QE-D1]4H$_\G`@`` MC0<``!@```!X;"]W;W)K,LP.FI338`/80QJ5#5N MGNFQ5Y9G]")(U>!7YO!+72/V=X<)[;:NY]X&WJIS*=0`R#,P^HY5C1M>T<9A M^+1UOWF;O0>51"M^5[CCD[:CX`^4OJO.S^/6A8H!$UP(%0+)QQ7O,2$JDLS\ M,03]GU,9I^U;]!>]7(E_0!SO*?E3'44I::'K'/$)78AXH]T//*PA4@$+2KC^ M=XH+%[2^65RG1I_]LVKTL^MGXF2PV0W^8/!'@Q?>-02#(3`,H"?3Z_J.!,HS M1CN']8?1(G7FWB:0.U>H0;51L8Z'HAF)*&5)%R2 M1`9).$D2:8D']<^`>:R;\416GFC)$QL\T2*/27)/,6.(K0SQDB$Q&.*'#/<4 M,X;$RI`L&5*#(7GF#7D@FI&D5I)T2;(V2-*O3G[QCCRCG#&MK4SK!5-L9-JM M%YEB/UU[46ALX]XJ]+TD_6*75)&UU26X9/+,P@2?A;(K;51@4CA;=,:_$#M7 M#7<.5,@:K*OHB5*!952XDA]&*>_&L4/P2:AF(MNLORWZCJ#M[?(;;^#\'U!+ M`P04````"`#&4V1'2;EJ6*T#``!9$```&````'AL+W=OK);]V-=FM;37KBQJ\[4) MVFM5YS,67I/;F9_[D[_9C3&TZ? M']Y_Z^6Z\-_RUFQL^7=QZ,XNVF@1',PQOY;=-WO[W=PU)-[AWI9M_S?87]O. M5@^315#E/X;/HNX_;\,W670WXPW$W4",!N,\O(&\&\@/@_BG!O'=(/Z_,R1W M@P3-$`[:^\QM\RY?+1M["YJAW)?6*U?%^E8AF^ M>S]W9#U%Q(#(S\B6(C`2H9M_#$)P0:P%,4#?<+;QZQ]/+&/!_L4Y7I`ZAY1@X@T0=G>D9!%*"<42B+`2X1"`%H@5SN&4CJ;6="*5:6H M*HU4*3I+)A&TH9#06B%5%%)9A"M-(>VRR&O*6$T9T:1P$3*J*=)(T^X7T*=( M-!N)II$`RJ[FE@/.+H4T`-*TI1!H)7!Z*25<-6?RZSL7=Q1'5!6,)+9QO8*@DF(R@BEL"8* MJ9E^"7S#!-HQ%>Z8$',[(B%58+!4XL-IRV'N>"+[G>5TIN9V!-\\(:'Z%-:7 MT)6,M5'DBP"LC$)T%3*.)K\9/DOB^SG0AJYP0X=IAU6/DL7D$&.P-,;M>LMA MKF14',=I+68:._"='::M??C!,UMTOH\";:3XP%W#M$EF0ZS14T06]133#XQ4 MGG6&C]4=C\FY\O.M&6AOQN?N&FBS3$4FR#'/86E"CB(.4_@W\X[W1HH?3NY- ME6E._8VU#?;V6G=#O]J'^]7RDI_,GWES M*NHV>+.=N^WU][6CM9UQT4=/;F.>W3U_?"G-L?./RCTWP\UW>.GLY7&1'_^; ML/H/4$L#!!0````(`,939$?TJ^9?J@,``"T0```8````>&PO=V]R:W-H965T M&UL=9C;;J-($(9?!?G>H:N@@8X<2[%'J]V+E49SL7M-[+:- M!F@/X'CV[9=3'%)5?1,._JOKKSY\=&=S=\W/]F)M%_RNRKI]65VZ[OH_G%Q3Y5W_V)S#]MK8_#@&566(2B5AE1?U:KL9WWUOMAMWZ\JB MMM^;H+U55=[\M[.EN[^L8/7QXD=QOG3#BW"["1]QQZ*R=5NX.FCLZ67U"L][ M-(-D5/Q3V'N[N`\&\V_._1P>_CJ^K-3@P9;VT`U-Y/WEW>YM60XM]9E_S8U^ MYAP"E_KS>IU_29`Z3`W`.P$?`(X\<$,T!T6=`/%8Z.1OK M^I9W^7;3N'O03(-QS8H[[G#\'+HJ+ZFMO]M4&PW[]L,-^'[T,XLV2TE M.$K@H0C[QA\94,JP0Q9.$NRY(HGE#)%80[2(CZ8:(CD^%N/C17P\QJ<)Z8-) M4H^2=)2L01FDE4@RDZ5&=J-%-YI7X^F-1(Q/6#69)M4D"YMZ&E$TI!2NT1'* M/E+11\I]T%Y-68Y8$:S+C&=U,])%Q'RGQD;$<:XSHV`JB&!+9B1&=&.XD M(TX,'YDT!N*$BS")/7TR,$Q:]HI[H3-@UGRI.-6>-!ZZ`$MC%$T#O)Q,>=*( MB'D%Y&F`4@R%04Y33QX9-,!)8SQK`F34`&?-8C;/3F,^";2FDT!0:9UYS,BD M`3Y7 M**,(.8H,Q2)R%,5@D*)$D&DTD<^/S"P4F&6H'\ZL=02>V8XRM)!#"Y2BB3BU MT'AF,%)J9R_(4,>1A]8H,Q!C-HE!>3"*,KF0DPOH]-PA M9U+"MIY$41][O^I/Q=([];&:[N>9G^W?> MG(NZ#=YR;G.]B[54S^Y+_W9_?%0VE,WW*;]?3.=9J>'SET_#N>/ M_Q!L_P=02P,$%`````@`QE-D1W/-VJ&B`0``L0,``!@```!X;"]W;W)K?<<_DH1C2OM@-PY%U);0^T M:$HOB1?1=BXD6%FPA5<+!=H*U,1`0,H@Y`N_S9H?)0-QO;ZH/\5NO?L3M_"`\J^H7>?-)I34 MT/!!NA<8C=[PL#([$3$?;\W"#Z3[S!U&%9.C;6[1^+R#*XERFR6W!SD%HQAS7 MF&S"+`CFU9<2V5:)8_:%GFW3=YL.=ROZ;G9XMRV0;PKD*X'\FQ8W,&GRJ0A; MG:D"T\:G8TF%@W;3X2W9Y77>9_%./N!ET?,6?G/3"FW)"9V_V7@W#:(#;R6Y MNJ:D\_]G"20T+BQ_^+69GM04..PO'V3YI>5_4$L#!!0````(`,939$>=*V%( MG@$``+$#```8````>&PO=V]R:W-H965T&UL=5/;;MP@$/T5 MQ`<$F]VTTIW\?P%['2IT78(9SSISA4HQH M7UT'X,F;5L8=:>=]?V#,51UHX6ZP!Q-V&K1:^!#:EKG>@J@322O&L^P;TT(: M6A8I]VS+`@>OI(%G2]R@M;#_3J!P/-*<7A,OLNU\3+"R8`NOEAJ,DVB(A>9( M[_/#:1\1"?!;PNA6:Q*]GQ%?8_!8'VD6+8""RD<%$:8+/(!242@4_CMK?I2, MQ/7ZJOXS=1O++NQ%1%E;#G\W0G'_"RZ$4+ M3\*VTCAR1A]N-MU-@^@A6,EN;BGIPO]9`@6-C\OO86VG)S4%'OOK!UE^:?D. M4$L#!!0````(`,939$=^;%E>H0$``+$#```8````>&PO=V]R:W-H965T&UL=5/;;IPP$/T5RQ\0`\MNJQ6+E$U5-0^1HCRTSUX8P(KMH;99 MTK^O;5B"$O)B>\;GG#GC2S&B>;4=@"-O2FI[HIUS_9$Q6W6@N+W#'K3?:=`H M[GQH6F9[`[R.)"59EB0'IKC0M"QB[MF4!0Y."@W/AMA!*6[^G4'B>*(IO25> M1-NYD&!EP19>+11H*U`3`\V)WJ?'-(JL$Z5#<*)8J_3;/0<1ZGG4,ZT[8)V4S(%L+W)!J?"D6; M/[CC96%P)&8ZVIZ'&TR/F3^(*B1#W]ZB]7L!41;7,DWS@EV#T(PYKS'9A%D0 MS*LO);*M$N?L$SW;IN\V'>Y6]-WL<+\MD&\*Y"N!_(L6MS"'#T78ZDP5F#8^ M'4LJ'+2;#F_)+J_S/HMW\@XOBYZW\,1-*[0E%W3^9N/=-(@.O)7D;D])Y__/ M$DAH7%A^\VLS/:DI<-C?/LCR2\O_4$L#!!0````(`,939$<@>W8LH@$``+$# M```8````>&PO=V]R:W-H965T&UL=5/;;MP@$/T5Q`<$F]TT MVY774C95U3Y4BO+0/K/VV$8!Q@6\3O^^@+V.E;HOP`SGG#G#I1C1OKH.P),W MK8P[T<[[_LB8JSK0PMUA#R;L-&BU\"&T+7.]!5$GDE:,9]DGIH4TM"Q2[MF6 M!0Y>20//EKA!:V'_G$'A>*(YO25>9-OYF&!EP19>+348)]$0"\V)/N;'\SXB M$N"GA-&MUB1ZOR"^QN![?:)9M``**A\51)BN\`1*1:%0^/>L^5XR$M?KF_K7 MU&UP?Q$.GE#]DK7O@MF,DAH:,2C_@N,WF%NXCX(5*I=&4@W.H[Y1*-'B;9JE M2?,X[>P.,VV;P&<"7PB'+!F?"B6;7X0796%Q)'8ZVE[$&\R//!Q$%9.Q[V#1 MA;V(*(MKF>$B^R M:7U,L")G,Z^2&HR3:(B%^D#O-_OC+B(2X%7"X!9K$KV?$-]C\+LZT"Q:``6E MCPHB3&=X`*6B4"C\,6E^E8S$Y?JB_IBZ#>Y/PL$#JC=9^3:8S2BIH!:]\B\X M/,'4PFT4+%&Y-)*R=Q[UA4*)%I_C+$V:AW%GFTVT=0*?"'PF_$P$-A9*-G\) M+XK+2=B#>XV?-P$&5,QKZ#11?V(J+(S\6&9SD[1Z$);J3+WB1=Z*!/\(VTCAR0A]N-MU-C>@A6,EN;BEIP_^9`P6U MC\L?86W')S4&'KO+!YE_:?$/4$L#!!0````(`,939$<2J70RH0$``+$#```9 M````>&PO=V]R:W-H965TK\@OL?@N3[1+%H`!96/"B),5W@$I:)0*/QKUOPL&8GK]4W]>^HV MN+\(!X^H?LK:=\%L1DD-C1B4?\/Q">86#E&P0N722*K!>=0W"B5:?$RS-&D> MIYU#-M.V"7PF\(7P-1'85"C9_":\*`N+(['3T?8BWN#NR,-!5#$9^PX67=B+ MB+*XECN^+]@U"LV8\QK#)\R"8$%]*<&W2ISY/W2^3=]O.MROZ/O98;XMD&\* MY"N!_#\M;F$.?Q5AJS/58-OT=!RI<#!^.KPEN[S.!Y[NY!->%KUHX4785AI' M+NC#S::[:1`]!"O9W8&2+OR?)5#0^+C\$M9V>E)3X+&_?9#EEY9_`%!+`P04 M````"`#&4V1'AH@Y>*(!``"Q`P``&0```'AL+W=OE^`&BK??=D3%7MJ"%N\,.3-BIT6KA0V@; MYCH+HDHDK1C/L@>FA32TR%/NQ18Y]EY)`R^6N%YK8?^<0>%PHAMZ2[S*IO4Q MP8JQ%1Y-=BPQ]R=HU"$^:\Q/`1,R-84)]+ M\+429_X/G:_3MZL.MPOZ=G*X7Q?8K0KL%@*[_[2XACE\*<(69ZK!-NGI.%)B M;_QX>'-V?IV//-W))[S(.]'`3V$;:1RYH`\WF^ZF1O00K&1W]Y2TX?_,@8+: MQ^4^K.WXI,;`8W?[(/,O+?X"4$L#!!0````(`,939$&PO=V]R:W-H965TI.W* M:RF;*DH>*D5Y:)]9>VRC`.,"7J=_7\!>QTK=%V"&<\ZC\COL7@N3[2+%H`!96/"B),%W@`I:)0*/Q[UOPH&8GK]57],74; MW)^%@P=4OV3MNV`VHZ2&1@S*O^+X!',+MU&P0N722*K!>=17"B5:O$^S-&D> MIYT\GVG;!#X3^$+XFB7C4Z%D\[OPHBPLCL1.1]N+>(.[`P\'4<5D[#M8=&$O M(LKB4N[XMX)=HM",.:TQ?,(L"!;4EQ)\J\2)_T/GV_1\TV&^HN=3]3S;%MAO M"NQ7`OO_M+B!R3\WR59GJL&VZ>DX4N%@_'1X2W9YG?<\W;[J9!]!"L9#>WE'3A_RR!@L;'Y9>PMM.3F@*/_?6#++^T_`M02P,$ M%`````@`QE-D1X.W3V^A`0``L0,``!D```!X;"]W;W)K&UL=5/;;MP@$/T5Q`<$+W;::.6UE$U5M0^5HCRTSZP]ME&`<0&OT[\O M8*]CI>X+,,,Y9\YP*2>TKZX'\.1-*^-.M/=^.#+FZAZT<'[95B:-7TL"S)6[46M@_9U`XG>B!WA(OLNM] M3+"J9"NOD1J,DVB(A?9$'P_'`*EHE`H_'O1?"\9B=OU3?UKZC:XOP@'3ZA^R<;WP6Q&20.M&)5_P>D; M+"W<1\$:E4LCJ4?G4=\HE&CQ-L_2I'F:=XJ'A;9/X`N!KX2'+!F?"R6;7X07 M56EQ(G8^VD'$&SP<>3B(.B9CW\&B"WL14977ZI#SDEVCT((Y;S%\QJP(%M37 M$GROQ)G_0^?[]'S78;ZAYXO#?%^@V!4H-@+%?UK&PO=V]R:W-H965TGTHGM-]*A,^;&`L?OV!336R7(3X/#]'8$4H](?I@.PZ$MP:8Y) M9VU_P-A4'0AJ[E0/TNTT2@MJW5*WV/0::!U(@F.2ICLL*)-)683:JRX+-5C. M)+QJ9`8AJ/YW`J[&8Y(EU\(;:SOK"[@L\,*KF0!IF))(0W-,'K+#*?>(`'AG M,)K5'/GL9Z4^_.*E/B:ICP`<*NL5J!LN\`B<>R%G_#EK_EAZXGI^57\*W;KT M9VK@4?&_K+:="YLFJ(:&#MR^J?$9YA9"PDIQ$WY1-1BKQ)62($&_II'),([3 MSFX_T^($,A/(0KA/0_#)*,3\32TM"ZU&I*=/VU-_@MF!N`]1^:+OVT4T;L\C MRN)29IN\P!5Q@&Q78 MK@2V'9P`W8;[:5"E!FFG$UJJRQ-X M(.'@?^!ET=,6_E#=,FG065EW?<(%:)2RX**D=RY+YQ[ILN#06#_=N[F>[NVT ML*J_OL+EKZ#\!E!+`P04````"`#&4V1'*O_2(:,!``"Q`P``&0```'AL+W=O MO&EEW(GVW@]'QES= M@Q;N#@V8&RR()I&T8CS+/C$MI*%5F7+/MBIQ]$H:>+;$C5H+ M^_<,"J<3S>DM\2*[WL<$JTJV\AJIP3B)AEAH3_0Q/YZ+B$B`7Q(FMUF3Z/V" M^!J#'\V)9M$"**A]5!!ANL(3*!6%0N$_B^9[R4C,B2\;E0LOE5>%&5%B=BYZ,=1+S!_,C#0=0Q&?L.%EW8BXBJO%9YD97L M&H46S'F+X3-F1;"@OI;@>R7._#\ZWZ-O3#7#U_V!J,&4X8ZZH#0?6#'*"W.XU4@AJ[5"W6@P):>Y+@ MF,1QA@5E?506/O:JRD*.AK,>7A72HQ!4_;L`E],Y.D3WP!MK.^,"N"SPRJN9 M@%XSV2,%S3EZ.IPNN4-XP&\&D][,D`;. MG9`U_KMH?EHZXG9^5__NJ[797ZF&9\G_L-IT-MDX0C4T=.3F34X_8"DA=8*5 MY-I_435J(\6=$B%!/^:1]7Z@*>C7R:+]30LE!R0FH^ MVH&Z/W@X$7L0E0NZNFV*VNXY1%GHZLT]B+X5FZD-&!3B1_LJ7;VN5D7'!KCIKF=J_D&S@LC MA_M[LCYJY7]02P,$%`````@`QE-D1ZI9.EY8`@``"P@``!D```!X;"]W;W)K M&ULC55-CYLP$/TKB'L7F\\D(DB;9*/V4&FUA_;L M$">@!4QM9[/]][6-0PA,NKF`;=Y[\V:P9M(SX^^BH%0ZGW75B*5;2-DN/$_D M!:V)>&(M;=27`^,UD6K+CYYH.25[0ZHKSTZ)OSOBE;LO'2Q>SEX*X^%U`=>EGH];U_6M!$E:QQ.#TOW&2^VV$`,XE=) MSV*P=K3Y'6/O>O-COW21]D`KFDLM0=3K@ZYI56DE%?F/%;W&U,3A^J*^->DJ M^SLBZ)I5O\N]+)1;Y#I[>B"G2KZQ\W=J*Z]3DLWN7 MC7F?NR\S9&DPP;<$OR?T<6!"8`G!E1#^EQ!:0OAHA,@2HD]51^RNO(!@>@VR!K"Q".K4\PHX9 M&)-4N4=/ZGH7:C+WFXH>I%XF:LV[6=5M)&LOH[>?_]D_4$L#!!0````(`,93 M9$?F_E]Z"`,``*\,```9````>&PO=V]R:W-H965T[$SG5YLKU.-RA2("[%VWWX3B!3"A[47!<(Y MWSDG2;^&Y,*KC_K(F+"^BKRLY_91B-/,<>KMD16T?N`G5LHW>UX55,C'ZN#4 MIXK174,J<@>[;N@4-"OM-&G&7JHTX6>19R5[J:SZ7!2T^K=@.;_,;61?!UZS MPU&H`2=-G(ZWRPI6UADOK8KMY_8CFFT049`&\2=CE[IW;RGS[YQ_J(=?N[GM M*@\L9UNA2E!Y^61/+,]5):G\5Q?]UE3$_OVU^JJ)*^V_TYH]\?PMVXFC=.O: MUH[MZ3D7K_RR83I#H`IN>5XWOZWMN1:\N%)LJZ!?[34KF^NE?1.YF@83L";@ MCM#IP`1/$[QO@G^3X&N"?R\AT(3@7DNA)H3W*A!-(/M&E2[0RYD+=\I1)I\IBCT$^=3%=*811^#6TS@ M#3'/8TQH0-9`F0[A2).=4PPY76#`13"4>`(PH8%90IC02#/&X"%B-4:8T[;^ MLC$+B`#Q;P>P5\72`RYJ+%E`V&M#%"<_E7$"@TXJ[' MH,CWS3D!0-B+X5`!&"H`0DT4",$"X?W32L`"!'!@Y%R24<[0E3^P3`3*1&,9 MXAHRT4@FN*$3@SHQH(.,M8U[.D&#B>-)&?7?!.I%+C!OR&Q&[B@1"OI*;2<` M8#B8-C31'!&0W-S5&M2/'MR(#C:W1X0!I5&/Q2,EY!G!5Q#(Q1-FX+:"/,", MV=TT:+`.*#;^F`>@ULS4O,`-"@$=B@2F%0@43NC`/0,!38,04P<"11,Z<&M! MX1T=5X,&2XC-';X:H,@$:@V@_!%J`Z&FMS#<]-"XZ\6^F6S<]7PT]OP#JG7C M](XX!:L.S7FWMK;\7(K60#?:G:D?L3HB&>,+-%LB8/P9S5;0^%J=S9NCUK=L MFISH@?VFU2$K:^N="WE@:XY<>\X%DZ'&PO=V]R M:W-H965TEZSWK.2-C?\P"KY9LOKD@HYK'=>G9G#OJ.1?.7]3@Z?-S/55#JQ@:Z$DJ+R\LP4K"J4D(__I13]C M*N+P_JS^V)8KTW^E#5OPXG>^$7N9K>\Z&[:EQT*\\-.2]35$2G#-BZ;]==;' M1O#R3'&=DGYTU[QJKZ?N3>+W-)B`>P*^$%#X)2'H"<%40M@3PJF$J"=$GX3T M2P+I"61JA+@GQ%,)24](IA+2GI!.):@U[U;.GTRY+#;2*%ZW2]H]=D\%G6($PPQCQ"F'",^6YBM$A+$T$TD2OXRD">7Y[)& M&%XC/!`(NC1(#"L$L$(P4`B[%(@V81VD:B%Q5P>)M)E?0B"BU;LR04D8ZI," M@'"0PD6%<%&A411*"*P0P0K1](DEL`(Q<]#GXXZ8DQ;[OM9`3R8J&()&R<1P M,C$P(;'6.[$1!F%[H`0.E`"!$BU0`M9CB9/"<5(@CF9.*P`36W:!\E?0`_WK M[=%CNGJB+DZH+^)RA(HMJ!6`"@,=]7P--2[-9N_(*"TUK!*92V6DL[J&&J=C M<3*$S=5*;1H6+T/!]*Y%%NM`@'<0X^\J-"J.K#L862P&14#%R*)A,1E$_J-B MBS<@P!STBA<(<`=[TR*+.R#`'E)LT;!T/DJGEXPM;8W-MC9*?L!FE]GM$%NZ M#)M=AM)`CP2!;`Y57CO'(ACYOM<7'+ MN6!2T+^1>W@O/\@N@X)MA;J-Y7W=?:)T`\$/YR^NRV??_!]02P,$%`````@` MQE-D1P?7K[Z7`@``EPH``!D```!X;"]W;W)K&UL MC59-CYLP$/TKB'L7;,Q'(H+4I*K:0Z75'MJSDS@!+6"*G67[[VL#85E[B+B` M;=X\/WL>HTD[WKZ*G#'IO%=E+79N+F6S]3QQREE%Q1-O6*V^7'A;4:FF[=43 M34:$B/^%VP3LS&CA9_Y/Q53WZ>=ZZO M-;"2G:2FH.KUQ@ZL+#63VOGO2/JQIPZ.>V0C(;JG*-MH&[NI!?U1:DS"?5-([+T M+4.;./7>--&(V<\QN,?@SX@#@`@GB*<$3"HPJ`+/XH-110(3!"!!,",@(\'& M.,:`J7M,W&,"/\*)<10;19(X1+`8`HHAEACUUQABR&R;L,=$AA`;@2)810BJ M"`$5R%`16GM\"0T9``0OZ(A`'1&@P_#//K(VT:DQ$GBP42HU9"$U,2@F!L0$ M,$$"$B3KG;H!"38KG+H!K\-TJHTB4;3Q83&ZED&_O[_"JR/HD5D!R));T4(A M0BO\.H(>&A;"X(4<([@<(;S"LR/(K">F:3_!IC0E2X+@\H;L^H9]LD`!%R5$ MUCL7P14%V27%]BX`(H%Y)W91P7ZT\",CN*P@J*Y8SK5!9.GFX8*!H(IAV=(& MV6>.;5LN28%+#TK6N-(&V5(2R[G8#TTO>+,6HJ%7]HNVUZ(6SI%+U8WT_<2% M<\D4H_^D$IJK+G&:E.PB]3!6XW;HFX:)Y,V]#9QZT>P_4$L#!!0````(`,93 M9$>HRNA>,`,``+,1```9````>&PO=V]R:W-H965TVRC`N(#C].W+`'9L.$.'C;F= M_W#FA\\#Q&=5OE4'*6OG(\^*:ND>ZOKXZ'G5YB#SI'I01UDT1W:JS).ZV2SW M7G4L9;)MB_+,8X0$7IZDA;N*VWW/Y2I6ISI+"_E<.M4ISY/R[Y/,U'GI4O>R MXR7='VJ]PUO%WK5NF^:RJ%)5.*7<+=TO]'$MB):TBE^I/%0F=S4VB)I%N]R+;-,.S5G_M.;?IY3%]ZN7]R_M<-MXK\FE5RK['>Z MK0]-6N(Z6[E+3EG]HL[?93\&7QMN5%:UO\[F5-4JOY2X3IY\=,NT:)?G[DA$ M^C)

=&ZC=^I& M-6.JFF-:L8K?5XSXL?>NC7K-TZV&=9I[Q1HH/DV\)L`U!8,IV$T][U,$V(!# M`WYC('J#<#",3E.TFK#54+K@@\&N@8J$@N`P`H81($PT""-N3N.W&L'\0`S" MC%7^0D04A_%A&!^$66"#`!H$]M03#'*U(9E M(!K?NI.:^R@89(I(%@8+C#*=P3+#+#,;EH%HU)!IS7T43#)#))MF8<,T/(-D MADEF-B0#T;@ADYK[*)AA9L,P&\.)9AX@$U$H##,'PPPSQ+"IO9AA-H-AAAEF M-@PSNPF9S9J1&2:9(9)#@P4FF5`C2#?3 M*2VH=4/=8S-JH&T@"8Y)GC]B09G,ZBK4WG1=J63]87\!UA5=>RP1(PY1$&KIC]EP<3J5'!,!O!K/9])'/?E;JPP]^MLMJI#W\ MHKIGTJ"SLN[^A!O0*67!!W#BP:KP^P_5?4/\' M4$L#!!0````(`,939$>8OMT&$`(``&(&```9````>&PO=V]R:W-H965T`',N9BS?9$Z*"=T9'>0I[I:8C`++I"1""OC&'Q^YE0/I_" M.+Q/O`Z77ID)4)7@X6L'1D8Y\#$0I#N%G^)C71B%%?P8R"PW_<"PGSE_,X-O M[2F,#`*AI%$F`M;-C=2$4A-(;_QKC?FQI3%N^_?H7VRVFOZ,):DY_3FTJM>P M41BTI,-7JE[Y_)6L*2`3L.%4VF_07*7B[&X)`X;?EW88;3LO*T6TVOR&9#4D M#T.<_M<`5P-T#&`ALWE]Q@I7I>!S():[F+"Y\O@(]:Q)T\(.D7I#4`Y([(.EF$[1DBZ`CJO>B)(:1'P5Y49`' MI7!0T&X7&.?00?&(<@3]*)D7)?.@'!R4;+\+#Y%Z0?`^R.=0% M)-^??.%HZKTF2__Q8`LO2.$!B1V08O<8479P1/5>E!U2]TS`IAQ,^$*^8W$9 M1AF[1(FW9^5 M<"1GJEYX]QWZ(R1&L.!4VJ]7G*7B[$KQ/4;>W%@W=NSV8QFBQ6-^)$[)?[/.>-9@7@D$/?5GI0R=YC&8A*+>8QB MO,3)I"+WN.5JM<*/T[)\46__N9X[(!I=+0;B9!^U]`I^;I0KRQ`=^L83-E=S M$L_#]3:]TGW%MX2:?I2TYP4\B3G4CO0-7^D'8*WWD7(&V'SSHAU#I3C@L M*!R5F2[U7+CFX!:*M]=6-_3;[!]02P,$%`````@`QE-D1[#8F)&/`@``&ULE5;+DJ,@%/T5RP]H17PE M9:S*:VIF,55=O9A9$T,2JU4<(&W/WP^@,09(.K,)#\\YW'L@%[*.T'=VPI@[ MGW75L(5[XKR=>QXK3KA&[(6TN!%?#H36B(LA/7JLI1CM%:FNO,#W8Z]&9>/F MF9I[I7E&SKPJ&_Q*'7:N:T3_KG!%NH4+W,O$6WD\<3GAY9DW\O9EC1M6DL:A M^+!PEV"^!5!"%.)7B3LVZ3LR^!TA[W+P8[]P?1D#KG#!I002S0=>XZJ22F+E M/X/H=4U)G/8OZM]4NB+\'6)X3:K?Y9Z?1+2^Z^SQ`9TK_D:Z[WC((9*"!:F8 M^G6*,^.DOE!">%#0C@0PF=7 MB`9"I*W@];DKYS:(HSRCI'-HO]TMDJ<*S".Q-X6P##S M/J30@%E-,8'"Q/`6LC$A8$1X(H`QBL`6Q2HPZ,'M`FL3$6MA;KX4V3X4N0D3 M6LV"$SX<+39))FU'L1ZB?,@DDUG8V)B6"J66IB MTNC.*4NM":6FHS,[?V;ESYYW5-906U'PG_!T`$W/#HQFFJDWH-Z-<*;_<2U* M(/"U\[RU2('$C^\D=J?:`4MBR1T):ZE:@N`_[+67$0"?L=<$A5!W%QK&I49E M_EIG^UBG3\F;W"@UID=UES.G(.>&]T:,L^-[81G(&TF;7X'Y&ECF-_)]H6ZP MJWR>M>B(?R)Z+!OF[`@7]Z"ZR0Z$<"Q"]U]$_3F)%]`XJ/"!RVXB^K1_$_0# M3MK+$V=\9^7_`%!+`P04````"`#&4V1'%@KHE5P"``"M!P``&0```'AL+W=O M,;Y0ZIW?1'"!)]-W>IM>#'FNHEC M75Y$PW4DKZ*U*R>I&F[L4)UC?56"'[U34\!WK!K1ZDJV@1*G;;A#FSVBSL1; M_*G$0X_Z@0O^(.6[&_PZ;L/$Q2!J41HGP6US%R^BKIV2)7_THE],YSCN/]5_ M^.W:\`]O;1[>2);T;[(![!SPX$.\0=R`?YG=N>)$K^0A4=[97[GXAVF![$*6; M=/NV(6J[YBR*_%Y@DN7QW0GU-ONQ#?8V:+"(K?J`P!!BCV?NF*QA`0+&2$8" MI!.@"2Q`00$Z$J"]`)ILLK-IO0WS-FF*Z0I1&,1`$`-`>`)B,Q!BB&1L84U?=6])MW`R.OS<1Q>Z.(_4$L#!!0` M```(`,939$=#?U]0)`(``(8&```9````>&PO=V]R:W-H965TVATFH/[=D!)Z`%3&TG;-^^MB$L M@LDEV.:?_YNQXR$;A/Q0%>?:^VR;3AW]2NO^$`2JJ'C+U$[TO#-O+D*V3)NI MO`:JEYR5+JAM`H)0'+2L[OP\S;YLQ`?=O*S//K( MYL`;7FAKP!R_'#_[LHUZ9^9XJ^B^5.7NC+9(M\K M^87=&OTNAA]\JH%:PT(TROUZQ4UIT3Y"?*]EG^.S[MQS&-^D:`J#`\@40.:` M,'&)CR"7YC>F69Y),7ARW-N>V2/$!V(VHK"+MFZ3HC+OK"+/[CFA)`ONUFC2 MG)8:XC1X5@3&?480"'$BFW!"0]@@!',,%P;A9!#!!A%H$"T,HLF`KHH<-9W3 M4*=),8T1>5(J!4$4`,4K$%V`4J>)=N1).3%(B0%*LJ)`FA2&)"`D`0SV*TBR M*"49]RQZ!.T!$%Z!]IN#H3M,8(J]Z=!M M0@!G73M47B%NG1X;PKPZM]P7 MXOK,ESS/>G;EOYB\UIWRSD*;;N7ZS44(S4TJ:&?^])7Y*,R3AE^T'29F+,I"-V"+P(``-(&```9````>&PO M=V]R:W-H965T$4$*=FJ:@^5 M5GMHSPYQ`EK`U';"]MO7#\*R8-3V@E\S_]_,((^SGO%745(JO;>F;L7>+Z7L M=@"(HJ0-$1O6T5:=7!AOB%1+?@6BXY2F;UGGF?L)NNJ MI<_<$[>F(?SWD=:LW_O(?VR\5-=2Z@V09V#T.U<-;47%6H_3R]X_H-T186UB M+'Y4M!>3N:>#/S'VJA??SGL?ZAAH30NI)8@:[O2)UK564N1?@^@[4SM.YP_U M+R9=%?Z)"/K$ZI_5698J6NA[9WHAMUJ^L/XK'7((M6#!:F&^7G$3DC4/%]]K MR)L=J]:,O3U)X.#F=L"#`QX=`N,`+,B$^9E(DF><]1ZWM>V(_H5HAU4A"KVI M\U8A"G6F+?+LGN,HS,!="PTVQZD--C9HM`!*?41@%^*(%^XX2-T"@3/&8"(0 M6($M=`MLG0+;B,/IW,2^B^2\W(> M$';DA.TU!^-:U5>`6[M=(VEW%W;-\'T[W!NWF>=>1*OQ-^K5KA MG9A4G<_TK@MCDJI@X$;=H%(],..BIA>II[&:<]MR[4*R[O&"C,]8_@=02P,$ M%`````@`QE-D1Y'L049,`@``C0<``!D```!X;"]W;W)K&ULA97=CILP$(5?!?$`P4#XBPC2)E757E1:[45[[1`GH#68VD[8OGUM M0UAB)MD;L,V9.=\8>9SWC+^+BA#I?#2T%5NWDK+;>)XH*])@L6(=:=67$^,- MEFK*SY[H.,%'$]10+T`H]AIZG,E]8)7Y-X4=ZP;THJ:M0XGIZW[XF_VOI$8Q>^:]&(V=C3\@;%W/?EY MW+I(,Q!*2JE38/6ZDCVA5&=2SG_'I)^>.G`^OF7_;LI5^`N.M&HVR"17B0K"T+0!.%L$D( MEAK.$H1C@C6<8`TF6,\2K$?*R-JK0=,:36(T&4JM2IYK[D`B$"0"0&(+)%J8 M1+[%\51RAQ&#&#&`D5@8\Q3[,VZ7T/XV=P*PBG9I95#FYM6IYOG)3#= M\U->Y!T^DU^8G^M6.`&PO=V]R M:W-H965T6)S M8!453_S(:O5GQYN*2M5L]IXX-HQN6U)5>MCW(Z^B1>WF6=OWVN09/\FRJ-EK MXXA35='FWYR5_#QUD7OI>"OV!ZD[O#SS!MZVJ%@M"EX[#=M-W1F:O*!`0UK$ M[X*=Q:CNZ.#7G+_KQL_MU/5U#*QD&ZDEJ"H^V(*5I592SG][T:NG)H[K%_55 MFZX*?TT%6_#R3[&5!Q6M[SI;MJ.G4K[Q\P_6YT"TX(:7HOTZFY.0O+I07*>B MGUU9U&UY[OXD?D^#";@GX($P^,"$H"<$5T+X)2'L">&C#J0GD$<=HIX070G1 MEX2X)\0&P>M&MYV;)94TSQI^=IIN01VI7K=H$JO9W^A./=EJ7H3ZIQ%Y]I'C MA&3>AQ;J,?,Q!K>8*+B%+&T(ND6L``0);S$O-@8GT8#Q5")#-AC*9HYM@5N+ MA8V(C"B6WXH\?R^R`D22V$CW*Z.;9`-PZH(1/>CHHQ&]$0A!@7`D$/8Q)L;< M=YBZQ<0MAOC&U"YL3&PM$!N#XM`0>K9!.`H#."4"ID2`E%)8(`(%HL<'-08% M8CN"U#<61SS*DW28$$=I#/LDH$\"^)A[#L`D=Y))09,4,#$VPRH=)9-TF">" M8!=]*T"'D`_X!.;AX%NCEF`2W+C.LKRZC?XXF"P3T+]'DN7N87.7S[$CW[!=M]D4MG#67ZL)L MK[P=YY*IT/TG=30YYT#&ULE59=DYHP%/TK##]@(8&H.,B,7YWVH3,[^]`^1XW*+!":Q&7[[YL`(L+- M5GV0))QS[KT)!VY<+`6CAYJ49Q[V_8F7T[1PD[A>>Q5)S"\J2POV*AQYR7,J_JY8QJN%B]SK MPEMZ.BNSX"6QU_$.:RX<)=HOL6A@=2(7RFK9&_LF.1WG+^;R8_# MPO5-#BQC>V4DJ+Y\L#7+,J.D(_]I16\Q#;$_OJI_J\O5Z>^H9&N>_4X/ZJRS M]5WGP([TDJDW7GUG;0W$".YY)NM_9W^1BN=7BNOD]+.YID5]K9H[,[^EP03< M$G!'Z.+`A*`E!#="^"4A;`GAHP32$L@@):^IO=ZY#54TB06O'-$<=TG-4X7F M1)_-WBR:H]"[)O4]@TCBCP1'D]C[,$(M9M7'X!J#2'"/V0*8#N'I#+HT,)3& M"H_H.)K>AUA#F-D]9@-AHD&J``9.-0!W+.C1PYH>^#XL$(("84\@:.*3$!8@ MH``998##P49L&TQ18TA[9BB8$4NF$S#0!"C5*DS4&#V_U(WLW&I MOOG!<2(P3@14:GDJS'L',I+_>*W(XD4$9#$PV@8$V>*`9ELB#$@0BP1L`A0\ M42UL`Q0^4BT$LL6!W8(`NT1H&&<,"OR))0YL%@2Y96J1@.V"GO`+@@V#QHX) M_*%CT-@R062W#((]@R#31):W/FP:_(1I,&P:#/EA4/"J!=V](_!=P>TG9HPC M]GW!L+TP8"]DDX#MA9^P%X;MA2'GC/8E!/:%C`OV>NU$SL2I;N2DL^>70C4? MT6ZU:Q:7V+0C@_45FF^:EN\FD\0E/;&?5)S20CH[KG2S4[&ULE5;!CILP$/T5 MQ`=A9 M)^2;*AG3WGO-&[7Q2ZW;YR!01%U^I<:KL0Y%DPQAVK MFC6J$HTGV6GC;]'S'J46XA`_*]:IR=BSR1^$>+.3[\>-']H<&&>%MA34/*YL MSSBW3$;Y]T#ZH6D#I^,;^U=7KDG_0!7;"_ZK.NK29!OZWI&=Z(7K5]%]8T,- MD24L!%?NURLN2HOZ%N)[-7WOGU7CGEW_)DF',#@`#P%X#"#HOP%D""!C`(I= MI7UFKJXO5-,\DZ+S9+\9+;5[CIZ)Z5QA%VVC3$W*O+.(/+OF!*$LN%JB`;.; M8K##S!![`!&M1DQ@,AC3P%`:.WQ'@&<2`"*"%0A8*)G$DZ%0#!.L0(+5A&`U M$)!9IR#,0A\B4"0""**9"(`)8U@D!D5B0&2!(`$)DL=[N08)UD`&R6S#>TSC M,$F/(2@-4U@G!7520&<]TTDG.M'PWPV7=LU^$B`7A8#00J9HP8CH\:8BT$1; MA!]HZP#ZMUZ\(DL%PVY"Y('.#J"IU#HF"SJPZ1#@*!PN4,"60M$G&@L;!D&. MN6ML?%PMM/Y$O;!M$.`;//\@H_3.H%$R3S68G$,U MDV=W/BNO$)=&]P?.N#K>`;;8G6,?\#QKZ9G]H/)<->G830S.02 M/ID]+LTM99QP=M)VF)BQ[,_M?J)%>[N&C'>A_"]02P,$%`````@`QE-D1U^I M\4MI`@``R`@``!D```!X;"]W;W)K&ULE59=DYL@ M%/TKCC]@%?`CV3'.Y&,[[4-G=O:A?2:&1&=5+)"X_?<%-,;5FT[V10'/.?=< M\`))R\6[S!E3SD=5UG+EYDHUSYXGLYQ55#[QAM7ZRY&+BBK=%2=/-H+1@R55 MI8=]/_(J6M1NFMBQ5Y$F_*S*HF:OPI'GJJ+B[X:5O%VYR+T.O!6G7)D!+TV\ M@7.8,>5NT;/+R@R$(OX5;!6CMJ.,;_G_-UT?AQ6KF\\L))ERDA0 M_;JP+2M+HZ0C_^E%;S$-<=R^JG^SZ6K[>RK9EI>_BX/*M5O?=0[L2,^E>N/M M=];G$!K!C)?2/IWL+!6OKA37J>A']RYJ^VZ[+S'I:3`!]P0\$(8X,('T!/(H M(>@)P8T0_9<0]H3P1@CL7':YVYG;44731/#6$=UR-]3\5>@YU&N3F4&S%'K6 MI/YF$&ER20DFB7`:FB.Q)@(:X1_D*R<($@`KC` MTTV%S))=D#MAX#)"\SI:WEE6!/__*/Q"KG`%H.B17*-9KG@QM>J-MO6*B9,] M4*63\7.MNOU[&!T.[36VQ\(-GB8-/;&?5)R*6CI[KO3A8H^'(^>*:2_^D\XY MU]>*H5.RHS+-6+=%=]!V'<6;Z[UAN+RD_P!02P,$%`````@`QE-D1SC?50XV M.```K]\``!0```!X;"]S:&%R9613=')I;F=S+GAM;.U]67/C5GKH<_I7H%S* MO>HJD,U%U.*9N(K-5ML:JR594MN92MT'B`1%3(,`C45JIN;!/R(OJ4K^G'_) M_;:S``?@HO9D)LE491PU`9SE.]^^G=_G>>&52?1S&4[2,BG^Z:OA#)/LV50P#^SQS?Y*@N#6;X(PV(9OQGT M>L=OED&4?/7-[_/HF]\7W[Q+I^4R3`HO2&;>>5)$Q=J[2'B$*$V\CI>Y=7$U:OI_`Y%D0 MPZ2S\+/W?;BNOW>?!;,H>?3NULN'-*X_#;*?G=\F99;AEMY'^11&_F,89`@V M[UU0..OK=/J#SK#?LKCW41QFW@2^>TPS9V7CZ32$Y_!TQF^V;3%=+@&4=T4Z M_>1[=W2^WG59Y`4`';;6>B;WZY6SX'ZO\T/K!S=A%J6SULTJ-'GU#__0A`MC M&&-&X[R/`V=5\R#.G1'US#:LW\./#@+7WY2E-K[[P]`YTNNK=^=7=^?OO+?C MR_'5Y-R[^^[\_/[.._R8!.4L@B-X#;3S\>Z==WCPVCOPHL2[7Z1E#A!VEQ). M`0Q](HBC-N0)\CPL\J^=QT&^(%J9XA_ASV7T%,3POC/)AR#[%!;!0QQZ>3@M MLZB(PKR3+]*L\(HP6];?O\G"51#-O/`S,)4<$`0G28L%X-^TLB2'/M("P+GY MG>;%Q"F05?-:@+-E@+FX!MSC"D_.]Y*P<)@+K7#3RIJ?*3#'4?`0Q;0>!]9` M7\B"`5`!H96#KW9N$\A!]G7A8^A4GI(K%Z_@B< MVH-O8(-`R-#B0H\$T:3*8@& MX"-A,G5?1M'U=;X*IN$_?06R*0^SI_"K;SR'-2!S6J3Q+,SR_TMG7JR=`P$< ME1WES,L.>MU>'XXG\X`*RO!W7M_O]7KX/Q%C7E`6@/+1OX:SWWE)JGZ-\AS/ M,,V\M)T-"MMLG8HG:IOL>."?GO7]T=$I@0C_.>C[)Z?]VAJ(S,PBO*#P@$T6 MX?(!\%J)5'H+V(;\*JS#AX/-5^&TB)["V)4.,V!+<+IPE$C8'4"M:;"*X&@; M\+Q30*.-3WG#"6S&/ M-K[+ESLQZ,.;`/%^$181B(`<.?:!]Z9%X[DK8$\D,:[G(#22`+`;Y4::1ULT M$P=--=9XAW`*LS2.@PRX"@":IG9@Z@S@X->N7S"2[?KVSL2P[X:J7V_=3>/K MS5MI?'73/C2>W-V/[\\_G%\!CER_]ZYOSF_']Q?75W?>^.J=-[G^<'-[_AV\ M>?'CN7=Y??WX=@M<-]^&28C:,TG&V3)*2!='AM0P8I&5TP*$/W(YHUS@8EI$G+/. M^GN7P)&\>98N/508R&)PWKE(0,6`R86-M3Z6.9H5#,4"Y24'P:]`L")[K/_^ M,0%S+$8<9^'./!1E_+)))6K`;HL/-TWP-LBC*9]2%)?(A!-9BB%'YW2OG%=V MI..?PNAQ@9,$3P#NQ]![<*:?"D$ZE$A3\,\N?VBARLGX[COO_>7U3R\C/U*6 MYW'Z7$42Q#\4FBU:W^Q/92[*39$"#8%V,P7KR@`6?L6_20,O<]@S:FV[#/TN MA-,$*4+R@TAFB1K8OP9-6MC8>H9*&WRZC,KESKA3_WZVGY9YE28=VB&Q5M(( M``T;5_JM#!@`>>-D:)%N6-C%$O21C!@4;:M)UV^;@M:\\U>310!::5X['[(' MZ,--RO\&>ZC9HJAKVTU$MQ5EMF%PE#P!K]J"9C=?CU1"%UY\B$+#>P[H10MN@.F?M;@M4 M*RL-EZLX78>AD,"^TT*;)FWZ$$1/AD3JD0*_H_7?ZB;PO8?P,4H2 MG!$%4JU*"W"Z2))X_1Q M3:PO2(`*>'TH_8`;@#D6!\_X^33-P)#F9<,9]<_.A@"F1QB(R!Q8!MIIS1H: M@!(.(WTBE0E?S8)56()Y0B14P,$CYB13L'SHVPPGG$4Y(D3>]:Y+H%)0C&EJ M176S<@K"*H5)O%E6/N;>8,R)3;0G[@]WD2V(2`3/N8@'3/4=Q M#%ROP)/&*:,E8BTM#ACF$W.5%"9>P:(1*;H@@&%_,ED19(^`M0!"`!["%-]; M/`?K'$>*X9>"X1+`3#,`#;)HB3I!CT]P%:U"^`4/!W0G5"-AACFMF@!$4)U%,U@,('4`.X;GSXL(CR@C M4N-]A#,?MT+<+^N@?9O`9*MTA1:O60EN'8]E"H#*UEXXGX/L!4Z!SD62C%Y2 MDNG.,R&D)>A(O&D3_S`4'X1'0.WITH@?O<'S[ M`Z#TR6N`$BP.=/UXK35]P">`3[Y$^"W3&.1"C+!;1`]1D=)F$6FFG0\AVB+3 M<(6_%NL,3&@X&MG7X:^__`>\JGWF M/,,]I%L^(##5&VMQ)L),9B$$*1A\R]$*D2V(\&M?QR)=@ MN5EG9%$NC14QFK=10;F"8=BG6!*^/9*568BWK%S-Z&_].?Y8H2IX'E@X;J;' MM2(/T[B"X%J`H@="')``B!J?9""5@>0!:J@%P1O?328"0ICIF86&^%!C)*L$ M28B0\3GU;E`%\(;`O*,@%N9KGSDAP@(,*&`[>4I$&2.C\4!"Q!%P&>9@"#AT M.3^JX!B\^``4(XR:45SF<`"`2FL6L0U3.SQ;CX5?.@((FB=G";`,UDI3(5#B M\>;E"KW%'CKZU!)E=N3EQM=8X=)JI\#V48EFZS#,R)&6,8M#,6<6AV2\*)>! M(L\*ZL"K-7(1\?JQ>P?X?UZBUNA[=V!T+KPQS`-?TG9%!!>*(Q':@R[S>1J7 M9)K^(0`)7Y$\#*%Q'N%2,`H`3!3(]1E^#1$%=MB60X:,DL%C%H;VT9#P5-BA M`8^06(&U&:'*/2])$UJ"&0KZ9H*OKY>LD&7I.HC)50IXH;@YZM&Y[V@;\Y(L M<=\^,CK!ZS-!=]%/\UCS+D'JQ=J"/^@('<\W/&.=K80;]7 MG<=EB[6I=IAF?'\/VB'JAC01G%@"R`%L",2GN-V'M-T`M+82,'3&<'('7`#C M>0C#!%1!D"RQT057T1-YMQ2?`)EV\:/L"Y>FB0&5[2(J8EQS21@5P*8-<#4V MH`*&9*NQXQD4U"0LB&&BM8^8C_R6'?6H(;#3!Z93JYBB[^=!J;'L>8,%\WXE MQI.#)<`L[QF5T!FH9X4Z=P\U9&7C6'82,/O<7NE/B"FX)EB;D3Y"-(CSA`\6 MS@KK$_*R_!FHF/3.!CZ\C?B+)Y$JY8//\OM[L%4!#\(WQ2(+T\0H';PE4OMT MO(,T([2V@">@$$IFJ*\!V'"<*GB(;FMH#<9?7B(!(4-;A%'&.D*,0(I8,P\K2Y])^,">U12DP\`I/833 M8$G,;X6*,/$2`+(P`F&,F"`R"[6^QBC1%Y2DO0JL8;AU*OP4Y3.:82"A[5G% M,O311GI&O0IM)4`-X6"-:D;K$1/RJ+,A,\-`30-GP5HLV]7$TDD'-GRX=E`- M2.:#R$O*>6![I]GA(?Q"[9]4>8.VZ/T$*?>1H$>+U2]8@*HS;M`M@$`*C,BBKF. M>:$N3S^E#W'T*-(8?A089R&'_PCSHURIS[F,;"\A]FU>-@>+#H`? M`"=_S-)GV!EB*QZ!,JM0DWW_[?M;LA+F`>#:F@\9UW!RW,6X8S= M"Z*]D665A%.T^`2&I?@E258@+3:Y05GI`'`#%4:L8J.%%9+O"92;(%.QX><` M';PT#IK`XI4#W0?@@ZY=MI?5/SH*55G`J<_2.2@_,J"P^93U/2#1G,+G9#&F M21).C01`9[YM@U@^"%`K\7,]V)H4Z%BM>HE:-"K/ONCNZ3PD+PY\C%,RK\MA M;5/C;YDJKV5[,(/A9J!E((CDI30[S9:TZ\"(MS1CL&">!L$$9D%!QMD2BG/I MH5B8$&M77R"W8@Y+`G>)`5"1"CFZ#V&DE@0'SFG`]6!X!1!%XPDJ-&8O,W1\ M).A#K:S#`$3[[-FCPVH@H[4.W("1P!Y@F..@?](=:/9,RN5@U-4,NYIGP6A, M8V3H&LU$F4>KZ0E9FCI<6*FH0&F.#KEG\A(GE"P1GW6-8=2 M79$7VYMP#%_G,,8:F4B(\4QV'%E6F?)1AE5-)M?F$8S3!VL'Q-G@(*/"_0ZW-]?:`88I:#"`#E(#@!YP0H#/*U:#@AV=$/#0 M@8@#)(*!\^`)T$Z^*>&`+^8H0`!H2%J\2Q3,>.+!4Q#%^*Z>D=@?G70.<`1*6B$_H=E`6HLBGF-47^&"Z_F"O:Q`P"F)3,-J+2Q:TEP"%`2#A5BN M+F.\(2L,+9(PA6&"J<07<%R$+'L4C/*5JPR0O&YC>%D9BT`!FTIYI)4:CTX1 MX+0J5L<)UI^G%!*EE&")&Z#B<'=.#JZN-Q'W1Y14/9SS-"T`Y*003>,T1R*& M,T`#AS05,9JBI&7A:L?H>(`-9S-REI(49><>N96GJ,N$E&.)+A>$"'!]&&T5 M*]E&)K4!$Z+.,B)+MP:L,669Y:*3X5>!+,V7H$L4QB)G'*P$9.W2Z_'*DQ%X]8RK):4:I$BFTPD,E]-7FZ`OT&Q2$:SH&5)G$H&@=92PEK&XP< MJ&N4&1M5YH/7-DDCW0#91YF96A&16=5*9=T%A-^N`N';CCY;DEHL547^!.+R6,P8V M3_H-$81(:JVI/&V(LQIW`1%(^\3(#?53YHDW-:Y;M?%)Y/XIC<@O5@F"1#,4 M'',5>A`G?:,'A,+`8A(2'MV\Z_3Y!-Y==OHZ=F36S5%:0`MF457W#N*]45D9 M`1,1Y9B1A78%BQNT@F;L]*A&4,SB;.\#A5/2%8@^RTN#4D]+R;I&)VUC#81]9 M1^XHJ_6SW,]CUN!"H0D4SX'3[ZBH1;=^)BX4T&LC&KUAQ@#=8I&EY2-`@;T3 M*D[X4$KZ`&U1#X<(PX$&^`N7@$GN*M"":I02TN))EIC&N@XX&MHX48-YP=%> MC_PB8@M:/BK4US%C+9]'HF:2`X?I&)9`QM=QKS,+UOFOO_R[\M2"71E&A(VX M?5A%S4UV;\)5ADU=)T9Z]T]1.O1.F_B5`!\-H(Y[HAN]P$U>9S8DZ,@5[_,M MNC#A07;9-OE8S6[@-%IC;[]II`U$S0+.$#-"U>_?82W0]_"?UVK8[U/0O&C0 M^R!ZQH\X^.:&>=!OZ3A^YVFVG63J&*:IDK62@V/CM.74/?%_\"D2UQ2L:_+C MD@7CBQ/"=@='%K(PHE`XHA)'/1A9D\,'%H>M[8J"?0VQ071KY9B*LR;&U1#R MR3%YYR-'VVN0,;)-D248$93N,4M+X$V=6?0(%J&)/C8!(&5_"R^PBFLT80)V M!%*R5EJ7P2-P<'2A"OY@86?.V4D2.V*F4>$J-I>2ASN@NK:11+;6UDY[9YB% M/Y?"]4(1F1J*`Q;2"J*.`U`;"LW0UY5EH'>%RE]D3I*X(O-"P[%+\$9;$LVS^0@4G:].=.('U+[3G$>-2<0(/I"ZBDK M_YZK2$CZB,ES*CM6*4G!DDOLQ/<`VE,IT930*BM;B_6`9A[[(TDX+U.PR+O> MK0R)P:(@GJI*IH0]U)T,4QA(_,/P%>L=++)5KOR@`(YP96(J-EM`!9%^0CUC MR:5.91;8+U>Q,,6SA53KZ9T@:OM0S0? M\J.V$Z%&Q`U(#%+E8*3Q5Z&.V"3[D:?/]+GV'0+E`'/!Z+")3-_7A4N;6X:" M16G2T4EWFZ4>B3P2=.$NK%;RC(8]0AXMPQJ63&\V():U'C<-:F/17E,8K=T_ MY;\8$A;Z;()!_ZP!!NV[2\)BCQUN.>:C_YIC[@W^UH_YR,?\C&U#UG=AI6?L M#$=TLVHUI0I.8U4`1$DUMKA.G9#1O-*J$L?Y:KDK%<](1F;&C&-BQ&1P(+)2 M$CI&R9$U7@`=M7K(4`5&%Q#HTD^D,U+`&N8YZWEHXBO[/IH;/X"CN8O)G*(5 M[WR&:\XLOT.EE*9M*$=?]VN[!DX?QR8>B(&/6-P:DEMQ&+UFKQ)IK7`V]80A MRMO!=AJA-GJEEP#6]V&@P$I653XB3!J)8.3(H8<%(;ZQH$B':?I>_@267UD> M[D?9+1+60[C%L3.(1'4(W\69;GWGLQ+/^;?KSL.Z(W^*.L]6N@Q%M4FY!`@< M\+&*NXJJ6CLYCIY@B^A,#**EZ.P!*B]X-.0:5GJ8R1$+?.&B1E7U*"LU;(0X/HGYD1_*(%Z.'PV(:\%^\.`-`I[PWAC9'`NHFQ6>VO8!CPQ.(%^W563N=\Z,>BD<^VN#VA,7++$ M=![68NF`1?PA33#<@.]Q/Q>=.D$`1&6\\]UD(@JYABYG/DGIEZB6/!=,BNQ' M1*PE6D3VAO(LBX!KDD-%TK6T12"G1?;M4Q0^BU*[$7FX/8"<5E38!W9LA"LF M`&OI2D)\)Z7JH%_/"SHR/U33@GR6CE7M@=6@FJ!_R5J.FM?2DJ*T?2WCIBXS M/@[9UW-P8C`9._4.1MT&+^RE]HE6O.)CD+6Q-S@AE_A)@TL\L7RW;G8OH9L[ M626;I^K8#6M^/E/;@7Y"HG@LZP`8>`=#O5FK75.0-/AY,5=7B)1M*2&EB12' ME@TYP#J'A^SA"ITB)!I\OH,3VS/0N(J\NHR4PZ,"WKH_6R+X.2#/8-@T-(&E MT;/4(D>&(G4`\;;/J*][VA MWJ;-M\WK;?)OVUXFJ66+9IT"#=8"5:SG3O$,,ZZ1_4Q)Z:9\FA;0M#O`FRBH M+01(ZF%3&-`T2&E)GS?Q2\I@$37$J6JRTS?F7Q"BH5/\0QF3+ZOGN(="B<]J M0M-.=*O4P")>(#$72/!_CZ"U9=%4PE0^P<@-L@#*-+F!%,K`.(8#XG)I\>/R M$90@J6IR)]^T&U,Z,73+B-YM*SW"(DH"`OSW\9$PL5HTX.R@);!D[8"Y@;MU MI6QD,Y8,=>ZNG*F<&%Z5(NJ5?75(/MQ=-4$1&B3"+ZJU:CAEE7M)C=P6YD5> M6ERSS0K]"@]7]!?&H*&84IF6TCM37\QI?)2@H[(Y%*G%N"@B?1$Q&@$!ORH3!KUS$A"^K/4RW4MITIX_5OT'#0QI+HUK\?7>4!DW&G%FDQ. MV\AELY3E#3L"A"]KK1B($S7UM6L@O]3D5>GG8N920$#2E#`]UOE(WM/!53;" M_\K6<1P`*U[4[6"=PZYT29W`_1>SCU_.V]`D>$@+92&B7;"K<6)53(!E<%2W M#(;-ED&38;#5*!B:T38:!4[7U_'M]^?WX[>7YYB-^O'VXO[BG%,`WX\O;KT? MQY33G%(O&)DGD$%.9ZITY5E,A50@[()<9)FY)[R#)A.J$V%Z1,M01 ME[E*S+AFYY+Z%\2$A=3NF\BDZ]U%)!CL-6+^7S*37"$@69IYR>87=Q3*K81< M3&G'X;A&]>J<:30!*)`[W60@B%&J5OB!M`=YGR78)70/') MPPE$`0LA?IQF[-4G$XJ2M;.B0PR1R]:67S13E*C0-,IM:UK,;S/1!)1WE('+ M;7AVA`=Z:5N7JCMNJ4XLE:6H"14O;#K^GW1N0`/.V3,"_E'2-;?QW(A4K`]* M;2,;NY6NAG0.OE+.))%@AJP5I?82"X^RM6]_A6WT6,#9O5TQ!X^[NR*SKD^@ M/N+>-RQF*\P:N1RFV]83;Y=AL1!'$??VL5+JBZ;FCDK.5?/1:WGD3F=&KD62 M9#PQ]N.U>+)R]EC(JEG1,="75'5S/.2.F*?`<5GU2=6>I".:8@YT8-9GI&4L MJ.2Z#FZ_375M3S7EL?<%J>&.A%P@39P6`&=2) MB:+")%VE#745$D%"B8=/T0Q#2T)+U&7&D!XM@OL;5O)[M6^4E#^C=)DW6!O1 MHZH$%AS0+(.]5`)D'V="^!16X9FXE&M)0%K2!U)@K9)J4K;5_/K!5S9EIRFS ME:B2[1<`1LPCX[27!T1Y8@EE$:?I)YU&1!UR,]L+`X`$G44*"&'36"ALJ2^\ M2(W9DB%N&M-9%:=JVZCR4;LGIQ2,$#5#A=07;%9[S[$*F`UFC:F$2G,T`3`+ M(L4P+5?6$2C0^-")T:801RH*6X9\"./\-!+H1'S2L'T/4FAC)$F"MQ'R4X.\0KQA5IPTM>6JM^*R^Q;#^2G0LVM6)2E?&S*6TB9=14+B^7R\#@8TTL MN138K/)ARZ00"&6/1OY?OVIX,^@>H0OX5_ MCD[WA]C1J7\RZIME'/,RX->C/F.[HW#N/'K$:1@4`DXI1[O*['1Y)JHB2^;T MP+KZ`^7%0)?S0=_OPZH:Z4)5IE:'90=:WDII@

<)%^\ M9UB1@ZIUOD-34WUTS@XVJ^SZ`2NE:-W,QJ-ASERIAZ6Y,B8U13 M/9/*F.8*GS"O,[Q%!,()3&+-#)GWD\*/G1KP?C)B=641,4PJ]@TY+IA[5VBU\SKP[)6)6Q8Q@9C*I5F)MB0Y+!,E"ON-6M3E"_+)\D; M9HDRU9?_D+_`]/KN,LEO6,*@O@1J@[C"FD7K'-('=",Q\E#-7UY=JL^5EU@. ME1&0$>3K"(4#'-*3M`20PZ-FE6IN8Z:S>5N%0.,65;12P,"2%'Y9LV\\"ZC5 M`MH1Y(7D?"W\E3N74''@%`M"9D`D:U4E7YT81S*-:LWN&5B^U:*ENO'M`!\J M@.,496*-;4->(3-MV3Y44<*5CP((LU3M1A4<,K:VHJ*@0+5$5L2,D0XZZPTS M$$1(.:%22JY,FF.SJ"B1BX205A0*PR\*E9:V@[*5'NLZP`\,^3NK-:/U]ZM) MW:T&?+_OGPU']A\H4NB_NXDREJ_TE?GS"\0]2)^!/SH^LI"49IIKNZ?T&:;33Y-Y. M%Z%IZBLJ$FXO-9B>X9^OG"D!=8Y0L1F,SEZ-96IXAB4E7M\?#4_@)/K#GGZF MZMS#6FO<2N$XY=,,_?[)$/Y[,AJ:D>L=N;SA:.3U1R>OY,*Y^N8'ISWO^.CT M%1P_:(-XUL?^V=&)<]I7Y_=\G=#-^:UW]]WX]MRYM#'(T!^7XPV%?%GCA@X+ MJ.$X(WH-][M((T6ZHL6X3)_K][F8&%SK/2Y=;Y<[9W1AGQ10"MENTD=R<>A0 M,IB4L^O4I.IR1-B9UJ3\$7GDR8,HX\<_. MSOS!Z9'>RXMC@Y7.9>`74SA@A][-Y?C*X3X3 MZS(8FNLV+"0X1`TUN$'0!K0][GJ[SBV]Q@%D'58][)MHV+Y'#Z*E$B.\'NE" MV!FY;RMY&E:!:-4>(JF//29]E?Y2C9)2GB(1NU4.JMH-8N2"7$^@>>A.>,H= M?&@B<:1)2P=%>2I3<]R#U_V:]$(53&[P150PR"+GMW$`8+J;+JC1I5'9)?GC M^W#-:A8E8BSUYZR][SR?S>_/J58ZA;+!3.I.F8# M7OZ,?';Z(QXCB_)/G3F21$71W.53Y<+3/TM+)8HXA$I!IQ-X"&/,Z3%AA`8C MB$7A"N0%AF*JUA#GI[)S<(;!(+E^2(.>^.2*VZ%*\;K"3UW\:2G.52C)&(0Q MQL6X%WMHM$852\[;J4X10KT[U43WD[+:`Z65ZUMPZNJM9NB%^?K5/3$X^[8\ M[PJW8O]BU`//*`JME]^!_G4TP/^>HMHP&J(SZ71T]*K]RCJ0\6?>T=D1Z!.# MWA#^>]([?E6]MPX5.-$83X>OK(LM-X$)9N^A1G!R/,3UB"XX\(^/ABI>]6+^ MCG>:;IO_F<+PU'A/E=8#]`5U8U9H7EW;5ZL2,KKNPQ,0O$?^ M<1\-E:/NZ=FK;X6F0*_L#_W34<_K=PPT?G)PU MS-*P!R/C<9K!T:MS9IZL4;=]!?.<#?VC'MH1HVY_(!G>C]A%G5A&D>%U,5/+ MLR=0V7ZK+'GESE3_D8-1WPYAA=;J9$CF%X[2:(1MWW(B99K= MXY'1T^JM6:]2/2GAMI)/^\V=9L(>Y:YT%-FA+=``//B;Q'BM4VPV=K*PBKP\ MJL+5CN"J^\-8'?.K'VD%-%^9\'(:5M,X^ZG?'QW[O4%?T`ZPZ`@Q_?1H6,7` MQJ\=]#OJ]O#K$?N4"[FHLZZ2H3MI'18U':H9PRVKUV*M!8VE%8:O2M07?$*8;Z%HM=,OEB(CT^9,Z,9&]::.N+]!*YAT=`2_=H42*2JDAKW)NK7SOS MU9+@F)%(`#,_6@-GP3>SOUCX=J^(8HF7,\,N#+)=GQJ0C;4>V0JJ4S M=CI^L%35C:#'+:)PCOQ@6DJW4&Q=GY&E292HUG.K]5=]G77A.XA,QC]H]HYN3?X:]J8>5)E$P2>\',AJBWQ):EY\Y;! MYVB)5]G.O>$9SVQE)0GE\%K*)%(A%Y)QVKO24G!A)V?C9.+@YR'ESH@N-Q6E M>U2(2;8!6P#9"D2PJS$E3_Q9N\UKM_L9;#MGO$]A2NUP&D[YPUZG_.$:K)"_ M&*A?!E_>I.G;W[C-Z[VV>0W(/!C]C>U3CFK'8^H/_LO.:9-83%(MKS"C5'KV M2!:;ZG:^>8U*\Y#,8"`G'T^($K9@IXX_\O9\C>WUU?P]Z2Y M/N`J?%:Q"42?FRSE\CS3?MNZ`;KRHFXJWNZC/`&YN64]WGO*(Y=&\/C_^:K( M2O_RZIHR[2>6`F+34ME:X!W:;:3XODWQVANZW&5\]Y:H0/?;S^4M+P\+^NPA MG562%H-92OW4:[7*IEY(4J;1F)C/I5LPYY%+U11-](P./NRP4.8Y:D//#:XQ MS%*;%BPRI]P*2_:9Z[U4.M&B=6`FY8V7AY@U2-/HVQ:+OD"5?$QT!"YN6Q5.,AUYN$N/ZTN>Y3TB"5V6A" M5(*J0A*R8GTKA6"P!0)1^;A711-&PN=7:5=0#G0%1$.#I;@'TJL[;XGQWJBZ MU)]4?OV]NM,%3G-,UV?=R,E0F[P`(XQ:,MSS/;H3Z6P-]"`=YTV[HUL=X;B3 M",<-FU=X4^J]VK%@$S=OH;8*:*D1,ID[K8.*5)([?)D_T/'FEO$IG06G.G3G MKJPU]L+75%E3Z81U7WGN\4@_2_6[(A/++F)3IA+QNB<*%A8ZOIO@+)%*_^;, M:O%:1'SUD3M[;F]6[Q6_Y`,VMP?P4'M2A4)H;C&Q%X6,?G.4;[K%@8K<&KAV MQ2-3;0M'E&+:H6RDEMX94+',L$1$&ZI*JC__0.^4B/>\>OE6+[@HTA3'V>47=`VRJL'HZ/HDA65\J,B>M22WB$== M.U]8[GG3+PAI'+O=Z"RDQQ1/U[ZY"[FUVB0ERB4J99W.2[+3.>I.'2!F<@J> M53?#:V!78VXG8K.K`!OZ.#/7A.UHXV&-.GB:.YV4?4P@.*G\5'J%POCGF@+> M4=B7CY&N[`DEY%?1<=1W%?C3_*K/*3LA3JBE4.6G4SXYVA&U%"5MGN4G.D.8 MW45R!HL4H41W"F#_>RD$X/F,*J:K%.N:V#9JE/(V9/,SY325&&3S_<1P;.&,8GI7 MUY<^5UGPG[+ZY@"AU.A,@RQ;`S8SRT8P8D3V,\7"`=H'0YCM#!G*07\T\(^& M1^R_&9SX=*MBK>\2(1U[A=&[^10`URUS3UW%P.;6H#<\4N]*=P05A9?NBM+# M0"J!,"97S5^5_:KKM"AYA3;B;=C)Z*2_>;IY;=A'KNJC-7"H@_;%#EH0%./J M^$#IU*Q3+N\Q9\(0.ST>FA"V'!%[R#CVS7*DM& M9BY6U-)XK91^RP?)Z%0.)6V!U_XSX; MU'?_22`5!+FY<.?I/8LH/;I1<"B5/1IO$)0K/_( MKCEF)E7U-=.R*GNJ54'T>E MBTU@=_ACO;6Z&JE0+0T*5:M6&@[5E^99JI3!.AUS92JWFC#7F,B^-;\BW4\/ M;+EM[:U5$8G$LI))1K@C,Z M5/J36+\%EI8'*-L"NED0[S31F7HO/7%F$[6+!$9^M7I(U1RS_6OE$2MA2@6Z MA(@5P.=$%P`J((N&]K%8XREUK\1OC48M`DDY-='B:1C2(OEF$22NRNI-K8+$ M(B.X4Y"J0WL9&+O>=^DSO(.=[Y@TZHBIRN)L=F%HM[9`5!#6NM"IH+*?BLAV MO?1W][=BO5F-S&@&`-Y+:LQ MGD_AVKJ'P==U:,IXCT.[/T6MJ6^EGW&J3?8C"Y(/X6.0,`!)$>;+,E@9?DZS M3["DJ5CMQP.2E163X*AG\DE4%()V/9<$JP]I;J@S4WHW0&09FMO)S1V-WR+S M4Y:3=;'((T![5BD_HWYOZPZ=@U^M`%'$QD:\]-!T$AV16\AEKZ%JHXR^VK"?"]DR/=IV33Y:_8>:M_)F>7JY725>AX M(;TR\DT*D1'(!T?]$_,F`)ZCE(K?5IHJ^KK/G-V7N+T/L;HY"G48S-:T)D"D)6;V[VL3X`SXM\[`/R]`\!?K@/` M)@06+\(>9>4[E1?^O9[U[_6LK26ENS#68(>RTYTP\7]^6>G.U72[P'U;A<=. M,/_?6M"S&:$E[=:JC6!+S2J,V8VW_N^M?]F(N?O5:^P&ZO\9U1J;P.;FY0NB M[@2@__YYWTY>X?@>+`#O^KUW?7-^2XR4S01@L!=W^/O-[?D=&`C,8P_?D8_, MNP>;'OLPO/8ZWL>[=][A`>I?8%W=+](R!VQPE/Y^A1TZ3P<;'_\!+UQ0=W$Z M6TB?NFJ[CO('\-9?.@\K_/>=Q7_'&=UUP7;0:B,YEGO_Q.4')9/-J.]<>7SATP?Z[?3S9)N]YEX0#D@W/3@;H8H?[F1[E` M8-M[36MQ;X60Y3CFYN3Z\G+\]MI&H/'EY<7X:H(*T(N1YGWXT`7%8.O1]D[= MNGU]QQ\(1^L\V2MUA=9\VRO>O>W#WG:^DJ?BK+UVD/?FL@]]:9"C3UH1V[WO M0'<@T'#!ZJK]@M4O_+S:OMF^+U6QY?Y9<<"P\[C]PLH7#UQO$;_Y MRDEWFL)*PJ.@8?7V!E7M9FYB!/TA(T^/R4GFSQV7,-_)\`53HH=`3]=R;:/# MBT^;I]V+QKW^[E3^(5AWO9['`9%6- M"P(6IJ+2)'BATTO'W;K`&Q,[1%517X]E*[0/UAU$';D(D"1'?3!]F99$)+]\ MLG*U:IO,O:WKRQW"'>_.=(G=ZOFUW'/""TC.MWID=N8.MO8^=N>U;LO8)*FK M7M/ZTV8GZM:WV*?J\!WM8G6VHOU7CO:EW%._Q;&-]W9RZB-CMFUVX%?N','D M5?7=SBJ<-=98YW`!A>HII&(O4M(^2#?,0VG+Z+B]=OX0 M9G\93'ZK&5KW;CN8V8MX;;IG7G!739EDX+K]]OGXQ3#X+6?9"0X?[0ZBU0F& M&V&P\>[!!RJDGPW=E^/.C0\MP,/;8]WCCVTCE\//]1?;(Y";-M.(YA\KU&P M-'2K;/*$L"/7T0[;VD%:G1=WZKKXXO!)AUVV.G<$G;QSM%3=H^KGOBO7-%+J2@O`!, M+=!I!_9]4LC\2.5(G?6Z!#<;4GM#?S^[!UL0OW1N8F[]]$[!R9V9.O)?*7[UV?\NV?30O?^]5 MO_C$FM3!OS!/=13SFIFC6=F^V1;M\VV# M]GF5JE,?2^TE:Y,5B4,)F%=IX?TQ+"P-U=^LW4V<%I*[M(6TB_";HT4#X4#' MPK7;%46J&JQ/E-<;/P()(K11IQE9#:4;"NXQBH,*^W>,;&'*OQF!UJ-: M>Q/G<+@QS\'.5G#R'&R%9F=#9@.7OZI?*?#8K,^RTE1M,_E",E8UE75:=I&D MF;JW;D'CW=8W!?>=F3=[>BJ=$>7;YN]>CF.#=J^`%9AT\<.*=_8']8=_*&/] MI1,IW-?80>Z<-1A+LW<[C=>TLVF/G@;R`Y?VIWL)DU-(33#_@N>-/=I MW#RS^_KAY'K_N2M]0%Z>-'6M5X/Q26]2J4O=9/M>6(T%3)WEJD(3.Y7L.J'P MC06ZSOJ=VN-HR\+\QDB!ZAQB>A8XV.E4W6]_8Y<.'E8##\]NX.'R75:5"OKNJ'J#5/D34#+W4#CMEQIFVMSX>K+4=F6=XZ919E!O:-F4ZZ:^DZ* M.E?D4B;OME2!DA(F(TZ;J13:N=96O3[2M?SU)=#VDJ8-:0AOVZLI'X M&2IVB3)"R/&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4```` M"`#&4V1'.43!Q;L"```@"@``$```````````````@`&/!```9&]C4')O<',O M87!P+GAM;%!+`0(4`Q0````(`,939$>;97)PC M$`8``)PG```3``````````````"``>4(``!X;"]T:&5M92]T:&5M93$N>&UL M4$L!`A0#%`````@`QE-D1QB$3U),`@``=@H```T``````````````(`!)@\` M`'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`QE-D M1TXXY3U/`@``]`<``!@``````````````(`!8Q4``'AL+W=O@7``!X;"]W;W)K&PO=V]R:W-H M965T&UL4$L!`A0#%`````@`QE-D1TFY:EBM`P``61```!@` M`````````````(`!X!T``'AL+W=O&PO=V]R:W-H965T&UL M4$L!`A0#%`````@`QE-D1YTK84B>`0``L0,``!@``````````````(`!>R<` M`'AL+W=O MH0$``+$#```8``````````````"``4\I``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`QE-D M1^I19X.?`0``L0,``!D``````````````(`!_BP``'AL+W=O&PO=V]R:W-H965T&B#EXH@$``+$#```9``````````````"``:PP``!X;"]W;W)K M&UL4$L!`A0#%`````@`QE-D1P&\_16B`0``L0,` M`!D``````````````(`!A3(``'AL+W=O-``` M>&PO=V]R:W-H965T&UL4$L!`A0#%`````@`QE-D1RK_TB&C`0``L0,``!D````````````` M`(`!'3@``'AL+W=O&PO=V]R:W-H965T MJ63I>6`(```L(```9```` M``````````"``?D[``!X;"]W;W)K&UL4$L!`A0# M%`````@`QE-D1^;^7WH(`P``KPP``!D``````````````(`!B#X``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`QE-D1ZC* MZ%XP`P``LQ$``!D``````````````(`!V4<``'AL+W=O&PO=V]R:W-H965T8OMT&$`(``&(&```9``````````````"``2M-``!X;"]W;W)K&UL4$L!`A0#%`````@`QE-D1^++5_W[`0``>P4``!D` M`````````````(`!&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`QE-D1T-_7U`D`@``A@8``!D``````````````(`! M_58``'AL+W=O&PO=V]R:W-H965T1[$%&3`(``(T'```9```````` M``````"``;Y;``!X;"]W;W)K&UL4$L!`A0#%``` M``@`QE-D1S&`UQ2V`@``_@D``!D``````````````(`!05X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`QE-D1U^I\4MI M`@``R`@``!D``````````````(`!Q68``'AL+W=O&PO XML 12 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814
INCOME TAXES (Detail Textuals) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2015
Dec. 31, 2014
Operating Loss Carryforwards [Line Items]    
Increase in ownership percentage of certain stockholders or public groups more than 50 percentage points  
Ownership change, increase in ownership percentage, term 3 years  
Federal income tax    
Operating Loss Carryforwards [Line Items]    
Net operating loss   $ 331,909
Net operating loss generated from excess tax deduction from share based awards   15,014
State income tax    
Operating Loss Carryforwards [Line Items]    
Net operating loss   152,434
Net operating loss generated from excess tax deduction from share based awards   863
Research and development credit carryforwards    
Operating Loss Carryforwards [Line Items]    
Net operating loss   27,761
Capital loss carryforward | Federal income tax    
Operating Loss Carryforwards [Line Items]    
Net capital loss carryforwards   $ 571
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814
NET LOSS PER SHARE (Detail Textuals) - shares
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Earnings Per Share [Abstract]        
Potential common shares issued upon exercise of outstanding stock options 8,342,725 7,999,284 8,342,725 7,999,284
XML 15 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
 9 Months Ended
Sep. 30, 2015
Payables and Accruals [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED EXPENSES

4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

 

Accounts payable and accrued expenses include the following at September 30, 2015 and December 31, 2014:

         
    2015   2014
Accounts payable   $ 346     $ 259  
Accrued payroll     1,537       2,130  
Accrued outsourced pre-clinical and clinical fees     3,173       3,753  
Accrued professional fees     355       157  
Other accrued expenses     280       648  
    $ 5,691     $ 6,947  
 
XML 16 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814
STOCK-BASED COMPENSATION AND STOCK PLANS - Restricted stock activity (Details 3) - Restricted Stock
 9 Months Ended
Sep. 30, 2015
$ / shares
shares
Number of Shares  
Unvested as of December 31, 2014 | shares 105,665
Vested | shares (36,101)
Cancelled | shares (10,929)
Unvested as of September 30, 2015 | shares 58,635
Weighted Average Grant Date Fair Value  
Unvested as of December 31, 2014 $ 2.51
Vested 2.51
Cancelled 2.51
Unvested as of September 30, 2015 $ 2.51
XML 17 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814
STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) - Stock Options
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 30, 2015
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Vested and unvested expected to vest shares | shares 8,156,021
Vested and unvested expected to vest, weighted-average exercise price $ 4.24
Vested and unvested expected to vest, weighted-average remaining contractual term (in years) 5 years 5 months 9 days
Vested and unvested expected to vest, aggregate intrinsic value | $ $ 843
Exercisable shares | shares 5,793,400
Exercisable, weighted-average exercise price $ 5.12
Exercisable, weighted-average remaining contractual term (in years) 4 years 15 days
Exercisable, aggregate intrinsic value | $ $ 51
XML 18 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) - Stock Options
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
USD ($)
$ / shares
Sep. 30, 2015
USD ($)
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Aggregate intrinsic value of options outstanding $ 908 $ 908
Aggregate intrinsic value of options exercisable $ 51 $ 51
Weighted average grant date fair value of options granted (in dollars per share) | $ / shares $ 0.77 $ 1.65
Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Stock Options $ 3,100 $ 3,100
Compensation cost related to non-vested option awards recognition period   2 years 6 months
Number of the non-vested options shares expired during the period | shares   689,759
Number of options forfeited during the period | shares   205,980
Weighted average remaining contractual life for options exercisable   4 years
XML 19 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended 33 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2013
Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based compensation expense $ 501 $ 763 $ 1,741 $ 2,643    
Restricted Stock            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Number of shares granted         242,697  
Award vesting period         4 years  
Weighted average grant date fair value for the options granted during the period (in dollars per share)         $ 2.51  
Number of shares forfeited           82,564
Number of shares vested during the period           101,498
Share-based compensation expense     59 77    
Fair value of stock vested during period     $ 68 $ 55    
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS
 9 Months Ended
Sep. 30, 2015
Marketable Securities and Fair Value Measurements [Abstract]  
MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

 

We generally classify our marketable securities as available-for-sale at the time of purchase and re-evaluate such designation as of each balance sheet date. Since we generally intend to convert them into cash as necessary to meet our liquidity requirements our marketable securities are classified as cash equivalents if the original maturity, from the date of purchase, is ninety days or less and as short-term investments if the original maturity, from the date of purchase, is in excess of ninety days but less than one year. Our marketable securities are classified as long-term investments if the maturity date is in excess of one year of the balance sheet date.

 

We report available-for-sale investments at fair value as of each balance sheet date and include any unrealized gains and, to the extent deemed temporary, unrealized losses in stockholders’ equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense) in the statement of operations and comprehensive loss.

 

We conduct quarterly reviews to determine the fair value of our investment portfolio and to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. In the event that the cost basis of a security exceeds its fair value, we evaluate, among other factors, the duration of the period that, and extent to which, the fair value is less than cost basis, the financial health of and business outlook for the issuer, including industry and sector performance, and operational and financing cash flow factors, overall market conditions and trends, our intent to sell the investment and if it is more likely than not that we would be required to sell the investment before its anticipated recovery. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in accumulated other comprehensive income (loss).

 

For available-for-sale debt securities with unrealized losses, we perform an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in the statement of operations and comprehensive loss as an impairment loss.

 

Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

 

The following is a summary of the fair value of available-for-sale marketable securities we held at September 30, 2015 and December 31, 2014:

                           
September 30, 2015     Amortized
Cost		     Gross
Unrealized
Gains		     Gross
Unrealized
Losses		     Fair
Value		  
Security type                          
Corporate debt securities-short term   $ 30,628   $ 6   $ (5 ) $ 30,629  
Corporate debt securities-long term     —     —     —     —  
Total available-for-sale marketable securities   $ 30,628   $ 6   $ (5 ) $ 30,629  

 

                           
December 31, 2014     Amortized
Cost		     Gross
Unrealized
Gains		     Gross
Unrealized
Losses		     Fair
Value		  
Security type                          
Corporate debt securities-short term   $ 46,690   $ 16   $ (23 ) $ 46,683  
Corporate debt securities-long term     2,061     —     (3 )   2,058  
Total available-for-sale marketable securities   $ 48,751   $ 16   $ (26 ) $ 48,741  

 

The fair value of our available-for-sale marketable securities in a continuous unrealized loss position for more than 12 months was $1,126 at September 30, 2015. The unrealized loss on these marketable securities was under $1 at September 30, 2015. None of our available-for-sale marketable securities were in a continuous unrealized loss position for more than 12 months at December 31, 2014.

 

The following tables present information about our assets that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. We value our level 2 investments using quoted prices for identical assets in the markets where they are traded, although such trades may not occur daily. These quoted prices are based on observable inputs, primarily interest rates. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. There were no transfers in or out of Level 1 or Level 2 measurements for the periods presented:

                         
    September 30,
2015		     Quoted 
Prices in
Active 
Markets
(Level 1)		     Significant
Other
Observable
Inputs
(Level 2)		     Significant
Unobservable
Inputs
(Level 3)		  
Cash equivalents   $ 11,935     $ 11,935     $ —     $ —  
Corporate debt securities-short term     30,629       —       30,629       —  
Corporate debt securities-long term     —       —       —       —  
Total   $ 42,564     $ 11,935     $ 30,629     $ —  
                                 

 

    December 31,
2014		     Quoted 
Prices in
Active 
Markets
(Level 1)		     Significant
Other
Observable
Inputs
(Level 2)		     Significant
Unobservable
Inputs
(Level 3)		  
Cash equivalents   $ 10,740     $ 10,740     $ —     $ —  
Corporate debt securities-short term     46,683       —       46,683       —  
Corporate debt securities-long term     2,058       —       2,058       —  
Total   $ 59,481     $ 10,740     $ 48,741     $ —  
XML 21 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814
STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 2) - shares
 1 Months Ended 9 Months Ended
Mar. 31, 2013
Feb. 29, 2012
Jul. 31, 2010
Sep. 30, 2015
Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted       1,513,850
Chief executive officer employment agreement | Chief executive officer (CEO) | Stock Options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Granted     100,000  
Chief executive officer employment agreement | Chief executive officer (CEO) | Stock Options | Vested upon grant        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Percentage of options vested     25.00%  
Chief executive officer employment agreement | Chief executive officer (CEO) | Stock Options | Vest annually        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Percentage of options vested     25.00%  
Award vesting period     3 years  
Chief executive officer employment agreement | Chief executive officer (CEO) | Performance-based stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of stocks vested during the period     390,000  
Chief medical officer employment agreement | Chief medical officer (CMO) | Performance-based stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of stocks vested during the period 120,000 50,000    
Chief operating officer employment agreement | Chief operating officer (COO) | Performance-based stock units        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of stocks vested during the period 125,000      
XML 22 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 13,130 $ 12,525
Marketable securities-short term 30,629 46,683
Prepaid expenses and other current assets 193 1,893
Total current assets 43,952 61,101
Marketable securities-long term   2,058
Property and equipment, net 298 133
Other assets 251 102
Total assets 44,501 63,394
Current liabilities:    
Accounts payable and accrued expenses 5,691 6,947
Current portion of deferred revenue 7,373 11,098
Deferred gain on sale leaseback   232
Total current liabilities 13,064 18,277
Deferred revenue, net of current portion   4,572
Total liabilities $ 13,064 $ 22,849
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.01 par value; 100,000,000 shares authorized; 62,891,548 and 62,821,781 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively $ 629 $ 628
Additional paid-in capital 510,072 508,270
Accumulated other comprehensive income (loss) 1 (10)
Accumulated deficit (479,265) (468,343)
Total stockholders' equity 31,437 40,545
Total liabilities and stockholders' equity $ 44,501 $ 63,394
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
NATURE OF OPERATIONS AND BASIS OF PRESENTATION
 9 Months Ended
Sep. 30, 2015
Organization and Nature Of Operations [Abstract]  
NATURE OF OPERATIONS AND BASIS OF PRESENTATION

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

 

We are a clinical-stage biotechnology company organized as a Delaware corporation in 1993 engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to produce novel drugs with differentiated mechanisms of action that will extend and improve the lives of our patients. These drugs target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our prioritized clinical stage pipeline consists of four product candidates, all of which are in targeted, biomarker-defined populations. Our drug discovery efforts focus on a number of pre-clinical programs based on our insights into kinase biology and are derived from our extensive library of proprietary compounds.

 

Our lead product candidate is tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (“c-MET”) and its biological pathway. C-MET is a promising target for cancer therapy based on its multiple roles in cancerous cell proliferation, tumor spread, new blood vessel formation and resistance to certain drug therapies. We and our partners, Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) and Kyowa Hakko Kirin Co., Ltd. (“Kyowa Hakko Kirin”), are implementing a worldwide clinical development program with tivantinib. Our strategy is to focus on the most promising indications within our clinical programs based upon continually generated and updated clinical and pre-clinical data. Our lead indication is liver cancer (“hepatocellular carcinoma” or “HCC”), and we are currently conducting two Phase 3 trials with our partners. We have also completed earlier-stage single agent and combination therapy trials and pre-clinical experiments with tivantinib and other anti-cancer agents that may provide data to support later-stage trials in additional indications.

 

We have licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where we have licensed commercial rights to Kyowa Hakko Kirin. Our agreements with these partners provide for possible future milestone payments, royalties on product sales, and development funding, in addition to significant payments that we have already received. During 2011, we received $25 million from Daiichi Sankyo resulting from the dosing of the first patient in the MARQUEE trial and $10 million from Kyowa Hakko Kirin resulting from dosing of the first patient in the ATTENTION trial. On January 31, 2013, we announced that the first patient had been enrolled in the pivotal Phase 3 METIV trial of tivantinib, entitling us to a $15 million milestone. That milestone was netted against our cumulative share of Phase 3 collaboration costs in 2013, and consequently we did not receive any cash proceeds from this milestone.

 

We regained worldwide rights for the development and commercialization of ARQ 092, designed to inhibit the AKT serine/threonine kinase, and all other compounds included under our AKT collaboration with Daiichi Sankyo pursuant to their formal notice to terminate our license and co-commercialization agreement received on March 26, 2013. Following the termination, we became responsible for funding the remainder of the Phase 1 trial with ARQ 092 beyond the contractual termination period, as well as any future clinical development and commercialization of this compound. The license agreement had provided exclusive rights to Daiichi Sankyo for the development, manufacturing and marketing of ARQ 092 on a worldwide basis. Under this agreement, we received a $10 million upfront fee from Daiichi Sankyo in November 2011. Following the termination of this agreement, ARQ 092 became our proprietary asset, and Daiichi Sankyo has no further financial or other obligations or rights related to this program. ARQ 092 is part of our proprietary pipeline of product candidates directed toward molecular targets and biological processes with demonstrated roles in the development of human cancers and rare diseases. Our priorities within this pipeline include ARQ 092, ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (“FGFR”) family, and ARQ 761, a Beta lapachone analog being investigated in investigator-sponsored testing as a promoter of NQ01-mediated cancer cell necrosis.

 

Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have consisted primarily of payments received from our collaborators for services performed or upfront payments for future services. For the nine month periods ended September 30, 2015 and 2014, our net use of cash was primarily driven by payments for operating expenses which resulted in net cash outflows of $17.2 million and $25.0 million, respectively.

 

Our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, our ability to enter into additional corporate collaborations and the terms of such collaborations, results of research and development, unanticipated required capital expenditures, competitive and technological advances, acquisitions and other factors. We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product. It is likely we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, and due to global capital and credit market conditions or for other reasons, we may be unable to raise capital when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates.

 

We have prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with our audited financial statements and footnotes related thereto for the year ended December 31, 2014 included in our annual report on Form 10-K filed with the SEC on March 4, 2015.

 

The unaudited condensed financial statements include, in our opinion, all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of our financial position as of September 30, 2015, and the results of our operations and cash flows for the nine months ended September 30, 2015 and September 30, 2014. The results of operations for such interim periods are not necessarily indicative of the results to be achieved for the full year.
XML 24 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814
MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) - Fair Value, Measurements, Recurring - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 11,935 $ 10,740
Total 42,564 59,481
Corporate debt securities | Short term    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Corporate debt securities-short term & long term $ 30,629 46,683
Corporate debt securities | Long term    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Corporate debt securities-short term & long term 2,058
Quoted Prices in Active Markets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents $ 11,935 10,740
Total $ 11,935 $ 10,740
Quoted Prices in Active Markets (Level 1) | Corporate debt securities | Short term    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Corporate debt securities-short term & long term
Quoted Prices in Active Markets (Level 1) | Corporate debt securities | Long term    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Corporate debt securities-short term & long term
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents
Total $ 30,629 $ 48,741
Significant Other Observable Inputs (Level 2) | Corporate debt securities | Short term    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Corporate debt securities-short term & long term $ 30,629 46,683
Significant Other Observable Inputs (Level 2) | Corporate debt securities | Long term    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Corporate debt securities-short term & long term $ 2,058
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash equivalents
Total
Significant Unobservable Inputs (Level 3) | Corporate debt securities | Short term    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Corporate debt securities-short term & long term
Significant Unobservable Inputs (Level 3) | Corporate debt securities | Long term    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Corporate debt securities-short term & long term
XML 25 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814
ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Payables and Accruals [Abstract]    
Accounts payable $ 346 $ 259
Accrued payroll 1,537 2,130
Accrued outsourced pre-clinical and clinical fees 3,173 3,753
Accrued professional fees 355 157
Other accrued expenses 280 648
Accounts payable and accrued expenses, Total $ 5,691 $ 6,947
XML 26 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 27 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814
COLLABORATIONS AND ALLIANCES
 9 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]  
COLLABORATIONS AND ALLIANCES

2. COLLABORATIONS AND ALLIANCES

 

Beryllium Discovery Corp. Agreement

 

In May 2015, we entered into a collaborative research and development agreement with Beryllium Discovery Corp. (“Beryllium”). Pursuant to the agreement, we will jointly focus on the identification and preclinical development of inhibitors of PD-1 and PDL-1. We and Beryllium will each be responsible for our respective internal and outsourcing costs during pre-clinical development. Following lead optimization of any potential drug candidates, we and Beryllium will jointly decide whether to advance compounds into GLP/toxicology and clinical testing, initially on a shared cost basis, provided that we will have the right to advance compounds on our own should Beryllium vote against such advancement. The agreement also provides that we will be responsible for clinical development and commercialization of product candidates that are not out-licensed. Beryllium will have the right to participate financially throughout the program but will also have the option to opt out at certain times and receive a royalty. The agreement will terminate after the last payment obligation is satisfied, or prior to that upon 60-days’ notice by either party.

 

Daiichi Sankyo Tivantinib Agreement

 

On December 18, 2008, we entered into a license, co-development and co-commercialization agreement with Daiichi Sankyo to conduct research, clinical trials and the commercialization of tivantinib in human cancer indications in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan, where Kyowa Hakko Kirin has exclusive rights for development and commercialization.

 

The agreement provides for a $60 million cash upfront licensing payment from Daiichi Sankyo to us, which we received in December 2008, and an additional $560 million in potential development and sales milestone payments offset by our share of Phase 3 costs. Upon commercialization, we will receive tiered, double-digit royalties from Daiichi Sankyo on net sales of tivantinib commensurate with the magnitude of the transaction. We retain the option to participate in the commercialization of tivantinib in the U.S. We and Daiichi Sankyo will share equally the costs of Phase 2 and Phase 3 clinical studies, with our share of Phase 3 costs payable solely from milestone and royalty payments by Daiichi Sankyo.

 

In each quarter the tivantinib collaboration costs we incur are compared with those of Daiichi Sankyo. If our costs for the quarter exceed Daiichi Sankyo’s, we recognize revenue on the amounts due to us under the contingency adjusted performance model. Revenue is calculated on a pro-rata basis using the time elapsed from inception of the agreement over the estimated duration of the development period under the agreement. If our costs for the quarter are less than those of Daiichi Sankyo, we report the amount due to Daiichi Sankyo as contra-revenue in that quarter. To the extent that our share of Phase 3 collaboration costs exceeds the amount of milestones and royalties received, that excess is netted against future milestones and royalties if and when earned and is not reported as contra-revenue.

 

Our cumulative share of the Daiichi Sankyo Phase 3 costs through September 30, 2015 totaled $99 million. We received a milestone of $25 million in February 2011 upon enrolling the first patient in the MARQUEE trial, the cash proceeds of which were subsequently applied to our share of Phase 3 collaboration costs. On January 31, 2013, we announced that the first patient had been enrolled in the pivotal Phase 3 METIV trial of tivantinib, entitling us to a $15 million milestone. That $15 million milestone was also netted against our cumulative share of Phase 3 collaboration costs in 2013, and consequently we did not receive any cash proceeds from this milestone. Our cumulative share of Phase 3 collaboration costs has exceeded the amount of milestones received through September 30, 2015 by $59 million which will be netted against future milestones and royalties, if any, when earned and has not been reported as contra-revenue.

 

For the quarter ended September 30, 2015 our non-Phase 3 tivantinib collaboration costs incurred were less than those of Daiichi Sankyo and $130 was recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue. For the nine months ended September 30, 2015, our non-Phase 3 tivantinib collaboration costs incurred exceeded those of Daiichi Sankyo and $119 was recognized as tivantinib Daiichi Sankyo net research and development revenue.

 

For the quarter ended September 30, 2014 our non-Phase 3 tivantinib collaboration costs incurred were less than those of Daiichi Sankyo and $102 was recognized as contra-revenue and netted against our tivantinib Daiichi Sankyo research and development revenue. For the nine months ended September 30, 2014, no research and development revenue was recognized related to our non-Phase 3 tivantinib collaboration as our costs incurred were offset by an equal amount of contra-revenue.

 

The duration and termination of the agreement are tied to future events. Unless earlier terminated due to breach, insolvency or upon 90 days notice if prior to Phase 3 clinical trials or 180 days notice if on or after the beginning of Phase 3 clinical trials by Daiichi Sankyo, the agreement shall continue until the later of (i) such time as Daiichi Sankyo is no longer developing at least one licensed product or (ii) if Daiichi Sankyo has commercialized a licensed product or products, such time as all royalty terms for all licensed products have ended. The royalty term, on a country-by-country basis for a product, ends as of the later of (i) the expiration of the last valid claim under a patent covering the manufacture, use, or sale of a licensed product or (ii) a certain number of years from the date of the commercial sale of the licensed product in such country.

 

Revenue for this agreement is recognized using the contingency-adjusted performance model. Through September 30, 2012, revenue was recognized based upon an estimated development period through December 2013. As a result of the October 2012 decision to discontinue the MARQUEE trial, the development period as of October 1, 2012 was extended to June 2015. Commencing with the fourth quarter of 2012 and through the third quarter of 2013 revenue was recognized over that development period. In the fourth quarter of 2013, following a recommendation by the Data Monitoring Committee that the METIV-HCC trial continue with patients receiving a lower dose of tivantinib than the dose originally employed in the trial, we reviewed the estimated development period and extended it to June 2016. For the three months and nine months ended September 30, 2015, $1.2 million and $4.2 million, respectively, were recognized as net revenue. For the three months and nine months ended September 30, 2014, $1.2 million and $4.0 million, respectively, were recognized as net revenue. At September 30, 2015, $4.1 million remains in deferred revenue.

 

Kyowa Hakko Kirin Licensing Agreement

 

On April 27, 2007, we entered into an exclusive license agreement with Kyowa Hakko Kirin to develop and commercialize tivantinib in Japan and parts of Asia. A $3 million portion of an upfront licensing fee was received by the Company under this agreement in the first quarter of 2007, and an additional $27 million in upfront licensing fees was received on May 7, 2007. The agreement includes $123 million in upfront and potential development milestone payments from Kyowa Hakko Kirin to ArQule, including the $30 million cash upfront licensing payments. In February 2008, we received a $3 million milestone payment from Kyowa Hakko Kirin. Upon commercialization, ArQule will receive tiered royalties in the mid-teen to low-twenty percent range from Kyowa Hakko Kirin on net sales of tivantinib. Kyowa Hakko Kirin will be responsible for all clinical development costs and commercialization of the compound in certain Asian countries, consisting of Japan, China (including Hong Kong), South Korea and Taiwan. In July 2010, we announced the initiation of a Phase 2 trial with tivantinib by Kyowa Hakko Kirin in gastric cancer, for which we received a $5 million milestone payment in September 2010.

 

In August 2011, Kyowa Hakko Kirin announced the initiation of the Phase 3 ATTENTION trial. Dosing of the first patient in this trial triggered a $10 million milestone payment, which we received in August 2011. The milestone payment was recorded as deferred revenue and is being recognized as revenue using the contingency-adjusted performance model with an estimated development period through April 2016.

 

In addition to the upfront and possible development milestone payments totaling $123 million, the Company will be eligible for future milestone payments based on the achievement of certain levels of net sales. The Company will recognize the payments, if any, as revenue in accordance with the contingency-adjusted performance model. As of September 30, 2015, the Company had not recognized any revenue from these sales milestone payments, and there can be no assurance that it will do so in the future.

 

The duration and termination of the agreement are tied to future events. Unless earlier terminated due to breach, insolvency or upon 90 days notice by Kyowa Hakko Kirin, the agreement terminates on the date that the last royalty term expires in all countries in the territory. The royalty term ends as of the later of (i) the expiration of the last pending patent application or expiration of the patent in the country covering the manufacture, use, or sale of a licensed product or (ii) a certain number of years from the date of the commercial launch in such country of such license product.

 

Revenue for this agreement is recognized using the contingency-adjusted performance model with an estimated development period through April 2016. For both the three and nine months ended September 30, 2015 and 2014, $1.4 million and $4.3 million, respectively were recognized as revenue. At September 30, 2015, $3.3 million remains in deferred revenue.
XML 28 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) - $ / shares
Sep. 30, 2015
Dec. 31, 2014
Statement Of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 62,891,548 62,821,781
Common stock, shares outstanding 62,891,548 62,821,781
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814
STOCK-BASED COMPENSATION AND STOCK PLANS (Tables)
 9 Months Ended
Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]  
Schedule of stock-based compensation expense

 

                         
    Three Months Ended
September 30,		     Nine Months Ended
September 30,		  
    2015     2014     2015     2014  
Research and development   $ 142     $ 186     $ 538     $ 854  
General and administrative     359       494       1,203       1,706  
Restructuring     —       83       —       83  
Total stock-based compensation expense   $ 501     $ 763     $ 1,741     $ 2,643  
Schedule of activity of options under stock plans

 

             
Stock Options   Number of
Shares		     Weighted Average
Exercise Price		  
Outstanding as of December 31, 2014     7,724,614     $ 4.89  
Granted     1,513,850       1.25  
Cancelled     (895,739 )     4.79  
Outstanding as of September 30, 2015     8,342,725     $ 4.24  
                 
Exercisable as of September 30, 2015     5,793,400     $ 5.12  
Schedule of shares vested, expected to vest and exercisable

 

                         
    Shares     Weighted-Average
Exercise Price		     Weighted-Average
Remaining
Contractual
Term (in years)		     Aggregate
Intrinsic
Value		  
Vested and unvested expected to vest at September 30, 2015     8,156,021     $ 4.24       5.44     $ 843  
Exercisable at September 30, 2015     5,793,400     $ 5.12       4.04     $ 51  
Schedule of restricted stock activity

 

             
Restricted Stock   Number of Shares     Weighted Average
Grant Date
Fair Value		  
Unvested as of December 31, 2014     105,665     $ 2.51  
Vested     (36,101 )     2.51  
Cancelled     (10,929 )     2.51  
Unvested as of September 30, 2015     58,635     $ 2.51  
XML 30 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814
Document and Entity Information - shares
 9 Months Ended
Sep. 30, 2015
Oct. 22, 2015
Document and Entity Information [Abstract]    
Entity Registrant Name ARQULE INC  
Entity Central Index Key 0001019695  
Trading Symbol arql  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   62,891,548
Document Type 10-Q  
Document Period End Date Sep. 30, 2015  
Amendment Flag false  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q3  
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814
NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) - USD ($)
$ in Thousands
 1 Months Ended 9 Months Ended 12 Months Ended
Jan. 31, 2013
Nov. 30, 2011
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2011
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Net use of cash     $ (17,157) $ (24,967)  
License agreement | Daiichi Sankyo Co. Ltd          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Milestone payment received $ 15,000       $ 25,000
Upfront payment received   $ 10,000      
License agreement | Kyowa Hakko Kirin Co. Ltd.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Milestone payment received         $ 10,000
XML 32 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Income Statement [Abstract]        
Research and development revenue $ 2,653 $ 2,662 $ 8,442 $ 8,239
Costs and expenses:        
Research and development 3,180 5,014 11,920 17,981
General and administrative 1,839 2,997 7,802 9,318
Restructuring and other costs   1,099   1,099
Total costs and expenses 5,019 9,110 19,722 28,398
Loss from operations (2,366) (6,448) (11,280) (20,159)
Interest income 17 62 81 233
Interest expense   (11)   (28)
Other income (expense) (5) (2) 277 75
Net loss (2,354) (6,399) (10,922) (19,879)
Unrealized gain (loss) on marketable securities 8 (21) 11 (42)
Comprehensive loss $ (2,346) $ (6,420) $ (10,911) $ (19,921)
Basic and diluted net loss per share:        
Net loss per share (in dollars per share) $ (0.04) $ (0.1) $ (0.17) $ (0.32)
Weighted average basic and diluted common shares outstanding (in shares) 62,827 62,652 62,753 62,621
XML 33 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814
RECENT ACCOUNTING PRONOUNCEMENTS
 9 Months Ended
Sep. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS

7. RECENT ACCOUNTING PRONOUNCEMENTS

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

 

In August 2014, the FASB issued Accounting Standard Update (“ASU”) 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under the new guidance, management will be required to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The provisions of this ASU are effective for annual periods beginning after December 15, 2016, and for annual and interim periods thereafter. We are currently evaluating the potential impact that this ASU may have on our disclosures.

 

In June 2014, the FASB issued ASU No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period.” This ASU requires a reporting entity to treat a performance target that affects vesting and that could be achieved after the requisite service period as a performance condition, and apply existing guidance under the Stock Compensation Topic of the ASC as it relates to awards with performance conditions that affect vesting to account for such awards. The provisions of this ASU are effective for interim and annual periods beginning after December 15, 2015. We are currently evaluating the potential impact that this ASU may have on our financial position and results of operations.

 

During the quarter ended June 30, 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), which supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We are currently evaluating the method of adoption and the potential impact that Topic 606 may have on our financial position and results of operations.
XML 34 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814
STOCK-BASED COMPENSATION AND STOCK PLANS
 9 Months Ended
Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]  
STOCK-BASED COMPENSATION AND STOCK PLANS

6. STOCK-BASED COMPENSATION AND STOCK PLANS

 

Our stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employees’ requisite service period (generally the vesting period of the equity grant). We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, expected option term, expected volatility of our stock over the option’s expected term, risk-free interest rate over the option’s expected term, and the expected annual dividend yield. We believe that the valuation technique and approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of our stock options granted in the nine months ended September 30, 2015 and 2014.

 

The following table presents stock-based compensation expense included in our Condensed Statements of Operations and Comprehensive Loss:

                         
    Three Months Ended
September 30,		     Nine Months Ended
September 30,		  
    2015     2014     2015     2014  
Research and development   $ 142     $ 186     $ 538     $ 854  
General and administrative     359       494       1,203       1,706  
Restructuring     —       83       —       83  
Total stock-based compensation expense   $ 501     $ 763     $ 1,741     $ 2,643  

 

In the three and nine months ended September 30, 2015 and 2014, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation expense.

 

Option activity under our stock plans for the nine months ended September 30, 2015 was as follows:

             
Stock Options   Number of
Shares		     Weighted Average
Exercise Price		  
Outstanding as of December 31, 2014     7,724,614     $ 4.89  
Granted     1,513,850       1.25  
Cancelled     (895,739 )     4.79  
Outstanding as of September 30, 2015     8,342,725     $ 4.24  
                 
Exercisable as of September 30, 2015     5,793,400     $ 5.12  

 

The aggregate intrinsic value of options outstanding at September 30, 2015 was $908, and $51 related to exercisable options. The weighted average grant date fair value of options granted in the nine months ended September 30, 2015 and 2014 was $0.77 and $1.65 per share, respectively. No options were exercised in the nine months ended September 30, 2015 or 2014.

 

Shares vested, expected to vest and exercisable at September 30, 2015 are as follows:

                         
    Shares     Weighted-Average
Exercise Price		     Weighted-Average
Remaining
Contractual
Term (in years)		     Aggregate
Intrinsic
Value		  
Vested and unvested expected to vest at September 30, 2015     8,156,021     $ 4.24       5.44     $ 843  
Exercisable at September 30, 2015     5,793,400     $ 5.12       4.04     $ 51  

 

The total compensation cost not yet recognized as of September 30, 2015 related to non-vested option awards was $3.1 million, which will be recognized over a weighted-average period of 2.5 years. During the nine months ended September 30, 2015, 689,759 shares expired and 205,980 shares were forfeited. The weighted average remaining contractual life for options exercisable at September 30, 2015 was 4.0 years.

 

In 2013, we granted 242,697 shares of restricted stock to employees, vesting annually over a four year period. The weighted average fair value of the restricted stock at the time of grant in 2013 was $2.51 per share, and is being expensed ratably over the vesting period. Through September 30, 2015, 82,564 shares have been forfeited, and 101,498 shares have vested. We recognized share-based compensation expense related to restricted stock of $59 and $77 for the nine months ended September 30, 2015 and 2014, respectively.

 

Restricted stock activity under the Plan for the nine months ended September 30, 2015 was as follows:

             
Restricted Stock   Number of Shares     Weighted Average
Grant Date
Fair Value		  
Unvested as of December 31, 2014     105,665     $ 2.51  
Vested     (36,101 )     2.51  
Cancelled     (10,929 )     2.51  
Unvested as of September 30, 2015     58,635     $ 2.51  

 

The fair value of restricted stock vested in the nine months ended September 30, 2015 and 2014 was $68 and $55 respectively.

 

In July 2010, the Company amended its chief executive officer’s (the “CEO’s”) employment agreement to grant the CEO 100,000 stock options, of which 25% vested upon grant and 25% vested annually over the next three years, and a maximum of 390,000 performance-based stock units that vest upon the achievement of certain performance and market based targets. In March 2013, the Company amended its CEO’s employment agreement to modify the performance and market based targets.

 

In February 2012, the Company amended its chief medical officer’s (the “CMO’s”) employment agreement to grant the CMO 50,000 performance-based stock units that vest upon the achievement of certain performance based targets.

 

In March 2013, the Company amended its chief operating officer’s (the “COO’s”) employment agreement to grant the COO 125,000 performance-based stock units that vest upon the achievement of certain performance based targets. In March 2013, the Company amended its CMO’s employment agreement to grant the CMO 120,000 performance-based stock units that vest upon the achievement of certain performance based targets.

 

Through September 30, 2015, no expense has been recorded for any performance-based stock units granted to the CEO, COO, or CMO.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814
MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Detail Textuals)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
USD ($)
Marketable Securities and Fair Value Measurements [Abstract]  
Fair value of available marketable securities unrealized loss position $ 1,126
Unrealized loss on marketable securities $ 1
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814
COLLABORATIONS AND ALLIANCES (Detail Textuals) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2013
Feb. 28, 2011
Dec. 31, 2008
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Net revenues       $ 2,653 $ 2,662 $ 8,442 $ 8,239
Daiichi Sankyo Tivantinib Agreement              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront payment received     $ 60,000        
Additional potential development and sales milestone payments     $ 560,000        
Cumulative share of phase 3 collaboration costs           99,000  
Milestone payment received $ 15,000 $ 25,000          
Cumulative share of phase 3 collaboration costs in excess of milestones amounts received           59,000  
Non Phase 3 collaboration costs incurred and recognized as contra-revenue       130 102    
Non Phase 3 collaboration costs incurred recognized as research and development revenue           $ 119 0
Notice period for termination of contract prior to start of specified period           90 days  
Notice period for termination of contract post start of Phase 3 clinical trials           180 days  
Net revenues       1,200 $ 1,200 $ 4,200 $ 4,000
Deferred revenue       $ 4,100   $ 4,100  
XML 37 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814
MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)
 9 Months Ended
Sep. 30, 2015
Marketable Securities and Fair Value Measurements [Abstract]  
Schedule of fair value of available-for-sale marketable securities

 

                         
September 30, 2015     Amortized
Cost		     Gross
Unrealized
Gains		     Gross
Unrealized
Losses		     Fair
Value		  
Security type                          
Corporate debt securities-short term   $ 30,628   $ 6   $ (5 ) $ 30,629  
Corporate debt securities-long term     —     —     —     —  
Total available-for-sale marketable securities   $ 30,628   $ 6   $ (5 ) $ 30,629  

 

                           
December 31, 2014     Amortized
Cost		     Gross
Unrealized
Gains		     Gross
Unrealized
Losses		     Fair
Value		  
Security type                          
Corporate debt securities-short term   $ 46,690   $ 16   $ (23 ) $ 46,683  
Corporate debt securities-long term     2,061     —     (3 )   2,058  
Total available-for-sale marketable securities   $ 48,751   $ 16   $ (26 ) $ 48,741
Schedule of assets measured at fair value on a recurring basis

 

                         
    September 30,
2015		     Quoted 
Prices in
Active 
Markets
(Level 1)		     Significant
Other
Observable
Inputs
(Level 2)		     Significant
Unobservable
Inputs
(Level 3)		  
Cash equivalents   $ 11,935     $ 11,935     $ —     $ —  
Corporate debt securities-short term     30,629       —       30,629       —  
Corporate debt securities-long term     —       —       —       —  
Total   $ 42,564     $ 11,935     $ 30,629     $ —  
                                 

 

    December 31,
2014		     Quoted 
Prices in
Active 
Markets
(Level 1)		     Significant
Other
Observable
Inputs
(Level 2)		     Significant
Unobservable
Inputs
(Level 3)		  
Cash equivalents   $ 10,740     $ 10,740     $ —     $ —  
Corporate debt securities-short term     46,683       —       46,683       —  
Corporate debt securities-long term     2,058       —       2,058       —  
Total   $ 59,481     $ 10,740     $ 48,741     $ —  
XML 38 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814
INCOME TAXES
 9 Months Ended
Sep. 30, 2015
Income Tax Disclosure [Abstract]  
INCOME TAXES

8. INCOME TAXES

 

As of December 31, 2014, we had federal NOL, state NOL, and research and development credit carryforwards of approximately $331,909, $152,434 and $27,761, respectively, which expire at various dates through 2034, which can be used to offset future income tax liabilities. Federal capital loss carry forwards of approximately $571 can be used to offset future federal capital gain income and expire in 2015. Approximately $15,014 of our federal NOL and $863 of our state NOL were generated from excess tax deductions from share-based awards, the tax benefit of which will be credited to additional paid-in-capital when the deductions reduce current taxes payable. We have determined that it is more likely than not that we will not recognize the benefits of our federal and state deferred tax assets and, as a result, we have a full valuation allowance against our net deferred tax assets.

 

At September 30, 2015 and December 31, 2014, we had no unrecognized tax benefits. We do not expect that the total amount of unrecognized tax benefits will significantly increase in the next twelve months. Our policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of September 30, 2015 and December 31, 2014, we had no accrued interest or penalties related to uncertain tax positions. Our U.S. federal tax returns for the tax years 2011 through 2014 and our state tax returns for the tax years 2010 through 2014 remain open to examination. Prior tax years remain open to the extent of net operating loss and tax credit carryforwards.

 

Utilization of NOL and research and development credit carryforwards may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income, and may, in turn, result in the expiration of a portion of those carryforwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three year period. We undertook a detailed study of our NOL and research and development credit carryforwards through January 31, 2015, to determine whether such amounts are likely to be limited by Sections 382 or 383. As a result of this analysis, we currently do not believe any Sections 382 or 383 limitations will significantly impact our ability to offset income with available NOL and research and development credit carryforwards. However, future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits.
XML 39 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
RESTRUCTURING AND OTHER COSTS
 9 Months Ended
Sep. 30, 2015
Restructuring and Related Activities [Abstract]  
RESTRUCTURING AND OTHER COSTS

9. RESTRUCTURING AND OTHER COSTS

 

On July 30, 2014, we approved plans to restructure our operations to better align our human and financial resources with our primary focus on clinical stage development programs and to extend our cash runway beyond the anticipated time for achievement of key milestones, such as the completion of the METIV-HCC trial. Commencing on August 4, 2014, we began to reduce our current workforce from 62 to approximately 40 employees by the end of 2014. Most of this reduction came from our Discovery Group, which had been engaged primarily in early-stage, pre-clinical research. The costs associated with this action were comprised of severance payments of $662 and benefits continuation costs of $74. In the year ended December 31, 2014, $319 of these costs was paid and the remaining amount of $417 was paid by March 31, 2015. In addition, in the three months ended September 30, 2014, we incurred non-cash charges of $83 related to the modification of employee stock options, and $280 for impairment of property and equipment impacted by the restructuring.
XML 40 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814
ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)
 9 Months Ended
Sep. 30, 2015
Payables and Accruals [Abstract]  
Schedule of accounts payable and accrued expense

 

         
    2015   2014
Accounts payable   $ 346     $ 259  
Accrued payroll     1,537       2,130  
Accrued outsourced pre-clinical and clinical fees     3,173       3,753  
Accrued professional fees     355       157  
Other accrued expenses     280       648  
    $ 5,691     $ 6,947  
 
XML 41 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814
RESTRUCTURING AND OTHER COSTS (Detail Textuals) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2015
Sep. 30, 2014
Dec. 31, 2014
Aug. 04, 2014
Restructuring Cost and Reserve [Line Items]        
Amount paid for restructuring $ 417   $ 319  
Severance payments        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost       $ 662
Benefits continuation costs        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring cost       $ 74
Modification of employee stock options        
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Incurred Cost   $ 83    
Impairment of property and equipment        
Restructuring Cost and Reserve [Line Items]        
Restructuring and Related Cost, Incurred Cost   $ 280    
XML 42 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814
MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) - Corporate debt securities - USD ($)
$ in Thousands
Sep. 30, 2015
Dec. 31, 2014
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 30,628 $ 48,751
Gross Unrealized Gains 6 16
Gross Unrealized Losses (5) (26)
Fair Value 30,629 48,741
Short term    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 30,628 46,690
Gross Unrealized Gains 6 16
Gross Unrealized Losses (5) (23)
Fair Value $ 30,629 46,683
Long term    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 2,061
Gross Unrealized Gains  
Gross Unrealized Losses (3)
Fair Value $ 2,058
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814
STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation expense $ 501 $ 763 $ 1,741 $ 2,643
Research and development        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation expense 142 186 538 854
General and administrative        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation expense $ 359 494 $ 1,203 1,706
Restructuring        
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]        
Total stock-based compensation expense $ 83 $ 83
XML 44 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Cash flows from operating activities:    
Net loss $ (10,922) $ (19,879)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 129 532
Amortization of premium on marketable securities 406 893
Amortization of deferred gain on sale leaseback (232) (416)
Non-cash stock compensation 1,741 2,643
Gain on auction rate securities   (75)
Impairment of property and equipment   280
Gain on sale of property and equipment (277)  
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 1,551 558
Accounts payable and accrued expenses (1,256) (1,275)
Deferred revenue (8,297) (8,228)
Net cash used in operating activities (17,157) (24,967)
Cash flows from investing activities:    
Purchases of marketable securities (24,203) (27,504)
Proceeds from sale or maturity of marketable securities 41,920 52,934
Additions to property and equipment (315)  
Proceeds from sale of property and equipment 298  
Net cash provided by investing activities 17,700 25,430
Cash flows from financing activities:    
Proceeds from employee stock plan purchases 62 57
Net cash provided by financing activities 62 57
Net increase in cash and cash equivalents 605 520
Cash and cash equivalents, beginning of period 12,525 15,579
Cash and cash equivalents, end of period $ 13,130 $ 16,099
XML 45 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814
NET LOSS PER SHARE
 9 Months Ended
Sep. 30, 2015
Earnings Per Share [Abstract]  
NET LOSS PER SHARE

5. NET LOSS PER SHARE

 

Net loss per share is computed using the weighted average number of common shares outstanding. Basic and diluted net loss per share amounts are equivalent for the periods presented as the inclusion of potential common shares in the number of shares used for the diluted computation would be anti-dilutive to loss per share. Potential common shares, the shares that would be issued upon the exercise of outstanding stock options, were 8,342,725 and 7,999,284 for the three and nine months ended September 30, 2015 and 2014, respectively.
XML 46 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814
STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) - Stock Options
 9 Months Ended
Sep. 30, 2015
$ / shares
shares
Number of Shares  
Outstanding as of December 31, 2014 | shares 7,724,614
Granted | shares 1,513,850
Cancelled | shares (895,739)
Outstanding as of September 30, 2015 | shares 8,342,725
Exercisable as of September 30, 2015 | shares 5,793,400
Weighted Average Exercise Price  
Outstanding as of December 31, 2014 $ 4.89
Granted 1.25
Cancelled 4.79
Outstanding as of September 30, 2015 4.24
Exercisable as of September 30, 2015 $ 5.12
XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 103 164 1 false 38 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.arqule.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONDENSED BALANCE SHEETS (Unaudited) Sheet http://www.arqule.com/role/CONDENSEDBALANCESHEETSUnaudited CONDENSED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) Sheet http://www.arqule.com/role/CONDENSEDBALANCESHEETSUnauditedParentheticals CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) Statements 3 false false R4.htm 004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Sheet http://www.arqule.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Statements 4 false false R5.htm 005 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.arqule.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://www.arqule.com/role/NATUREOFOPERATIONSANDBASISOFPRESENTATION NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 6 false false R7.htm 007 - Disclosure - COLLABORATIONS AND ALLIANCES Sheet http://www.arqule.com/role/COLLABORATIONSANDALLIANCES COLLABORATIONS AND ALLIANCES Notes 7 false false R8.htm 008 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Sheet http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Notes 8 false false R9.htm 009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 9 false false R10.htm 010 - Disclosure - NET LOSS PER SHARE Sheet http://www.arqule.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 10 false false R11.htm 011 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANS STOCK-BASED COMPENSATION AND STOCK PLANS Notes 11 false false R12.htm 012 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://www.arqule.com/role/RECENTACCOUNTINGPRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS Notes 12 false false R13.htm 013 - Disclosure - INCOME TAXES Sheet http://www.arqule.com/role/INCOMETAXES INCOME TAXES Notes 13 false false R14.htm 014 - Disclosure - RESTRUCTURING AND OTHER COSTS Sheet http://www.arqule.com/role/RestructuringAndOtherCosts RESTRUCTURING AND OTHER COSTS Notes 14 false false R15.htm 015 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) Tables http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS 15 false false R16.htm 016 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES 16 false false R17.htm 017 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSTables STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) Tables http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANS 17 false false R18.htm 018 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) Sheet http://www.arqule.com/role/NATUREOFOPERATIONSANDBASISOFPRESENTATIONDetailTextuals NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) Details http://www.arqule.com/role/NATUREOFOPERATIONSANDBASISOFPRESENTATION 18 false false R19.htm 019 - Disclosure - COLLABORATIONS AND ALLIANCES (Detail Textuals) Sheet http://www.arqule.com/role/CollaborationsAndAlliancesDetailTextuals COLLABORATIONS AND ALLIANCES (Detail Textuals) Details http://www.arqule.com/role/COLLABORATIONSANDALLIANCES 19 false false R20.htm 020 - Disclosure - COLLABORATIONS AND ALLIANCES (Detail Textuals 1) Sheet http://www.arqule.com/role/Collaborationsandalliancesdetailtextuals1 COLLABORATIONS AND ALLIANCES (Detail Textuals 1) Details http://www.arqule.com/role/COLLABORATIONSANDALLIANCES 20 false false R21.htm 021 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) Sheet http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryOfFairValueOfAvailableForSaleSecuritiesDetails MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) Details 21 false false R22.htm 022 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) Sheet http://www.arqule.com/role/Marketablesecuritiesandfairvaluemeasurementsassetsmeasuredatfairvalueonrecurringbasisdetails1 MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) Details 22 false false R23.htm 023 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Detail Textuals) Sheet http://www.arqule.com/role/MarketableSecuritiesAndFairValueMeasurementsDetailTextuals MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Detail Textuals) Details http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables 23 false false R24.htm 024 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) Sheet http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESSummaryOfAccountsPayableAndAccruedExpensesDetails ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) Details 24 false false R25.htm 025 - Disclosure - NET LOSS PER SHARE (Detail Textuals) Sheet http://www.arqule.com/role/NETLOSSPERSHAREDetailTextuals NET LOSS PER SHARE (Detail Textuals) Details http://www.arqule.com/role/NETLOSSPERSHARE 25 false false R26.htm 026 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSStockBasedCompensationExpenseDetails STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) Details 26 false false R27.htm 027 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSOptionActivityDetails1 STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) Details 27 false false R28.htm 028 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSSharesVestedExpectedToVestAndExercisableDetails2 STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) Details 28 false false R29.htm 029 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Restricted stock activity (Details 3) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSRestrictedStockActivityDetails3 STOCK-BASED COMPENSATION AND STOCK PLANS - Restricted stock activity (Details 3) Details 29 false false R30.htm 030 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSDetailTextuals STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) Details http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSTables 30 false false R31.htm 031 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSDetailTextuals1 STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) Details http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSTables 31 false false R32.htm 032 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 2) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSDetailTextuals2 STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 2) Details http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSTables 32 false false R33.htm 033 - Disclosure - INCOME TAXES (Detail Textuals) Sheet http://www.arqule.com/role/INCOMETAXESDetailTextuals INCOME TAXES (Detail Textuals) Details http://www.arqule.com/role/INCOMETAXES 33 false false R34.htm 034 - Disclosure - RESTRUCTURING AND OTHER COSTS (Detail Textuals) Sheet http://www.arqule.com/role/RESTRUCTURINGANDOTHERCOSTSDetails RESTRUCTURING AND OTHER COSTS (Detail Textuals) Details http://www.arqule.com/role/RestructuringAndOtherCosts 34 false false All Reports Book All Reports In ''CONDENSED BALANCE SHEETS (Unaudited)'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. arql-20150930.xml arql-20150930_cal.xml arql-20150930_def.xml arql-20150930_lab.xml arql-20150930_pre.xml arql-20150930.xsd true true ZIP 48 0001571049-15-008783-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001571049-15-008783-xbrl.zip M4$L#!!0````(`+939$<>838U`&X``/%U!0`1`!P`87)Q;"TR,#$U,#DS,"YX M;6Q55`D``V@D.E9H)#I6=7@+``$$)0X```0Y`0``[%UK;^LVMOU>H/]!DP%F MOM2QGG[DG)R!\VK3)G&:Y'1:W'L1,!)M\QY9V7I/R09/DABY)E MAT#1XU"DN/;FVIOD%K7U^5_O0UMZA=A#KG-ZI!S+1Q)T3-="3O_TZ.O35:UU M]*\OWW_W^6^UFO0C="`&/K2DP"/7IJLSX)';D#;L!NJQ,K_&2BY<,QA"QY=N"90> M(G7?D#^@/5Y:R'>Q]-ND3^58)WW*]%9/@P![%AC_('5-WWV!6%+;/T@,A6R< MJ/*)IA,4DX[>7["-3NC_):(!QSL!^$_[]&C@^Z.3>OWM[>V8%`0V/#;=(9-$ M;FM$-V%=&SG?8G7I?8Y=W"P3JI5".U($;FK-WZ1O$&3'%^JE:-4*O^M*KI!HZ/ MQ_&Z'C2/^^YK?7*1#K)6DY6:ILR:!1@38UC6;G*5-M3C#2V(TMN0"RG5X;LY M2*]/KS#VQ1L@YQ5Z?GJ3\%J*-`Y`II?>AEVB391X$P^9Z0W(A;3J_@@OJ4^N MI#0(O%H?@-&L30]X+VP,)Q=21"=7*!F\U#;L2DJC=WL%?W^_B1A5X..E5=MU M,[`'V).861('8F+7AJN-MS["[@AB'Q&<$3?!;D#1GQYY:#BR M9V4##'NG1]0WU:9.Z/C=LX[J4T=Z[CH^?/>E1VCZU!_&W)LYN8BLTZ-)Q6?M M]O)95IY_!LXSD:GY),O/X7]/W6=->;X%.%E.8'5['8R!TX?4)W?>D??\R]A] M`S^!;]_<7Q!&S@TRH4,GA4X?0U;K%@Z)"SZ:@R%ER!_/_T86+2&^'4M,E7'- M39ES?OW+T1>9^#19:3?:QN=ZLO'\AA[LTXZG!1;I\GUD(Q--L$@6&E*0=**; M$.PD5;BC+U3A)QN*^+F>VAN%45\`5D_7!:$$*]9`(_R/=CB].BV9=UF/D64U>\X#SW>'E$"=T0)1NL]J,ZU<$*@" M!-*S$DBOJ4WT`R MS4943'6>QJ%0;X?-MV6Z2*?<6H(=&,];-5G-Q'/60&T7R?,+:"[R7$LM3R7N M!4#('*!'X'P;NT_H%1"5..AESWB[BC^;25@*?92L]"$-BEVH_1S8A":*G*3/ M8ODEV7FX8Z;;J>88@M0G*&+A$=1-^9E,@%V^;-@9'7Z:7 M5PP&C]YCXSGO=ZB-[3)L\.'M\C?H^70:IO7H;VA]';G.C\0% M^ZF6&_8-X:/OFM^Z(QJ0$+:[9[8;&?.)!E)'OD`WL91%PE'LCZ/H.`YI:(^% MG_A@?B(^\,)-5-!-9+=O3HYES[W`;@VODCY(V.9&MOD(1RFV*:>4WP^`![UP M'TQ_/KVY3Q@!^P-%*AF5YWJ8<'N]-CY,E)(RMIV5XNV:)A4>#2^E58N MHI0[C5+24QB9HI1A`[55)'TZ07^1/EI:^8*''!#]=7R?*L%UF'OH>`A\5`^Y M2AL?QT,2QK:R4KQ5\"+@SGU-H;B<4GX#^\"^9!(O^L9S=S@"SOC&MR84?X`> M!-@<=`AB^`IM=\2&93Y"%`H&IO_D3B*P5R[N^@.(O;/Q;#4>#A:<#=43Q,.* M1]XMB$X2JDISM4F%\;`"+CJ?KY=7*+\48U$R'2\*&Q2QG+CZ(W(X;7$R")]X M"DL1EK(S2\EV$(]:2C'/=W-;2F*N%K:RWE;6J$Q82V6M96&;JJ8?&HN6KXQY MWD(+F<#.\R@E?HN/=!)B0^45^(QD&98#/@*A9MWTJ\6?;)O,7MK"(XO%8Z3,79']'U\Y/3SF&/R)A_)(#=68%GGM=('0]AEH789CZ4M&.4DEA8I MC]L&6;KX&)D^M-AQEVI;QAHZI,I2S1530:&BCO?<[3W+^O3)LQY_/S6MG"DM M,/T`$\,]=SV?+&+I>A:_)@ZZD84MII:V'Q19(U;*::^X?$70)DQ/XH<>GZU7-K_5:G1CB$WCO!/[`Q;,ST*30\Y%Y'G[_8I_,+RG+W/)2 MA:JFT56<'LS%D?F/>CC[9^+)/`N9^Y.C:1U1UHCWH2@3'G=))<<^>.K$Z8^$ MDOB>".P:POCNZ)Q]66Q/(KQ)H2,'VE=)OX(8&W>]3('3$_Y1-0HB;D'$.]<17.3" MQ:0F/Q0=KP#"OP$[@&=D70"\`+/0R16&?P;T`XJ,:K,ZD1K>`QTH&D/9#_IM M(.>U7P?B>\UP3O=\I[[0/R_@F\GV-H(?\<8#SNN9B>?XF= MT=@/4BZ58_$PQ@<=T>W9IV'.ORSX"(/-^C;K"!_R@; M+$X!GXW[VW!T2@PSB"WF/AKEEMM08=S6S22?:8M@!D\WD>'$P&%X"F&:^V2:(J0AK%M$ M-82SJ:2S$8$-X6Q$;$,X&Q'>$,ZFNLY&1#@JXFRRO*>WXOC..1@A']@WKN=% MK^V'5?-^OV_CCC)U9B-K4D2CG#R: MZ[4JTO?M/GW?P;%'I.\3W%G/'9&QK2H9VPZ41")CFR#2QD2*)Q.=?=6)IM_L MCO8G9<62A*)+Y1&DR#%%B31^!T^9>.;'O=^E9DNZ51FMBEUJ)7:IA\4>L4L5 MW,FZ+A1)YC\T&43(HD(ABT,DD0A9"")M.36)D(4@A0A9[#)D41'*3`Z!I&Z$ M]B!H$3M_L*`DSB=E,BA)Q"!V$(/8,S*(D,('I()8AAW^&(OLYI7**%UN.NE# M)*+(;LZ+BZ5G-Z\2'3_*>Q_[]X[!(;)$9#??WVRW964W%[P7VY'W6F24$WFBA%&*)%'"KBNSK1)N1K@9D1Y*N!F1&TJX M&9$82KB9*KN9#YT5:B_$HPMFZ`DK=B,^DN5-',L^AXH22]VK;$]^4[M1;\20F1,FN'8UOP'BV'W8J7G2MBOW^KU:2O#O(ELN^AJ"6I5IN6 M?__=]7^4_[[Z[?XG^`XOC$:S]<<#_!-]N<6V-WY#U_^AUQJZT39U73<-PS"? M_F_PY?*JI3=//GU2&@VCI;1^;K>4T\O3GY3FYU;C]/./IU?ZZB7D^A*I?!<,R=[.=_&672^TIX47T'&'R$F[[:8*BMVB'D>_ M6O)1$!$XWBV]M$Z/E$R7-MLZQGCVV8+HY)*Q_0'V628OQ[\#0RA-&/H`>WDR MZG8>?OUZ3$,P5\DQ@_P$!O@RW4YQZKX4N*@2PK*_X.%PA M&^)S4MQW,:]1Z)@FM*EA04MB]X\.1JS#!"?Z='UW=71U\::JNM&'HK1J`5P*8B7+AF0.V.3EF< M]$AVE;^&,*(W3W9XSR8=OD2:+VGB_%G[/[BI1X',6/"Y[H)QU&J!V>0'[5TF!$^J%`YM\A\VC*3_H/#<.^`IM& M$#OAE\L(4UEP<84=9?DH7<2.Z-0?,:*:1HBK&JI!?/'G>B9L7(7)DEQMM3": MHLF[%293!&BU,(;1;%=4F+1(S6IA&G([IS"W`'^#/GBQX?QQQ&3B+,52]$:C MI<5$6(&(`W!N5J')#;6]#?![#$<`69,DLF2PNOX`XH[G0;]4S2NM=ESQ&P#C M*`<_]Y1/C/(5WU#($CT&.3\X;MK4M;:A;@8NC>]WKF.6J$I5-EIK;7".*4Y? ME^RP_?&]3;9GDP>W+$WX'2S)_K0D;Y<#X@&<&T74=FLKX!$[+)DFBARG="J2 M7%#Y*==0LD$-KY7CN#2MK:?XAFQP^+DJW4CUHS$XIDD_B.S=@S%U"C25NVGB M`%HW"+P@N_3E3J.M-^.0-P=8@%S7F\:;6E/+B/:1[`9N(/#@"S"_/6'@>(!%2*3>D=6239LS?T##`3]"EYAM:-IKJ*S>ES7T2B MQ_93I-H(PP$]1]87W=X3>"]E<&J*G%PP9\%8D'C\9B1>PCU` MGRS]H'4)L$.F!R]R*[)&H.=STT?H)P&YB:WFRK#2.'(,R\ M!JYM0>R%KSN4LT24#3T.>Q'(]C#Y/1=0=*V9`69DH48603O2[6)D9QTL7B(4 M&`W*(D)\X74/S+WE9;&Z_AY@=>RAD+"('O2(BJ4=?Y&-9B3W6V``A7YFV M'IR29`K/HG0"?^!B]!>T^(_/DC,R;.Y./'1:@8N/!-N-1CD27'M>4*+^U^`. MT>3'S%7C7#!O=B"L5&4GCH)Q0%^FVI>@CVPDJC@9;`"/HS1%3P/;2[/K"6!) M0&"5]]P2?1'.GP?ZDAU_0VVI2K.53IYECG0+T%S5/3]1FP?T+ES_!NI>[T!W MY_LW4'P"/DL5D/[Y^,F3B%3PVN1@:V#S.-:G-AIAM&L]FA(QY_RX['*)#>*0 M](D[V@>)-_R"ZFJ!U3($CI^WSDO+EJJUJX>Y2%JR>-^^2,R#EKI5A+G29(8,N/C2V65D"%YPBLG0+YL);-B\H`75P7F M?\VMJ:H;`^R.:/H!LH*;'ZXI@82UAJ['!SD%QS8P^7*Q1M7>+@(G7TK65*W1 M*%Z=N6$JBII8W*S!>>V\0H\=_`VO7Q-8F)240-%&W(:6(=D:+6>OF7A'D#M< MSC-^LTSEYMZA*UN@#N8X;]POEJ;&6\@+H M4CPYD?-5.^LC+T8M26?S4EMQ,+_:78EIVE_^I@"&QZ=N,GUZ:/MNG;D[1QUXEDIL>( MAG@O`II=/4]]P)$V9FZ.!N3GC*!'9*Z^-IWZ["5Q3O`6[JV M4FY?IN]IZ&HR6+843Q[8W"?4=L)K%H2;^V2K-\I7-X^)6-E*W=/7J*:'5\^` MATSZL`39@;_DW&$^AJ(149E&`QM&A%S; M(2U(UASFM$Q65:FHK#G,;HFL+;5945ESF.<269N&QE/6"T@F.1.!,/W.R(;L M2VJ.U1FZV$=_L?(2ECN&ELP(LQY6`6+D7ETG\D9D%8.FS0KK1"IT>Q?("Q-L MD:;W&`Y1,/3F$>Q2XCO)_*';(2U%UOPOS3NUD4@ND8Z$"];\C_ET M94.L;"3F@8).P)*Z/0`_DI^UO(K.4<)6:>':Y'=12A,T_LJK1*%S81%+$4A9YZL)3_C6H>(N0>VA::CMY+B6# M"'?0IU]3(!Z6?K[*.AM_)=/\0!*1L0#PQR82Y4^O^$U%:,HZ8FELG7[D]LQR:2*85IZ^3(6A\21QA]7;X2L"%%R MKV1T5=9RBH)=$T++N\+ND"Y_B".]!3ZM..[V=C1"AMK6$B.4%671(N9.L+7P M'D@^$9/#OO0S`B7(IBG&:DXN!;=JU!+K\I)E2OE,PZ;H-I@!PJA&%>8_U=`3 MGZ?*![E4X?-OQ9MR4<+'"#/_VJQW^0ZQB;Q"G@(N^-7F<@ZG0>*-/W_6X.WQ M+QG)*^0`QZR"Y6VV[MH0;ZF2,B!GG1)#GVTYM'9%7KD-FR,GX@,9_:R?-G9/XOY M#]O_-)(\?VS#TZ,W9+EOWHFD?)+H[6KT@\->S\7#$\EQ'3@I10[]+OF))(_> M/TE#@/O(H7_X84'/I=<4^O<_?30D"TH'ODG$2P'GGS](K.0'R2,*Z7V2W@;( MAS5O!$Q(>\!$KY\D&_H^Q*R4D'M>;KJVBT^DOX>)14AC%UOS6JSOVAM\^88( M;@K3\['[#=:(3/[@9(Z-ED/?',QN?/2/OO^)JN&%_E".I;O.T]>'2ZE[)77O M+Q\Z3]?=NT>IKQ]I^?W#Y>/EW1.[1%O67Z;WJ(_HK^^_$VH-U0J& MHT]_5QHR-^4<&\@Y&/7\&THT82*03!LYR`0VJ0;Z4'I!K@_-@4/Z[M.Z2*X[ZR]X]I50Q&,/"1Z4F^*Q',@&PPR-0#L1[KFC498=<*3$C$))U(%@[ZGO2&_`%IU.M!^MD5Q#YF/23R M$6F\H42T\# M(M^D,Y]0`_I4A41Y5*>TWN`-C#UZ)YN4^*%>`.G)(JJAR3SH+:-BDA\TCSEE M8,UUS'`<"`=I:SK1AI*/B%>GVU&6<'$R@E(X@B,T@J2$34'$A_L,=(^A9@IB M6K601<`08@(B,;E.B$F'B&B8#AN3`UH_4%&&=`N,:Q;LT>3JTL@=T9SJQEA6)NA)6CZ&)!!>*'/W&A5BA$1 MS/T!N0%RR)!^(XL/#TXT.F;Z82P@UO1*VO2(E;%6;,SH>48R3"^$*..P-_?_ MV_O2YK:1I,W/VQ']'[!>[[[N")#F?71/.X*69;>FK6,L>>:=3PZ0*(H8@P`; MAV2^OWXSLZIPD.`!$CQ5$1/3,@C4\515WID%,('Z[O&-[(:.Z9<5-5#$,B\\ MN,]M9ICS)XA(3U1X1WO3^_(/H(+M7^!@P7[VX'3!KA65%H`$P9'RQWCDQJ[- M!J&-QVUD]:W`I?.!=&90N@8:XK$!F^#38.JY*)_)H_"&+U6G5JO\!J]>/D3_ MKO[V"R=:<'CF25!9N\"W<;P&3F-,(>Z29,$Z"B(D"/$T/I78WCBT`VL"P_5@ MW'@VQ=LNWI'.;#K,MC44R@`L9#B&%GTX[P9,&9>X;[NNJ0$)]8$VX[;A3(,( M.T,RA>TA%9?TC^@*'XR%]!X9%KS,J:\7.$`O=4T40-)X!23MPBWKVN?`+*=@ M2K\TAQ>5C=*H;I1&A:,6-#/W7K(EG=-.H/)4>`FA-7`/VB91^HCH)1F@(("< M1\6;B)-5*LS!D/03;XO(*6Z1L>L'B35,,`=JR^*4=!&A#2'`T MX=PG4(0#HR6^^./B8@9B&,DSEUO$/6HV7HQ18/ZYI97+Z'L0$-GY0$4-2/SX60L3'%)4,EG*#&Y??#"\OC@AD*Y_%^1LXQ M"F%2\LPGJ1&\.D.AA5+PM7P/)/8R1-N]KMV[(1R2'O0#7]()$8I#()DB45(= M#M;`#JGX\M\-T$M2\C(_5#W?PJ%@B`*(?H#P,SQE2#76F-8=4SI#E].1I M)I%?$I3HK"(2$Q<4DCX0CF$8A-#OV`)V&<"F@=>Y,T:'+3`U;')W`2F1`H5O MV"2-S^A(PY#BG/7D*2=Z8#TZUA#00C8B6A8J3$3=D/=.29!`6;FL\70VK5:I M5G5\3?ZBO:XU<:`VMDT2]5ROI?N8Y[TQ7:W33>WBXO$%C".\(5LR!S0&<#83^.DP4IENG MZ1J@:X:P0TV.TWR#(^!E?<8<4&!!F+%C#79B/;D!S$&R%A"CKOXIYH5#BPX# M;%#X([!QS"'M*`,F'8,;[094&Y'21[OCV4#R$!`/?H3=C#L?63B_P`KU&HJ: MQ^[D*(`,V$9?*M\#+*.$`^;SY1P+=OI?(>>2SZ@ZFW#4`[GN&NKU`\,?X1XD M>[Y<7N#B\4@5E51,9`,FXK%'NHPM(0,+.HMDDDA(@LP)`4M09)G6`)L=U:E* MMZ;#VTCR\/"Z4F7BQ__/!YJ_P]X&(X^Y3JPJ\5-`]@UB#9$)`!I`-H*B,,#O MT4G#=M(GBDC]#"6(M,3F&I]=D,*NU./DJ:Q]A9.XSB;@P9]D%:5IPL/ML8(R)7T[0XD/L!T`6 MO$/PTK%A\+%H[85U+S)W&1AARP_`3+\CY#0`4.C1H1AR M[QYR,D^<$[=O6X]"@(.'`F./T4V*?.=;OE0JR]%(\!F(1)&%-#&:R"+)C7(S M-DA@3(`A;_O9\$QI&P$ED5LGN(:5-&D@P_*Q8B$W[[(QC#7@*FQDH)BE,=!W M4DY=:%.6EE46*=-\OG(.@GC$I(G^Z+0!;6XF*0E+36S921(O4!2E+1IU[R0M M&UI]#\`W@/D_>NXSS`QW*RZ!-`8E]>F/GSY^2=DRA@;LO2E?=!Q3NU7%,;V' M-0"]$4C[""4-`[1$]Q'V#;<<4#S%H[1+Q_]VD6<`JJZ'P^9!%]SVCW8'-^"4 MY.8?E6IIS$QN5Q<*`-F#'#9`N]5&2NC//YT_BU02Q$J#:^AS?PO)J$C0H\)5 MY+/AH0AH5!FH!7+#D?'(N/1!#H/QQ':G#" M&U!G\?.HL2G9>FPYZC$:?-#.HPLSDSMDY/."C[%+SC!]&-L@]DYQQ("9"`?) M0MQBM&($D49+C3+B;9&C)9:17(_#`GOGB3"!7G!W(O1>Q/ZBIKA$0O*!_`)9 M'F?3)+4!$4>H2+3P09-"5G\/=(_SR'J%A*$FP8#!'SJ-!Y0FW"C1/D%%*IZ+ MB6XB1^M/T^.(`6&R]"WW?W'UD]-";)F:=,,`L21T7U?;Y5K$XTFIK37+$=?7 M20C#E0>^,U6ZDZ)\&U$^VG8>HYA=OFO1)OR$HI2D!["YA;;N^NCQ?M8FMN&@ MC&$RV-(D^).A7UC28%M'Y&'&8SMK!R)+^#I/ZYFB\,*P.";WS"9LSC(( M@*4U*#^RY*$L2[W[(1RR]$MZ8$649L`L3[@5@Z47T1``R?`YA,**DA1,2S:M^+!<@&82UW<4S!`LQ'(8Z$! M>S!@+#*R4:A`']I'=0OP$*,E/2B)8:$RE`!9U*,5J%*O9V-XOB>T$/MYKR[G2C#E,\T);B*T>>Y110M+BA"X? M+9'K@Z]=_L!(K$>FX8V6(I8KJ>/>7Z8\P&7M0CA[+"<=0C!TW0!.+>GR`]OU MD0^(N9*2+>Q]EK-@(A(!=+,``)Y)T0@DNW/O.,5Q#%`-1TL/SX%%A$#6A-8F MMI2HR8$0PX;49VR177\&+'\!7#*B;`7T_L@-;?17(&&4.L=_0B>A=!#O!O4B M6-1&$KB$@0<=9D%L0IL"1Q;2^`>@E5P8YXZ51@I9ZL_!F`)HB[S5,!*0\,=P M,$I_PA#0I2(=:!HL;6SI;'#97E$Q1<5RPX/Z+T@"8J.O.#9BO^IRO[H34,11 M;T,W@6'^)Y35>-X(U9ALPPY7BWFOJ!2''C2=<>C MFKA<\D2K&OPXK^GJ24]X4GY/"'(D/TEM/_:MQ/KT"D5Z[G&#&Q22/<:]D;J/ M(KR%>H`UCI1U*31)#"P[#EE]8I(#R$:!N*#@/!A9C&P+8M##$-8`J4V"#,39 M#?FS%-)%.".=XXDE;M'[$+$+E=RPV^2&&C#OV\^?>^]ODVD-O<^?KWHW%Y?W M*I5AKQS@G,`!&"S\XSWSIK9MA6/M0V3;N'"]25F+[L,D^"RURY2*Q16 MIX(S/S-N"R/)5UAU$AQF<=)+[-(F27CQGDVJ0=%;:67H;D;]2ONER5SS']>B M\)]4^+"%RT/18Y'^E'10S.7H"#D@G$BL@`M M)I&%9=8:)V+"YH8N$<-<2Y.A+8G,3V3Q)+MA*HX$'G_Z?/#,\NR:S*.` MD0;"&AR+U(!N,/+<\!%0X!YU&6'?#T5N%TTQ:LZ=R'A*^`N'H&'*F3`Q<,K$ MM7,1,"="-Z>SP%'3<>"/,0QX'H5&OGSA>DK$5:"M%ZL+^D-+F"@IZ("?8Q@" M&>Y;E9)I3'UYY*OMWV2447^J,8MV)<*@W$Q*9MI89IH)#HJO$%8?I'PA M)67%RI*W5A`KSZN<.4RQ+B;%R,#BB<"F&X(L73*M1RM()`5E`>#R<"0^ MP#1YH@X=/Z3XB\B[,C8>0>/`,%5!L52<%*J%C^N01TC MYY[0!6?&3G/GF+&_0B&E,Z'B12C6N%(I$9V+CXL\6MGHXUJ18]]W;29C8^*5 M)"F>R^[QJL)RIH>JZ)ZB>YN8A MJ<1$HI968(EK8E,8U^`& M/*IB$O#?%M"Z^=W$%]]/C@.^B&B?GR!^%HM#>G7>#7X-D[7FT@]G$UAGV[&& M/*H:8ZU`PG9$]0!LB'(,$1M>+B@]>45DMR:R/__T\@"Z79`-B[M^YKRE!0-A M$8U8OYS]VN%!"%;!1E=,4B!`9_)_*DX0A_9'V/THPQ?8O;['CFL*1O MJ].B=4YC4TFX43&F9]3K_+`?)_$:E!A`,:'KDH>3RH?._(U"^LEN>YP)TMJB MK;EL'$(YIQC5Q90[VHA+-C%(L:^;T?Z56T?8[//1=)T3]:D^1]5YTF#`MX.B M[4J`+A">C[/"[*)X)4KW<9U25.%GN91-(C8)UFP=D4Y4J*A7B-Y$LG+&+JALCLPU/[9LIDI`):/+*VFSP-CF1?W'EDK'?HW(NB?W'P1I2HUO?0 MK(>1.[YK/Y']B]*:H9]N1VUF=F#0J(;<'A M?*3Y7F3R(6[P=+81D85#!%)$LB>^T[E!DE>'FY;ZTY+X4Y@FN;-*-(7**X:V M1PE,*?BXN6YBI2V0%._S!%/$&###&@O[HX$Z-:/[K` M1+9-L5KDWGFRV+,PSRW=/(ASM%I6D%RP5BS`8WFZ2((G16$M7?]U=;;@2"-^ MD*XWHG,)/*VA<.U\1IG89"R-[+$LJ'VR>BR]('N^C7(UZH.7K2.SK2DN-U46 M!17UNFW4ZWRPW.VUGA+TZB?C, M^9*7Q.7F=VJJU$PZ>)/-!&;%-;(QL(L$#2R/#:17>UV/:"PZI931,LF:&`&0&`"ZI5PUKTO'^$-N63RYA=G/?K^KKQCC[)4@E7 ML@B03E85K67I1C1(:,K#PC;GE<4E,V3I"BVAA"89ZK#I_,\A]N M$89-J_CWT*9@@,JF`%G(/.G1:K%GLEUF%D]1$:]\8*Z M:7U'OI+7VL'IP;HV"R%GH+*I=JHZR!L11 MB4J*]<)(8\P#H7O4T(AFBC;8#`-YIU)4:5?Z610Y:]5:=,$:&C<3%N+'235Z7O M!M+)AJZ5=?T[B6KVKZOEQJQSI9[M7,GRK:STJ]3CUM;TJ\3%]W*4STM6W?LH M*[-OBKNUJ2%][[V+OZHOVS M]_GKI79]V;O_^N7R&I1P589/4>9MRDG'M9('(-3XUI!GS/,JYCP_.U$`VH^+ MK)>&>.$0BB9")J/0+ZP;%7H#LA/Q0DPE]F38(1571X&"7ZP4QZ0.1>4QPR:Z M[H\8:(4HJY2U>XL4NN08L?R88XIJ(2`W4<]C[IPAJSVYK&555ZS&CLWQ:]W^ M"BT3R^6G;FE8,E>Z%HT@L43D,':`'\.$>&E:+DW)V`2\Z0&_!O5T3NJ2H.@4 MJ0=L!@9"0K'K\7!FB13O##*5W*1`LJC8 M,Y(FMIP.<6NQN$&.>T]!U>4AL90P@"_HT@XG\L%-E&]1VQ[C-2O>5$]^!;*4 MSQ53/P!9:N3:)O-25>.0R&#-NB]S'Z:.M3N>>&R$_E%TB,/0U+%5QW:3 M8RN+?XG``WLJ@OE\'CTA-CHWA\8'5U17CT\VA48,7="8N+7+E<>`5_F,1!$Z MZXG/R+`THCM19T^JOLC`/&:&#/RG$U1"5EJ*CKQFC2>$)\@<4.3B*J= M*0,2:>J&N`%5EM5PN1-0GUWXU*22-5FY^U$6[!\!C%B$B!>^Z(MZ]%@VU';= M[U$A$VB!UL9OEW'V\EI-[8J.=2EMIB(X"3&EW,1N.7T%%4*"+(JH" M&U\W(J[>6M!DGPVQ'=H;J1N[>'5C-/[.\BX4WN(4PFGAG=\\*3]IF9N"`Z9D"2A>'7ORA.I#C11OFK&1L; MKVI+[F[B`7,2'5$_024H6`X(PQ1)9T!^/J0\LC;U,TNHLG0F*2PH^I&?WA`1Z19'&?AN.#7-,NS'/E\,GG`O\@Y.3^VF.Z3/T+9*>K78OD=ET@2)S-TJZ.(3TU<<.2' M>`&S)68N"-%"(I06,]7!4P=OHYB'.)L-W8VP!\=C(^9^,WK3/+_/MH#"AA\Q M8,M&EKN.UU&=O6WO5[5""_Q=&X$BR^@I6%[L7A&G'F&/]-T@<,>9W"4PES37Z!396K552&L$K/AX0.E;T:K7*HU= M=U&O[;H'!=-Z,#5W#U,QAVD93%4%T\:3"-S)RN;?ILAE)ND4+(*/%\9M&X/O M&FQ?+%QOF2LF)B-[Y@7&F;B=[#EO#=I6@R^B@ZQ56PNQGM0.TT#U/>UMZKT+ MT!W7PC+W2#;=E,>+Z2,;&_A4O?D*?M$+^`,A_)JO,X:`O'*6#+LU' MP_)6`/Y/M!44AG=!?&G5Y"S.=X17()A.^`RL%3/8>J$*/=ET"58!N^?P#:A9 MO>Q9K=%F080A9?0H=('I0F[(_:=6K5VACQ,3>N3W>BXF M?.)#HGNSBN=*GK&RU_77?O5`=B^ZO``0=RHVO0#\EHILR8Y0[)CO9VR9)@QI MI1#W`I`\B`#YEFAR_&\5GK$B[$K%)*B8A!?N;%I< MA22HD(13=8RKD`05DJ!"$E1(PG&89U^DF_OP#:A9%=CF"7L?SRHDH='26]W* M&4RD>A8Q";7ZAH,X@J`$W$J=9>,_;[)PED$)-;W2JI[3A,[4;_]FWW1C1YNM MNCH[>9."=`+`'&WHM$+`/!-;1F"*O`@YX%N+#O01Q5X M<-9A!W900%6(GW\Z-UA4$9QE\#QD%DI=N]0-%EN4M[>[H3]7:6WB^OSZ,2RA M.>;EY@Q'J];D[1EX!]_KJEZMM;++Y?!;>&:;Y7?]^`L+\!B^N+OV=751LS=8 M6CSO=.ERCJWG#".:@B,./Y\P M+VY#FX?=M<3ISAQY:B M:R`3L^=@Z?@:]&^)NSSBB:\&O"X!QRY")]%V$GFYF6G*R445]89E)7^@Y:$H M!1KAX/'"TE80T/W@XJI)4;&9]A"Z+1?W0(A0942/+G?D-(MYA#R\2(=U&&UA M>"*WDCBNXNKR1>=159-3%<(*B<9=QZ@@%;Z5!H8MS(RO$$P8L_/[J]IJ2T8! M(]ES=\Y4H77[/*`T]EP M]QSUG-02K=/O3B2.+&FH@$#!A,J[L0#:/=LMI?VO$RA>;Y2;31G_3=&?.1:YL?TB+PK%BE>YX.@N'JA5TYNM MQE8+FV_N9X/`73IC#JYU%-^MFI*:T@&FI`*@5=VU M4XGT.#4_6S(:%SM,>."72^+7=SQ6]W5A6)N,% M>.#W#<'+]#PK')0'?M84FZ>PRJGHN^?E@5=+I#SPQ^VMRU-<17D[E>]=[<)C MQ$_YW-?LY22]>,VNWNBL6QR%AO+S3\H#NK%ZJI#CLFN>DCP*N6/PNL?^O+^] M#?W2HV%,?OUH.88SL`S[RO$#+Z24[P^6/[!=S`!_@$&\M]W!]W<___0W^4EO M,'!#>.W.F&)[/<>$)U[(S,]QP8*,)JB8"?SC"QO^_NJ"__VM>WWYK5+]]G?# M^8:)B`^5RC?^OX?;;_7*MWLV23]_]0XGLJDC$OG(N;@A;5%YO5'6>A<7MU]O M'NZUN]Z_>^\_7VJ]FP_X\,O7RP_:Y7_?7=[<7][3!NC+3XM(VS\G-!US:M4CAG^4`2Z8M M'5#YW'?+W3[;E2I=XIWJ=-9JO=[(5\IU.]?=22#7K:S5>JV9+S([C_-WKX=" M'@.2>>`4>,`9BZ+;Q;A?JGJSWBZVQP/.IJ97Z[D,,\>[6]PP\-W0&U!9.E8: MV);#Z^"!$!S]8\@RR[X?<`7J>K5]/L[)NMYN%CJ;`U(?SQTRW[=J[&=,W:= M^>_RI,RY-2^\VG5U[=O#Z@,L'[?/M_;UV=_E%N_^C]^62 M5E>Y<90;9P-X;E@@[HX`Z<_'(XP%Q@?N>!)BR71>N!V]-]Q`B17W@:T:CTQS M0G+4N$-\>^PZ_&N?--L`U%CXL*R]-WQK0$JM:=G4HC/?H3'F=D3\.T[O6%;T MGU?Z)^<2JCPXB(D;8"UYT'[2PQ$5Y>/1BNW=`VM3XZ MM@*K1&]@A?[`G1E^6;O+[EJGID5W5&X_:M+R?92RPPF_3@3$;>8-+%]<"Q+A M!QL42:D[H2KP.J_:WM'KC9K>KG&'65OO=KMZK=.(YA*,/,:]<0Y>8B!N_F"P M>\U%7CN M'_CT]7LLP0^LA\(+%-_8+=]HE;7[A]N+/TOO>_>7'[2+VVN,`.@]7-W>4&0` M_:C=?>[=J*``Q4TVAN&.8'2(_%KV((^'$PY>/_ MA6Y!P=?&F"<0S%UNE2+E";[Z'C6+TOU@Y.(5.O$%-6/79'99^Y--^:4B>)E' M.(X^YW?5K-U?,@XC8C9T'\H,GHC;`!'G7U)N0^+IDPOK03>)R!NL1#\29OY9 M`F,__IBWY5G^]](0>53J>I4\3>"B\YF(QX;CA,!^0AQJN4S-U!M*_IG@I^-R@, M'@M\:M.O5[Q'7:"U$!=5UDSMER/;+WLJ7_4%]"N\C9B[0[AE`76E)1,\XAI. MC=IV(SCU&E:=S:*_SZ6`5;.>+][GW`I7=9KY*MH?1<&J3]RHS>V=YMAR+-"Z M#2J069"B552TZ/E<0=3HYMHH1SV7JEZKG$_T=U5O5W(1\3V_)Q3)#KEN%)5+*D(%/,5E%/@J2UXBEMP+T4!J?!4NL14M5VNIRI,K72A MY5CWDRUITZRH2D`;P-9N;7=07BAL555Y:C/@:GJKL?L=I^Z041$K6\%SY6P7 MW.RXJ^-:G@U?&Q@3"S@XCR3D868>XX'7T$0BS#`P?FA]YK"AA9'KON\.+(I4 M?+:"$0_\7M&="MS:SS'(B#[F_^6XG29,MSPZT\!P?0S&I.#$1&3AQ`9,HI2` MMJ>#U+YDGV.-Y@BG8+F7J`=W5MOO9%G`,YNN>W282 M]`P*=)ZK6KED9KLHZ+6-*R1=]HR;(/1VK:&WEDZC:`]OX7!L4\*,.^[*G;V7 M*5N7&W[B"2-%,:#":HU5ZWJG66B%KL/.J%PKM&S1+AV$%X:#XE;FICA7G\*; M3K>IM^O;W?,>@9#WHL131JY1;A>$VGZW>V,Q$YY7:8_-?%M\VTG_FBP+H(S@ M&UQ<4:[E$W:VMH$73/U?I$MY0U%1@7@@$'?)#X1FR>UPBA]@%;=VMZXW*NHB MHTW`*U?SA;'SWVR`M/!)[E8+FMJ`:(K"^1+"F5??<* M.G]>=RL=7EOC=;.J>;Q>$U492=!6T619>\BJ"1:7:# MK)9;S;@,UTS]*NW&C3HE[ZVL>I*O;]=313;4\=P,'NXCH-I!+%E9!TX4/J-- MG#Q:"VY%\M@NW+)GA?0L**IBQK'Y7_?L9%7=[=Y/O)7&?(R>2^737>73+1V# M3_?,X/O"QH;EB*2NZ"E6/O6,01#RZZJCYP_,&VMO0(*=,L/S\WHL7@3:/:D1 MI8"[DMI1ZND_43_9_9SW5&#@GR1IDEP9.ESLS)`ZLZ3,)1"(;NKY[)Q%)<"O ME8O?T4%2TRNU?/'_6V7D%P_'II?5=>-XA9P^C.T`J!YO_$JSW-ACZ$KQ2&Q? MG"!G1L>>BA,DI(7%"N]&$O'.(D`VLJ+O/*8EWP;9R*)]U'$YC7+EN(HJ;+(@ MN;B5\B4H8^7.?0D!Y2[/UVQWW`#TC6"FR'JFBS7I-@#,2D(*%<7$J<:XS^WX M]7)5&UNV#<]UQ&$P`C9DVW@[1J(?*@IN1(Z&DG0TQ(78:^4F5X;*V@G3R!VQVN:+``&-$_-2^U4=YPW2)6$GU?'*F,CG5FO4]%:W'=W3,T2/ M&6C%I![RM#%T]LE[$O3HU@->7=^>RM,XQ#PSW)OB&"XX#O-W-LSU)VKR(XKX M#GX^2-+AI($"UZ8UFB:8)(SD$",+P& MDD0>SG8[7PK?RKM\U`E1!&0]>+[,'=5TJBGNR3O;<(XBQ_2LD)\%94>YI76R M6RC?YDXT0Y5;NI/":>RP0=5F9PZ;`F/MYXO<<4?C<=F$ MW]1;>C5?R;F%67\'G$;>37&@I*,E%1!?9")JM:)W:RH/-3=PN6G@L>4=S;#I MEYYTU-%;=96!NDD9QFT/@LHX4E;!_=P;FC+KS]FO!3GXJ["S8;;DB\A-9PIIHQYML1JW<.1A8;HEMV$.)>@VT]M`;,X]B* M&ZC?X,?R2:WRV\7E;?+WZ)?J;[\(%QI>[:09CQZC"W'1U\/=6S2*RUO`LJ+# MC+745=`ZGBGN#:\U_Z\\3.'$=<37=%;B7]*N.3IQ`)(HDTKN8^Z\,F!%?UCC M<(SMU[N\YPGSY!["36."7-5B+:[K^BCLF%RW&#+`+P1R[IC7DM[.OU;\Z'XI\ M;$`^/K*^%QH>D9#:*A(R9B8J%.L1D.NM",CUK=;]'M=+4X!J39$`10*.%9YE,5>.&P5# MC0R?QUMA!)6'!P)#2O"`+-_6,JP-3H40J74\W#K6;(##D=BR?WL;^J5'PYC\ M^L'R![;KAQZ['5XD(K.^\("L"]?.@]2XN;K_>/%S=?-+NOMS>P-\7E]?PPSUMCK[\:D=U M[D\62$77EL'S$0;(0U:1],!_=1JV$9UT;9(B!U3"P_+]$(A5GVNL'RT'J)H% MJD),'[1[+-%#`?+O7?B/]B8A\WSLW;]/"3H83XYWDVB^^`IP"JB9/BC&3'!] M*AYBNI,@[CJ2/GP9E8LV-FMH8;+H<,C-;53"IZQ]=8!:^;RC9TSQ-H%^AKZ/ M(;'/&"5KHQ3!N\*6+&AZ$'"S(,9WV%,Y;S^:6S0NF540=TKQ__B88FO19`&+ MBR#)=AVZX6(8@3=Q?8L":P$-C_FA'?B\V!")DQAK3Q(/(0#_5%*,.NV;*#*] M\#$$Z9E'5M/QA=,H=W;&`=:^3J@$5O(`]^Z_ILXO-E9"2>@.-B[`Q@/$8?/& MI`&:"S@%B52#VF^?7.P)9`60V1WMS7W8#]R)-PPM M$^4S'9;;,1ZY1A'G\?P54D(-M&D`U0!2`GVS^;Z-N.]!JN]'5V338-_^-Q]=$!(M69@>8-PC"1HP$3E,FK"Y\71D`I:`,#] M5Z)+,3WB`0JJL*12$,<$!(K<*7*W MFRX&[#D6@J M)V&5-)&FF(_(-@NGFADB)8XK4Z949%61U=SP)%*3_PH-#WR;8?JP;-I8O7 M+.'JKK5BR64"<9[!O#WR*5+[EQ$1Q90'N8PFT/4IH]M*9Y1X^5T*?^K_[X9# MCDV>3]#&6:Y)X)+\YB_QSFF)=9@Y")*^!MJV^(&5-%?;&MP M/0N.,TQGUM2PBJ"/&2P#)?Q+;5Y>S[J`UD<@%D7L8RMR$:;?I"GYRH$=R!Z, M'['NIDS$NS41P]Z^NKFXO;[4'GK_?:G,P8JU;PQ/+SL_BRRD(P.(+4..8VLW MMY]U)(E`D^E/07,8>8?Q'R9P!]N=D`EEX#&0PK6!X7E3P)'+ZDC\)B!@_[#0 M,@HT\G4=>NNB6/"ZVJSIC7J#AT[6VGJ[54U7`9"L@A7=#6>:?43+CA@#KZ1-\^+%(T!#Z*7;!_Z,$:9(W)$% MQ&O"$>NTZO*W:(EXT9='YB`S8()KLA\#M&/AK$%\"P=<4Z*?DF4?N$K$18+$ M3>%Q=)^TD?&%%ES5Y)H7%08`2-'9A:K;U';&!QPZ9W>GWYX0=/I;(L.OHMO,9$!%` M#II)PHJX'!TM?NC\<+!^!E>UD<&*Q8>K"W(5=N/` M'LAH6*EABE;GI]79)?9A`R^FWXZKA4ZBNDOB./MTS$R7#@O7'F*M@E?3$KH( M')F%C?#SYEOP$^A-!G>;.4`8@))$KE&Q.?YM7Q?C@@._@Z+&WJ)*^[Q&<4[XP"J"6Y6Y3PQINPKOZZDO^95O5`G M`4@BP@RBB1_V_T,4#0XQ_@/5>5*SA;G6ML:6\%L**H7F MC4!8]=UGD)O\D371!J00<\*(P5[N@$06($P>>T()%-,7/&$\IQ]E>T+TFX2> M'QH\`/*>D?2CU3LUFDR]4Y>VA2ND,"@\23/+A6N2_:/:[;2X#,(C+NEOH*4V M_M>'6=B&)`ZQ^1IH7L8D$!J:-P^CC(C[9D!SIX&0>FGEDBD=W::5'TV=#E`K#>`N1B8L+P+:> MM:B$)`AG)%[VI\G5T2.#"@G'=`B-0<*Q$+$XL@M%#2?"42G:;^3:)EK%D&V$ M?1L-BT"<)[Z<9%0U#6V)'DR13Q@&0S(N";=-"I'%B!2J'>E:Z(L2Q>SB5)FH M6-R_A',E<-WO\`9(T(9E4Q!+:$ZE]+OIBG/.(BUM@F.B\="-1744]WEP#[E7 M:)?Q,"(ILKNX96@CIH#WZ5P`5'`LB&E+J3MRQAAP0*:^Y1.+CJUM0H:1$3UH M#WDC&,O:'^XSO./I\FC,;DQ? MN,>2Y"(^NS,#1#5D*@\@;BJ?I:6\+"/@,J-=TKC7DU/]Z'KWALU@1*%'JO). M;7R%\[A-6/**TF6\XLW_+:P(V8+*8;SUJ&C8FD7$LK*PQ9B;]3JBMZQ^P))4 M;EF0IK.RC1SE;:@FS/:M915H$CW4*HU==T&7*NRT!P73>C`U=P_3ZB.T+4Q5 M!=/&DPC<2=ZR*IM4A5E%0LDELZ"F2G\%G=T:M*T&OZMR>6LAUANCI/\_H@13 M!%3?X[7QHO;R8?O)`_H7E;(7\`Y#^[ M&(A\..@+1^F@2X-5-E<`'M?@+`+O@OC2JLE9G.^0I@8JXG3"9V#MFN44>K)% MX3_0 M_,@,5/)'(*UI:/H[U,+F+&6[K"D0T5NUSAE,I'4&\IC5--2TSKF:>V/NBP;ZP./(9(NI-+0]4J^83-1 MXH[<*S'1V"7(*^O:+B)\XD.B>[.*YTJ>L4$UWP%('D2`7%A46_GC#^N/SW-5S(EXYG_^Z;RQKR91K7KGF3]5!K%SSRC6O7//*-7\<9LH7Z>X]?`-J5@6V M><)>N+-RS3=:>JM;.8.)5,_"-U^K;SB((W#.XU;J+!O_>9.%LW3.U_1*:]D5 ME":RCMY?>'WV*0*D3>P0[2YW8W>"Z5(<]19!R MX?#S3^J\JO-Z2KB^J2T[L/.!>:>$FP@:W!2:K>(,3PDG=6Y/#U>4C!OSDO&" MH,VXO-,:99N259[0VTKNU!X5I[UF!A:$,F^=+_@=WOWPWO"MH[KY\ZSJ'FX< M\YKWD.P@3'818(4!M&'$[3JV04FJ5@IR6Q@27R&N,&98O]IJB;&`D>RYN^.9 M^'Y&,F.4+72;R<:D1T?RS%IT.IX9S@B;M\T=Q^ED]#>+8ZJV$?8H@W2B,D=[ MFM^I`/:/T`V8F1Z!Q.S.HQN!+"?YL$?W'V1_<$UV;S_YZ,UGK#VI59<)M2\6 M_'LKJO:9Q.P6:Y6F'O3QDB02JA)/KYQ)F`EV38&]/MA?'3\.>P*)W`E6N*BB7)[-O)BI05!RRB91%%$D?S2):E7O MUO-E^)ESR?(TO?V2+H9W8[E= MH:A05"B>%HH%4.[9;BFM?YU`\'JCW&S*^&X*A\RQR(UB(Q:R5[E@/R#W@=7T M9JNQU<+FF_O9(+>!HJJ0VU"*5<@52XO7`6"7KIB#ZQS%=ZNFI*9T@"FM5V%, MA7\L#/_X^2<5`'+H`)!3<[\E*QMAAPG'_#)1^L6Z*Y5C_OA\QZHK<;R^ICO`#'_+XA>)D.:86#(SX*6?\FKV#$3-#F]T.>X.!&SJ!?V=,L8N>8\(3+V3F9\OH6S;/ M<<=?HG94LKI*5G]1OLIM5.O86U#?D?J?OZ-#9%Q74>#;QGN3VSO#8L4Q^8U:,'1-LL";I$M&QYA=6U+;7M6J0H2-8`[&LJW5@K#-?YS/[+ MS<5+"\!L8]7N=-9JO=[(7>-I"Y/_22#7K:S5>JV9+]0SC]-HKX="'@.4A_`4 M>,`DBZ+;Q9AMJWJSWBZVQP/.IJ97Z[E4NN/=+6X8^&[H#7#C>*PTL"T'&]8, MQ]2B?PQ99F'E`ZY`7:^VS\>I4=?;S4)G$.?[2LNX+6SI10WJMLYVU,-_\SPV]5F,[ M)\XZ\]_E29ESAY2;6ZUGWN^/R(K9U%O=[;&OQA3M&OF$$((?@G;18#G5D>.R]X3,3&A\S)^AYGN$\,OS3 M[]G0%KU].XQ?G&W%?S^]LPU'F9F5F5F9F;>T_IY3:5`UDIT'U`D;]7;A-<>5 MEM'B$20CCS'M&EX<^=HET">Z;UKF7,P56MW7;$\%OAO+.1KTU)9?+Q-)%0E> MB(O*T53[Y8$2.!Q,S#=T)JF9+)GC$"6F-VG8C./6$O,YF M+NESR<9KUO,9(<\M"Z_3S%>WZRBR[SXQAWG"\VF88\NQ0/TV*-N_(#6K*!?6 M^919;71S;92CGDM5KU7.QR5=U=N57$1\#^=V8:H("`^!%PZ"$*.)VX"ENP;UD.*^=15=ME^NI)#KHPQU\+_71[P:*;NQXDR$@ M.7;#R>;M-"LJW6D#V-JM[8[/"X6MJM+K-@.NIK<:N]]Q*Q/K#A+ND!UOD=W( M/9+TVPG^Z5/=/"N8'EWP!'*LF=`)_E\>5:&"*-8)HJC6FO5$RL7QQU&HX(EC M&4D!K#7C,=4]^`DDB(`' MY1R3:;M9K>N=9J$9?(>=4;E6:%K3+FWU%X:#PE;FICA7\]Z;3K>IM^O;72P3 M@9"W`/,I(]B$K6N?%L>*;HX9_,!Y6SYYB7/R9L`'\^N/@H MA$CA5`NW>5[*5W'B,YGOEV%CEV"@=@6/CO-#[PL:& MY8@88_D010;/&`0AKP0O'S\P;ZR]L1QMR@S/5U?294#=>WSTV*,1S%P\%WB6 MXUN#Y$.J'[W[&>\IUXU+J)1H$CI/_!],"*M:X&KX2#."?)JAZ*:>3\\O*A=K MK;2PCEYMMO1*+5_0V5;)8<7#L6DQUV[LK\MIP]L.@.KQ^F^;Y<8>7;?%([%] MGES.,,(]Y31B%25K](^ M<)8!O-5*4V^U\D4"G4?X;FP.J)7S29C["M]-#2!'-B\70(]+#WE3;^G5?+FU M"R,M#SB-O%OE0(%>N1/`7V1(<+6B=VLJ(C@W<+GIY;%%@,VP])<>_M716W45 M"[Q)%OJV!Z&0V*]-;$9)F],7]L28O310B?C-'H])'UO]4JE4[*Z%3K9CS_S`R?)2QK#],)Z_VP_&]_3MUG MXP_C^W?W3\NSG&LZGM_PY]MAXOVL=S];H,_X@'+OT6/T%O_ZE1;"[&C(7^\_ MO-),-K#&ANW__JK4>O6NSDU),:KY4=DIIL)@5UE@R$L\OQL!ICXA0W\^/+L/ MGF78>X>T>>20\NU8K::W:2?K>29('PS+&HRL>\/Y/G4?K"?0?BW'ZN?"J';L M(/7"QWF0ZEG/Y_8=EE7O!0$@`<.@+=CS+6/W^ZY:.4I,/_X[:9&?`_0#&\P\ M_\P>#?L2T`NF\_L-71.&,_T\<\-$Q_=#VZ MZ<17AC"(U_PAMY:]!G=N2QP7ZD>SVF'P+Y^BSR&<]W1F2KQ[DW M-P'II&A"\;AO/)VD)_?2\)P%2U)/>DTK[=GUN#:\V>=[E4@+G/Y^<8VW^K4Q MG8>VTLYZOCMH:^VSQ)9SLQF]JY[Y?&>TMI7!D,X`VAOW*4.`J&0\/RT*O?O5 M,KR_;$GW/WKN^,XEC<"P/X9!Z+&(_OO0XQ=W:MAXP>`JI60R1X=!RH<&Q^+"K`(NT7!,X)')DRQ'U7B4+O8,?O0?W/C`\:/9^ M`B,86LRD#7L$`+V[ZU8^"`BVG4X^7`!3TS_]V.UPPD5P3W%[6:8(N6I\1$V>F<+#9;7W687*-ZNK)T;I_G0P]F$`$ MH>0+%X8_.@6)M9X6RI9-)YHS['(,#S0>85`1\XL#V]^CJ88!ES51MDM1QL_N M,_.^X"Q.TUWX;FR9I8`Q1YMP#`1L12!2`+Q?)Y/3AM=VGTO!,SR8%@9PC$DN M?K-+_K(V'#F9;9+B]IX,RT:A%HO.&S:[9X/0LQ`U$%F\`.42%%.64>)J"=3# M4EK,_,#Z@6B*FS(N7&^"2+/$+]#).O)4H]-N5E-$=LU!%SU/Z?)I9*O'F\__ MVWO#QB"Z^Q%CP6=1VY]_%@(S64_L;+1:WD&A.GUD:I56L>PGRHE(`2E M-"$H\MS4*ZU:YQCFF4-2.\"Y>R?W\5>"%[]9;KZZOG?&SD M(1\5[=37W`WK;8!C`R,OK6RN>SCV"\=ZB_WMVO@/2$$@7OFW0\0)4VO_"@'" MQ`E=#28F(E$>TOOI-0BZH4?BUT>/_14R9\"7(WHG\09:=V`X(+.=]MX[%-C1 MGW]8S$/7TO0S.I;2>%\YDS#PZ8?JCM=KGAZJ19A;A)HZ-">U7O47>6AFV>!) M<8K3X\J[AUOQBM-7C,GHA9M5MO'LE9.P0ZNR=F"N!3(V:G!E-^8M;S?98)2S2J8R/V MRP]9L]OHS$2'KISA:>-Q`"%,09J;4LW%Q#?4+CU6JG9\LEFCUFPU#K9?3HT+ M;BB-*4BWI&H9_A<%:9%4;:$U$Z&PG-`-_:^.QPP;$Q8^N[Y_Y_I4:NOAF=E/ M[!K>&OFWWF?7>61>-*:"0%UUW&JM-5US6TVF&+RJM73ST5V9^%)!!3%6"5W% M@+5B)BFX!@.LNV3W2K],9_M1%T]I"*&7QQ:]%L;CAX*N4F7O]L&7W+YAQFC\BW&NGHWN5#*F;PA2%/::@; M#?[*&7#YTK`OW/'8=43]_E31JOF+)^-Z`]D2B2QI&MKK59=*3,^G`21G6'GU MKMWM=FN=1CS#[<>]!Q3RUM@Z3Q32>R'75L]$H5-OU-JUYHFAL(6,?@@4>K:- M(27,S+Z7%@NC.`MJ9&UQ]C-(6[LUDZ.WUL`.-)5OL`CNF-T'T!U"F@K+R2YR M*KI?RV[4:9T)%)^8PSP2R7KF&&0R/_"H:F(.,!K=QIF`01?HA(,@1./.!8SE M<;TJ';/)J_L$8`O.EB6^M!HG-)=O=.UV5*9JYOZC=5:NW3ZAV>Z4I'6:!SS% MA4)1`$FKMBL')/!%;XR3HVE;R*E9T0"5ZNE,9<=R2Z-V)E`4<,CKL_;FDP5C M_3.^S+%4%,':VN8[%Q9Q..*[QL)L+8,<#9O)W@BSZZ(@+#P?M7;T+LNZ@X@C0!N!Q/;'?*&!U_ MWO7<5.?-2%]_>3 MY_JK;GH1PD-E%M*,YU9@L]OA%0S]R3)#@P>D7(PL-KS\P08ADJ;;X=`:,$_$ MM'#8:8RR4O'B;S)>%LT4MI:S-=IW@/8A%G-+:6,;0)O5>J=Y.HA^=+TAL_#* MH*B/(T.TTVVVZ]WB`,V8<9&`PB'V!I:/WH@CY8?-=K?>*/+0STUY1_SP7PSO MB&=F[PF$P$P7V0+27X5\MYY*ZBP.CT#7(X!>GMA"--K8_#1"9@`JLU6I58M#OQUD=@O^J=W M)(H5D+9#:&ZM^JM'TB]J)%_8V+`#DP%^^SB2 M3.";G5;]?''GYW&I\V<3WVA!GL[\+M;T@L.LAJXWYG5$<6W7E>;JW8(\HSD7 M('VEPY$L.[_4N%I++7MTV7'R^=)EOV8F9J=NL^CI)HI=\J9:\6C%KPV\0;U: MGSWH\\]/><6K-;7D12_Y+:AA,`'G<9M%GVVDZ&5O'G#9*9&?Q(\KWP^9^8'B M]_@;?![9X\G'J+F`5-^+@%0%4;?;$24*MIY908<#A"F^"'.+E/!?'1.*'2Q$ M5L"F7&OB^Z)`D4@[HW^3,_<#Z'CKE$K:H::US&Y4*S>+-;&=K%DA MP?YJS98RFLT6;O+*'VSXTDDLVH4__!Y16#HM\O7#^X<8-_,YCXP'UTL*YG`IG" M[J_:GOPTL?[?3(K.7B#8"^9\_8&SBT?XWMY=T;5_MZ[W`&[F7(N-C)U8'GUS MA(D\E5?O6IUNNUE@.'[&?#-L&ELPZFB5TQ*H=,[=#KE%ZZA`KE6:W4Z!PLJ: M&!#PNY$,CS>"92G&&4C+@UQJU5K<( MZ3`G!(7`3O^'AHC(-IZ]>T_*ZR[F0^_)"!\'/K2G.5.6W]W59X]602#O=?%V MV8X!R#K>L0NFI.RRG)O'E4UGU4'6P>QJN;QN(D5F,? M]9=:!9DDBUV-3<2T)+W\@H?1AZX&\"L&YTV'KD>FF:)NZN-5N!Z,'[TP&+D>T"."YP,\ MA-$-+O".&F^Z5G7$>K5;25>F6SS\HY@DU1[K.2:6'K/_'GJ6;P(C6--Y4FW6 M&O7&44X7)GKA,=,*DJVG"NZM,\%:N]VJ;C"_[-['N)$.L6F7H'%A3"Q@J;.S M64L@:Z>A63+I5'T]\S]`4XG7/[@]TR1CJ6'?&19P>3$<:.IR.&2#X*/GCK-E MBS74A[T>_6H3&DZ7'BQFHJ>&W584I3-[74)Q&%+XXNVSPSQ_9$TN1LB?Z-() M>/G*B7Y8(0_DKMKZ;NQZ3`N@.ZU9T29QZQ/7@EF)L,H\X]IH,FA7+&A"9,+9 M:`#)K9PN;^GZQ=_$DWDW8#?-G>='L<$8B[U-(.<8Z>K/J_$$="(\)J)0Z#YN M/9BYM"E[(&FO36HJ0".^,!LKK?:`/CS1%4_QS:4/,.+W-@BF!>W:_V<'OTTT M/YC:[/=7SY;I/ON_:M7?-&RN%("TZF.T^:^:XSI,/+4<$R;RJU:9_/A-&\-T M+`?_$?`'0Q=_J^*__RNP@%]H#GO6@`09SG_I&CW1-1^TUN%OVO/("EC)GQ@# MACUX@.)OFLV"@'GT%-"(GP]88K\+'KF?%;U'?IF?6_6S!N'"9` MZGYG)9A3,/HU'AL^9\%@%#7\ZO\]!K\A#'W\HUO6OES>/WSY>O'P]M M=_-!NWWXX_*+=G%[_W"/+[[MRT_>3O"OGW]2*'(4C?'DM_]3;54*`Z??6T8!@3[5Z1=>0HNC:,].,R<1SGYBI36Q`0@ML;8IU:A3Y@I@[^PF8'ACS0O=)Z-*0QEZN(+(YB% M`V*A-4&J1?!#-S#&`2CE3Z3M:NY0^\ZFVMBR87:PT+@^X6"D&3Y]#R+3!-8$ MA3!X$Y]<7SY<_;/TQ\6%%G@PI;(&@@NTA`N!H^^%CR`!:8T$DGWV"$`0@&8X MX-@-Q'5]L([?84CP=`B[1&O5\#V"_@?`$C!8E49%8T+S][7^E`9!LQY2%V7M M&G@,'YWE\SZXT&B,1:O8(5)J6$X`^I/GAA,=MQ],TLK+V0"@AKS5\WX551JAI=6D\!A_,,_,XF"!? M,AJ[S]"$[L#,)]S*X./3URV``%>WSQPVM`0'MYQ0"L*^>*\-$[]R"(PIC`01 M@79!ZB6I5:M7Y0*\!AU?K)TO1_H,JPN,S^3[")KPI&M7,[C6AUTTJNWX30#^ M&BP*."7)=EYM?=9K2:V#VM-.MB+_C)["K MX,@&4WJ'_15:_%3A2VA,EIO+2W+]AI MI?$-CMJ\8)3Y?$XDHSZ!#C_-6-;DGES+I-ZJ+9;[EDSJF(&XASXM'M4`-!MW MU'MQ#M>Z:*JQ*2`)2(3-T:?HK$0#A2C!JV[W34ORBX8R&V&S^-+RWF`0CD.: M-A6+CJ\N_P3TYCV#,XH:>5%&I@^L'XC.N7)_X7H3%Y@T2_QBR=3,;^\-FZ=K M,I:^RT#SZ/S/T"8KQ35!X5NM]OAPD'.?CLQ\2V!I;`4C,M^-4'='Y_)0G:["Q>O9._+)T.'\)<#^_DT**! MO,V:]82'9TL,',Q>#=XAO*5*MU2O1!,4O\A_R^_>IA8,5O!_[4ERW7X;G))$ MOS[CVC$N!V'HAYQPO=*J==><]%H$K%H"J;>TC=2K"-@Z!*Q1JM9*]>JQ$K`" MML&^C3U[TA9W#$QM>V`*)F&[GG&C,W>#\5(2=A3E]78<=Y^9!5IO`54\WZ*& M41+JT0%?K71K1:0XYX=`^`>6,NXJ(5*Z-KS2/"(9SW?-G]?@@\#K/$IV$J)\ MO52).&'\6S1,,_5JS#3E+SF89BZ?4&YDE].Y:GM=G]"2U>8Z=0ETZE*&3BVE MS1R..MJ#J9>.6XQ;,9]8JELTL44"'1J.TH.*GZR]F1NE2GO-S=Q(J[`;;.8E M;E%IT,"_E]AF]K&/EH?]UM=U]"9GM.F?X/+OU:`DEZ3YM,KQT'G#NF!!A>[KGG4T>Q MEZ`Y6Z*239+[ZQ_)F./-EF4"1G"3#R%&N][=WVJUDE;*'W^]!+XU`\8Q)>\K MEQ?UB@7$I1XF3^\KH^%]]??*7W_^^,,?/U6KG^_Z;:M)W2@`$EH/HLT8@V<] MXW!B.5^KCH=#RJQ/+ET?F7U#V M5+NJUZ]KBX:5>UCX_M`?N!`)4Q82'B+A+*LDFC>[RYN:F M%G\KFG)\RV/Z-G51&)LJ5RXKLX7\J[IH5I6/JI=7U>O+BQ?N5:0-&/6A#V,K M?OUM^#J%]Q6.@ZDOQ8Z?31B,WU<0^]>O2CO6;Z[KDOKG1K?3=#H#IWEGM^U. MPQE\=)SA8$10)-`!KV))UJ-^:TU^P2;RX<*E04U^7?4)H6I.6 MJH$?\L63V';5^F5B^Y^3Q__8G$/(&Q%CPM,7+_#1(_CQ:_]);U/*7\V^$9\@74G`[;"#&7D7__83\"!32Z]%O@FVS=041PGHQK-P(1J?`PM>>CT@H.J\<)J'7F4D$GXNGK`(O$)J M%.%R1`_+UFEKM"QB%O/&TB:,00CG]6$&)()\`#,(3@*K+&7-&S\'8DK9!L3A M$;E?A@P1CEPITT*##P@3]5"JR^$D@-,VAWF#[8J2>M'=$$2RH#C)L*:5YF33 MF(V(0E<#`UM(W2\3Z@NYN,R3PU=5#-MN7/8T)K%M+$G>\F9:ZR.Z3K:I4]9: MMM4TKU,W:!!0H@7%5M.3P&%;0?,ZL.UY>"Y##V&O11IHBD/DKXBNRO[SB4\" M*!TCF)>*B(E)%$C#PGPQ58@[93`!PO$,6L2E`;0IYR*1ZHZ'Z$4]BRO$Z31` M+6H>\U84^A"*3!@\!S&"R1-?44ED"=C%JOQ'@_@D<-0Q0@+=.W.@6TGT;.(5 M2I-R2U MU!SI:QL%+'_^^,/R9Q\5.(.A/70>G,YPT+WO]IR^/6QU.P.[TVQT'WI]YZ-H MU/KDM+N#GD>QCJZ/#1M.R=Z[[P$'T(UG:TH09 M^#3>Q$K$428.*KJCEAIDF7\[9U"J;F(ESP<@P)`O-QR\`!/,0R8L,H-\O/(H M3P*Q7/5-+.P1;A:RR`TC)D;*6%-UM]IL?!+(I"EI8J%.=PK29D:MD3F0Z$ M6NZ_WNZ(`*0*O%4"DH:2>;/(%IF)6"G=?RYGBX3`Q!,%#IDDID.2K:MY:]P+ MV?)3J!^I+T_>R0(:J427+"N,;8:Y^*H9Y_$] M8)AZ&N@>[)6GY1J'L[SF<)FYVKCOE<:&/?AXW^[^=R^+BBG,2EH_3'ESR?-1 M`;$\4=9C=(:%.G>O(PY>BWS+96TWQ+-YX56\U!Z)9\F7E.3D[F]A7/:\?-$;5'3Y<_Q"F&YIYK="6)P)V3T9$(KLMF\L)Y! M<$:XYIE&K[[HC5UR.76PH_@X1!^%*R=$LSIB'MD9P:1GI@2L_QC5Z>(#C*U@ MBC"3<;XA'.U)63Z007!&:.:9)L'Q-Y/RI97IO8CTW?':6>%O!X55F_5Z#,X0 M9EW3);#_;E3W%1,W)H?U)LQ_MTARH<5B^$^]V$*YT[`3PS/TBUU-F_C)C>%^ MHG.@N)"?:#'\+OQ$S[3?UEE,&D>VE=DX]E?()39IOPOTMPRV`-JH%;4,:\QG M_`=8!=9E7/+!2_0:KVX,J>V*D9Y!VA4X"F7UZ(^[([P'F+<.&M%0D$F0S M.3\O*&!``PN!-IUX8PJHZP`%N)R?!Q0QH7D%1AE&N<<$$?<`R9`NXR/V`WG^ MK!L#PYT78"[FR\J'/.]/I37/YPO"J_3Y='.95ZF5?J7PO/9G:/A)PT.:"+M0<7P0[P'-)%V#'KKX=\WE.,]V/V_G:%]UW8& M3F/4;PU;CCS\>F^W^I_L]LAY<.S!J#\OX:P+Z'B9R]XNS!0HJ3Z0.]3*DR6Z'$K?",V6 M:WFQQP=&.5_6ULJMHSL84P8Y]]B\F?=Q+U(O!OK6/NK;+:NYDF2^Q\B-QD-Y MS#KO[\UC-BQK9%%CIEH[><*90ES@%'=*MO.&/,=N-+HC,1#W[/_)$5N,T^)) M?^0TG<\]6<>_'*$S-_@69W`+)38'>._^,YD#"%E^27'I%XL?5-MB;AJ8*K:Q>] M?9V2+]^)*_-V&.=S"$\=RSR[:!\L2$O!O_VG4/''_P%02P,$%`````@`ME-D M1V`Z4^0;&0``G>0'K8)I(#TSGVB%%N`MHW-R"()\^FO9`R!8%FRD2R9N*9JFH`EG7^2CL[Y MZ?@?_WR9^2=/$$-CY8B$^.3'JJ^3QH>/'RX^7)S0 MC\/I`D<>6/[]I.>2\!'BD\O/?S^YO&A\.KGX].7RXLO5IY/[NY.S,S:0CX*? MCR"")Y2P(/IZ.B5D_N7\_/GY^27EPCM//U\ MM7ZV_TH?C="7*&[?"5U`8E$) MZ3KA/L'^.EL_=L:^.FM3<0[/SY)ESX/MT)$;#%[*GQ& M^2=&\]]8;^<'4$,_PX!9S9D'QV#A$X6T[?>MB-)P!E"@A]!5UP?1&7=Q-H,S M.MU4$KG3[R$43BDQV%T\PK,-XPKI3.O]$&J#D#A*ITS284S3FB!1YP#_Z9^Q M9?/B\]5%W$O7&3[T6[W;WGVK[PS;O>[`Z=Y<.X/VH'=[WV\-6MUA_/4-)`#Y M0_A"%L"/3D_>\LWHI;TO?/C!#6?G,%!NC>E5(/``^MQO'@]L:W`.$?P%_`WMAYHM2`1Q_>AG@`?#B` M[@(C@M;RE523?C(.E1/`/VE/=(1HTS55RYB2\,1(F$$0+3!DCE$$H@B2*/G& M`V3S4!A@UAA3UXIN_"C1I:Q-Z"7A0/D,AKWF=[HVM&Z:O;O[%ETJV,I`51C_ M<-]QNH,!"=V?U]3A\9KA;$Z7Y-BX6R_L(\QE+:H&T\]S;\Z&=5R"GA!9WN32 M=_'N2]#E%&`8_8`1@1X3JDO_'8;L;[K$ME[HSHLB9JD)29?J])IW8/VRZ-/! M,6*$Q$;W1AM7RE@7C:.?TR(;8^`@S!M%C?(Y91&<3 M`.;G3(;GT"?1^IM8JF<7C22$\;?DZQ%=LB`]0$WIVGP#GZ`?SIEWXF`,@DGL MJ#3#@&#@DF%X#_$XQ#/JO_7(%.*(B@BV"9Q%:[JH>P?]F-J1RNY'%ROEE"@5 M%HCRJ#9[XP,8&+)=+D,VZ@89-=Z:KX-W945[7U.2')=SQ9_&.)QI4>R:R%"C M:$Y"[$'\]92.MH@HWV'LD@'&7'S@_^+2+NCT:_EQAW1E@A/VX?5W/Z1>ZM=3 M@A>P=%,\0`#7RR&ESGE!FF;H:_^C2QT&F!%^VC=(M2:3;I:J9,6UR`H9%V/G M9B>^JM:X7OL?7>DP+EZ46.E2MZMUY4:U(Z/:J/();'2SG6O09ER[R9*J6M=& M6-9860>Y+%#D3#",^1A"/(ON=G(I*;:3T6KT48LEI"5YE%K![B*0;@79;"O6 M:03=#Y/PZ=R#B*GS(_O`M/AQ2XOTJU$'3H#?"@@B2XZ/DO+4Z--1>QKI'*\5 MU"A90RLBN`ORVT=&OYC9J#E"VY?L&V(-V7UNJ1K>J0J*5^66L1\78M^,;@!" M[A0-0/!S&;(L`@B6'>)Q=P%QH]&O!C:!--/$ M42`K:4&ST6_VREI,NNHU^1!_^PD&"]B';CA9R?$.^3`B80#O()F&WNX#?[W& M,%.=Z[R=C3Y7TV^2"$,5$H9-AE%8.#LI68`#@U(LJ+6M71JW MM2XD31!-[W'XA#SH72\?(NBU@Q[UJRG-P23)A2(8,1Y1L*#?)3^&059\\K". M1PTMH7$KK.EPR:S-YRK=?,YWTV&J$V32P*^237F+KB>XI2Q&8C<,7,[/0_HI MHKIDS,BDQE0.8S1%IH`1^529JL$,I,P4*UR8.E,HJFJGT%B$K#?>8E&0$DM] MWJH4ETK5IIL13P;6Q'_WN0;IC`ICPCE[,IV.XFHF79'YN:M5;$UR2+>NRX[1 M#=$38*XH>MRD(G($Z[BMC:9N"DPP47`OBU%K9F2EE*.`ZA:7BKB M69RU(0F?W5))W8?T]$@0\&\79('A)L[&9-,/E\!GYUC>*I&W'TV)*ANLH*@\ M5$22.%IN+F8+/V;G?@HBV`PCRBLA&#TNXKLRPW`G$K!9\KCJ+MRAD>Q.B7H_ M1#""6-`[RF>82$N5O444$,K:0#Y:M$*T@]:+"Z.H-]XP<`^6:X$)]PW=XQI- MC=F\WLC+;VUUG]1;W1W5R6PQ24Q5JQ MOZA7;#)70W9!+36A[7!;>-/7J*$EAEPQ_:<(9:WSWW0<,=-. MPXE_PS]/9C0:-?0$@*W1HI#[M;H^&S\JW,`QQ!AZ?'URGAPU3(8,R_'R4UA^ MC>5H<.+W-OQVP.I80(^Y=)N]WXE6*X%@"A;L[5AU>I"$UTKG1/!*A7ED%=0XCQKG4>,\;``!U#B/HU=QC?/0=$=H=>.4H9#E@!Z2S8\`Z2'/ MJ343M`-!M+._B,N*\)I8=7]7__::(09[[@FE$2FLPL!O9.H:L(S,Y;6DZY:P M16JR9/-3JZ_RM[I<&YO!:\9RUB[>L4JXMVE'VN-4*V M5N-P%Y>]9S0!'81+?HI0N%+;4*K;;/.(S?`27$1^)2RP\8##YW"($?!SK;;B MEF9P&*EVR!.UD'[=DJ>/0(?$P-$PB$EQ(@1D))_5T@S\(9_D1?3;X[17$WY_ MQ`@(;0([1@#^\6,H\@M$HS_W,*=2",@FUK0&6[+Z`3R=9K4Y9OB$%/,U6GX# MY7P/-ZJ*2$4C7I[N&]0N"9BP&H3K)>3U71O7C!)(6?;8^K.#O^B$SQ#WF1RX M?IR"OD>-([]@I4I(&M'MQ4E\F,^UV*\;9;`L@*9KAKKJ?T>B,?`GG[2.!`8V M5S]&0:Y\^N2QJX(^#$!2\\J?,^'RL%AM*.D-?"0)3[SB]+Q'K0*02NB)M[;N M<64-$.(._(?Z6G24J#?>HA-EI-YDFYH&?::)/5U!$IR\#X59@F)1J3G[WK;2 M#/&<^6MPEV`A(#>SG5$PI\S\2=>?B"=KE'8-?';/:C"%D'38,$S"V9L9KXE5 ML,W"FUH&=_8D=M.(%"Z3_$:FT9A9,I?7DGUH3.5JLF0?4ZNO$L!"378#5G2] M8.2G8\V*5(NQTZ%^Z#&:G;[,5K0P:S)X4[`$$\=DI9`EF(9O: M5;P-L.0@=70GC0#^">-RB=&&*A!X8X#P$TL+S2"(%GB5/@-1!$F4?.,!LGDH MI);)2L&@8/(((I245BF_ILHFF>7$E#J!UT'@$?E)A&1%=R_HKXE=Y0,WM%\S MVF422DK',9!P4D&_*"&E;`P#"2O5^N6L"RI%5.V$UT82U\N[UP7G%L,_%S!P M13DPB=86I,64:EM@4)F"L":(M2$WC5AA-$NBM>E\FJ0^!,K,Y.\]*=.2&*5^ MK=J7@4LC.]HL5<)$G$QSH_DXR68Y!G,VC?;R]6V?9MU&6JW M>.=N!_,%B6*6&_(;]GXKH_G+W+-0H-54]JS6W64AW5U:D"O5J+M+"Y.I:71> M%5)>TLIHTE2C\E[9LR?O]1:?1QW#UI\+1)9;Z9EL'UFR!TU)3]N\Y!S2J)01 MY$80<_O0EP(HK-H9W>78/\R->0+^3LSA!D4, MLT*WQ2QO3;8/LP6!2@(N$+H%5&WO<#N@B!0<$D)@Z MR5!21BL+L,;:-)UN6-G"L"9>P2%3&++(;&<:8RR0?2Z%V8!EXM<)\RT2K8TBAX53*5V+Z(IU/*HG^62!3L8-JD_,)'(>O(;:<+UZIY\?&XLBHVLW#+H MI7MMB8EEQ4>D.C`*Z"SM\",M"\%,-1\GZ<7T."Y=9A!9WABZ:\W1U&LYY>OE MZR/)"TR<9X`]F6#(X9T;C7\(R8]X],O'/`X4CV4T M"J;/.+0;XT9Z1[,2?J,/DJ@=K*)3<>%&C8:8,IK1<%[53#%=?L>S*%(!CB%B M;W[>,*G1&E-&,WKCO&K6F"X_>Q(2A_+7>H'811&+TFC?HO?&,EMSO&*6F"8] M>ZZ(*93FOR&:3`GTG">(P00F?,-[C%S()#TN\R0C28SA0NG5..;DD.7Q++"2 M_)NW9L.EV\V8F5&;MZKF0O$(7*K?KLO6U5%AN(Y]I>Q=K=0K=)83,9YR/#!E M^3E)T51@X5V:?P'1'X^#LW4N,>3@2%*@J^S$,5J\.HG;?\>1,1K]@!%E@D$. M7?KO,&1_LV(]KXPFJ+[+&M57H_IJ5%^-ZJM1?36JKT;UU:B^"EM2C>JK47TU MJL^N=4-P\EJ=4^*3R?91I4RDE2P)-?+O<`%6*%1Z,-.&HD>'$59-E*$51BX0 MJV41TD>Q*!Y5B:(/F?K916AZ`,;`)0O@#R&>-433P`HBJXEVE)T2MHCX>*`_ M8K$XDPF&$T!@FXH!T5.%&U?5,[HI<&BJ)KC2BOV`+U'!^]BK;^MEHC!E2:@F M.-.<)6?A,S^]`\.URWV7SE#6N$U=['1MS/&_]3K@#TV^??$=Z'Q[\U M"BWLCZU>$=P.6$GL6&P],H5X.`5!5&(\`_2// MNK[$5UX:JHGI*6QDQHS]B"J-"9E>AHJ"8FIS*FGB9OR\";>N7_)N<7%\.X`01N7O]JC9>>A](:_U.:G.O9LBT; MRZ=(12%#^HS7WEFVC4(ZXJFUZVO:.;]RTEA1"-+Q3+("^GI')QQ6Z9:' MP(H"G8YGDN55EL!/-`^A6F&EAK3K!?"C&C%5(Z9JQ%2-F*H14S5BJD9,U8BI M"EM2C9BR$3%55TJJ*R5Q+ZMLW2PO[-0(CQKA42,\*FQ)-<+#1H1'71.GKHDC M":;?/6L9N7RQ2T*-^3A<@)9!0(HP'?^/7:="P63%ES`RJ6B8XX9YJ!/2>[A^ M;4%D436-U:Q@8]'Z*B/A(WC-5#=,V-\3S];].QT&+S5P-8O3Z+1B6;&IP#(! M_*6Y'T0)Z-PN\V2Q66=5TQH0%OM1T?'15692)Q1Y, MD./'G4,OG7+V\H0@RMIBY3JH:"$2B:5#GG_+(#E:-NU=2X]1&\HUJ9JTP@)ZRL.7/8FD(2+,NVD''GI"'CV5"8!YJ<_K M2;#8XJB)6+-D7S8=@*"'M5J0@ZE;,G3;D):7P=5S62 MFA1R9PTLQJ"*+0&^Z=:U?=BV5%]-B'#+:&4T-U1@\J5K-IO!4OW5W,YI0J;1 MQ,S!BA`S9\_6F.JBR M@2`I.Q4)M$ M";?@G>=U`?FE'[*TX,X7^2K,U*V!1J5OBL103?PFIYA4N[V$>!O'5B.QH M4.K#HX9)=/^^Q:8$>KATZY:K$P0+X/M+&;'N/CMJF`QTYI#J/MGV[*UJ2QM] MPV&D!47)'VUT>:SP=TW"LLSV'L4,/F;=W^RSRVL1Y=&EOX*)$`JO>KS1Y5$C MW76(JT+Q2PMO<7F'S+"!!P9U6 MS5=]VMUF[ZXU=/YH&7Z3YR9SV:&^2Q-@O!ROWM(:=22N[$BT-G`GAT^5Z*:- MH*6!^S-R$N;,)S$[U2Z&.`0O30P]1+9Y$^$O>6TLN"PCH:]T16C*3+:F>T`%YA)8E8LB>,U@ZHYPXIH\Z"3$-,SQH" M+R.]@9X+.>6X&%R.;-:2<(OB-=%4\4S:I>!+6U8[&SZL6?F4JL<2UT&=GNQS M&"AE+.#G-L-%0#`_>YCYO-&B:UFS(ET_/!ZL4;&GGV)O^<6"D69O?2B*2!EUV67]!/AC"T*N4-+<2NSEUT. MTIF`*WLRC8[WGT5$XO#_,'0\#ZWHN`?(:P?)68,RTQJ/H4MNJ9#2TPT9"E8T M@J9+-648@T()J,@=<`8G:)JSEEF2.ZNV!(26@'FQ\RP0RY^]!UP46C M0@OQJ+$.;!Y2V+L)5:B-]6/VFD$YJEOS*:C;JCGEV6\-AOV'YO"AW^Y^<[HW MO>'OK7ZS-Q@F&=#24Y_Q&SP6+HG+X+(W8E-WDL4-\1.4R7W*-#=:D'"'P)@X MGU5Z9:0*$Z$Y>C&0%)44/>_HD(NW:F=(,R0EB&`*6EJ0+F1#(Z.5566!#MUZ,R^L.?F+B9D+^L(7"A_AW6W MA=G,:=8T2=<2GPUK=#.80Q>M7DZ.@O@D>0T#*EXBOHHJ:FHVA9I?6Q+\V!-/ MB^&8.^P)]<5K8O156P7TE,%'=NAL_9\Q=W'7D6*O@G"3SUE`?-DNC.8;#CM` MY'H!\`I=F;_;9H3]#E;PF9A,0A^DNBZ?L\)9E\[$=N`N,5Y^+3<>='JJJ M3VD)9;_9XY#097LV!P@SJ^J-[W%(3[!D22EA=Q+FXI*^DJTKL>?E$D?VRK@? MC(SGWCD;C]V&HU_\/U!+`P04````"`"V4V1'ME0`L``00E#@``!#D! M``#M??USW#:2Z.^OZOT/>+E7=TG5R+9L)QOG;O=J+(\3762-3AIG=ROU*D61 M&(D7#CDA.;*U?_T#P,\9DB``DN@>>6OK+K($--#-_D:C\1__^7D3D`<:)WX4 M_OFKTV/:"L!]7][LX\9S'&5FZ M:71+8_+RS8R\?''Z+7GQ[0\O7_SPZEMR]8&OWSQXM7S8N!7V<@?/B?^WNA/KXJQI\__]N'B MQKVG&^?$#Y/4"=UJ%@?3-N_TS9LWS\5?V=#$_R$1\R\BUTD%J7KW13I'\'^= M%,-.^*].3E^>O#I]]CGQON(TB*.`7M,U$L("KVRC>Q].)_PA.N/5X\>;5"X$)_\UOA66:ATSL4S]]/`_74;P1 MZGI^FZ2QXZ8%(+%U`?ZW[U^]^=/K5S^]_O';UZ>_J0-Z_I>"`GL;CFD2[6*7 M:F&??83]G3FWO[WX]O3-=]_^UW?G?_KNE<;.N&%C8+C]IN')QYNO_E+:;"?T M2#:1U&:27XNY_^\_LLV,AQOS+&ZC4@PPHCB/]UG.B=UBH^S''ASS$<_=B+D4 MV_1D[U.NXV@SB,>*?46#B/5<6;!R-`6*"76?W44/SSWJ,U1/7_,?N-"]/GEQ MFKLJ_\)^]5NV[C6]\_ER87KI;&B+E+W_\/7Z]9LWWY^>?GAY^MU/W_WGPBI]0]1..24_.\D M&X!&S0_;-JA>;V6:7H7>QC%3L?79+HZ9'+WW$]<)_DZ=>!%Z[UA\IJ+,.^=" MZ',)(H<,DP\EV5C"!S-WVB-\.+A:GP@/$.W>QUR="KZ'LZ9U:][[`8W/V&IW M4=SFU/1X3^?G/OL*^^W*7\8($;)PUG7P8%T/.7(]?E18M91$R;D6PBJ!]WOV MFT1'EQ].A=3F330ZU6$]AR(&H]'H8R(!JM4[F*I7K[=SE!T1R&Q*EQ#T>FQ- M(!B\]C;4^G@J=Q=`1,,Z0BB\_4X&5';]N[A/5W363G(K\-LE)W>.L^7R\^US M&J1)\1M1J503I/S7O]VDS!7C6UFNW_NA$[H^VT^4^#KE2EJP;%L;340/F;*< M1I9K4DXDQ4PL14NC81EI8FG=7IDP;JL!,^!:>V(Y3Q*:)A(!;%5.';.A+%HG M,HV(0`P`E*6!V[^Y6:QNT)@H.0]);9.4@6QS?W[$J&N%VB=#F9TN5-I%8$:* M$V-D=D45C6+[CAC_`QIK(>4HJ7F0L9,]B3ASDOMYZ/'_+/[8^0].P':3S-,S M)XX?_?#N%R?8*1]4Z`&%MAZJJ#=8D4T0==CBA]K4&7%24LPF8OKH,I;6;EU8 M1)=6,U"9T,'?T)T:N[1V]0@??\Z(N.`T.M;;QD4QX.\Z([?TS@]#CCD+1;+] M381V=:KF/7E``@!.9T*\B3 MU/7N%R9[NN$JIEO']Q:?MS1,*--=R_2>QGO!@:[[K0(2VOE60_N00_-9))\F MC)Z82`["7%1.ZC!<:38M$N&1XF[D+/="@/85>9!4#C6H. M*N=@"'HU+SV(PCN`J`,4-7#SKR:'2I9?20AM1B71EL;IXQ7[/J+]QA\[?\O/ MLB^IL@\@A0'E$O0@UG1-L^$S(B9D[5>**4RGT/&5B33#/R9.`AE:(1-.@(R) M!X08'7V_2!,9]ENR;44((D5O1X)FY&V9FG_K!+Q[H?W$O"U4%^*261>>8!ZP MBKZ7.L0*RMZ>]:I%S>9N<3L0:&^X"[5#7MS/BB'U??6009?M4MU^%OM&$B3` M/5FIQ"@YL#)QL9VLTLM2`:>G.O-2*)RQSCUF3(TL_Z2Y3^"$DT:FR;H@7?C. MK1^(,)19/II6$"O#A3:T&@0X9+G:U-('9.X\TBKD(8B> MS]^>7YROSA+>XOODWLOCOC^>KOZ,S=;JN`*)RU@&U'N3&X3V`@ZVK7G;0%W9Y^>T?7E*WL7=,'&NZH9H%'QVPH MCZ`3F<9=\'P@R4?B*OY01J/P`;91+.[11FOB%9C%V60$0?GPKP*H,'387L6U MD4J,Q7OY3D`OJ)/06\?]?14[8<*<*\9"Q?9^=/RP_9!7JD%5P4*[,^KH-ZZR MLYFDG$IJDY%\^'>!8>"*4KZD3^/]@:-VQ(?REL_2>DH2!0^6EF>-7?K8" M/XX;"0I8Z-P43=E5L$"4J%!,4*#P1I1VOU_863V^\-$FXV?;L0M M^M`[B\+4#^]HZ+:+HORVOP04M!67H]G(OE6CLT8;]?&H#/DPO%P97N!63H$U MU7I&]/*ES:Z9&H4V'>T+(4MJ.AHA:M24U`<7E3/S-(W]VUUV,V@5D2L'XR&^ M,9K_)JK\TT<\I_CJ53&ZE`!HKY!YL6)/1MW,VD!`VZMVM%HNUN?!2_ZP3][S MZ3Q)=G3\[D<#>R1H(91D"/W?%\]>G)*M$Y,'/N7?R>GLQ8L7_/](DCUBY.S2 M^RCF6>Q_)V%4_-87%"!13"+81XZT.4_'LG5SKET',G]KJ4OZ6E508QZ4]6I! MH,UOJE[/`A6R@2ATBE4F5%V"]=W+V?=O3F??OOY>^(W\GR]/9W_Z_O1`WD1C MCTK@>#^Z&R8<='-+8_+JQ8QP)A*CWE$W_^VI^.WK&6%PMM1-_0<:P+]@W,?> M4OO8P=L6:]L\3[2A=H(KQ_?.PS-GZ[-HN;8O[9*V?HC0-E,)Z4994SF)\%GD M/"3YO-G>HWFHC.E03'D/FA,_)&XV#UUWR%&^I-_Q)5%<1X5$'_Z*ZE!-H^,C M*2LNJY7'N\TN<%*:]7]B>]G&])Z&";-]YZ$;;>A%E"27-%VN5\YG58]*%RS8 MM3AM]%MJ40L(>7NX/1@D`T*^YF"^$>4Z_!$.!@N%MS8N_GD?M3W\_1S_@../ M()$_/<8<4S0=%$`8/!(,CL*XX2,*O,D;16.KQ!YF5L">\;NFJ>.'U%LX,>?2 MI+;?=W3MN[YV[8@"1.C01`GI9G5F-HD4L\C7=1'()XZOWX=$)D:(UK'RLE&( MBDG0HC0TRIJ2*5'8(4#LY0;''/4W&>HAO>,+HN)G\,!1W;(H!8[*9@7R]-C\ MU!C1:7'O\:GTF!A%3*>$U%2*4#\@4]IN5F"5M!QDHXFT0,EN%@<-V3*B>@'# M.@%T?6YT@XU>>-"AA@+":OUL4,45!E@UZD,%;E;4F7FP815/<(]-53A':=$# M7)K$G)5E+)X,]L29\!6-;_C9N:H'IP@-KN^R(K*]-4QL+EG&))N=%5OP%]V) M`(#"V1L!U[P.HZS`(%_[(?&B('#BA+_FEM55-'([@/UC=7BYIY.L!B-#2:O8 M0S(O2V"&U10VH$$[";W(]DII-H=4DU"Y"P/PRR6S402%SGBJ,:Q!'6$'M\** M8E9M9V8L]R#@,)`'2*F*&Z*:0T-\]L7+;\4'B95K8SP-R];"=;`BM*P*,\

$69'$^0I ML*?R'6@Y;P**G%YLUS4=@<'KB8+:Q`KK/3(U5%2B.8#C[7$^";;>I#URHVIZ M0>/2QCX&!*526.@,KCQ8:^=#K,&H&7+*8>A(E1GFE9&:^.75&L*-S[`;ORAW M6+'C^`CA\XQ,\P0*:L2>?LP*]$5@M#%XRZ5K.I1OU(W.(?5"L#__S6_7-*$,J?MYZ+VC#S2(Q/NB M>7="5>=``1*4:Z"$9+/B/!N?-TTH9Q3M*A'T(3?"B]_.RAN*XNBH-OSK>+6O M,]4;#5[D[O@"#K_2/"EJ\[N[6-PR*'`AWB[F=QIXC_C,&R%TTD;U\=D/3D(*8?9O(+:)KCYMG2S$')@T&F(/E25W8U\"@I3/0IR M-4N%J/Y[*I3`PW4EF5.\E]$1&3@!E-I%I,536(B%'8O`E=)$2[R[P;40LZ&(QN![.I6MIV M3H.+:DVC6311K%+TBL)"*NP\?UJK$;`B,(@C[AY-M&T495L7V>66>!;#,V%?D:*T2@,N18J MV9_R#J)H+&$?>_4<6$MYRZ:09`L;9IH/IT-;Q"8ZG>R$,7NLL7TZT?;-S1_D MYD?H03=\^^!6NT.8E2QVNR1;=-%YSN(R"J-]ST$S9]T#!\TG6_?$/=79PU38O]A/WIG(D7YUDRY-L_?JK"'A\&CL$KE'O3E`M M**BV<>+?:6:WDA(X+C=I0J'N=["FDVBK%P\/<9!HM[Z;1YV@H-TV.9HM%_-4 M7DV:(>F\/1GFR/RFL5$!]Z<4A$_UJEZ/Y-E3*,6S`$7GDK=.XKN\)M$/=BGU M=,OO5<%!>4+JZ![R9_E41MG!9T;$[*S&.)N/K5[?'-T*-2]'+BR,1E)US7\?.&@7H!]=(PE%E,C1QY#[,K1\LB=S_$MI1.7&F.&V MKUX4^XD!>CAC8(GJ0,OB9P/WYA3UJ9)'IZ9,[=F*OU+_[IX;*R;#SAV]W/$W MZI=KL;=:7XA^$])J;0VA0_E\QL0XY/4"$,DAD0P4#R^;;5=MV!X3EW!\:C@Y M-6X;+J.;=\QIM,J!;LDR)ENK^)2#),;FPVQY-XSE^LQ)[M\'T2?9!6RI>I7" M@G8N>Q!M/N-6-$%AHLXG$#$#,-J;!KM($3MPVZW"J$J&6X%+K9Z[\TU/'A'KG85D8.W=3_T&DI,^BD/UBQWZW+`N"=5,U(ZT&9=5'(U:;1RND MH`!-WCZ2KSETR']"]HH!5I(B8J?\PR1Z@_8Z)"-MH M>E0MPX^YRH5(L]R)_5E3V6'U>@!HFT8D+FE;YL?9;_G/+B?KCE.2Q3IH-*)] MF=-QQR84>GO:\QW=,J[PA0YG/P>4_\!O[F^B./7_T=KSK,M6*<&"[ING&VDMHOE^IV?N-$N%'?"KV*Z\7>;I+H1IUVE;K@*N/]H2IR&%U,` M(E_707W#$UPE-"$"!3Q^&[2$B,OQ&XTH=2T=K788W3D`OJ)/06\?]O<_1U(1FV]741E;* MQ%RY%:\)BI+S94@X`%)"`'7*QD662:Q7("LJQ?E)'$\@[.(BJ_I_L.=S\E^(6IG?C[[:.8']`DH;3N`[*_1>QCBK^R0&+# MH68C&8Q&9^BI+0`JOK'N"9NIP%9?V$C_63R1S:M)J,>+AEG8V)4]D!^7M4.! M]F8[D6N<4/*!)V(DJ0]%5,RGB*]4)%<3-+8=]/B\5M4 M;K"*2H0*'/:01U?)-@0ZX!RQ7'VHGY#+=,<"#K6Y:S7._X1ZCYZ^9@T'Y MRV2W-/U$:?;KM>,7#RESMY/_RG7B^)'#$K^>D2@N8'"MX^3]J*N)R8Q[;Q5I MR3T-F`/+B\;=>W*;/X>6W%.:$H^A.&.PV%\_.0E')MAYV6%566*^CN+:.RD( MG%Q#'E1G/AA75E$7=CNP:HK08A*714_I.6-1/^:2>,9LR%VK3I?G;]JA0+NM MG<@UPBH^D%0C23X4D=NJC$L-"Y$*Y`?:Z6/6XI"RUAE;]HH2.I5E^N%:[\ MN]REKY46G3E;/W4"TX)&#CLW#HF+Z-^0\K)42YB"PUA$.0IY9 MT9!9T8.2/VYIL]/TP'=N_0!I^9\^[RNV"=5D?$AIOXHI\XB\X@P@;\$X#SW1 M0DCX3,JO=QA"!WSEVHP8BAH@AU9T41;RD+4+RR"A\%9&(T*!;?$<1_V5'7[4 MR%^6G09M_7*Y8T9Z@-=F`^UV=`$[T`]1>'T/JIMK.TB5/W>S6ITKYY%7-/$" M2->-=XR9*F,]W-E36@6?XZ=('$434$`C.;BLYCL#2&H0D3N$AD0IL=_6L'=R M[&$>G4*,.$)W6$=3&+K&&FH"4F<6.OW@M7E]C_@0$![GMXFBHI(K2PSSF4C] MVG[\2D3B=D00>3$=_*CIL+0SX[$T`-#U40:N!NVK#"96_\7_V^(NK*]W\1_1 M`=\D5-HE(EG-JZ!0>6J3(-M[CQ>1QX:#`.">VSAZ5/6EA.%*%-S"9'=3;+68 MT5T-68L9?6)IMI@I%W@R+6:&D^RPQ8Q?TNB(6LP8BIE)BQDS&;.GB%A\F[=Y MF+M_[/R8?BBO%$J+@*5Z7PTHM..JBGHCRYS/XSU;\IFDF@I8*SP-MFR3]PY/ MIC-/<^);MX/]KF-`HHYPLZN$X,++P09QYZ M'YR4[^9QN5;4R:TF4!\PE)MG0H+F"6`&@W`@V9UBGN,NX/";QRA4]?0$$-Y9 M5LX6,UG/\<>AP[%C#^:O&FL!J6MJJ@(`O="]*D2V7UD!LI[]Z(:,SA^5$:'3 M*4TKI[28/\OJD6="%8(5)4^'^]SS_"P*9\CCJ$Y&A2P^)ZY7O,T\N3[9AG/G M#NJJ>S2:DFV0@<3BPLG1EEOOF[P4'Y<6FQSM([F!8,#@6CY*/WS]T0M?6J:GN:LA.3?6)I5F?4R[P9$Y-AY/L\-1T7=+HB$Y-#<7, MY-343,:`PCO>?FJY%1M:?*:QZR?ZK\#V`X3VZU10[@GH1)^N?!HIYZ'RRH9C M23?;('JD-&]+MF5#R;8X=T/G:R@SLEI"1I&+C\5CL.,I'*F',*EG\`3<`4,W M`,%)W"1\T8C%5)`_4A?(@NMC79/ROG("GWJ]$1[K#&QRZWH\6 M;&A'2),0K3J`YW3%#S4(,Y+!("W7F5#Y2`,)P)5!T:B15[*[!4'$#[2"B"@[ M-0+*99=*'93!_4,3J5=R%0U$?D"3VV5\YX1Y8W&VZB6O?J#+M7YN2!,:2.-; M'60/.;4^5W!H-IO73>%+VX!C"].E5)N9N_N5ZG*R/7?C[2[Q0YHD[VCBQOXV MWR!_F#WA1X/BB0FQQ17]G+YE&VE[846JV@Q6@'8]C(ARR/0%$%*#(IA?P,E. MW"M(Y%<.BPA@N/J#C4*,R_GJX_6"+-^3Y=7B>KXZ7U[>D/GE._)V?G-^PW]_ M=;VX65RNQ)_0F6=S*5$RTL8B8D]/U#48BY.2*/"]0IW5=[AQ)%#",HNRE@'D<\^Z4?$?\@;H@2IC79>S'Z("&=F#TR-!(G=1GD]IT M4LW'ZZ\,Q'UY<3%_NZR[*/.+B_/YY=GB!IU;8L#M:DD#;58?D#-HNQC!=,Q[ MQX]_X8]\?*`.7U'+D3`'#))),"3!(>^VWK@2YHY#(@(4J_-=E= MR7;K\;K5JX=<^21%ATU",KOK`LO%8K+`92O.SL^5' M)ESD:OYW(8O"93X[N_ZX>$<6?[M:7-XPJ41D8S484GZ3II<;+;X_IM!%=00[ M:KH,M%TU)T]G9]^>ALY'87I')(N*$D!G?@=*C=JK8X-$QIX&6>1O8%[16+R` MJVN;.^=#&68)0H?<6PSEA4%$#,9FDC60$>_J;ADB"1^(Y[)#'X-);6T/=\&) MB;$I[08$;2QE**I(#E9KIX/7Y6)%+I8WS)XMKLG-3_/K!3KCUS^*/Y.IB?HDO?AU)QI0@`3D>QZ<;:X7)$\E7U^^2.YNEY> MLI_/D)X>CRESBEV,1A,XJV_Y11NZ[>OA/E!A,C;?4EC09KD'445FQ&I!=;&[9&'Q@JSF?T-XB*O" MDJIOT_;QHSU!NZ:\>,OES>/#.Y';$V%VU:M"UX:I`X2R:#HH-WRW^MP\*9SE MN*KI&&V#]F>66@K=;XR(G4>P)T9K0-L90\(8\?\Q6*:QZ+&X65U_/%M]O.9Q M',_C+E<_+:[)V?(&82`W1#J43-L`T;!8P_C@^`&OD7H?Q;PS>75-0:826M6J M"B@H,Z>&9J/`KIAUPJ:=B);]M=LMOZY$+2*@4(^(ZHU[3[U=UIQ_S:_L/(@K M.^Q?3DF$-2.":."/^YDA#9:6&G9U?K9X5:>X.#1/$IHF^?4A;QE>\\UQ12/Z M%YC?V=&%#VW*#0C2N,53WE";D0Q*<5/-(TM^;IL#REN(P(O]U`2IZP(G(\BF M((B3[JF'D#@D+@ETRR&C,_2F,J-V\<=,8.QIC.)C+MBL)K4+B#=%B%4FM@D,P#L2W1MZ0:>`@E>2M>0^I505)E#[-):"\(ZM/( M)'VO^(T#(2Q^R,O>;NME;_5>)PESP^TS#>&0)$>W?<1'?QS MRKIUR@)J882BK>,,0BH?"#O0OM/ZVPAYLNMQJ%]IO!*\=SF`2#(?LUX_7`<\ MVW^)9%;DHA\1Z$@`2@F7,R<`^SG*WV?9A1Z_K%<^8H(G>S6>="EZG@-%RZ+> M:=UH38N^?6SJV$].[.5H_$(3GGX/O04S<"[[<17Q7^7/MPCMO<'[G7: M_R`-.>_0@GO]\]X^MMVV(&(KLTI19MO)'N#--T16D?CUC-0VA4"1HO\L=3^3 MKY60!P%U)KQ+0=HT$K_+7@"N8.-S.X'4CIK'":-S+):X1V'&.>(TU>=;%*9) M8#70O32"#79GQ(P0C1+U`@RIX.0>8P8)O;\X$B'J*BJN2)&YA(7+B,8K'"(& M\FLOYC(`$7&R75)&1_ZXRCOZ0(-H>Q!)\]>D>+'5*KJB\3J*-RSR7J;W-,ZR MI^;IQ,$K@WMK8Q)1)DT%>&'9:PO4?;+L83R^!O<#\E5$@C!;)U<^R!RKIT!! M>']J=&'6S,V-),E6ZSA--_SV<<5V-__L*[_V.3P*%05W_.[:./XH4$-^@B+0OMG8Y%N2F', M%L'EE1TQWW-%;UJV0@ MH+PE.5J-'I?9:%(.)V(\^36;,;Y62-E'UW-H]!`J)=RM7E[A!ZCTLQOL$OX* M3Y"C+%ZSC4[<:+/AB5$G*)_5+%9"X<^9?<].',"\+`5QD_I._;*FJSH2ZCZ[ MBQZ>>]3G6N,U_X$KB]/ M(-D0H)!FVMV#V68)&TDM;#:#?&V[9Y+1MN]-7-^0'(RQUY MN]:U=Q=+M*KJ#GX8\*+9.\?WW7O_Q@E_?XSX::@3/EZD7J>7UBI\"I"@]+(2 MDHU^E-EXDDT@^0S"IDSGMIFH[7&0>\81&QT?+W+%@S["XYL4H?.4Q'2;/?/) M;TC$:<@S^=&:L`!(%.DR`,_06"IUL9,:+F69&Z`"'/"E2WH^0?DT05:$O.#(_04/RCB++?>&']#RE&^70<-0UCSC' M72?<%*E:\BM?@8@ECD*#"=IM7V1$<%U\+'%6O%Z M^,@R;4\A\G*QY;JV)9V"##D0:.^S"[5&#ID7'_)^9#5N+^2A6P+P%',8X1NU MX^OHX0ON!TG95\F?D?&NQ0;##97AM&L)O7)*7;!@C8>UT6\T(6ZS9MW2BZ%X M96+DNT492RG,0.:7MR4VXORQ"FM6_H/#7YGR;\LX>FB%33=(/*4V,K1[RE*J MJ;7*:>3%-R.CB[4D1P?-(OC?.4%5,7U$I3F]@JM9H],GM3;?L!\ M%1]Q32C?9&3"-25FM-P&X-$\4LJIIC.`S^>G%QX5EVD":1W@3^4'@>\9D:ZB ME*WC.\'[7;J+:7EBR#=V'3TZ`6_[K.59:0,'];$,2-%UZ,YAD!((R:!4I^^9 MY)2`$!R#C46`N>>)XV:&]+9$WZL=&7+$^;,M"=D22(S(LU59?]_JRAKAR@^L]VFUT@S,S5 MO9-0T=-YGJ:Q?[L3SRFMHIJIBL+2L^[U2P="!RE='T*,AL=4PB("6-X>O@Z. M]_+<`UC%I];5H#5BB.:;0AT(JKS:O^K,_I4`J,!IL>Q=3<19Y\,Z`N MM052CZQ\R7E(LJ7Y665505JL/K'G;NRQPE):1;,S[<:;67#*LH&;6BRTR1YA MZJH"`_2"`:A:LQ@%02K*(?.&;6G2?N_9DAH=8'4^^*&_V6WFXM/N5;+DSZFH M7VG0A@?B4>LAW*S=%[-)-OV@.JU\<6G"6POJ_7Y&P/:2870E59W\_4:F">(2 M"G&XQJP59MN#/ MEM6P%B2I0442-!@HNNXP05_+#5#1EU'JN_2*QG[DO8]BWJC)#_-WL(H3UROV MQW@5W:1.S/9SLZ6NO_:I)X17R_$?O!BH8S\"J9HZD(,D&4S"@)(:U,P`Y!=, M!&#NQ`O0XOVI`GBF1?&XY=/1:9O1B=^P26MT$GHBI]-6T"F-2"+HQ)\_*>F4 M34?D:D]`*:Y$PQTO`^"X/S)36;RU5=5,%/EF3L?2G":[[3:*4W39Y[$45+\_ M/9)VFEH9,PN0+]^E@)OVR0@PB`=M2((!BI5[&*52!5&E4U-!16UR*I0JLW3+ MV4Y]ESED+*AT`@QYZI$(U5G[^B:\J`H/T14=42[ID-? M*6FBTZCSS$<4_0M0>'P&V^^(5\$O?'0PE-)5CW9N&J]?6M90UP_O^HN^>]L_ M=<+"T#]-@FA_O[%R,H)";^N8(K#.YABB+>XVEZ9>*ZLGEA9[[5-FSNM5F(^= M#QA)]6DG'&A3*T&PV:>:>\)[/3^`7\4Q([F.+>OY;K",J-;L6@$"V),/,J24 MV0_;/;O^3R5_+Z#O.XWG21EU[K@WS[F%5!P13K2+]RKQO>X(C!S*CWB%YS(JAE.4"ABT6GZG)@KH)[-HZ' M716Y0%FQMO#.4!9>?8I6/.6OZCMU2*`<#)S^[4.OE>D)FT7$M):>[WBR3`,1 M3-L1Q&*,=!$[HKR2NN#UV#(5J1NL(-@0.D_%G:TH%,O-$]\Q"*X4P,';PSYT M.^2)SR+EM%QY\(D(H[!)\,3F'NCBAU9]#)(G/<]"138'J)/\SG"9_2XJT<^< MY%[)TY`"`/$Q>E#JNC5=G>D4$V:$3X'W*301XK\FNQRKH,0*[,;W:%^HB0O[ MP<\K:YA&J)6CS\C&"7=KKCMB/H%7JV^<^'>:\G_QAVO)IR@.O$^^1\FMD_A8 M0F<5>>QV0!2$<8CK01EGL.]\1Y?K\IK*XO.6NBGU5M%;WMM?W![B-\KWZJ8O MHD\TON;I93WG9(P%8=V7<4C6,/PE6%XU5P(F!61>J?Q6O+"1W>82S4'VKS8( M^$0L@,@+FIQ!IHXALC6AZO$D#TU_!:6%SY1@@>9W08IOVW/A`Y MEH:HULHI0E6LD;F).A(\SATVP)>1Y@^.'_#>%&QO-TY`;ZB[BWVN.0T?/.H# M"/^.43_*LN>)RMDG;/H)GT\J`$B?'!J`<53'F,GP2:*&,8+7@1196_'1'S6^ MMGG9ZC;-]_!H4@O>F`]=`]Z"4//"TFU:\-XCQE=Y1L(!O&J]B[D4;UZU.%"V3`'!1BL'C,Q M7`/1B]31`[-2JBPJ-4Z*_&GSV8EXRT-JNK\;O1H4-6#0UJH/U6;=0CZ^R9M3 M%9Z8/T-LCIS'D4O*&:B,\VA8G23W49R*:);\J[/9_CL)HO!._!N=)5<2226S MKB*/]E3-6X=]*Y?>W%.:7O!E>#]%A2L'O?.A;+H$H4/&S(<2,984@X'\8:O( M@-GK/G:3VND>7H,5&KVK$0J0H"VS%$E5[@-RA\$0`[=3_:RI9*1Z^7)0Q_8X MUFOSL3\#Z$6)_4TWVV>+OR.Z+M&WXYO2^4)P^MNWV?=^R/B1%U_[89+&NZQ$ MTQO`BJ<'?&J>/K9*!ZZ3Q0O>I43V@F$\<+R1/7FJ<.EX@ M>PQT--3[CQ\EJ*,^@VPP_>!SR$..MR?DW7N:;YBSQONB\S;IND&F*ECHB%,= M_<9#E3*QGI%RNGAH@KSEEU)0N`DC8+Z'FA92XV]./:7.'T,H**6'$GB$K4D. MI7!;3T)1*"0W?_Z.>C_&49)\#&/J!'RC/SI^^)8R&T-7SF=53V3X0E#>R1@D MZE9G+:::J;,*,!&0206:<-@SA1\S!9%:,1]1K;_)T`WI'=_KIE*&^J99"P:!SA[NC"/U,774'^+BB$3+O'3\FOS@!\`N(1GL? MH_9I^/>I1]LVOP]";W2@FVE=EW'B"MK.F2D2K]A>^,ZM'^0U8TZRBZFW#*_Y M#GD[%C;@,F)Z./^G2'5UW4"2&IGQ%H;V)\@HT`G>]1A=')1=L;%D$4%]O'VO?_GU,_]C1T.VZ<-6JTU5`03EG:F@V+EM4 M0TDY%E/YZ?1H@7D(&HPI=174N1)`Z-IV9%:GJ@(2C9V7HMUMG6:D@W,Q%K': M1A:/Y>UG:CV;VLO1L(*;E%9=K6!6"Q:XO90CJLB^>ZXDB@+%;- MDO8S+(C_6O[XDT]C_F3NXP5OBFK2,T`1*AJ#VH>\C'_+"1C[#%C!$(_I5&)B M/>NIPL'`!K2Y0;WV!7I`49E4">KJ-J>6OZFQ.J9&!TAPQV6#^]A>WQCW\#R` MF)^'VUV:"'US:M8=008*C?UM15/&Q-F$&1%3R"FNNS%FZ/WW+N+5&5>Q[]*$ M^"&9NZG_0,D'T7H^(5_GN'Z#U_QVS>UD55@)?&D8H+:``#>BK6BI2]Q+ MI&&H$EHW_EWHKWW7"5.R3.]I3):W"8T?^`%"CF7O5D#=T%MSH`QZ%S7XUDLU^!:15 M#MN;8(\M05MHHEL+7:@(3`:.!!(1/ M0HPIP&IIBQ&EUV*C8R>Y9SOB_^$J^,$)]LX9WOF)&T0C0X+6 MYVBY?(@?:M/W#JXJ$*A\F\&(TVH6.L]%F['56@=KN\NY0%P`(_Q6_'(9&@.LSH?R"V"J3(CA4BM__S58$U7*' M-]%)L>*,9&N2;%'"POQLV;K91V7K[5%7$.!!Z-EH39QBW?R%>O%C=0F7["H* M!YS"VWQ5=/[$Q-(_L!'`&*)_#)KT].4^#O.[NUCTL,@:12B[.)-M`%]S@N$D MG4)_GKYLT9WETF(T#H_,(ET_'NC"*&Q7FGA\O:GEV+!'P#A";%$?NFZT8W'D ME?/(\'6=ZEF$4.^L:!VJONUQ_;\ MR4_O??;GD))'ZL0\[,I_Q8>'4;QART1;&K-],T3=1Y?MTU^+IF@T_@;9.R+F MRJ[_I1%C36??X8FC-4T2]MG[]+K4F'5`@79\.I'K='YJ,X0ZQND`:>.UK>/5 MIE[!W2$Y'RJY1%(FM"=9XKI-OJ=:'8=A2-X##3HT[T7VD".SRT@%7]:FX(S5 M#?$K+#/]O*4AQO;#:DRJ%,$K<:@]\3L/W>RJLQ.<19M-%-[<.XQKYFD:^[<[ MD0A=1>)W;YU$!%)\\#R.V5?,KDBK&K\15H(RD*,0Z9#U:T!)!I5D8$D=+O<^ MW_G!3ES\7:S7W`ME'J<8>7++5R/Y.)H-3NCR9_$"\` M+C;;('JD](;&#SY_I+?8)D.%VXSL8>P@R-_M7:ZOJ1O=A?P$C+K M"CS-)J`]D:E(*WN)L%B)Y$OE6DPL1NJKS4BU'I]8K4BR)<4S60G*ML+6"1MU M$O963MA(F[#@?MBD"D')?9M2&UCU^J(-O4F=5&CVBWR/.G=A92``_30)6BT. M&!M-RN&UI^[QW''50VE*I3`CMX_L;SSMR0+1D&*[&JO`TWW^40]#@\NGV;57 M.3!H1Z0/50VIQ7B=51>]\:5V3V2Q7GM58G@E`ZW"[?8$^9HFE+>-FX?>.]X( M(]KR32VR/)=>\R@54%"&5PW-0UXO9HF3M]H\DD_$U5%J!!R]:AX:LZG!H5+S MJ]J3O1QK26)PASKV-'_I)R@];'VB?_$E5E1I0:+.JBGKC03'0V4HN;E6RE#BM;M9EIO'/3';]T=L;CAD!0&YJG#K&-*),#0J8S3%L:X(K6"7W25_ ML(6>YL>#*]K4TCORXDT=I0-1J-%A%&I5)&\?FT4FGYS8&UB<,71A:*=S3!+* MBC`ZE7I]`?+V<6]@66+&5T%>=C$A^0X*[[K)=_O87J$G(Q^X:SFZ$&L65(PC MP1;=2;$T6T6G;&)_$IAS>+#UA@\H&)4/P%0+,7C7,@`;W4G%#4U`SR=G`%DP'E, MN!0%_GI'1MT`H&RT#*7N'*BXX9"-QG5@I(-.'0L\]S1Z>4QJT/L8#)%Q[Y)W MXP.B$59$;[A5B-:>H)/'XCVA.-9SGPGI)0^^>V)OS&<[XPGF.(9?52J/0'7E MMF1970:\CH+@?13S/ZKZ"!.M#N5@3$;,T=7KGCOD.9D<3C)4TKHE(7:U+Y/$HEEW&)-7>M.W@\KL2/;&": MG(=9^=Z/<90H'W1.L?2Q1DKM9)S2@]S<3M8I#5]MQDV')P\TX27]>>^[0@66]&)_\K+;AGS"=AJJ00;4:G0[X[W%@V!,^_@F MPST4S]W`A(<#<3_Z*%"BW*W$@=V:_7@,Y")KJXU=+Y/Z5^G?WS)&;,SEW[FB.&[V*?9?R0^-U9TF)K42W MZ@Z//;8T^BC6#FV++9%\3X4MHD3L"KAV!?^'Z:'?DXM1S%6,[:,L/?WRY)0\ M0+&@=#O'&@VIDQN+SGX"P9,YT5NJ<.P3#+@B4Y=D..MSCHY*`-4ZZ&F$HW8' MU/!9K@A6,,*(?)W..YNM9[::_LY$]UGUMX8^A!WU,YCX0?).+M*"(63&'?&' MZ*BIP1^3CJ\E)KYQ;JHBCD@SMQP66@E'Q]X7VKAT_`]@)_/IWN=O-L3BY7@L!3)8R0Q: M.8)#VXT2C$RC@A'9/O6#0JL1R4C;0A^-C$9^:U4KJ*P<4N*W%+L\L>!M,M*9 MU,3@C^K&U;)6CA?U5.SQ6+1?A#F-EE/ZXB_BN5&_J3Y%:5]X,V>AN/ MX%,:L6P;XE&I8B-D%8E?V[G<#W%2-H#V-7KMPCP$HP7ATDA$97F)WO'$&"/K MADD/.C05PU/2P)A"C8&[/?8(9/#'PJ'3OR3G>_1/IF(*9N13#O2D/;/WY)SV M<=28%5]^%!UFV<#<]J-[.Q:ZUY1W2.9O!D9A&CMNNG."%8TWIUI!`(X=@X8) M.$B`UNB46R:U/1.^:3S1!M9/:&B$XI+D;HWD*5N$?.V'Y)$Z*[OSC!#F'\T[71IQ_Z='\B'`:HW!\I-TC$ M#K^P>$?].ZE9&:>DJU_2]:&-KE]`D-.CII#$-W(==?1F`ZP5A/)^GMCIA>W& M$5*=;Z.K!*+3"]W6"E_&(05,(P%-^7]*BO8(#BF^E#*IP1\+A^K^YR'%@$^V M1\E_GD68:"M(7QUUN='X*:YN=+&>19CL^(F=19A]-*2VYAPR)'?]ELDSO:;RZ=\)<*UQ&^=GPM?3%XFGTI]GNCM8S M,OT8HS]4SAP=L152VPL1FR$IVTWE+)4;*@[CJB>!GV2/V;&^$(;WDS&)K!4_ M9X@V>5*JW%+=A/:&CJYPPH#D$X2NG;IZ)=?5*%Q'2-I_+,K>GFQ_U.F)=/3M M4<):EL?Y*I.Z^GFX,UO@`[7753Z$YT'!:U%XX MXMF1I&AP!][,[@@(ED71TQ,,\HG(J:3M"1W<)KN?9?1AF%$G\]+,O);4?9//:)1_HJ-&H8U@F(HV9)$1+G M"%OHCJ_1@4+5+G7^%*QG&88?%)J)#OKOF)"\=_Q8U!#@/EW4VO[3#7U-/R>* M\\E&5;#8->';)GS?6>G6%WYJ.?##JM'X"PK6!BE`+*>A!MKORS)>\#&AQEZ? M7K"H]:%0G+^:ZQ(-!<;R!PIU!<::"V[?)+TW)WN^TX^+@/R4W^9""8.)N%#T>0>]#:[=/+/FA^+#@;7=LH3O-\ M7!^N\;KKG:"@QRFX+NWU$\_A#*3A%WCNK*7488^D=33Z$9C='+E:IUS8UA_= M&SG:F%:!Q!.2D89/!)5`)].7*0J\%:Z:_1) M^_&T^:LU!-G'Q%K;/LD.CK4-GY2H4^K,O98\P#H3GK)*RI)6$''YK9,*]:2M MZGHE^GC\2^$B)_A.7@RW=^R^J/[GF+*Y7+:;+_.<9+0/TIYY.3G(O-0UMABP M?XN.MR9]4C'!5'0]S&BUT97W>O6B('#BA%]/S*Y8@/1]1:4[;<879GK=GEE= M;+9!]$CI#8T??)>VHUN6:@C,DE64.D'][V=1DEY&Z=]I>DW=Z"[T_Y&W71<5$C78;W0X[W4\F>2.1MFK1)M[`=@7;25+MXBB)'W_B7XH'CONKZ)9=9 M6OB0BH6"/%7#,^J2*LS,7"C6#WX1H8/)]_C28PLDE9@3&9.G8/_W>WF($W1$ M'2RDNSNZB&?HQX#KUIQWD?(KL_W%-,/4_";[#:'J7:`*Z_I4`K%15`M0'P4% MO:*BW)WXCT"H[!=O7KT0"IO_)J]=$KNYBZG8Z?RSWU8#WVJDI3"@PI@>Q-KK M%S--4PPEO_+!.#JW(T;'BUS!M(+9)\+G/&0AP"8S%K5:1EJAZ100GJ%Q7E5D M2^I'*@C6N%+_+N('L'UN5,]LVVY.+S)JPI$-MR[MQX1*GZ0/P^72V5#BA-QK MJX2=^21HA%Q'"&3N@I+\#!#LLWN?KA>?J;M+_0>Z7*]]E\8MZWV@'8^W=VLS M3="@QE^;#(TR>@Z`E!!(#H*T"UT&!I&W,!+^M,0_RO%O$TA$7L5@O(4BR@M^ MVW`EG_STGKCMU$'F?ICI@GZOQ$@1#-5I'ZCGNTY@H-&:JEL+((A+HXERN_3F M\W'JKHEPWN0XH])7H^.JHZ4.*(+$>S*1Z6Z'RD"@A^JCY9;RBPGAW?@^ECIH M>!]+APSM$EM"P*FG)L<_*O%'I;,FQ%M'>S6H@]''TM8%BCZ6KB*P=\:W\M.` M>7[GH><_^-[."3IRQJU9_/;)4"=D7:@<(TX0:=__4VXC=DF/7W_)BZ M3*82C*&P3'P5HUZ)[%HVTX?QMX&9[@`!:J8[T5)-T.$STYHH-7-N7Y\ML9EI M.??UFVDIZ]F3I"L:BY*.,&^,ENC9]#XPT-%M-WJ'K%<;F54Y)],)DOF-(2-\ M\GKMK()X%_JI]7ZZDWTC-#9649Z4@F2Y,-G3#?E-59WD<7T*E!7=WW;;P\#< MM"#+JK;06FI#FH2VSA=F^=']R=#VX1"53F[!FJQK_19*6J;M0PQ(#V3W(#ZR MR$E<>BNE9$)PV#IG(?AS@F"1X.\72L`T)1=!TH=;%Z,0YBGTT"$ M./DH1$DYQ>T?B&R)";(TF4Q0^C-D$BDY@BZX]?8TU_S>>L(B$9!>[1 M%S^Z3K8]I)S@^O5^:ZIL3?$F0[XJBFR@+7I6?ZR_9):Y"N#N@14YG:9/K(*0 MVM-S90;U(DJ2,R>.']=1G+W>P#O8Z@:F?>"@0]5^=`^EH#H:X%/(WASRJYB% MPPVRBR)XS*[(N$I1O!K76JRNM,I/.P&`E:!*4&H4@3F?239X MCQ=1E:).A@Y<26H?T\G+4GLX#EAX>#V^82EJ#SAHB]:/KB(_SHBXM("SL-02 MDN!639%YUTX0R&MWKE9@XQ)+?UT>&E M6AY]H$&T%9&RFZ'FUKTD-#:LG<6DAJN5ORP683E;/W6"0\?3K(!$#@S:4O6A MVJACRL8W@Q)>AZ`4[)V';K2A3%_/=^E]%/OI MHTZ,U3$;RD!U(M/L-<8'"C-5#L446DV!")A!DK.8U#!)^0M22,SBJ$XXT&9) M@J`:QV$,F*9""MP6];&CDAGJX45[PL66Y><`[EFT"].XNZ2@5;>T3X:R/UVH M'+);,>Z0X3!%1ZJXO*<>C9D+YV*6=)[8Z,K2R>OZ=.2N>A=\&6 M"/YK%_N)Y[O\@,TL,NH#!VV$^M%MG';S&2(Z%W-(?1+.`,D41UCI&L16.D9) MC44QG`Q?^"$]3^E&.512`05EM]30U#LRY3.)F(K#GEG&$U%G?7L2=+<^Y]=DHI'7E;1 MW&.;8AZL$UPYOG<>YNE_MM_%>DW=]#VC2_NC,KHV;:QEH0W@>.1KO#Y;0>;M M-BK8A`/G3TGEX&>DEA%\2T.Z9@J!+HO%Q5_$.XTD(YT#IGVLB)"."S"NV`ZXVK7\Q#XD;YUV=L_+ MMYD$Q)2M^[&$6R^4)M"`C\-=GJKT@N3XR!!V[YJ$2^/487\7?2+NH\!CHT@4D^WN-O!=KN`(!)!=63?1( M]SU6`R5B20>N:+Q1]=',@(->BS4@Q7#].",<%`IG:GPBN#D1_!X=.B/I%$0P MOYD[`A7VE27'K^R'5R='I_)$IO5&%'(57W&(^K!X7NG>,X^?M^6]IOR94S<5 MK\O.0^\Z>\_Q+$K2SCMU[5<;-4""W>W50KMQOI?/YH9^;[XXU\PA$`$"\A[: MX*^CDL31_]I6*_>K'?%]B%TE-'Z@.@_IJH*#3L+TH]M2+5]CWA7;+F`AXB#: MZT3O:M_18A:?+7`@/FHOOO8#`,O@2U!JY.\YVS4T*60EGR:1E7+=/9_('K=E M+]50>D.9A\W;#)I5)G6!@5:"W>BU/])+*2F'XJP_4L>H0F2;]6W`EZWMX3XE M_2UG/8N^\Y:ZOA-PO]T/1826'SMT]]%M=\GZX(!YR?T(-E@PFT)J/RM$RH9TV2\R2**?J&S-`*1+I.(][-T6%,$-CBYSZ^?#^CG; MXOLD>13[/MJWCZI&J',^E.&1(-3H8ID/%4=N>X-11$\:F&05G63+R_4X,K$, M&3!#V<=K4N,H930](]CU`%\4L-7S>A)QI'(>NKLXY@V'F<"ZT5WH_X/](SEC MH6GL7-,'&N[:CNP&0/M-V;;5N&>$W>N(8:-;27WE_$BN6)O,A8$K5B?SA&3K MDWP#6I)F'^<#N6W4?3*$K^[Y(?TK9LSJ9!`9"WZ&GY&!V_FX(H.3Y3=BYR1N M)X,-&1W&I@71F8<07*.(%[F(W'0 M6QK[D5>KZ.C[WU&T0U]F&0]` M7S,#T6B(-A^A57J^R1DIMUW\BI0;9W\46^>9J/:GQIX`C??>H6O8CA+_HG_Z MNEBQ*?M/D#@]IO6,GSH%0;.?_#&C_B9#/:1WW$9HHV[#*P`B6^%'P.CT`5'# M#<^>GR?)CGKOA-1>"8'-P+??2,3D/LY%=`<1PP(:1Q&@8#3%#X^QD4'1A ME0Z*ID*,<9J2O\7L,=3QB7%7D`XA@ZS&1N. M085>5OXZ8O\2!\QI7I9'_]CYZ>,WG4R^%_E9C^T:*#>M\-M#*\S,;V9X%P*U M\Y!G[(K\'3?$.X60;KJ%!T9RDU,$.(!C>SW)-DNRW9+:=F>DMN%1G',4Y)0: MX+]2_A@3]4X<7@YW1PM1+B.VIT,'76ACG9I@AV\I"I\$'(V)5N3,(1`Q(?YYNM MX\=CT./48^QIJS.!O"]2X\-!B4;"(59F#V@)315+:C3Z5OZ_)=]J/(;.?+]@N M_L)^9O_A<0#[T_\'4$L#!!0````(`+939$&UL550)``-H)#I6:"0Z5G5X"P`!!"4.```$.0$` M`.P]VW+;.++OI^K\@X_W=1U;2C(S3FUVBY+I1!595$ET)O.D@BG(QH8B-2!E M6_/U!P!UH20"!'B#R/%3'!MH]@T-H+O1_:__O,[=LV>(`^1[G\];[Z[.SZ#G M^%/D/7X^O[=O+WX[_\^___=__O5_%Q<_.J/^V8WO+.?0"\_NR)@9@M.S%Q0^ MG9E_79A3%/KX['L$ZZSU[L.[JW=79^1'^VF)@RE8_?/,*S]O4_S]I7 MK8]G5Q\_M:\^O?]X-KP[N[B@'W*1]_,!!/",(.8%G\^?PG#QZ?+RY>7EW>L# M=M_Y^/&R?77U_G(S\#P:^>DU0'NC7]YOQK8N?]SUQ\X3G(,+Y`4A\)S=+`HF M:5[K^OKZDOV5#`W0IX#-[_L."!FK4O$ZXXZ@_[O8#+N@O[IHM2_>M]Z]!M-S MR@/LNW`$9V?L\Y_"U0)^/@_0?.%2M-GOGC"B$*5SUOYN,YP_G\C,*]'_7VD"6#8]R/S@$4=8]PC7R-L&I/OLE_+(2T-+3>G^WVC8^V^8?3[ M/::]LLSESL^)V9TQ^F;:1J=/B.T2-.R>2>'?&KW1=Z-_3P1IC`F+F#SE<%6" MF!-[H]NU[@F#R:NUIDU7+M&R\5=C9$HJ MY\&DG#B,;:O[C>BVR2P*(8LI$Z&5_6%(C*DDMV0`Y<1U9';ITHO$TAM\&8ZL M`?FQJZ*'*3!R8M@;$.*)FO^0U;'XA+S<@4&(ETZXQ.1@28X6%MGO<-=UWPX&-VT`_($C-<%]&;4I"%!FEHA6(-O"G8?&?*OA.NO]/*@K8(7(56 M9[R6;-;@/!WX"ZA-3.>"394DV]]/`8N'$.'F,80;?A;@I'*AD9>/@'\ MDT"B2W8+FHAE1E!XIBC,(0B6&-(+:P""`(;!^C=3$&X'^1ZFD^G606[<:"U+ M69TH%X7"^+-C/5EM6Q'=Q9#+LHYSP"][-]OJH^$X_I)\?PA6%%%J;!P'+^'4 M?%U`+U!<$B5\M]B3>*8M10BB_#U\'/K.SPX(X+3KSRESF(%=\TE)/$5]K'R: MK07]K.&$Z!F%JQLEFY,=?`6R?`(8!M_)@3S2=(?\:_OT_]1E^`JQ@P*Z'M8H MM8N3J^J'R^<%NY8@B@A3N@-IO"^,]+3OE$]I%JNC#C:5CE(^VRJME0/9A=*<[C$.`P!]:Q^17A;?LA<#-A')M9$:X#F(VWVWE5\13B`&;C MZ6YF@;B&QW@J,W+'06*E%N1\16YR[+S<)VCL(4CL+O2F-+86_98"R!Y)9J%^ MW]G[@DN#ZSY.L]ST-Q,1<..!G):`$VX`N91$!GXB/7=R%1EN*1S73&`,#J#S M[M%_OIQ"1!C=^D!_H/A_N+AJK6/\_R"_FD1?'L%'1#_HA0,PAPD(\X9.UD>, MN,@,O(\KP,X&(OGQ2%[[20GK$9<+%HV^<)Z0NQ7U#/MS=?YM M-WSRH8Y"$%"SD<=[+5;H%KD0=PDFCSX6VZ"]D9./=91",B$;`7S0LPWX\[GO M,?=*Y&BREB%-%:1K5KPG""9.?JFO>%+HVDCK8\72VI!E$[`O07[1.+8R6]UYOXA*1LQ_%JQ&`R"S)0B=.L"GBW:&S.YKB/; M#TG8L/LW35J_.R3'+IU#^O.[>=+R\3,IQPP$#XS/R^#B$8`%U9"/E]`-@\UOF$\H MIBKK7T_&A"Z6CV#-;I$'/`<1IOD!2G$,J4S/[!O*3I7!$DLD\-\?J,E+I,C, M`Z7GDL)U$YT1^F:0W.RBV(``?X;\,\0/_LX?JT.2ZWNHM$`/QFMR//$E(Y+@ M,>Z-$&07!$_$FM-_S#^7Z!FX-`G*"+L`XQ6Y(['\*(%@I>9KIU^/NRRC.0]3Y#G!%P87Q#`+]1GG@>TXFN[R;J,F+ MJ'K>2B6B*6;97T`,`13;8_XT38Y*50&GD-`,TQO;5:26 M;N)X32Y058'R<"_,%I_`)IJZ>^KRE6:[SL9]H<>AROILE7T$'I"[>='#XGQ/ MODO("JA5"5<2O@E9$+H\K\7XH52H;,8&&Z-8WE'%GS1IZ757*0DP50<2B&N$ M/X/[G.V8=I%%EXEU;J7(E+,'J-'7",VX66,Z@L_06\)T)4B>,&GI=7!E MDC>?E&:8>OIJNP]!`!^`\]/&P`L(/P@9&[J_`.2)KU62$"8MO;ZN3-)7H*T9 M=R\E6Y]D\O1ZP#().9F,)GC##HR7U&V:.V?2TNL$*^`4)Z2M&?8\QB6YE3MI MZ75]%7LXI]049HDUKER:?(M"5E:#!E1]+T3>(R075Z%8!;,F+;T.L0+$G$)= M,UQFF?PP`G:V];K6"A"[F+C"/'&Z`\T1JHS8M,R1A-&3MFX/FU!(W'AR$AV- MN#/'7D^D)@(=#)VT];K+,LDRB8AFG*B,Z11%:`\!FO:\+E@@L$R25N.K&9G)H`>^1<&L080:Z=R$&B`USZY$E; MK_LLDS+(D=6,(]PQ@Y0.[).V7L]9)ODFD\%_&5J?^W?:O25'4'S2KKT?38;$ MTK1`_Y.F@X8=;P^<"K\!$PY;F&$Z9;>)(<3L#;KTI9@'H-8/HJ1);,0->I_: MJ`2!L0R??(S^VJWE5$TXG*CYZ521&I!`6C.NW$ED]H)@J2SV:)+F1U3%BWQ+ M5C-NV$DDBJNO2,[4_**J>,'OT]:,BW/,:91AVY>8K?F153XMD*.O&5?HHXI# M4MN]8);F]UB%23Z!KL*N5Z\*9H>0PX50T'A$I$"VD!11N MX#-T??:P;YVJEH!2^B3-S@X^KP[6A10EC?!IL(Z%K%M)U"%(0N-X4S3[,:2% M*T%',YP6R0J\)E<8^Q/,T^RZ$`F-%_(34].(9?P%>A`#ES[^FM%:WH@\&:71"9EO$Q"Q/ M4!=C`@%->-=B+2`U,][C+J%((,6$T9K=!<]$U-#N1"1UO-" M2(0BOH,E3]'L$U`6JH".9GCV-P2E'XL.1FHNWI)!DH?HYW?()_=ITU")9^![ M_K[Y29>G>*+N>B_JYC>5G&:XXP\] M#(%+@T9??9F,4D#_=L--^5&%<(IV]K$_J+A>3S3R4Q(@2 M@P'51H`.F2.A8()9NFO'9'!_"FGA][JHCPG:9/EO\A(Z($`.]0,B=TF.,!*^ M;DD(N@O)*`M?@2Y^EXTZK?<4@K.K@.XJ,BJ2S*0+\5(RM;X[_`[1XQ-E"5%$ M\`@'R_D#Q-:,T1R+=\MK1C:`NBO2*-N*[&0*>L'4-G&@:XR_WO:MWT^BGPSM M:W#K^B\R85O1-`W/*\A9@Z(QQ/XS(D+IK.X#..UY6[^BX83H.2J!Q.IJ+,GO MUG_T/1EZB_G`Z3S/2!(:_SY9#.F-B(UF\R'HO?$5)T$9CT-3ZH5._[N,W->! M[8^@XWL.J;8OR5:9/D@E?$YS=D79:E<2RYH1T;^!!%D'@:B MU)C[.$1_L=\+U%%FNNZ&/B6)/UG9)!G2#-/G.#BB+T:<-;M!050$7W;!9!X]B%EFNZ.1]59A71&-"-;@[6GZF/R!-V= MDZH]5?!8T(R$CEC`F6Q_UFRO?]BV>9@H7UT*@.Z$GFIU1IXG^1-+3L&N$"9B M>G"Z@=&_,;:MZS[*/9R3!*([GZA:95+C2S.R08YI'D:=93E+!QIJ#':ZAN5G3V&W0YT]L0D+:.-G\@\] M;CZ3@RB-3;&2"8>1"8&NJ8#1WW4OR_:F2F$32L(ETVR0=8/QBBR'U":\,O/U M-^DK3AT22"OLW+Q@JD:PQ6&CM>%DF@X4KPT%-O"+M,'TXNZ@"MZ3#PS[?F0> MU)[O&./>V+H=CLRQ.;#9K^4?E'/RLRW\"+SUJP/"V0%UU4)K)G4;4P.@X>%X M9QD@#P;!#0PDV,`;>(\.)OJ1S_8#HN,Q25H"BN:A#47+B[:=*C*CUVKXS1M], MV^CTR>;9O1_U[)Y)5_BMT1M]-_KWYIUIC,F6RTJWY-Y5D^*<1&*W`&%V1+DC MMQ?"W+35FAF6AI6YU;^>1ZNO,W345J4D!)V[:D99<%:?/,&U7GE&MVO=DU4U M-/Z@RX]NJ]WNZ-Z\,7\,:DX:B837MD+!F<4Q'T*6Y5ZSURZ[4P3813&+-Y82L>66J28VS6/.S MH-9+>F1VJ7LT.G7V!E^&(VM`?NRJWNV*"CN_K(\;M$0Z]CWRH[.^(7C3[A.] M<@?;UVIL#"*7@H4K55BN`.A:"GIFQEK&!!0!7K,=*$:NW(A\(?RIM9'H#QU4=R\ MP(^Z1^KL7\E.1>P>MC^H!DAZR46S5]=G,B&G+$-B*=>,NAJ"C-FD]3B]RR M"5"2D5406DJ.%]&!$R=\A*?BIY"+$S53+]%Q+89A+%\:073GJ8.'17QY*5`L-E:+$T MJ.3ZR.S:VF$/?C,L_`KQ:4+X01?C&G&LW#$OF0'Q-WKKN^TJ@TIG!:ZYUU'! M^IF#"\VH6)+,@-B2[*R.%^P+P-,U>[[#@/I8/%:HTR$_VOYWUDJ>/1YE/)/6 MS8I1T=P^J1A-KIYGS7@S/O!9009:^I'P&%'2V:IGW%*WJUG`:>ZO5(C^9:2[ MQ!(K)_0TZP:&`+F4;GKQ>GNH)7?J(9H$B2;35WXW\!FZ_N+@D$@?B5,L;7\( M\X`K=[GD[D5X`Q`BR(Z!]W/ETPLP\%;]<,JU:^F3-+6>3.+:/E^E4-=L MF#A2^K;R7\!7\/.G_PUAY,G**66:IHZ1DI)*1[X9_N8BOMQ8@-F4\386^9F3B9V5O^44S+9F7,7KZ332VU"B:$6J MPG>DO^\R9RM=^V-I&ZBA3R[U(;F+W"YI;N'6<4OY.O)7P.7TQ,T$1U,$M1H= MRLJ1TCP\>32DNYPO7<:(X1,(('N)980A1@]+]A[<]O><.]NS!5=5,@/4%,NM M4&?RL*89#4QU1^?T1H&KVMHRL*6P/DO%[E^95TS/,U\=&`36;$O\IB*FS'Y7 M]G=UAXE/V=@IL+"P?E#%:NT=N87/EW-C3@LM[%V^UD^=A>9-%83N(&\%NJ3( MC8U:_'I*!ZV!'R('1AT/R5V")A,C;QTGV%PVAN2/V/99ESIK-EY`!\T0G+(% MQ-.4O'!UQV4K4)\B6+31J=].R]1(D496R)JN_)IT`&O2TOW@^C2T)X$M&XVY M/BV-2?9\K,^$_/N_8-*DI?O17[UWCRE8$SA48O M[FFZO%RNE^3T1B1[R=/:B&RO/@3!GDE,K\K#F_(WRL(2L*"P#!4].T(29:F5 M0D+]GTX@HG8=65;+C6"@QRS$XWSB=>BX&YJ`..-3T8H3DKIPKC M>4RQMC?P0H%QS=W1&$UY+@F,Y')ZB^B)V2Z&G?WBVYC]EK'=R!-2NUHE5$:-)EGI[D_:GL)TJ3DD&,MRLP3W;LQ1TWN%X2% M7KCU+FXR;VEQ$YY*B.8T*C.$(_XT^IO17$/WTXU6@YXEBG:C+(S1?4KBW5# MB-=]NT,,]_I$V@>H2'U-5D`-]9XR^ MF39M]#XVN_>CGMTS:;.X6Z,W^F[T[\T[TQC?C\@_`WL\7L[G`*^LV2U`^#MP MES2]ZQD@E[I1:>-^73EU-@Z.P4EU$>G,6I0G*]4TIOX$.XIHG7_88W]&32B25D MQ+/!1Q356YIWX+_D&$F^$EBS&'%(D"4A.U5S"G"2J)*%*D%(O87<]?&"GC_@ M/G6I.=_">9J3@66$Q@NMBJDJ2M8:'Z!V@$O?DHV?(`S[]#-4-F);S9MR,DF_ MF6VV@+*:Y_(F499JMOF3-.?RBN0D+]E3S>7MTA>M:>\P]@9ISMT5,S?!37&( M_&G&[\F%7$H4A^,TY^\J2R,!?]VA\NHNJ'V)S#0E."?3]BSS+JA*;C."[7Q: MC;F/0QKWI14'!&HB"4%W(3IE\29KB0*UA1V3_1"X)Z<=CA.5W8/3+]@/@GL/ M0^!2\K\0D]N!,Q]#&[QFTQLYV+K+T96O4?)\:,;.E845??*_LM1M#_;I)%=7 MKFY'?,B_]UU'ZN;!1_J]4U.W3'JD.XVY=`6)YQSG3@#3T#QN%]`(MC0!;SH# M"#_3@,8\%M``00##8/V;*0BW@WRR*FCQ)>0]/H``K:L1J90A>@NE;51MBX_! MN$TP["/P@-RUNS'BO>6--@R/PL5;_G0PR<7$<4YQI&^'"T1RIE)>M@D$1T-J0W:7G+99AP/C3DM]4CF=I M#HPJ2R]%"1();-9F$B.QG4GR[9,(PI8H^7;#HK1)-+[/)/KU+,T1V!)%OR-0 M;V/#`,J<`);976*M.:_V_OVI8;MY'H M)VWL5&6SCQI9,]&N1U))FDWRY*(I2.8N33J\>,;[]0N`M*P+<:,`-@"AIBHS ML0D2?;IQZS[=4.8C,]\!'5E546MOP_@0U>W=HQGN,G"P4TU_W38@%##PF(]8 MI,#ARP&6"Y[HV@*;?C"=@8LI<34EK]P/8=PG.P/7-Q+`>ZR3[NY[QG<&KA.D MKI`N"3P[3%^P=MQ+4**U?@>Z*-"0/GY=>$$7!]*T98]*4JN"_$5VM:]1>N0L MN4O*.,T)-KSMN^P[H`L#Z;!`-&PH?`3\6Q`;"#N/? MH\_5FH+SJG+-)=;(DJ_/ZA'B_ MR$M:GG/]':6OZ"M^ZJF<%_=YMD/%7KI>$_Y%7_2'#FL.(,]W&2)X;FZ/H1GM M=@7-]R`/]=RD7/A-(#ZN558KALC@'FB`!6TT'L^_S=:KQ>A/4CIM-+O#/UE^ MF]Q-_EA,9JO)1ZFT41SG-49[$;T1)+$R\$^*&FU(3=&L[%$F3<^0:_M3OG<( MK[42%T=S6D$L=,?8MHXGWICO;`!\+3,?4];09$GBQWK0#!$L'.Y+NHY^X!E' M1KF,1L`9$GT5S)8&^@#)V&NW?9[759G718S(K>(Q;I;$44K<)NT_/R.>.GN^ M"3B]04G'_47TI"!$:]M%OD5E2?O/MPFYAL#I#1<-GKY--CF^1ZLR3;E0M4K)ZP=B4./JPF`*>>:18W)_@H'>?/ MSWE&.U2.JJI('FMZ^%_G]&>?HI+N($_N@.-Y12Y_.?!IBJ,HQB#4(K*Y8]<` M@W.UGH__]6FTFMR-YU^)_V*TGLYGH]D=_<7B?C1;K:H\_B^5_^B>P,:'`>3" M..P)N9$.54FCR(\8BL3(5G@+:"7XR?-+FK\AM$+%:T(X.>\&>21`FK8TG?GV MXU:MYJH24C-,H6J\QN\!3PEJ&F;,$J:`<9L8CN?._!FML$HIH)+T8$XK:ZK3 M:]8R<^GA`.&E:0@)P]QVP%X>@;Z4E.Q)V8KN>Y':C8$P042B-;!71ZB];J7+ M">:%L_X+RE!!?9:CS7.2)60E);@%PF0P#VF?XL&71,)4*:X>#;$ZE&<5X>4^JMSOEBJW!):;N M$F,8]8%G]M/;N>/V>U1LY-U@%W[#+]?7Y6"X?=AM1,%?$3BXCIZSQJ6E07N, M)>!$7+>5W!^F#QRRS2*-LEGTC(3^+A.?`W:3G=D#8UXQ([G;UK??MY&`6[.I M$)ZAF6V`?6>F%"PX[W2@X(6C30@G"TV9H_;E+[?FDDICZYP6C/PX1/>&HAF8 M):&]5E&V2;+=,D_3SWE!?FG"/KD?!/8QZC$HS<8J`NRZY])S=&:U8'G6_BUH M/Z8QRS)NR7O\=!GQ"_65K:JHJ-PTY"_XP:J<9HW3CU[*9="4.[X&["=US9B[ M$0R;"H(-!G^+DJK&EO0.D$%;[O@:]`VUCMER-X)^7/SG]@8#^B)=QPRY$T!M MF5O-'F.2.6K)DQ^HB).2'*V-6_+9MZ#+3+MFR9T`^I&1IE$5OZ-D]X27EA$6 M*-JA%C2T*)(8$35MAW1G2'8&NMRV([X.!33#IEL!._BQ`%U\',A(04?,8=5S M_UTMS+A"Y]G=U&C1UPOH"NUNC1B]N%_)XB("K<-%`#5N%+L"74S?K\'3`WP_ MR/97M#US-!;K]/;LE^"F.O=\``T4R1Y`W^G@U4!1P-R@%\R.%`8*5/EO5%9- M==(8_[W.R?^3J]$^@&J3&VY#$Y`8[ MCV_W(;DA)#=88HOMH;(Y0M%#T^$I:DA*EVP70@*$#@BO>P:6Q@O(KW99QUQ- MMK!BA`B`]6BY>!3#^*@+QB4BFT527RK/J'NCCM(U*IYO1(/(BDZZFO`A.Z!L M`3G$/^4@W=]--L40)EF9Q*+K#L'ZY&I^B15K$1M3/^Y8,83@D/1]V2XXFY\" M-Q`Z,0S$?CG$[#JX2,>L'4U]L6*0B)#5=AD/_-#1OV%EXVC1T:5')[W/H;$& MY??A]8O[P\OH-&7-X47<)V?S;ZQ8CSB@OH^5O_M*3*,UU1,""PU_GA39_3GP MT`(/+?#0`@_-[_A\X*$%'EK@H6F\J>9C0R%W2-ST33C%P_175!+YI?/T59>\:D^51 M,Q?.5.V#JQRSWA8*-E)"`6!YT!JGI,E*JHI=<)4YYLPP.8/[\CV5T[58A8"U M94F`1\E9+USEB3DS4+H0O_*ZQ4[NNUSED3DS4#H`O_J",_*@G3`F:`6Y.SPW M?(Z2@H9_K3G*J_0T$-,&A3KXQ70!:_D0L-'7^-5UE):!DQXXZ8&3'CCI?O/V`B<]<-(#)SW41@VU4>T\ M$@9^>N"GVV*+Y[=_#):RSOQF8)WWPLPC2WX4(_3(0.@@.?\8(9.U3-@?=95# M+FO+ID`SYS5F_0'95:+B-8E1MY;VOCP*6KG.JR@]_/TX+ZM97OV)JB6*\UV6 M_*]-`VSQE=FA&OV^KX8_D/:85>!^6O#@&O6BE*>Q<=_` M^#DOVA^1YWC;E8$[XNLH&%J?_M0FO&#JF/QX20K:IC29GHJVE>APE5KMZM,;)_>A%&@4;/M MB/C5US*6QPRAFT`1"A2A0!$*%"&_0Z>!(A0H0H$B%,I6PE"#0MG*0`L*M""; M;5&8:'(<`0+)3#KN0B`-Z8!0UPP,[?[J@Q;]#\E`3K)=`XC0KZ7I,[Z3A/3! M%*9EE0%M9T:I8A]=+2]IT<0N@[$VPIV+4_\L;X$[`_8@V]W$8)'ZL*MU(TV. M`%G@H)E'4?%72LWUIW_\_!,U5O*3!WKNG99EC39W=;%?XIHH9#E[L M;/%%CK7I0\:/JWE'*7TYVG2+36Z[RTK>YD#N!3Y7%)1'X,II7XHUGRB_SJ:Z M8<<=6"#H+P-#Q_ M022')-M=I&/IMP!%??MK644R/RJGKI.*;$*FV29Y33;X_"-@8G8^#QTA-<]: M88FM;;##D./.Q/H]J9Z6*&WRS)Z2EW4^R:JD>A.R+A7?!!PV9*I34OM"X=SF M3'9N:H3,24XKX!A9#_UU&P)?1&>V=LK[N%9$X.#3Q6H4BP>]>=,X?D_W,G+C MM[L5=*Q([P!FR^C'GJY?5@UT[&3HM)J#R,;%Z@Z)-7VS$("O]3DWB9[1MYZR MN[U/U%M^U_;;8_JJN-NBN#AXD6JS0,4V+YZCK"W>4PIM@]'"^JM+]%H&!P5M MVU-`&FC+&A?L30Z>>K@!3AXQOS,YD58;+1)F66BE$6XHCIY[N(%U(IZJ@*NH MCRY;%JYKN#S?7O*,TLCY!_W.AQ]N8%USYPAWG.&9/;?3!=-T=Y1E^.2:OLDH MY?C9AQM8_YF"3LX[[H=+Q?:\X5M@7K@3B<.WOE#$>V/1F8#TIBZO_=PZSS/7&"])A"[ M\HT`8`+[K:-WIQN=;!E`^1$"&BI;Q((4H(=;R_W&(-;=`T1M7J=3Y^(`63[3 MV7C^=;(>_3$!OE-XFN$^H77T0REYA],*(%EG'Q^_QSO/<504;]OFTNQ2E((C M:`F<6,-'F3$"Q2*Y'2A>J7"_8*6 MP"4QN1I34+)?E2X1!O%)IL3EP8/`M2TEM-*MSC,IO/"/C*.7I(K2TPE,3-[C MM0.N*ME;Q2*A_/`H[+8;$8Q%\4C_,ZJPIV()?[/'#J"T\YW>ID2>'%>KO""B#L MK'O\B?2?=9&4FR26(C(*6@*GO*BK62R/'\LM>Z&2"=5+M(9.D^F]$DO*YH>' MG"UL+^U#9\C(ZDY5\X=9,4[KN]MA\$S6-&5/%VT%G3!SF<8%@ODQU8\V_ZG+ MBH8_UOEHLTD:&191LIEF[>$2`S'9;E%"E4>KX`G09SF2UI!`%Z M;6$0..??,U20/,/Q$PF\X!6EP@M:6E,L4DJ'S'B90$2WE4_2+$\` M$L>X66V`H]L2NF(?;XT(M>D9#&2SS0_;@$=[^9IJ%NI;$&\\,RL M7E"<-!>:)QE5QR>4H6U2B1/&14VA`]_JNI:0R`_?#.6C'D$CU#:K"7#DNX>6 M.9)`>T",[\1DHBPRS:TI.FEF3W8HIP$FQ/L?"TZG1&YR(TO<_IN7%B/["N@8 MG*QB)M01HC75?T]*H+Q'"A3Y]?HJ0@UCS?+HK\!175&Y:!9":]B"N-2[9V M9..G!(BYB$B73YR.^[^1WI*,7OR#_P-02P,$%`````@`ME-D1VE.K,@0#0`` M[W```!$`'`!A`L``00E M#@``!#D!``#M'&MOVSCR^P'W'WCYU`/6<9RT>YN@V87B*%NCCF783J_W:4%+ MM$U4IKPDE<3[ZW=(/:P'+4M.NNN>"Q2I+,Y[AL,A1?+]+\]+'ST2+FC`KD\Z MIVU0&''V*:*'.Z=O3L],S!(^315P91P='[Y`SH_Z[Q# M9^^NSL^N+MZBX3UJM10CX2[($B.)^9S(`5X2L<(NN3Y92+FZ:K>?GIY.,?\] M],FI&RS;BLC9Y862VB=*KKN`+V_)#(>^O#[Y/<2^%O($@9I,7`&FOYN4ALV! M/5V=]N?[_EC+F!#U*?N2@WZ>7K9U:P+*R!Q+XFTE?MGF@4_: M,5B"%8K6'.-5BC7#8JHQX@9M[M99IW71*:"TL)3;T:"1TVDHB4C0W"!DDJ_S M!A7$/9T'C^VX47&[R'-S0\XATK?AQ:T*\6T>T2/4C`,-!G#R["[,\*K%8`;* M'HF09I2HS:`-P]059AS=I%`Z>11!73,"-!C`P0%RO2+"Z!K=8M!%R!7?P@1: M#%PXF6T-M!_;T+KQPHH3=T=@8N[JV)QA5[;(\\K'#$..6M_![]1R`6/ATDS$ MD[RM5&L#4`N@"*=NBK<;*49060TS%D@L(3'^_!ZO5I3-`O5:];,K)>($$)!Z M>!CUMB4HK4J2?RWFV4Q2N>X!*;[4I$\0!6M40J1,/3*CC&J!(*FAUB:Q9QXQ M\U!$`V6(O&\7*21$0T$\A_VLG\$]`FAH#)6I8JP8Q(2Q(5@/WL6^&_K;&;1S MUMW/W%UG<&L/QO;MC=6W!EU[_,&V)^,'AD,8[52V4Q;?!60V^CE8>@SV(;'5 M4RHH)H,B.NA-2NG?WTV?VF*((4'+!9$4A!&U'%%`,;OE8@^WH#=YTL?II_'$ MFMCW]F`R=NZ?+O5BQL> MR+E#&RX(V*`<'Z08'7WOR_JD:XT_W/6=_]9RH`'8[*MW-7VE"")-\5B=,K`F M#R.[T#=NK'$/S`UQ.P9+Z=>15VI#F]WRHZH$J'#]0(25 M%5%'[PU^'8Z<`3QVLWE^!XS9^N=%ZT=4T(8,RM,Y)JOW!A!_,,Q]3E)V]H79 MGA=%>T8H2.,NC+DE,TMYCER07@W$#)>J:AH-UOV;3E2QY/10Q=* M7A^A-Q."H)K,["\"L ML^H"FSU4FLK6JAF/TBLU*IFL7^J#FSU3FNC6+7^.TCEU5W1NB<34GY!G&:9K MXWOBFMU6FA$W6QM";R(N*&%S5%[L!KZ/IP'77`0,_I;O4_5Q7IC\5AO:[*G2 M=+EJ)>F[7S:6QLS#B:4];149&Z5C4%^D!!:"2!&_\;!,@0+&%;*:PDVQH'&_3_+#UV5ACJ/2>L8^<61I M85`B#<(R%T\,890*A;14:0P=6U9*7;SIZ#!"IPGA/N-BT]C^`GRS_TOK+WM, M18^Y!-@YS4R3ON7JK85BB-?*?ZHN$L]^7A$F"N/*5Z!K#H#2,E&]F6YN M\,"Q"&@5R:"W@>%("D1B,8YSV"A\13'.LRI!S%XKK2"5/[L<=[^LLXX.UT- M?SDK)8'E2OI(Y?HV5X?MCVYV\/Y+5BT4,8)D&G$ZUKJI3@]<8%#U$Q$R&OI< M^'\2J-]J7_,SX2X5:G"*#7A>OVLW)6R.@M(*6)-NKD5`CUJ&'W3G5E(@&>AW M>KPE&TDV47+^/4KRSM2?T:@RGDZ=A1Y\43LH=M$QQT!I;:U!#&PX(J%8&G+" MQ7=OY[UD*K>:HQE]>5%:C:O_(>)[8=;`_/4'Y2*>V6][[Y\Y]A75QAZH/\06 M\*ZU5[>^YXQH7,]MP3!EQ>[/9#Y5[=HX[N^7VV$`4ZATV>H--;D*Y&\QL M^69[>O[O7*'^J+GNB,R0/G%\I8Y-7I\(NESYZJ2R?K?01T+5P>U6KM.U$^)/V*^@#!F^J3]Y' M!Z6-CZ=-M0$4XA^<(A#7314I=(5754?UI.3L,#QM3A1#`^@2<(F8\;Z$;5G@)Z^+-$[5X)TCZJ1GW71>FU$E&/NH%CS/>< M-!,B8(-]Y*B^16;_,5/3,F;(^*(H+4OU;2G65$BNPU+-\E1M^%L]\*C`U'%_+X.A=&?;UO*X$5(2!3 M&:K67WD0KA(F%,B#=JBDW@AF/=!7%B#O+7DD?K!2C2-X9(I@JM<.N*Q"RP"R M`.9KDTHSF);NT"EJFV)?U9+7)RXG'I6OH:JUA`BC?V@VSNR6S`@,TMZOF#*' MJ;UX?0+%XQ2[7S)J-\#Y%DR@!.\'0CC,"EV%-H*Q8K.U**/X3LAO05V'SS&+ MO0>!.\`RY,29.2!&O%NZW($;X!Q.+VZR3\R@\W[HAZ/^+:;47=`Q9E_6@=J0 M@=FZ+[U[LIP2GDW.U7"10M%]7U=>L(0N\'=I]'$=/.$/^,N7X",%RU;HM!/R M@+3*V7]"'S&,D(Q.K3DG&JS:814(!Z1C/"3>\6`Y#"2\I]B_"U42N:<^S)$A M5:J^-0K6V"_DW.:HWT(2[H9+O>#U2(8+&"SU&58KOJ1149X$N8,2J6^SEGD! MC:]G(H],_V8+]9C][!(8I&=I@`SQ.DK3YA#[^JR^`7O?0PY9ADNH[4(FG5E. M8VV1$7&#.10!R?55T2#9!.M;Z)B#0%*7##73NX!/"%]2%E>ZW8!I"8?0R"?! M&.0'G<"N$OM6& M*XF=O#XT(T^>@@F'@FQ7S-0!/CC=%M!'H0Q0)6?`M.26H'B+;M7`!Z3;PVK& M(=VFJ2@I6+I8+#):58.]XDC^"MXBW%6;%.;$F:4UUV:3\@V!&H1`<>>I.42N M0ND'3X2/,)MG!ZK7(5T3Y;<`=FG3F72L)`YL,*EJ[^\ELN3 MPOL#RE(#F#YL$;K<=$!RQ\<.G5"*((1^X@TY<7V8)+DP(#"O&S_>$2)B);+K MZGL@OS@31QM4Y%><4MG+E1_HT2,M>PNUV5:(0RS4#,*6JK8*F`,*UNZ"DIG] M3-Q0K7TXLQGD-6X0O9PW&B(>FL[W$-K0D9IJ7!OMT/2-O].P>5.-&R`>FLYY M9]5QZ`%J$AVX>U@I>&QPTI;V@]/``DFP[Z^W*%!L/B#YG2=&N%C057>A"M<> M@W$1YGL]EC9LZN'L!]-&:`=4##<17)6^>^HT+V)5!=R%6K4VF9DAF+IC(7?H9=/_J49T\(J%%O]16LT20H M.IBK_Y8._T?]N\`Q0````(`+939$<>838U`&X` M`/%U!0`1`!@```````$```"D@0````!A`Q0````(`+939$`L``00E#@``!#D!``!02P$"'@,4````"`"V4V1'8#I3Y!L9``"= MYP$`%0`8```````!````I($">```87)Q;"TR,#$U,#DS,%]D968N>&UL550% M``-H)#I6=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`ME-D1[94',\(30`` M$ND$`!4`&````````0```*2!;)$``&%R<6PM,C`Q-3`Y,S!?;&%B+GAM;%54 M!0`#:"0Z5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`+939$``!A`L``00E#@``!#D!``!02P$"'@,4````"`"V4V1':4ZLR!`- M``#O<```$0`8```````!````I(&%"0$`87)Q;"TR,#$U,#DS,"YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``X!8!```` ` end XML 49 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814
COLLABORATIONS AND ALLIANCES (Detail Textuals 1) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
May. 07, 2007
Aug. 31, 2011
Sep. 30, 2010
Feb. 29, 2008
Apr. 27, 2007
Sep. 30, 2015
Sep. 30, 2014
Mar. 31, 2007
Sep. 30, 2015
Sep. 30, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Research and development revenue           $ 2,653 $ 2,662   $ 8,442 $ 8,239
Kyowa Hakko Kirin Licensing Agreement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Upfront payment received $ 27,000             $ 3,000    
Upfront and potential development milestone payments         $ 123,000          
Cash upfront licensing payments         $ 30,000          
Notice period for termination of contract                 90 days  
Research and development revenue           1,400 $ 1,400   $ 4,300 $ 4,300
Deferred revenue           $ 3,300     $ 3,300  
Kyowa Hakko Kirin Licensing Agreement | Phase Two trial Kyowa Hakko Kirin                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Milestone payment received     $ 5,000              
Kyowa Hakko Kirin Licensing Agreement | Phase Three Attention Trial Asia                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Milestone payment received   $ 10,000                
Kyowa Hakko Kirin Licensing Agreement | Kyowa Hakko Kirin                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Milestone payment received       $ 3,000            
Percentage of royalties expected to be received - lower range       mid-teen percent            
Percentage of royalties expected to be received - upper range       low-twenty percent